triazoles has been researched along with Breast Cancer in 1789 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.06) | 18.7374 |
| 1990's | 103 (5.76) | 18.2507 |
| 2000's | 819 (45.78) | 29.6817 |
| 2010's | 817 (45.67) | 24.3611 |
| 2020's | 49 (2.74) | 2.80 |
| Authors | Studies |
|---|---|
| Dokala, A; Gurrapu, N; Kolluri, PK; Praveenkumar, E; Subhashini, NJP | 1 |
| Aguilar-Morales, CM; Araujo-Huitrado, JG; Chacón-García, L; Contreras-Celedón, C; Cortés-García, CJ; Granados-López, AJ; Islas-Jácome, A; López, JA; López-Hernández, Y; Solorio-Alvarado, CR | 1 |
| Akca, H; Alvur, O; Baygu, Y; Gok, Y; Kabay, N; Kucuksayan, H | 1 |
| Al-Jabi, N; Ali, A; Bajbouj, K; Hamad, M; Jabal, RA; Muhammad, JS; Shafarin, J; Unnikannan, H | 1 |
| Chin, CM; Scarim, CB | 1 |
| Li, S; Shi, Y; Xu, S | 1 |
| Cao, LY; He, S; Li, X; Luo, L; Luo, S; Ren, XM; Xiao, H; Xie, XD; Yang, Y; Yin, YL; Zhang, JD; Zhou, YY | 1 |
| Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC | 1 |
| Boraei, ATA; Nafie, MS | 1 |
| Cho, I; Choi, J; Park, J; Sheen, Y | 1 |
| Cheng, S; Shi, Y; Wang, J; Wu, X; Xia, S | 1 |
| Eisner, JR; Lerner, LM; Michmerhuizen, AR; Pesch, AM; Pierce, LJ; Rae, JM; Schwartz, R; Speers, CW; Ward, C; Wilder-Romans, K; Zhang, A | 1 |
| Chen, Y; Ding, S; Liu, S; Peng, Y; Zheng, J | 1 |
| Andersson, M; Buch-Larsen, K; Gillberg, L; Marina, D; Rasmussen, ÅK; Schwarz, P | 1 |
| Barrow, D; Eissa, AG; Foster, PA; Gee, J; Powell, LE; Simons, C | 1 |
| Korzuch, J; Malarz, K; Musioł, R; Serda, M; Szubka, M; Zubko, M | 1 |
| Alam, MM | 1 |
| Chandra, S; Roh, J; Thomas, AA; Venteicher, B; Way, H | 1 |
| El-Ashmawy, MB; El-Ghobashy, NM; El-Sayed, SM; Shehata, IA | 1 |
| Chakraborty, R; Dey, A; Gopalakrishnan, AV; K K, V; Mukherjee, AG; Nagarajan, D; P, JP; Renu, K; T, TP; V, A; Vellingiri, B; Wanjari, UR | 1 |
| Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I | 1 |
| Jaswal, S; Singh, S; Singh, Y; Thareja, S; Verma, SK | 1 |
| Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL | 1 |
| Egawa, C; Hasegawa, Y; Higaki, K; Hozumi, Y; Iijima, K; Iwase, T; Komoike, Y; Masuoka, H; Mukai, H; Nakamura, T; Ohtani, S; Ohtsu, H; Saji, S; Sato, Y; Takei, H; Tanabe, M; Tanaka, M; Yanagita, Y | 1 |
| Bandos, H; Brufsky, AM; Chia, SK; Dakhil, SR; Fehrenbacher, L; Geyer, CE; Jeong, JH; Lembersky, BC; Mamounas, EP; McCarron, EC; Rastogi, P; Soori, GS; Swain, SM; Wade, JL; Walshe, JM; Wolmark, N | 1 |
| Basappa, B; Basappa, S; Gaonkar, SL; Krishnamurthy, NP; Lobie, PE; Mohan, A; Pandey, V; Ravish, A; Vishwanath, D; Xi, Z | 1 |
| Albasanz, JL; Diaz de Greñu, B; Durá, G; Fernández-Aroca, DM; Jalón, FA; Manzano, BR; Organero, JA; Rodríguez, AM; Ruiz-Hidalgo, MJ; Sánchez-Prieto, R; Santos, L | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gersch, CL; Gralow, JR; Hayes, DF; Henderson, NC; Henry, NL; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Medley, S; Mehta, RS; Pusztai, L; Rae, JM; Rutherford, DV; Tirumali, NR; Vandenberg, TA | 1 |
| Bozhenko, EI; Chernoburova, EI; Ilovaisky, AI; Merkulova, VM; Povarov, AA; Salnikova, DI; Scherbakov, AM; Shchetinina, MA; Sorokin, DV; Terent'ev, AO; Zavarzin, IV | 1 |
| Arnachellen, D; Augustine, TN; Pillay, K; Xulu, KR | 1 |
| Chacón-García, L; Cortés-García, CJ; Fraire-Soto, I; Granados-López, AJ; Gutiérrez-Hernández, R; López, JA; López-Hernández, Y; Moreno-Perea, M; Reyes-Estrada, CA; Sifuentes-Padilla, JL; Suárez-Castro, A | 1 |
| Bernards, R; Caldas, C; Chin, SF; Crown, JP; Das, S; Di Grande, A; Dowling, CM; Fan, Y; Gallagher, WM; Haley, KE; Jirström, K; Linn, S; Madden, SF; Mooney, B; Moran, B; Ní Chonghaile, T; O'Connor, DP; Rueda, OM; Tarrant, F; Varešlija, D; Walsh, L; Young, LS | 1 |
| Boraei, ATA; Satta, S; Sechi, M; Singh, PK | 1 |
| Jana, K; Manna, T; Misra, AK; Pal, K | 1 |
| Banjo, S; Kolawole, OA | 1 |
| Bernhardt, G; Keller, M; Kuwert, T; Maschauer, S; Ott, JJ; Prante, O | 1 |
| Camacho, CV; Chae, M; Kraus, WL; Li, R; Murakami, S; Nagari, A | 1 |
| Ali, AA; Berthe, A; Chen, C; Diaby, V; Jiang, X; Moussa, RK; Wang, CY; Wang, W; Xiao, H | 1 |
| Airola, K; Biegon, A; Bonilla, P; Cohen, J; Dhawan, J; Franceschi, D; Pareto, D; Shroyer, KR; Tahmi, M | 1 |
| Bez, G; Das, B; Khongsti, K; Pasupuleti, BG | 1 |
| Bhattacharyya, A; Chatterjee, S; Kumar, S; Manna, D; Morla, S; Panda, S; Pradhan, N; Roy, A; Saha, A | 1 |
| Engelbrecht, AM; Joubert, AM; Mqoco, T; Stander, A | 1 |
| Barwacz, S; Bogacz, T; Dulak, J; Józkowicz, A; Kachamakova-Trojanowska, N; Podkalicka, P; Łoboda, A | 1 |
| Abd Eldaim, MA; Abdallah, AEM; Abdel-Daim, MM; Abdelaziz, SAM; Abdul Rashid, S; Abdullah, AS; Abdullah, LC; Abramson, MJ; Ahmed, HB; Ahmed, MM; Ahn, YC; Alexander, DC; Ando, T; Angelone, AM; Anglani, F; Ap, Y; Arthanari, SK; Axelrad, C; Bai, S; Bakonyi, P; Barnes, E; Beckmann, NA; Bélafi-Bakó, K; Bennett, CM; Bestha, RM; Bitsch, RG; Bradley, CA; Bu, Y; Calò, LA; Cañedo-Villaroya, E; Carlson, L; Caruso, S; Casado-Flores, J; Ceol, M; Cesarino, I; Chen, IL; Chen, R; Chen, X; Chilvers, MI; Cho, WK; Choong, TSY; Conceição-Neto, N; Culver, EL; Dai, X; de Lama Caro-Patón, G; De Rosa, I; Del Prete, D; Dharmage, SC; Dimitriadis, E; Dittakavi, S; Dobrowolski, JC; Edin, S; Elgarawany, GE; Emam, HE; Emmens, RW; Erbas, B; Erwich, JJHM; Farghali, M; Feng, L; Funston, RN; Gabler, NK; Gale, P; Ganesh, M; Gao, J; Gao, L; Gao, X; García-Salido, A; Gatto, R; Gautam, S; Ge, C; Ghogomu, SM; Gianesello, L; Gonçales, VR; Gooch, JL; Gooding, JJ; Gourley, GG; Gu, H; Gu, X; Gu, Z; Guerreri, M; Guillén, M; Hazzaa, SM; Heylen, E; Hicks, R; Hong, X; Hoshi, M; Hu, B; Hu, LX; Hu, R; Hu, S; Huang, J; Huang, K; Hubbard, WB; Hui, J; Hwang, NY; Iannacci, J; Ianus, A; Iglesias-Bouzas, MI; Ihara, I; Iwasaki, M; Jaeger, S; Kandel, YR; Karpińska, G; Kim, HK; Klopfenstein, TJ; Knorr, D; Koók, L; Kotb, S; Kruithof, S; Larsson, P; Laurence, C; Leng, J; Li, H; Li, J; Li, Q; Li, S; Li, X; Li, Z; Lian, J; Liang, JX; Liang, X; Lighaam, LC; Lin, CW; Lin, HC; Lin, J; Ling, A; Liu, J; Liu, P; Liu, YS; Ljuslinder, I; Lo, GH; Lodge, CJ; Löfgren-Burström, A; Lowe, AJ; Lu, M; Lu, N; Lucero-Prisno, DE; Luebbe, KM; Luo, X; Ma, Z; Maes, P; Makuch, M; Malekbala, MR; Mao, Z; Martínez-Romera, I; Marzo, G; Mathew, FM; Mattei, A; Matthijnssens, J; Mayumi, M; Morita, N; Mueller, DS; Mullangi, R; Mummolo, S; Murthi, P; Myte, R; Nabeshima, T; Nakamoto, K; Nehdi, IA; Nemestóthy, N; Niessen, HWM; Noh, JM; Nota, A; Nunes, D; Oh, D; Öhlund, D; Olsen, KM; Ono, H; Osawa, Y; Palmqvist, R; Palombo, M; Park, M; Patience, JF; Peng, Y; Perng, DS; Persano, A; Priante, G; Prince, SJ; Pulipati, S; Pyo, H; Qiu, X; Quan, J; Quaranta, F; Quinzi, V; Rademacher, CJ; Rajaraman, G; Rashid, U; Rauch, JC; Rector, A; Remmerswaal, EBM; Ren, R; Rispens, T; Rocha, GS; Saad, NM; Saito, K; Salamova, A; Sarfaraz, K; Satoshi, A; Schnellmann, RG; Scholpa, NE; Schonhoff, M; Schwartz, KJ; Schwarze, M; Schweer, WP; Seiichi, Y; Serrano-González, A; Severino, J; Shemesh, N; Shi, ZQ; Shike, DW; Shim, YM; Siciliano, PA; Siebenrock, KA; Silva, MKL; Smith, DL; Soltani, S; Song, YM; Spry, ML; Stalker, LA; Stokes, RS; Sullivan, PG; Sun, JM; Sun, S; Svanes, C; Syo, K; Tai, CM; Takashima, S; Tashita, C; Taurino, A; Ten Berge, IJM; Tenuta, AU; Teo, SH; Tilley, RD; Trivedi, RK; Umetsu, K; Unger, PA; van Bruggen, R; van Ham, SM; Van Ranst, M; Vanitha, J; Vekaria, HJ; Venier, M; Venkateshwaran, K; Venkert, A; Vermeulen, E; Wan, C; Wang, H; Wang, N; Wang, P; Wang, T; Wang, X; Wang, Y; Wise, KA; Wolbink, GJ; Wu, J; Wu, P; Wu, S; Wu, Y; Xia, Q; Xin, W; Xiong, Q; Xu, H; Xu, P; Xue, S; Yamamoto, Y; Yamashiro, T; Yan, F; Yan, H; Yan, S; Yan, Y; Yang, JM; Yang, L; Yang, P; Ye, W; Yeh, JH; Yinda, CK; Ying, GG; Ying, L; Yoon, HG; Yu, H; Zainuddin, M; Zakkula, A; Zeller, M; Zeng, Y; Zha, J; Zhang, F; Zhang, H; Zhang, M; Zhang, Q; Zhang, S; Zhang, T; Zhang, Z; Zhao, C; Zhao, J; Zhao, Y; Zhong, Q; Zhu, J; Zingmark, C; Zo, JI; Zou, Y | 1 |
| Abulkhair, HS; Ahmed, HEA; Bayoumi, AH; Sherbiny, FF; Turky, A | 1 |
| Awolade, P; Cele, N; Ebenezer, O; Gu, L; Gummidi, L; Kaur, M; Kerru, N; Palma, G; Singh, P | 1 |
| Chen, Y; Jin, H; Li, J; Lu, Z; Mi, Y; Qiao, J; Wang, L; Wang, Q; Zou, Z | 1 |
| Bonnefoi, H; Castiglione, M; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Harvey, VJ; Láng, I; Maibach, R; Neven, P; Rabaglio, M; Regan, MM; Ruepp, B; Sun, Z; Thürlimann, B; Wardley, A | 1 |
| He, L; Jia, JJ; Luo, L; Wang, G; Zheng, S; Zhong, Q; Zhong, X | 1 |
| Alexandrova, EM; Eyermann, CE; Haley, JD | 1 |
| Belcheva, A; Boone, T; Chang, JCN; Cohen, AL; Darcourt, JG; Ensor, J; Hemati, P; Kaklamani, VG; Koca, E; Li, X; Murthy, A; Nair, S; Niravath, PA; Patel, TA; Qian, W; Ramshesh, PV; Wong, H; Zhao, J | 1 |
| Alam, MM; Almalki, ASA; Alsharif, MA; Elhenawy, AA; Malebari, AM; Neamatallah, T; Obaid, RJ; Syed, N | 1 |
| Ban, M; Bansode, S; Biradar, S; Gaikwad, NB; Godugu, C; Srinivas, N; Yaddanapudi, VM | 1 |
| Abdi, E; Aebi, S; Burstein, HJ; Chirgwin, J; Coates, AS; Colleoni, M; Courtois, A; Farah, S; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loi, S; Loibl, S; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio, M; Regan, MM; Ribi, K; Ruepp, B; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G | 1 |
| Addo, R; Goodall, S; Haas, M | 1 |
| Dedes, KJ; Matter-Walstra, K; Schwenkglenks, M | 1 |
| Cappelletti, MR; Corona, SP; Cretella, D; Dester, M; Generali, D; Gobbi, A; Petronini, PG; Ravelli, A; Zanotti, L | 1 |
| Beer, B; Czech, T; Daniaux, M; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Sperner-Unterweger, B; Sztankay, M; Weigel, G; Wildt, L | 1 |
| Ahern, TP; Borgquist, S; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Garber, JE; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; von Moos, R | 1 |
| Averineni, RK; Danilenkoff, C; Deshpande, PB; Ginjupalli, K; Nayak, UY; Raghavendra, R; Reddy, MS; Sadhu, SS; Shavi, GV; Udupa, N | 1 |
| Pan, W; Sun, X; Tang, X; Wu, S; Yang, Y | 1 |
| Bai, Y; Kwok, HF; Mahadevappa, R; McCrudden, CM; Neves, H; Wen, Q; Yuen, HF; Yuen, SM; Zhang, SD | 1 |
| Gaikwad, A; Gonzalez, A; Mathew, L; Nugent, EK; Smith, JA | 1 |
| Flockhart, DA; Hayes, DF; Henry, NL; Kadakia, KC; Kidwell, KM; Otte, JL; Seewald, NJ; Snyder, CF; Stearns, V; Storniolo, AM | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Ali, SM; Budd, GT; Chapman, JW; Elliott, CR; Ellis, MJ; Garg, A; Goss, PE; Han, L; Ingle, JN; Leitzel, K; Lipton, A; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW | 1 |
| Kim, ES; Scott, LJ | 1 |
| Ahmed, I; Bartlett, JMS; Brookes, CL; Cuzick, J; Dell'Orto, P; Dowsett, M; Forbes, JF; Mallon, EA; Putter, H; Rea, DW; Regan, MM; Sestak, I; Seynaeve, C; Thürlimann, B; Van de Velde, CJH; Viale, G | 1 |
| Chen, Z; Doyle, TM; Grenald, SA; Largent-Milnes, TM; Salvemini, D; Slosky, LM; Spiegel, S; Vanderah, TW; Zhang, H | 1 |
| Alizadeh, E; Milani, M; Mousazadeh, H; Safa, KD; Zarghami, N | 1 |
| Andrade, DB; Barros-Oliveira, MDC; Borges, RS; Borges, US; Costa-Silva, DR; Silva, BBD; Silva, JM; Tavares, CB | 1 |
| ElDemellawy, MA; Elzoghby, AO; Helmy, MW; Mostafa, SK; Sheweita, SA | 1 |
| Aka, JA; Doillon, CJ; Li, T; Lin, SX; Wang, XQ; Xu, D | 1 |
| Hong, N; Kim, SI; Park, S; Rhee, Y; Seo, DH; Sohn, JH; Yoon, HG | 1 |
| Akıncı, MB; Bilgin, B; Sendur, MAN; Şener Dede, D; Yalçın, B | 1 |
| Ding, H; Fang, L; Huang, P; Tong, Y; Xin, W; Zhou, Q | 1 |
| Balkenende, EME; Beerendonk, CCM; Bos, AME; Cantineau, AEP; Dahhan, T; de Bruin, JP; Fleischer, K; Goddijn, M; Kopeika, Y; Lambalk, CB; Linn, SC; Louwé, LA; Reddy, N; Schats, R; Schipper, I; Smeenk, JMJ; Stoop, D; van der Veen, F; van Golde, RJT; van Wely, M | 1 |
| Eswaran, S; Ghoulam, E; Jakate, S; Klapko, O; Usha, L | 1 |
| Alviggi, C; Conforti, A; De Laurentiis, M; De Placido, G; De Rosa, P; Di Rella, F; Marci, R; Picarelli, S; Strina, I; Vallone, R; Yding Andersen, C | 1 |
| Dang, CV; Fan, L; Fan, Y; Hu, X; Hu, Z; Huang, Q; Li, C; Montone, K; Pi, J; Shan, W; Tang, Z; Tanyi, JL; Wang, Y; Yang, L; Yuan, J; Zhang, L; Zhang, Y | 1 |
| Alkner, S; Bendahl, PO; Fernö, M; Jensen, MB; Mouridsen, H; Rasmussen, BB; Rydén, L | 1 |
| Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; Nydegger, JL; Reddy, PS; Sharma, P; Yeh, HW | 1 |
| He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S | 1 |
| Cui, MK; Li, J; Li, S; Liu, XY; Wang, EH; Zhang, Q; Zhao, Z | 1 |
| Cuzick, J; Dowsett, M; Heindl, A; Naidoo, K; Sestak, I; Yuan, Y | 1 |
| Blok, EJ; Duijm-de Carpentier, M; Kroep, JR; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Putter, H; Rutgers, EJT; van de Velde, CJH; van den Bosch, J; van Leeuwen-Stok, AE | 1 |
| Boughey, JC; Hwang, ES; Youngwirth, LM | 1 |
| Helou, J; Naimark, DM; Pritchard, KI; Raphael, J | 1 |
| Messina, C; Messina, M; Zanardi, E | 1 |
| Barriga, S; Bourayou, N; Campone, M; Chen, SC; Di Leo, A; Forrester, T; Freedman, OC; Frenzel, M; Garnica Jaliffe, G; Goetz, MP; Huober, J; Manso, L; Paluch-Shimon, S; Park, IH; Smith, IC; Sohn, J; Toi, M; Trédan, O | 1 |
| Brasil, OFM; Correa de Mello, P | 1 |
| de Boer, M; De Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG | 1 |
| Alba, E; Bachelot, T; Burris, HA; Campone, M; Erdkamp, F; Favret, AM; Germa, C; Hart, LL; Hegg, R; Jakobsen, E; Janni, W; Miller, M; Sonke, GS; Souami, F; Sutradhar, S; Verma, S; Villanueva, C; Wheatley-Price, P; Wist, E | 1 |
| Adachi, K; Enomoto, K; Fujisaki, S; Hara, Y; Hirano, T; Kubota, H; Makishima, M; Saga, R; Sakurai, K; Suzuki, S; Tomita, R | 1 |
| Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N | 1 |
| Alameddine, RM; Kikkawa, DO; Ko, AC; Korn, BS; Lin, JH; Mimura, M; Parker, BA | 1 |
| Bergh, J; Eloranta, S; Krawiec, K; Liljegren, A; Lissmats, A; Rodriguez-Wallberg, KA | 1 |
| Freedman, RA; Tolaney, SM | 1 |
| Derakhshandeh, K; Hemati Azandaryani, A; Kashanian, S | 1 |
| Chlebowski, RT; Pan, K | 1 |
| Aebi, S; Bernhard, J; Burstein, H; Chirgwin, J; Coates, AS; Colleoni, M; Di Lauro, V; Di Leo, A; Gavilá, J; Gelber, RD; Goldhirsch, A; Gombos, A; Graas, MP; Hitre, E; Jerusalem, G; Kamby, C; Karlsson, P; Kuroi, K; Loibl, S; Luo, W; Maibach, R; Marth, C; Müller, B; Neven, P; O'Reilly, S; Rabaglio-Poretti, M; Regan, MM; Ribi, K; Ruhstaller, T; Simoncini, E; Thompson, A; Viale, G | 1 |
| Christiansen, P; Ejlertsen, B; Grundtmann, B; Handler, J; Jensen, MB; Knoop, AS; Laenkholm, AV; Rasmussen, BB; Skriver, SK; Tvedskov, TF | 1 |
| Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE | 1 |
| Chen, BE; Goss, PE; Liedke, PER; O'Shaughnessy, J; Parulekar, WR; Ramjeesingh, R; Shepherd, LE; Strasser-Weippl, K; Sudan, G | 1 |
| Gondo, N; Hamazaki, Y; Ikeda, T; Kanao, S; Masuda, N; Minato, N; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Toi, M; Uozumi, R; Yamagami, K; Yamauchi, A | 1 |
| Alaamery, M; Alghamdi, B; Almutairi, MS; Alomran, N; Alyafee, YA; Bawazeer, S; Daghestani, M; Massadeh, S; Sheereen, A | 1 |
| Hashigaki, S; Inoue, K; Iwata, H; Masuda, N; Mori, Y; Muramatsu, Y; Nagasawa, T; Nishimura, R; Ohno, S; Takahashi, M; Toi, M; Umeyama, Y | 1 |
| Durairaj, C; Ettl, J; Finn, RS; Gauthier, ER; Hoffman, JT; Huang, X; Joy, AA; Lu, DR; Rugo, HS; Ruiz-Garcia, A; Wang, DD; Wilner, KD; Zheng, J | 1 |
| Asano, Y; Goto, W; Hatano, T; Hirakawa, K; Kashiwagi, S; Motomura, H; Noda, S; Ohira, M; Onoda, N; Takada, K; Takashima, T; Tsujio, G | 1 |
| Akami, T; Hatakeyama, T; Matsumura, A; Mugitani, T; Ogino, S; Okano, S; Sakai, T | 1 |
| Fang, T; Lv, C; Nagle, DG; Wang, JX; Wu, T; Yang, PM; Yuan, X; Zeng, HW; Zhang, C; Zhang, WD; Zhou, YD | 1 |
| Ellis, MJ; Fazal, M; Noguchi, S; Robertson, JFR; Shao, Z; Thirlwell, J | 1 |
| Adachi, K; Enomoto, K; Fujiwara, A; Hara, Y; Hirano, T; Ono, Y; Sakurai, K; Waga, E | 1 |
| Abubakar, MB; Gan, SH | 1 |
| Telford, C | 1 |
| Evans, DG; Howell, A; Howell, SJ | 1 |
| Huang, L; Huang, Y; Huang, Z; Jiang, Y; Liao, Y; Shen, Y; Sun, X; Wei, G; Xu, X; Zhao, C | 1 |
| Iwatsuki, K; Katayama, N; Morizane, S; Motoki, T; Omori, M; Sugimoto, S | 1 |
| Chen, L; Ding, W; Li, Z; Ruan, G; Tu, C; Wang, C | 1 |
| Cai, Q; Fu, S; Luo, Z; Wang, X; Zhai, L; Zhao, Y | 1 |
| Bortolot, CS; da S M Forezi, L; de C da Silva, F; Ferreira, VF; Filho, RI; Ghasemishahrestani, Z; Marra, RKF; Reis, MIP; Sá, BVFE; Sola-Penna, M; Zancan, P | 1 |
| Bhattacharyya, D; Bhattacharyya, S; Biskupiak, J; Brixner, D; Dalal, AA; May, JR; Mishra, D; Mistry, R; Oderda, G; Suri, G; Tang, D; Young, K | 1 |
| Akiyoshi, T; Kuwamura, T; Murakami, S; Ogasa, Y; Suematsu, F; Tanaka, H; Umeda, S | 1 |
| Amir, E; Győrffy, B; Ocaña, A; Pandiella, A; Pérez-Peña, J | 1 |
| Adey, A; Alvarez, MJ; Aswani, AJ; Boniface, C; Califano, A; Chapman, MP; Chin, K; Dobrolecki, LE; Fields, AJ; Gray, JW; Johnson-Camacho, K; Kendsersky, ND; Langer, EM; Lewis, MT; Pelz, CR; Rantala, J; Risom, T; Sears, RC; Spellman, PT; Tomlin, CJ; Wang, NJ | 1 |
| Barrero, MJ; Garcia-Carpizo, V; González-Corpas, A; Ruiz-Llorente, S; Sarmentero, J | 1 |
| An, P; Chen, Z; Chiang, CM; Du, J; Li, W; Lin, X; Lu, L; Shan, H; Su, Q; Tian, L; Wang, H; Wu, Y | 1 |
| Baskin-Bey, E; Brown, VV; Eisner, JR; Figg, WD; Kindrick, JD; Madan, R; Peer, CJ; Schmidt, KT | 1 |
| Fujiki, K; Fujimoto, T; Inoue, F; Ishikawa, H; Maruyama, N; Nakano, T; Nakatani, K; Oka, H; Ueshima, K; Yoshimoto, S | 1 |
| Boccardo, F; Bordonaro, R; Fini, A; Guglielmini, P; Massidda, B; Orzalesi, L; Porpiglia, M; Roagna, R; Rubagotti, A; Serra, P; Ucci, G | 1 |
| Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V | 1 |
| Anan, K; Higaki, K; Mase, T; Nishimura, R; Ohno, S; Sagara, Y; Shibuta, K; Tanaka, M; Teramukai, S; Tsuyuki, S; Yamamoto, Y | 1 |
| Cleeland, CS; Giordano, SH; Lu, H; Malveaux, D; Saleeba, AK; Shi, Q | 1 |
| Aapro, M; Bartlett, JM; Coleman, RE; Markopoulos, C; Putter, H; van de Velde, CJ | 1 |
| A' Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ | 1 |
| A'hern, R; Anderson, H; Dowsett, M; Dunbier, AK; Ghazoui, Z; Miller, WR; Nerurkar, A; Osin, P; Salter, J; Smith, IE | 1 |
| Channon, E; Dixon, JM; Ellis, IO; Gee, JM; Hyman-Taylor, P; Jahan, A; Nicholson, RI; Robertson, JF; Sibbering, DM | 1 |
| Goto, N; Hashimoto, M; Hatori, S; Inari, H; Iwasaki, H; Tanabe, H; Uesugi, K | 1 |
| Brodie, A; Golubeva, O; Kazi, A; Sabnis, GJ; Shah, P | 1 |
| Akinci, MB; Aksoy, S; Altundag, K; Ozdemir, NY; Sendur, MA; Zengin, N | 1 |
| Haaland, B; Lopes, G; Montero, AJ; Tan, PS | 1 |
| Carpenter, JS; Dantzer, J; Desta, Z; Flockhart, DA; Gersch, C; Hayes, DF; Henry, NL; Kidwell, K; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Bachelot, T; Ben Larbi, S; Cohen, PA; Corbo, L; Ghayad, SE; Grisard, E; Heudel, PE; Treilleux, I; Vendrell, JA; Villedieu, M; Vilquin, P | 1 |
| Aibe, N; Kagiya, T; Kimoto, T; Kodani, N; Koizumi, M; Nakamura, S; Nishimura, T; Sihomi, H; Tsubokura, T; Yamazaki, H; Yoshida, K | 1 |
| Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
| von Minckwitz, G | 1 |
| Akiyoshi, T; Asayama, T; Hiura, S; Kato, H; Masuda, S; Ohtani, H; Okamoto, Y; Shimomura, Y | 1 |
| Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bonardi, S; Bottini, A; Cappelletti, MR; Foroni, C; Fox, SB; Generali, D; Giardini, R; Gussago, F; Harris, AL; Martinotti, M; Milani, M; Strina, C; Zanoni, V | 1 |
| Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT | 1 |
| Banerjee, M; Gersch, C; Giacherio, D; Hayes, DF; Henry, NL; McConnell, D; Partridge, AH; Pearlman, M; Schott, AF; Stearns, V; Xia, R | 1 |
| Ingle, JN | 7 |
| Brauch, H; Precht, JC; Saladores, PH; Schroth, W; Schwab, M | 1 |
| Dowsett, M; Gao, Q; Isacke, CM; Mackay, A; Martin, LA; Morandi, A; Pancholi, S; Plaza-Menacho, I; Robertson, D; Zvelebil, M | 1 |
| Ding, K; Duan, L; Liu, Y; Pan, X; Ren, X; Xu, S; Zhang, L; Zhang, Z; Zhuang, X | 1 |
| Li, JH; Zeng, ZJ; Zhang, YJ; Zhao, ST | 1 |
| Adams, J; Basu, S; Butt, SR; Joshi, R; Kleinig, T; Otto, G; Vatandoust, S | 1 |
| Digklia, A; Tzika, E; Voutsadakis, IA | 1 |
| Acquaviva, J; Friedland, JC; He, S; Proia, DA; Sang, J; Smith, DL; Zhang, C | 1 |
| Bratton, MR; Carriere, PP; Llopis, SD; Preyan, LC; Skripnikova, E; Tilghman, SL; Townley, I; Wang, G; Williams, CC; Zhang, Q; Zhong, Q; Zou, J | 1 |
| Cao, W; Li, F; Liu, X; Ma, Z; Qu, H; Wang, H; Wang, Y | 1 |
| Hashigaki, S; Hiraoka, M; Iwata, H; Masuda, N; Morimoto, T; Nishizawa, Y; Noguchi, S; Ohno, S; Ohsumi, S; Rai, Y; Saeki, T; Sasano, H; Sato, Y | 1 |
| Hamilton, J; Kamiya-Matsuoka, C; Kumar, VA; Kurzrock, R; Langford, LA; Moulder, S; Munoz, J; Pasche, LJ; Taggart, MW; Tummala, S | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Amano, G; Amari, M; Ebata, A; Hirakawa, H; Ishida, T; Kakugawa, Y; Miki, Y; Mori, N; Nakamura, Y; Ohuchi, N; Sasano, H; Suzuki, T; Takagi, K; Watanabe, M | 1 |
| Buzdar, A; Gonzalez-Angulo, A; Hortobagyi, G; Litton, J; Mac Gregor, MC | 1 |
| Davies, C; Gray, R; Pan, H; Peto, R | 1 |
| Gohno, T; Hanamura, T; Hayashi, S; Ito, K; Kobayashi, Y; Konno, H; Kurosumi, M; Nishikawa, S; Niwa, T; Takei, H; Tazawa, C; Yamaguchi, Y | 1 |
| Bauer, M; Hadji, P; Hars, O; Kalder, M; Kyvernitakis, I; Ziller, V | 1 |
| Chen, X; Xiong, T; Yang, J; Yao, Z; Yu, M; Zhang, Y; Zhao, L; Zhou, Y | 1 |
| Colacci, A; Guerrini, A; Mascolo, MG; Morandi, E; Perdichizzi, S; Prete, L; Rotondo, F; Silingardi, P; Vaccari, M | 1 |
| Bhan, AK; Binns, SN; Carney, E; Erlander, MG; Finkelstein, DM; Goss, PE; Ingle, JN; Muss, HB; Porter, P; Pritchard, KI; Rimm, DL; Schnabel, CA; Sgroi, DC; Shepherd, LE; Steffel, L; Szymonifka, J; Tu, D; Zarrella, E; Zhang, Y | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dunbier, AK; Ferree, S; Lopez-Knowles, E; Schaper, C; Sestak, I; Sidhu, K; Storhoff, J | 1 |
| Moore, JH; Penrod, NM | 2 |
| Ravichandran, D; Wylie, S | 1 |
| Afentakis, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, J; Howell, T; Salter, J; Sestak, I | 1 |
| Child, T; Fatum, M; McVeigh, E | 1 |
| Balic, M; Dubsky, P; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kwasny, W; Mlineritsch, B; Pfeiler, G; Samonigg, H; Seifert, M; Steger, G; Stierer, M; Stöger, H | 1 |
| Buzdar, AU | 19 |
| Bliss, JM; Braybrooke, JP; Brunt, AM; Cameron, D; Cheung, KL; Coombes, G; Dodwell, D; Dowsett, M; Ellis, P; Folkerd, E; Hayward, L; Howell, A; Im, YH; Johnston, SR; Jyothirmayi, R; Kilburn, LS; Robinson, A; Sergenson, N; Sin, HJ; Wardley, AM; Wheatley, D | 1 |
| Erman, M; Esin, E; Kilickap, S; Yuce, D | 1 |
| Chapman, JA; Goss, PE; Liedke, PE; Shepherd, LE | 1 |
| Anserini, P; Delle Piane, L; Levi Setti, PE; Merlo, DF; Porcu, E; Revelli, A | 1 |
| Dressel-Ban, G; Dubsky, P; Exner, R; Fitzal, F; Gnant, M; Hadji, P; Königsberg, R; Maroske, M; Pfeiler, G; Seifert, M; Singer, C; Zellinger, J | 1 |
| Hou, G; Liu, J; Liu, Y; Zhang, J; Zhang, S; Zhang, X | 1 |
| Ganjekar, S; Kilara, N; Mahendra, JV; Manjunatha, N; Srinivasa, R | 1 |
| Dimitrakakis, C; Glaser, RL | 2 |
| Korytova, LI; Masliukova, EA; Meshechkin, AV; Sokurenko, VP; Zhabina, RM | 1 |
| Cuzick, J; Dowsett, M; Dunbier, A; Erlander, MG; Goss, PE; Lopez-Knowles, E; Schnabel, CA; Schroeder, B; Sestak, I; Sgroi, DC; Sidhu, K; Zhang, Y | 1 |
| Gebrim, LH; Logullo, AF; Madeira, M; Mattar, A; Soares, FA | 1 |
| Bell, MJ; Bender, CM; Terhorst, L | 1 |
| Bedoschi, G; Moy, F; Oktay, K; Turan, V | 1 |
| Bai, YX; Huang, P; Li, YJ; Liu, L; Sui, H; Sun, XW; Wang, JX; Wei, XL; Xie, R; Yuan, HH; Zhang, QY; Zhang, TT; Zhang, WJ; Zhao, S; Zhou, JH | 1 |
| Bode, AM; Ghazoui, Z; Grubbs, CJ; Liu, P; Lu, Y; Lubet, RA; Vedell, PT; Wen, W; You, M | 1 |
| Gopal, G; Rajkumar, T; Rawat, A; Selvaluxmy, G | 1 |
| Badovinac-Crnjevic, T; Fan, L; Goss, PE; Strasser-Weippl, K | 1 |
| Goldhirsch, A | 1 |
| Goodwin, PJ | 1 |
| Chan, HP; Dantzer, J; Desta, Z; Flockhart, DA; Goswami, CP; Hadjiiski, L; Hayes, DF; Helvie, MA; Henry, NL; Khouri, N; Li, L; Nguyen, AT; Oesterreich, S; Philips, S; Pinsky, R; Rae, JM; Robarge, J; Skaar, TC; Stearns, V; Storniolo, AM; Zhou, C | 1 |
| Anandappa, G; Turner, NC | 1 |
| Brown, CE; Crankshaw, DJ; DiFrancesco, BR; Holloway, AC; McNulty, J; Nair, JJ; Nielsen, AJ; Vurgun, N | 1 |
| Chen, HY; Liu, ZH | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Fisch, K; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Mehta, A; Tripathy, D | 1 |
| Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
| Balkenende, E; Dahhan, T; Goddijn, M; Linn, S; van Wely, M | 1 |
| Bulun, SE; Khan, SA; Lin, Z; Moy, I; Rademaker, AW; Reierstad, S | 1 |
| Frederix, GW; Hövels, AM; Huitema, AD; Raaijmakers, JA; Schellens, JH; Severens, JL; van Hasselt, JG | 1 |
| Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M | 1 |
| Bonnefoi, H; Coates, AS; Cole, BF; Colleoni, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Huober, J; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wu, J | 1 |
| Akçay, HT; Bayrak, R | 1 |
| Cameron, DA | 1 |
| Bonanni, B; Cawthorn, S; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Knox, J; Mansel, RE; Palva, T; Roche, N; Saunders, C; Sestak, I; von Minckwitz, G | 1 |
| Nakamura, H; Yoneyama, K | 1 |
| Wise, J | 1 |
| Fan, L; Goss, PE; Isakoff, SJ; Liedke, PE; Ryan, PD; St Louis, J | 1 |
| Bago-Horvath, Z; Balic, M; Bartsch, R; Cowens, JW; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Knauer, M; Kwasny, W; Liu, S; Mlineritsch, B; Nielsen, TO; Ressler, S; Rudas, M; Schaper, C; Singer, C; Steger, G; Stoeger, H; Storhoff, J | 1 |
| Blettner, M; Bolten, W; Hadji, P; Harbeck, N; Hindenburg, HJ; Jackisch, C; Klein, P; König, K; Kreienberg, R; Rief, W; Wallwiener, D; Zaun, S | 1 |
| Boyle, F; Bulsara, M; Holman, CD; Kemp, A; Malacova, E; Preen, DB; Roughead, EE; Saunders, C | 1 |
| Enomoto, K; Sakurai, K | 2 |
| Cutress, RI; Layfield, DM; Mohamud, M; Odofin, O; Royle, GT; Walsh, C | 1 |
| Yaqub, F | 1 |
| Bighin, C; Bisagni, G; Cirillo, M; Del Mastro, L; Giraudi, S; Gnoni, R; Levaggi, A; Lunardi, G; Mansutti, M; Marenco, D; Picardo, E; Piccioli, P; Ponzone, R; Porpiglia, M; Puglisi, F; Sini, V; Stridi, G; Turazza, M | 1 |
| Chen, ML; Li, K; Zhang, J; Zhu, ZL | 1 |
| Adhikari, B; Chaudhury, K; Siddiqa, AJ | 1 |
| Beer, B; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B; Seeber, B; Sperner-Unterweger, B; Sztankay, M; Wildt, L | 1 |
| Brodie, AH; Chumsri, S; Gilani, RA; Goloubeva, O; Kazi, AA; Kronsberg, S; Sabnis, G; Schech, AJ; Shah, P | 1 |
| Aebi, S; Campone, M; Coates, AS; Debled, M; Decensi, A; Gelber, RD; Goldhirsch, A; Guerrieri-Gonzaga, A; Johansson, H; McIntosh, C; Monnier, A; Price, KN; Schönenberger, A; Sun, Z; Thürlimann, B; Tondini, C; Zaman, K | 1 |
| Carpi, A; Ferrari, P; Nicolini, A; Rossi, G | 1 |
| Hampton, T | 1 |
| Baier, M; Beckmann, MW; Berghorn, M; Fasching, PA; Grab, D; Hanf, V; Hauschild, M; Jud, SM; Kahlert, S; Kreienberg, R; Krocker, J; Kühn, T; Kümmel, S; Lux, MP; Müller, T; Muth, M; Paepke, S; Schulz-Wendtland, R; Schütte, M; Stickeler, E; Wackwitz, B; Warm, M; Wolf, C | 1 |
| Finkelstein, DM; Schoenfeld, DA | 2 |
| Guo, RT; Li, XL; Li, Y; Luan, JW; Nie, D; Wu, J; You, QS; Zhang, LP | 1 |
| Dowsett, M; Haynes, BP; Lønning, PE | 1 |
| Bauman, L; Chandarlapaty, S; D'Andrea, G; Drullinsky, P; El-Hariry, I; Fasano, J; Gilewski, T; Goldfarb, S; Haque, S; Hudis, C; Jhaveri, K; Lake, D; Lim, K; Modi, S; Moynahan, ME; Patil, S; Reddington, L; Robson, M; Sugarman, S; Vukovic, V; Wasserheit-Leiblich, C | 1 |
| Allen, JW; Foster, LM; Harmon, MW; Luh, JY; Mahoney, ME | 1 |
| Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Brown, P | 1 |
| Andrews, C; Carpenter, R; Cordiner, C; Doughty, JC; Ellis, G; Gandhi, A; Gui, G; Moss, N; Skene, AI; Wilson, C | 1 |
| Bock, VL; Friedlander, M; Kossard, S; Waring, D; Wood, GK | 1 |
| Bari, SB; Chaudhari, NS; Deshmukh, PK; Pandey, AP; Patil, PO; Tekade, AR | 1 |
| Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E | 1 |
| Ahn, SH; Chae, BJ; Choi, SY; Han, S; Han, W; Jeong, J; Jeong, SS; Jung, SY; Jung, Y; Kang, E; Kang, HS; Kang, T; Kim, EK; Kim, J; Kim, KS; Kim, LS; Kim, MK; Kim, SI; Kim, SW; Kim, TH; Lee, JE; Lim, W; Moon, HG; Nam, SJ; Noh, DY; Paik, NS; Park, CH; Yoo, YB; Yoon, JH; Yu, JH | 1 |
| Chlebowski, RT | 3 |
| Brufsky, A; Mathew, A | 1 |
| Badovinac-Crnjevic, T; Chalchal, H; Chapman, JA; Cheung, AM; Elliott, CR; Goss, PE; Hershman, DL; Ingle, JN; Khosla, S; Linden, HM; Muss, HB; Pritchard, KI; Rowland, K; Scher, J; Shepherd, LE; St Louis, J; Stearns, V | 1 |
| Abramson, VG; Arteaga, CL; Balko, JM; Cantley, LC; Forero, A; Isakoff, SJ; Kuba, MG; Li, Y; Mayer, IA; Sanders, ME; Van den Abbeele, AD; Winer, E; Yap, JT | 1 |
| Andrews, C; Clark, K; Edge, SB; Fetterly, G; Hicks, DG; Kulkarni, S; McCann, SE; Morrison, CD; Thompson, LU; Wilton, J | 1 |
| Bardy-Bouxin, N; Bellet, M; Chow, L; Duvillié, L; Goss, P; Láng, I; Lebrun, F; Leip, E; Moy, B; Neven, P; Sarosiek, T; Turnbull, K; Xu, B; Zacharchuk, C | 1 |
| Atkins, L; Barni, S; Deschamp, V; Franquet, A; Gnant, M; Kreienberg, R; Markopoulos, C; Marty, M; Neciosup, S; Neven, P; Tanner, M; Tesarova, P | 2 |
| Hasegawa, Y; Higaki, K; Iwata, H; Kihara, K; Ohashi, Y; Ohsumi, S; Sakai, T; Shimozuma, K; Taira, N; Yamaguchi, T | 1 |
| Fan, Y; Gong, DD; Man, CF; Xu, J | 1 |
| Kawano, K; Tashima, Y | 1 |
| Goto, N; Hatori, S; Inafuku, K; Inari, H; Kawamoto, M; Masuda, M; Tanabe, H | 1 |
| Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
| Carpenter, J; Clauw, DJ; Flockhart, DA; Harte, SE; Hayes, DF; Henry, NL; Kidwell, KM; Stearns, V; Storniolo, AM; Williams, DA | 1 |
| Kim, DK; Kim, MJ; Kim, SJ; Kim, SW; Lee, SJ; Nam, JS; Park, SA; Park, SY; Sheen, YY; Son, JY | 1 |
| Brufsky, AM | 1 |
| Bedoschi, G; Moy, F; Oktay, K; Reddy, J; Turan, V | 1 |
| Schiavon, G; Smith, IE; Yeo, B | 1 |
| Agrawal, A; Cheung, KL; Gutteridge, E; Marenah, C; Mathew, J; Prinsloo, P; Robertson, JF | 1 |
| Bradner, J; Coarfa, C; Creighton, CJ; Feng, Q; Fu, X; He, B; Hilsenbeck, SG; Lanz, R; Mitsiades, CS; Mitsiades, N; Nardone, A; O'Malley, BW; Osborne, CK; Schiff, R; Shea, MJ; Song, Y; Wang, L; Zhang, Z | 1 |
| Albert, US; Hadji, P; Hars, O; Kalder, M; Kyvernitakis, I; Winarno, AS | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Coşkun, HŞ; Mutlu, H | 1 |
| Bertrand, HC; Clède, S; Guillot, R; Lambert, F; Policar, C | 1 |
| Atkins, JT; Falchook, GS; Fu, S; Hong, DS; Janku, F; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, SA; Stephens, PJ; Tsimberidou, AM; Wheler, JJ; Yelensky, R; Zinner, R | 1 |
| Ah, YM; Im, SA; Kim, HS; Lee, BK; Lee, HS; Lee, JY; Noh, DY | 1 |
| Dryden, R; Harrow, A; McCowan, C; Parsons, M; Radley, A; Thompson, AM; Wells, M | 1 |
| Chottanapund, S; Hunsonti, P; Navasumrit, P; Ruchirawat, M; Timtavorn, S; Van den Berg, M; Van Duursen, MB | 1 |
| Blackburn, GL; Findlay, B; Goodwin, PJ; Gralow, JR; Levine, M; Ligibel, JA; Mukherjee, S; Pond, GR; Pritchard, KI; Robidoux, A; Segal, RJ; Vallis, M | 1 |
| Irwin, ML | 1 |
| Asensio, SN; Boni, C; Cavazza, A; Damiani, S; Gnoni, R; Lococo, F; Pagano, M; Rapicetta, C; Zanelli, F | 1 |
| Batra, U; Doval, DC; Dutta, K; Talwar, V | 1 |
| Barry, W; Block, CC; Borges, V; DeSantis, SD; Guo, H; Partridge, AH; Ruddy, KJ; Winer, EP | 1 |
| Chen, D; Deng, Y; Feng, G; He, P; Hu, R; Huang, T; Li, E; Li, L; Li, Y; Liang, Z; Lin, Y; Liu, J; Lu, Y; Ma, R; Su, F; Sun, S; Tong, Z; Wang, S; Wang, X; Wu, Y; Xu, Z; Zhang, H; Zhang, X; Zhang, Y; Zhao, Y | 1 |
| Dowsett, M; Gao, Q; Garcia-Murillas, I; López-Knowles, E; Martin, LA; Segal, CV; Smith, I; Turner, NC | 1 |
| Alluri, PG; Asangani, IA; Chinnaiyan, AM | 1 |
| Coonahan, E; Giangregorio, R; Kaplan, DL; Lovett, ML; Yucel, T | 1 |
| Agarwal, V; Cawkwell, L; Drew, PJ; Fox, JN; Garimella, V; Hussain, T; Kneeshaw, PJ; Lind, MJ; Long, ED; Mahapatra, TK; McManus, PL; Radhakrishna, S | 1 |
| Bowman, M; Bruner, D; DeMichele, A; Farrar, JT; Mao, JJ; Seluzicki, C; Xie, SX; Zee, J | 1 |
| Liu, M; Liu, P; Xie, F; Yang, DQ; Zhou, B | 1 |
| Arthur, LM; Dixon, JM; Kay, C; Larionov, AA; Renshaw, L; Sims, AH; Thomas, JS; Turnbull, AK; Webber, VL | 1 |
| Chen, L; Fang, L; Hu, Z; Huang, Y; Li, D; Li, H; Li, J; Song, H; Wei, C | 1 |
| Andou, A; Higashi, R; Okutani, D; Yamadori, I | 1 |
| Olin, JL; St Pierre, M | 1 |
| Klein, KO | 1 |
| Barman, P; Buzdar, AU; Desta, Z; Dudenkov, TT; Flockhart, DA; Goetz, MP; Ingle, JN; Kalari, KR; Northfelt, DW; Perez, EA; Robson, ME; Wang, L; Weinshilboum, RM; Williard, CV | 1 |
| Andò, S; Barone, I; Brown, PH; Fuqua, SA; Iacopetta, D; O'Malley, BW; Rechoum, Y; Rovito, D; Weigel, NL | 1 |
| Abubakar, MB; Gan, SH; Wei, K | 1 |
| Babacan, A; Duru, NK; Ercan, CM; Ergun, A; Keskin, U; Korkmaz, C; Yilmaz, A | 1 |
| Billen, J; Christiaens, MR; Jans, I; Laenen, A; Lintermans, A; Neven, P; Paridaens, R; Pauwels, S; Van Asten, K; Van Herck, E; Vanderschueren, D; Verhaeghe, J; Vermeersch, P; Wildiers, H | 1 |
| Armengol-Alonso, A; Dalmau, E; Muñoz, M; Seguí-Palmer, MÁ | 1 |
| Aihara, T; Andoh, M; Aogi, K; Fukuuchi, A; Hozumi, Y; Iwata, H; Kim, R; Makino, H; Mukai, H; Ohashi, Y; Ohno, S; Takatsuka, Y; Tamura, M; Tsugawa, K; Watanabe, T; Yamaguchi, T; Yokota, I | 1 |
| Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Lopez-Knowles, E; Schaper, C; Sestak, I | 1 |
| Bak, M; Duun-Henriksen, AK; Kirkegaard, T; Lykkesfeldt, AE; Lænkholm, AV; Pedersen, AM; Rasmussen, BB; Thomsen, MB; Thrane, S; Yde, CW | 1 |
| Albertini, S; Kelly, E; Lu, CY; Vitry, A | 1 |
| Fearnley, GW; Fishwick, CW; Gage, MC; Homer-Vanniasinkam, S; Kankanala, J; Kearney, MT; Latham, AM; Ponnambalam, S; Wheatcroft, SB | 1 |
| Ahn, SH; Beresford, M; Bliss, JM; Cheang, M; Cleator, S; Coombes, RC; Fallowfield, L; Gong, G; Guttery, DS; Kilburn, LS; Kim, SB; Mallon, E; Mansi, J; Morden, J; Mousa, K; Page, K; Palmieri, C; Primrose, L; Reed, S; Rghebi, B; Shaw, JA; Thompson, AM | 1 |
| Abehsera, D; de Santiago, J; Panal, M; Revello, R; Sánchez-Mendez, JI; Zapardiel, I | 1 |
| Balic, M; Bartsch, R; Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Fitzal, F; Gnant, M; Greil, R; Hochreiner, G; Jakesz, R; Knauer, M; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Moik, M; Ploner, F; Seifert, M; Selim, U; Sevelda, P; Steger, G; Stoeger, H; Taucher, S; Wette, V | 1 |
| Kaldygul Kabakovna, S; Kuanysh Shadybayevich, N; Lewis, L; Ramil Zufarovich, A; Suriya Ertugyrovna, Y; Taylor, M | 1 |
| Ikeda, T; Minato, N; Shimizu, A; Sugie, T; Sumi, E; Suzuki, E; Tada, H; Tanaka, Y; Teramukai, S; Toi, M; Yoshimura, K | 1 |
| García-Arpa, M; Lozano-Martín, E; Rodríguez, CR; Rodríguez-Vázquez, M | 1 |
| Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V | 1 |
| Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V | 1 |
| Gradishar, WJ | 4 |
| Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Fowst, C; Huang, X; Kim, ST; Kulyk, SO; Lang, I; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Shparyk, Y; Slamon, DJ; Thummala, AR; Voytko, NL | 1 |
| Bihani, T; D'Cruz, CM; Ezell, SA; Fawell, S; Grosskurth, SE; Ladd, B; Mazzola, AM; Pietras, M; Reimer, C; Zinda, M | 1 |
| Ardestani, SK; Asadipour, A; Dadgar, A; Firoozpour, L; Foroumadi, A; Moshafi, MH; Pordeli, M; Rodaki, A; Safavi, M; Vosooghi, M | 1 |
| Evans, A; Lacey, R | 1 |
| Lanuti, M; Lerwill, MF; Moy, B; Rafferty, EA; Specht, MC | 1 |
| Bachelot, T; Barrios, C; de Boer, R; Di Leo, A; Janni, W; Jerusalem, G; Neven, P | 1 |
| Osborne, CK; Rimawi, MF; Schiff, R | 1 |
| Chatziralli, IP; Chrysikos, D; Ladas, I; Moschos, MM; Sergentanis, T; Zagouri, F; Zografos, G | 1 |
| Overmoyer, B | 1 |
| Hansen, SK; Hole, S; Lundqvist, J; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Bachelot, T; Cohen, PA; Corbo, L; Donini, CF; Grisard, E; Vendrell, JA; Villedieu, M; Vilquin, P | 1 |
| Hole, S; Lykkesfeldt, AE; Pedersen, AM; Yde, CW | 1 |
| Addison, CL; Arnaout, A; Clemons, M; Kuchuk, I; Namazi, M; Pond, GR; Robertson, S; Simos, D | 1 |
| Aktas, B; Anton, A; Carrasco, E; De la Haba-Rodriguez, JR; Garcia-Saenz, JÁ; Gil, M; Guerrero, A; Liedtke, C; Loibl, S; Margeli, M; Martín, M; Martinez, N; Mehta, K; Morales, S; Muñoz, M; Ramos, M; Schoenegg, W; von Minckwitz, G; Wachsmann, G | 1 |
| Blok, EJ; Derks, MG; Kroep, JR; van de Velde, CJ; van der Hoeven, JJ | 1 |
| Biarnes, MC; Clarke, R; Jordan, VC; Sengupta, S | 1 |
| Dube, M; Matey, P; Selvakumar, D | 1 |
| Egawa, C; Goto, T; Hashimoto, T; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kimura, K; Kusama, H; Matsushita, K; Morimoto, Y; Nagano, T; Nakahira, S; Nakatsuka, S; Nitta, K; Okishiro, M; Oku, K; Sakisaka, H; Sato, Y; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, K | 1 |
| Chen, R; Cui, J; Hu, H; Li, P; Liu, X; Wang, Q; Wei, W | 1 |
| Barbie, TU; Ma, C; Margenthaler, JA | 1 |
| Dhillon, S | 1 |
| Bandyopadhyay, A; Kirma, NB; Liu, Z; Mukhopadhyay, KD; Sun, LZ; Tekmal, RR; Wang, S | 1 |
| Behl, G; Dave, V; Deshpande, PB; Kumar, AR; Kushwaha, K; Nayak, UY; Raghavendra, R; Shavi, GV; Sreenivasa Reddy, M; Udupa, N | 1 |
| Bevers, TB | 1 |
| Akagi, K; Hayasaka, A; Igeta, S; Ishigaki, N; Iwahashi, H; Kudo, T; Makino, H; Matsuura, R; Sakurada, J; Shima, T; Suzuki, H; Toyoshima, M; Yoshinaga, K | 1 |
| Ahrendt, GM; Bender, CM; Berga, SL; Brufsky, AM; Casillo, FE; Dailey, MM; Erickson, KI; Gentry, AL; Kratofil, FM; McAuliffe, PF; Merriman, JD; Rosenzweig, MQ; Ryan, CM; Sereika, SM | 1 |
| Cheng, J; Hong, Q; Jia, X; Lei, L; Li, D; Li, J; Liu, G; Mo, M; Shao, Z; Shen, Z; Wang, Y | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Balic, M; Cowens, JW; Cuzick, J; Dowsett, M; Dubsky, P; Ferree, S; Fesl, C; Filipits, M; Gnant, M; Greil, R; Jakesz, R; Lopez-Knowles, E; Nielsen, T; Rudas, M; Schaper, C; Sestak, I; Stoeger, H | 1 |
| Kitamura, T; Tanaka, Y; Tsuboi, K; Tsuda, S; Tsujii, S; Yagi, K; Yamamoto, A | 1 |
| Biggers, A; Charlson, JA; Kamaraju, S; Laud, PW; Neuner, JM; Pezzin, LE; Smallwood, AJ; Smith, EC; Wozniak, EM | 1 |
| Chang, CH; Chen, SJ; Liu, CY | 1 |
| Brodie, A; Guha, R; Jaiswal, AK; Khatri, R; Rassool, FV; Shah, P; Tomkinson, AE | 1 |
| Atkins, JT; Janku, F; Kurzrock, R; Moulder, SL; Stephens, PJ; Wheler, JJ; Yelensky, R | 1 |
| Azim, HA | 1 |
| Arthur, LM; Dixon, JM; Dowsett, M; Dunbier, AK; Kay, C; Larionov, AA; Renshaw, L; Sims, AH; Thomas, JS; Turnbull, AK | 1 |
| Hall, CD; Jabeen, F; Katritzky, AR; Kondratyuk, TP; Panda, SS; Park, EJ; Pezzuto, JM | 1 |
| Aguggini, S; Allevi, G; Ardine, M; Bedussi, F; Berruti, A; Bertoni, R; Bottini, A; Brugnoli, G; Cappelletti, MR; Ferrero, G; Forti, M; Fox, SB; Generali, D; Harris, AL; Milani, M; Strina, C; Vailati, ME; Zanotti, L | 1 |
| Lin, JB; Mast, N; Pikuleva, IA | 1 |
| Henry, NL; Morikawa, A | 1 |
| Munster, PN | 1 |
| Bedoschi, G; Moy, F; Oktay, K; Pacheco, FS; Turan, V | 1 |
| Antolín-Novoa, S; Antón, A; Blanco-Campanario, E; de la Cruz-Merino, L; Galán-Brotons, A; Gallegos-Sancho, MI; Murías-Rosales, A; Peláez, I; Pérez-Carrión, R | 1 |
| Audisio, R; Cheung, KL; Collins, K; Morgan, JL; Reed, MW; Robinson, TG; Wyld, L | 1 |
| Delbaere, A; Demeestere, I; Englert, Y; Gervy, C; Goldrat, O | 1 |
| Ajay, A; Bhattacharjee, A; Bora, HK; Das, S; Devender, N; Dwivedi, S; Gupt, MP; Konwar, R; Mitra, K; Saini, KS; Tripathi, RP | 1 |
| Brodie, A; Chumsri, S; Goloubeva, O; Kazi, A; Rosenblatt, P; Sabnis, GJ; Schech, AJ; Shah, P; Yu, S | 1 |
| Iwase, T; Komoike, Y; Nakamura, T; Ohashi, Y; Ohtsu, H; Saji, S; Shimozuma, K; Takei, H; Yagata, H | 1 |
| Bonneterre, J; Delbeuck, X; Kramar, A; Le Rhun, E; Lefeuvre-Plesse, C; Pasquier, F; Skrobala, E | 1 |
| Dimitrakakis, C; Glaser, R | 1 |
| Bachelot, T; Bonnefoi, H; Breton-Callu, C; Dalenc, F; Daly, C; de Lara, CT; Debled, M; Fournier, M; Gros, A; Iggo, R; Lortal, B; MacGrogan, G; Madranges, N; Mauriac, L; Nikolski, M; Pulido, M; Quenel-Tueux, N; Rabbitts, P; Rudewicz, J; Soueidan, H; Wood, H | 1 |
| Fujita, Y; Muranishi, Y; Nakayama, I | 1 |
| Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, B; Mallon, E; Metzger Filho, O; Price, KN; Regan, MM; Thürlimann, B; Viale, G; Winer, EP | 1 |
| Bozhok, AA; Dashyan, GA; Komyakhov, AV; Lalak, IA; Manikhas, AG; Paltuev, RM; Petrenko, OL; Semiglazov, VF; Semiglazov, VV; Semiglazova, TY | 1 |
| Colleoni, M; Munzone, E | 1 |
| Johnston, SR | 2 |
| Dowsett, M; Yeo, B | 1 |
| Atherton, PJ; Dakhil, SR; Hines, SL; Lafky, JM; Loprinzi, CL; Majithia, N; Olson, J; Perez, EA; Wagner-Johnston, N | 1 |
| Adiwijaya, BS; Brodie, A; Curley, MD; Garcia, G; Kazi, AA; MacBeath, G; Moyo, V; Sabnis, GJ; Wille, L | 1 |
| Bañales, JM; Becerril, JL; Benítez, JG; Juárez, JJ; Navarro, MD; Zerón, HM | 1 |
| Ketkaew, C; Kiatying-Angsulee, N | 1 |
| Harbeck, N | 2 |
| Berger, MJ; Lustberg, MB; Mangini, NS; Ramaswamy, B; Wesolowski, R | 1 |
| Dietl, O; Muehlenberg, K; Pech, O; Piso, P | 1 |
| Bagnardi, V; Balduzzi, A; Cancello, G; Cardillo, A; Colleoni, M; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sandri, MT; Viale, G | 1 |
| Dewar, JA; Ellis, MJ; Feltl, D; Hewson, N; Jasiówka, M; Llombart-Cussac, A; Robertson, JF; Rukazenkov, Y | 1 |
| Kuerer, H; Mitchell, KB | 1 |
| Borbely, G; Dahlman-Wright, K; Haldosen, LA; Zhao, C | 1 |
| Bibeau, F; Coates, AS; Colleoni, M; Ejlertsen, B; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Lelkaitis, G; MacGrogan, G; Mallon, E; Munzone, E; Price, KN; Thürlimann, B; Viale, G | 1 |
| Beckmann, MW; Findeklee, S | 1 |
| Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K | 1 |
| Deshpande, PB; Kumar, AR; Maliyakkal, N; Nayak, UY; Raghavendra, R; Reddya, MS; Shavi, GV; Shrawan, B; Udupa, N | 1 |
| Jeyaraj, PA; Julka, PK; Kamal, VK; Mahajan, MK; Malik, A; Patil, J; Rath, GK; Roy, S; Shankar, A | 1 |
| Abrial, C; Arbre, M; Chollet, P; Devaud, H; Dohou, J; Dubray-Longeras, P; Durando, X; Herviou, P; Kwiatkowski, F; Mahammedi, H; Mouret-Reynier, MA; Planchat, E; Pouget, M; Van Praagh, I | 1 |
| Martin-Kleisch, A; Zulfiqar, AA | 1 |
| Tamura, K | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA; Yip, WK | 1 |
| Blackwell, K; Burris, H; Campana, F; Gao, L; Gomez, P; Isakoff, S; Jiang, J; Lynn Henry, N; Macé, S; Tolaney, SM | 1 |
| Dantzer, J; Desta, Z; Flockhart, DA; Hangartner, TN; Hayes, DF; Henry, NL; Kidwell, KM; Li, L; Nguyen, AT; Oesterreich, S; Peacock, M; Philips, S; Rae, JM; Skaar, TC; Stearns, V; Storniolo, AM; Van Poznak, CH | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Demir, L; Dirican, A; Ellidokuz, H; Gumus, Z; Kucukzeybek, B; Kucukzeybek, Y; Salman, T; Sutcu, R; Tarhan, MO; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Choi, SK; Choi, WS; Han, JW; Hong, SH; Kim, HS; Nam, SW; Shin, CY; You, JS | 1 |
| Ditzel, HJ; Elias, D; Knoop, AS; Lykkesfeldt, AE; Lyng, MB; Lænkholm, AV; Thomsen, KG; Vever, H | 1 |
| Abramovitz, M; Arnould, L; Biasi, MO; Bouzyk, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gray, KP; Harvey, V; Kammler, R; Leyland-Jones, B; Long, B; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Thürlimann, B; Viale, G; Young, B | 1 |
| Cuzick, J; Forbes, JF; Howell, A; Sestak, I; Spagnolo, F | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Bratta, M; Candeloro, G; D'Orazi, V; Fumagalli, LA; Pasta, V; Rea, S; Recchia, F; Rosselli, M | 1 |
| Boughey, JC; Chow, HH; Frank, D; Hsu, CH; Lang, JE; Ley, M; López, AM; Perloff, M; Pruthi, S; Taverna, JA | 1 |
| Calvo, F; Chakravarty, P; Del Pozo Martin, Y; Derzsi, S; Hill, CS; Malanchi, I; Ombrato, L; Park, D; Ramachandran, A; Sahai, E; Spencer-Dene, B | 1 |
| Abdul Nazeer, KA; Palakal, M; Pradhan, M; Shabana, KM | 1 |
| Azria, D; Bourgier, C; Crompton, N; Fenoglietto, P; Gourgou, S; Gutowski, M; Kerns, S; Lacombe, J; Lemanski, C; Ozsahin, M; Pèlegrin, A; Romieu, G; Rosenstein, B | 1 |
| Bonanni, B; Bundred, N; Coleman, RE; Cuzick, J; Eiermann, W; Ellis, I; Forbes, JF; Holcombe, C; Howell, A; Jones, L; Levy, C; Neven, P; Sestak, I; Stierer, M; von Minckwitz, G | 1 |
| Albain, KS; Brufsky, AM; Cecchini, RS; Cianfrocca, ME; Costantino, JP; Fehrenbacher, L; Ganz, PA; Gross, HM; Hopkins, JO; Julian, TB; Mamounas, EP; Margolese, RG; Seay, TE; Soori, GS; Sturtz, K; Vallow, LA; Whitworth, PW; Wolmark, N; Wozniak, TF | 2 |
| Boué, SM; Burks, H; Burow, ME; Carriere, PP; Collins-Burow, B; Davenport, IR; Davidson, AM; Hilliard, A; Llopis, SD; Naiki, AC; Nguyen, G; Nguyen, MM; Nguyen, TA; Parker-Lemieux, K; Payton-Stewart, F; Phan, T; Pratt, J; Preyan, LC; Tilghman, SL; Williams, CC; Yearby, L | 1 |
| Cui, S; Lü, H; Niu, L; Yan, M; Zeng, H; Zhang, M | 1 |
| Ahn, HY; Chung, KH; Kim, HR; Oh, SM; Park, YJ | 1 |
| Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D | 1 |
| Kim, J; Oktay, K; Turan, V | 1 |
| Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW | 1 |
| Ahirwar, DK; Ganju, RK; Li, DY; Nasser, MW; Oghumu, S; Powell, CA; Satoskar, AR; Wilkie, T; Zhao, H | 1 |
| Creekmore, A; Crowder, R; Doyle, A; Ellis, MJ; Erlichman, C; Gao, F; Guo, Z; Hoog, J; Lockhart, AC; Ma, CX; Naughton, M; Pluard, T; Sanchez, C | 1 |
| Bacci, M; Chiarugi, P; Dowsett, M; Fearns, A; Gao, Q; Giannoni, E; Isacke, CM; Martin, LA; Morandi, A; Pintus, G; Ribas, R; Taddei, ML | 1 |
| Aomatsu, N; Fujii, N; Haraoka, G; Hiramatsu, S; Hosoi, K; Iwauchi, T; Kosaka, K; Morimoto, J; Nishii, T; Takeuchi, K; Tei, S; Tsujio, G; Uchima, Y; Wang, E | 1 |
| Aruga, T; Goto, R; Honda, Y; Horiguchi, K; Horiguchi, S; Idera, N; Kuroi, K; Miyamoto, H; Saita, C; Yamashita, T | 1 |
| Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
| Callet, N; Fourme, E; Noguès, C; Reyal, F; Sénéchal, C; Stoppa-Lyonnet, D; This, P | 1 |
| Berishaj, M; Bonafé, M; Bowman, RL; Bromberg, J; Ceccarelli, C; Chang, Q; Chen, J; Colameco, C; Cricca, M; Daly, L; DeMichele, A; Fabbri, N; Feldman, M; Gasparre, G; Healey, JH; Lyden, D; Mao, JJ; Nnoli, J; Perna, F; Rajasekhar, VK; Sansone, P; Santini, D; Shih, NN; Taffurelli, M; Vidone, M | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, J; Hayes, DF; Hertz, DL; Hortobagyi, GN; Kidwell, KM; Livingston, RB; Mehta, RS; Rae, JM; Tirumali, NR; Vandenberg, TA | 1 |
| Bayliss, E; Boyle, FM; Campbell, I; Coates, AS; Cuzick, J; Davies, L; Della-Fiorentina, S; Forbes, JF; Gebski, V; Gill, PG; Green, M; Kannourakis, G; Kling, N; Mann, GB; Reaby, L; Saunders, C; Thornton, R; Zdenkowski, N | 1 |
| Adlis, SA; Kirstein, MN; Lerner, RE; Liang, S; Richter, SA; Robien, K; Shapiro, AC | 1 |
| Chai, YX; Dai, TM; Shen, YY; Tu, JL; Wang, Y; Xiong, J; Zhang, WJ | 1 |
| Asmar, L; Collea, RP; Diggikar, SM; Fox, PS; Hellerstedt, BA; Holmes, FA; Krekow, LK; O'Shaughnessy, J; Papish, S; Peck, SR; Reddy, PK; Resta, R; Vukelja, SJ; Wang, Y | 1 |
| Bell, T; Bhattacharyya, H; Crown, JP; Finn, RS; Huang Bartlett, C; Huang, X; Kim, S; Lang, I; Randolph, S; Slamon, D; Zanotti, G | 1 |
| Amico, AL; Olopade, OI; Saha, P | 1 |
| Batson, S; Jones, N; Livings, C; Telford, C | 1 |
| Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C | 1 |
| Bender, CM; McCue, M; Merriman, JD; Nugent, BD; Rosenzweig, M; Sereika, SM | 1 |
| Booth, CM; Eisenhauer, EA; Goodwin, RA; Goss, PE; Jamal, R; Shepherd, LE; Tu, D | 1 |
| Amaral, C; Correia-da-Silva, G; Sobral, AF; Teixeira, N | 1 |
| Chapman, JA; Elliott, C; Gelmon, KA; Goss, PE; Ingle, JN; Muss, HB; Pritchard, KI; Shepherd, LE; Whelan, TJ | 1 |
| Bromberg, DJ; Nanjappa, S; Pabbathi, S; Valenzuela, M | 1 |
| Chavarri-Guerra, Y; Goss, PE; Liedke, PE; Pritchard, KI; Shepherd, L; Stearns, V; Tu, D | 1 |
| Cheng, J; Jia, X; Liu, G; Shao, Z; Shen, Z | 1 |
| Cordeiro, CN; Hancock, K; Lekovich, JP; Pereira, N; Rosenwaks, Z; Schattman, GL | 1 |
| Barry, WT; Carey, LA; Cirrincione, CT; Dickler, MN; Ellis, MJ; Hahn, O; Hudis, CA; Hurria, A; Innocenti, F; Lake, DE; Moynahan, ME; Rugo, HS; Schneider, BP; Tripathy, D; Winer, EP | 1 |
| Diao, H; Hu, GZ; Zhang, CJ; Zhang, Y | 1 |
| Baker, SG; Bonetti, M | 1 |
| Belosay, A; Churchwell, MI; Doerge, DR; Hartman, JA; Helferich, WG; Iwaniec, UT; Song, H; Turner, RT; Wang, W; Yang, X | 1 |
| Chirgwin, JH; Coates, AS; Colleoni, M; Debled, M; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Neven, P; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B | 1 |
| Ananthanarayanan, PH; Arul Vijaya Vani, S; Harichandrakumar, KT; Kadambari, D; Nandeesha, H; Niranjjan, R | 1 |
| Hai, T; Kang, H; Li, K; Rong, G; Sun, H; Wang, Y | 1 |
| Cuzick, J; Dowsett, M; Schnabel, CA; Schroeder, BE; Sestak, I; Sgroi, D; Zhang, Y | 1 |
| Almajed, MM; Esfahani, K; Panasci, L; Pelmus, M | 1 |
| Budoff, MJ; Chlebowski, RT | 1 |
| Beck, JT; Gelmon, K; Goss, PE; Gralow, J; Hudis, C; Ingle, JN; Kaur, JS; Muss, H; Parulekar, WR; Pritchard, KI; Robert, NJ; Rubin, S; Stopeck, A; Strasser-Weippl, K; Sturtz, K; Tu, D; Whelan, K; Whelan, T; Winer, E; Wolff, AC | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Dedes, KJ; Klingbiel, D; Matter-Walstra, K; Ruhstaller, T; Schwenkglenks, M | 1 |
| Buddana, SK; Garimella, S; Jain, N; Katiki, MR; Murty, MS; Nanubolu, JB; Polepalli, S; Prakasham, RS | 1 |
| Fan, S; Fang, J; Gu, D; Jin, H; Qin, W; Tao, X; Wang, C; Wang, N; Wang, Y; Wei, L; Yao, M; Zhang, Y; Zhao, F | 1 |
| Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
| Alran, S; Balleyguier, C; Becette, V; Bourgier, C; Boussion, V; Cherel, P; Kerbrat, P; Lavau-Denes, S; Lemonnier, J; Lerebours, F; Martin, AL; Mathieu, MC; Mouret-Fourme, E; Mouret-Reynier, MA; Nabholz, JM; Rivera, S; Salmon, R; Sigal, B; Thibault, F; Trassard, M; Venat-Bouvet, L | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Bardia, A; Beck, JT; Conte, P; Curigliano, G; Dhuria, S; Di Tomaso, E; Gómez Pardo, P; Hurvitz, SA; Lolkema, MP; Martínez García, M; Meric-Bernstam, F; Miller, M; Penault-Llorca, F; Solovieff, N; Tang, Z | 1 |
| Bjørkøy, G; Dixon, JM; Flågeng, MH; Geisler, J; Knappskog, S; Larionov, A; Lilleng, PK; Lønning, PE; Mellgren, G; Miller, WR; Prestvik, WS | 1 |
| Arellano, C; Chatelut, E; Dalenc, F; Filleron, T; Iuliano, L; Marquet, P; Poirot, M; Roché, H; Samadi, M; Silvente-Poirot, S; Voisin, M; Zerbinati, C | 1 |
| Bartlett, CH; Boer, K; Bondarenko, IM; Crown, JP; Ettl, J; Finn, RS; Huang, X; Kim, ST; Lang, I; Nadanaciva, S; Patel, R; Pinter, T; Randolph, S; Schmidt, M; Schnell, P; Slamon, DJ | 1 |
| Yu, R | 1 |
| Buus, R; Cuzick, J; Denkert, C; Dowsett, M; Dubsky, P; Krappmann, K; Kronenwett, R; Petry, C; Scheer, M; Sestak, I | 1 |
| Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
| Bala, V; Chaturvedi, S; Gupta, G; Gupta, S; Konwar, R; Maikhuri, JP; Mandalapu, D; Saini, KS; Sharma, V; Sharma, VL; Thakur, S; Wahajuddin, M; Yaseen Malik, M | 1 |
| Brufsky, AM; Davidson, NE | 1 |
| Beom, SH; Han, SW; Han, W; Im, SA; Kim, TY; Lee, KH; Moon, HG; Noh, DY; Oh, DY; Oh, J; Suh, KJ; Yang, Y | 1 |
| Andreucci, E; Chiarugi, P; Fearns, A; Francica, P; Isacke, CM; Martin, LA; Morandi, A | 1 |
| Ellis, H; Higgins, M; O'Leary, CG | 1 |
| Burris, K; Fisher, J; Miller, M; Patel, M | 1 |
| Baake, G; Baier, B; Bayer, CM; Beckmann, MW; Belleville, E; Breitbach, GP; Brucker, C; Brucker, SY; Dall, P; de Waal, J; Deuker, JU; Fasching, PA; Fehm, T; Fersis, N; Fischer, G; Guggenberger, M; Hack, CC; Hadji, P; Harbeck, N; Hein, A; Henschen, S; Heyl, V; Hohn, A; Jacob, A; Janni, W; Kohls, A; Kolberg, HC; Krauss, T; Kuhn, T; Kümmel, S; Landthaler, R; Mundhenke, C; Noesslet, T; Paepke, D; Praetz, T; Rauh, C; Rezai, M; Rezek, D; Richter, B; Schmidt, K; Siebers, JW; Tesch, H; Thomssen, C; Vollert, HW; Wachsmann, G; Wallwiener, D; Warm, M; Wolf, C; Wuerstlein, R | 1 |
| Arpino, G; De Placido, G; De Placido, S; De Rosa, P; Locci, M; Nazzaro, G; Pagano, T; Schettini, F; Vallone, R | 1 |
| Basik, M; Clemons, M; Cristofanilli, M; Dreosti, L; Grzeda, L; Hegg, R; Johnston, S; Lausoontornsiri, W; Mann, H; Stuart, M | 1 |
| Niraula, S; Ocana, A | 1 |
| Alba, E; André, F; Arteaga, CL; Bachelot, T; Blackwell, KL; Blau, S; Burdaeva, O; Burris, HA; Cameron, DA; Campone, M; Chan, A; Conte, P; Favret, AM; Germa, C; Grischke, EM; Hart, LL; Hirawat, S; Hortobagyi, GN; Jakobsen, E; Janni, W; Marschner, N; Miller, M; Nusch, A; O'Shaughnessy, J; Paluch-Shimon, S; Petrakova, K; Sonke, GS; Souami, F; Stemmer, SM; Tseng, LM; Verma, S; Villanueva, C; Winer, EP; Wist, E; Xuan, F; Yap, YS; Yardley, D | 1 |
| Akudugu, JM; Hamunyela, RH; Serafin, AM | 1 |
| Carrillo, JA; Gervasini, G; Jara, C; Martínez, R; Olier, C; Romero, N | 1 |
| Kumaran, AP; Mishra, D; Paira, P; Sinha, S | 1 |
| Baron, P; Beatty, J; Beitsch, P; de Snoo, FA; Dul, CL; Lee, LA; Mislowsky, A; Murray, M; Nash, C; Pellicane, JV; Rotkis, M; Stork-Sloots, L; Whitworth, P | 1 |
| Ashraf, R; Das, S; Dwivedi, S; Konwar, R; Mandalapu, D; Saini, KS; Sarkar, J; Sharma, VL; Siddiqui, MQ | 1 |
| Athota, VR; Day, CJ; Elsworth, B; Freeman, R; Gasch, C; Mellick, AS; Mittal, V; Nikolic, I; Pouliot, N; Rasighaemi, P; Rogers, K; Sax, MJ; Swarbrick, A; Wei, M; Westcott, DE | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| Burki, TK | 1 |
| Bondarenko, IM; Cardona-Huerta, S; Cheung, KL; Dvorkin, M; Ellis, MJ; Fazal, M; Grinsted, LM; Manikhas, A; Noguchi, S; Panasci, L; Philco-Salas, MJ; Robertson, JFR; Rowbottom, J; Ruiz-Borrego, M; Shao, Z; Shparyk, Y; Stuart, M; Trishkina, E | 1 |
| Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hertz, D; Li, L; Nguyen, AT; Rae, JM; Robarge, JD; Skaar, TC; Stearns, V; Storniolo, AM | 1 |
| Diéras, V; Finn, RS; Gauthier, E; Gelmon, K; Harbeck, N; Im, SA; Jones, S; Lipatov, ON; Lu, DR; Martin, M; Moulder, S; Randolph, S; Rugo, HS; Slamon, DJ; Walshe, JM | 1 |
| Guo, W; Huang, XH; Liang, RH; Su, L; Wang, CJ | 1 |
| Genc, M; Hadda Taibi, B; Karagoz Genc, Z; Sandal, S; Sekerci, M; Sirajuddin, M; Tekin, S | 1 |
| Fitton, JH; Lowenthal, RM; McGuinness, G; Olesen, I; Oliver, LJ; Patel, R; Peterson, GM; Shastri, M; Tocaciu, S | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Goodwin, A; Lee, CI; Wilcken, N | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V | 1 |
| Bender, CM; Brufsky, AM; Clark, BZ; Conley, YP; Ghotkar, P; Jankowitz, RC; Koleck, TA; McAuliffe, PF; Ryan, CM; Sereika, SM | 1 |
| Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D | 1 |
| Yamamoto, C; Yamamoto, D; Yamamoto, M | 1 |
| Endo, T; Hasegawa, K; Higashi, Y; Kamiya, A; Kaneko, J; Kondo, I; Maejima, S; Takatsuno, Y | 1 |
| Grayton, JE; Miller, T; Wilson-Robles, H | 1 |
| Brower, V | 1 |
| Klinge, CM; Muluhngwi, P | 1 |
| Hoseini, M; Keramatipour, M; Koohdani, F; Nourbakhsh, M; Rahideh, ST; Shidfar, F; Talebi, S | 1 |
| Bergamaschi, CC; Coscia, EB; Gerenutti, M; Groppo, FC; Sabha, M | 1 |
| Dimitrakakis, C; Glaser, RL; York, AE | 1 |
| Abdul Salam, AA; Das, S; Kamath, PR; Rao, BS; Sunil, D | 1 |
| Altundag, K | 1 |
| Corrigan, MA; Jinih, M; O'Reilly, S; Redmond, HP; Relihan, N | 1 |
| Giorgadze, E; Khachidze, N; Tsagareli, M | 1 |
| Bagante, F; Connolly, R; Pawlik, TM; Spolverato, G; Vitale, A | 1 |
| Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F | 1 |
| Brentnall, AR; Cuzick, J; Sasieni, P | 1 |
| Alvarez, CA; Balasubramian, BA; Jean, GW; Murphy, CC; Tiro, JA | 1 |
| Partridge, AH | 1 |
| Azim, AA; Costantini-Ferrando, M; Oktay, K | 1 |
| Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N | 1 |
| Akgul, B; Camci, C; Kalender, ME; Karakok, M; Sevinc, A; Turk, HM | 1 |
| Doggrell, SA | 1 |
| Plosker, GL; Sanford, M | 1 |
| Kurmann, PT; Nemitz, N; Van Linthoudt, D | 1 |
| Brodie, AM; Goloubeva, O; Macedo, LF; Sabnis, GJ; Schayowitz, A | 1 |
| Paydas, S | 1 |
| Vaidya, JS | 1 |
| Balduzzi, A; Cardillo, A; Colleoni, M; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Intra, M; Luini, A; Peruzzotti, G; Rocca, A; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Bogliolo, S; Costantini, S; Dugnani, MC; Ferrero, S; Moioli, M; Papadia, A; Valenzano Menada, M | 1 |
| Chen, B; Chen, S; Evans, DB; Lisztwan, J; Pornon, A | 1 |
| Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
| Doerge, DR; Hartman, JA; Helferich, WG; Ju, YH; Kwak, J; Woodling, KA | 1 |
| Grossman, J; Hahn, BH; La Cava, A; Wong, M | 1 |
| Nagykálnai, T | 1 |
| Kahán, Z | 2 |
| Chen, S; Lui, K; Masri, S; Phung, S; Wang, X; Ye, J; Zhou, D | 1 |
| Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I | 1 |
| Eisner, A; Falardeau, J; Thielman, EJ; Vetto, JT | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fitzal, F; Gnant, M; Greil, R; Jakesz, R; Kainberger, F; Kässmann, H; Kubista, E; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mittlböck, M; Mlineritsch, B; Piswanger-Sölkner, JC; Ploner, F; Samonigg, H; Seifert, M; Steger, G; Wohlmuth, P | 1 |
| Gibson, K; O'Bryant, CL | 1 |
| Cuzick, J | 5 |
| Douma, J; Kraayenbrink, AA; Lince, SL; Wiersma-Van Tilburg, AJ | 1 |
| Ambroisine, LM; Atkins, L; Cuzick, J; Fallowfield, LJ; Howell, A; Jenkins, VA | 1 |
| Chlebowski, RT; Col, N | 1 |
| Gurwitz, D; Newman, W | 1 |
| Goss, PE | 7 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| A'Hern, R; Bhatnagar, AS; Chaudri Ross, HA; Dowsett, M; Eiermann, W; Ellis, MJ; Evans, DB; Luo, J; Miller, WR; Smith, I; Tao, Y; von Kameke, A | 1 |
| Boyle, F; Butow, P; Coates, A; Forbes, JF; Juraskova, I; Lopez, A; McCarthy, N; Reaby, L; Seccombe, M | 1 |
| Aas, T; Duong, NK; Ekse, D; Evans, DB; Geisler, J; Helle, H; Lønning, PE; Nordbø, Y | 1 |
| Brown, JE; Coleman, RE; Dodwell, D; Ellis, SP; Gutcher, SA; Hannon, RA; Horsman, JM; Lester, JE; Purohit, OP; Thorpe, R | 1 |
| Bienkiewicz, A; Cialkowska-Rysz, A; Gora, E; Gottwald, L; Jesionek-Kupnicka, D; Korczynski, J; Morawiec, Z; Piekarski, JH; Sowa, P | 1 |
| Bubert, C; Chander, SK; Chen, S; Foster, PA; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Sutcliffe, OB; Woo, LW; Zhou, D | 1 |
| Hashida, S; Hirano, Y; Iga, K; Inukai, M; Ito, M; Kanaya, Y; Maruyama, S; Shimo, T; Yokoyama, N | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cardillo, A; Colleoni, M; Goldhirsch, A; Luini, A; Mancuso, P; Orlando, L; Scarano, E; Torrisi, R; Viale, G | 1 |
| Chaudri Ross, HA; Ellis, MJ; Evans, DB; Miki, Y; Miller, WR; Sasano, H; Suzuki, T; Tao, Y | 1 |
| Cella, D; Cuzick, J; Fallowfield, L; Sestak, I | 1 |
| Braye, SG; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Gusterson, BA; Knox, F; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Olszewski, WP; Orosz, Z; Price, KN; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Dos Reis, FJ; Ferriani, RA; Filho, FM; Martins, WP; Nastri, CO | 1 |
| Boyle, F; Forbes, J | 1 |
| Baum, M; Cuzick, J; Distler, W; Duffy, SR; Howell, A | 1 |
| Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Needleman, SJ; Tobias, JS | 1 |
| Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Buffa, FM; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Papotti, M | 1 |
| Doherty, M; Hopkins, JJ; Jang, RW; Warner, E | 1 |
| Berga, SL | 1 |
| Cianfrocca, M | 1 |
| Bielajew, C; Collins, B; Mackenzie, J; Stewart, A; Verma, S | 1 |
| Cheung, KL; Haynes, AP; Wood, JP | 1 |
| Wardley, AM | 2 |
| Fricker, J | 2 |
| Callam, M; Glen, J; Thomas, RJ; Williams, M | 1 |
| Alberts, DS; Bartels, HG; Bartels, PH; Fabian, CJ; Frank, DH; Kimler, BF; Ranger-Moore, J; Yozwiak, M | 1 |
| Albert, US; Hadji, P; Holzhauer, W; Kalder, M; Wagner, U; Ziller, M; Ziller, V | 1 |
| Al Mufti, R; Behranwala, K; Hadjiminas, DJ; Lanitis, S; Sivakumar, S; Zacharakis, E | 1 |
| Ejlertsen, B; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB | 1 |
| Zhang, B | 2 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Aguggini, S; Allevi, G; Banham, AH; Bates, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M | 1 |
| Brodie, A; Goloubeva, O; Macedo, L; Sabnis, G; Schayowitz, A | 1 |
| Bjelic-Radisic, V; Dubsky, P; Eidtmann, H; Fitzal, F; Fridrik, M; Gnant, M; Greil, R; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Marth, C; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rücklinger, E; Samonigg, H; Schippinger, W; Seifert, M; Steger, G; Stierer, M; Tausch, C | 1 |
| Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA | 1 |
| Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Renshaw, L; Sing, T; Walker, JR | 1 |
| Ellard, SL; Gelmon, KA; Kennecke, HF; McArthur, HL; O'Reilly, SE; Olivotto, IA; Speers, CH | 1 |
| Campbell, I; Colleoni, M; Gelber, RD; Goldhirsch, A; Price, KN; Ravaioli, A; Simoncini, E; Sun, Z; Towler, M | 1 |
| Brodie, A; Macedo, LF; Sabnis, G | 1 |
| Alacacioğlu, A; Bilgi, O; Erikçi, AA; Kandemir, EG; Karagöz, B; Ozgün, A; Sayan, O | 1 |
| Abreu, P; Cameron, DA; Campos, SM; Guastalla, JP; Subar, M; Winer, EP | 1 |
| Azria, D; Belkacémi, Y; Gligorov, J; Jacot, W; Ozsahin, M; Romieu, G; Zaman, K | 1 |
| Cobb, P; Henry, D; Houts, AC; Kulig, K; Schwartzberg, LS; Senecal, F; Stepanski, EJ; Walker, MS | 1 |
| Aliev, DA; Azizov, VA; Musaev, IN; Sadygova, TA; Zeĭnalov, RS | 1 |
| Baselga, J; Bellet, M; Bianchi, G; Campone, M; Dixon, JM; Gardner, H; Greil, R; Jonat, W; Kubista, E; Lane, HA; Manikhas, A; Mayordomo, J; Molloy, B; Phillips, P; Rugo, HS; Semiglazov, V; Steinseifer, J; Stumm, M; Tokaji, E; van Dam, P | 1 |
| Botti, G; Chiodini, P; D'Aiuto, G; De Feo, G; De Maio, E; de Matteis, A; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E | 1 |
| Bandou, H; Inaki, N; Kadoya, S; Kotake, M; Kurokawa, M; Morita, K; Murata, T; Takayanagi, T; Yamada, T; Yamamoto, M; Yoshino, H | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Hojo, T; Katsumata, N; Kinoshita, T; Kouno, T; Shibata, T; Shien, T; Shimizu, C; Terada, K; Yoshida, M; Yoshimura, K | 1 |
| Bailly, C; Baldeyrou, B; Beauchard, A; Besson, T; Chérouvrier, JR; Domon, L; Jaunet, A; Lansiaux, A; Murillo, L; Picot, L; Thiéry, V | 1 |
| Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM | 1 |
| Chao, J; Parker, BA; Zvaifler, NJ | 1 |
| Al-Sukhun, S; Chollet, P; Durando, X; Ferriere, JP; Mouret-Reynier, MA; Nabholtz, JM; Van Praagh, I | 1 |
| Chen, Y; Gonzalez-Angulo, A; Guggisberg, N; Hennessy, B; Jorda, M; Mills, GB; Slingerland, JM; Tan, CK | 1 |
| Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G | 1 |
| Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Wenz, F | 1 |
| Bae, K; Budd, GT; Carey, LA; Commean, P; Ellis, MJ; Esserman, LJ; Fleming, GF; Giuntoli, T; Harris, LA; Leight, GS; Luo, J; Marcom, PK; Olson, JA | 1 |
| Mazur, L; Mendyk, E; Pachuta-Stec, A; Pitucha, M; Rzaczyńska, Z; Rzymowska, J | 1 |
| Aebi, S; Gelber, RD | 1 |
| Calabrich, A; Katz, A; Saad, ED | 1 |
| Gerber, B; Reimer, T | 1 |
| Berruti, A; Buttigliero, C; Dogliotti, L | 1 |
| Dong, PW; Li, LN | 1 |
| Agrawal, A; Aleskandrany, M; Cheung, KL; Ellis, IO; Green, AR; Hassell, K; Morgan, DA; Okunade, G; Paish, EC; Winterbottom, L; Ying, M | 1 |
| Ando, M; Baba, S; Dokiya, F; Douchi, T; Kosha, S; Matsuyama, Y; Ohi, Y; Rai, Y; Sagara, Y; Tamada, S | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN | 1 |
| Fischgräbe, J; Götte, M; Kiesel, L; Radke, I; Smollich, M; Wülfing, P | 1 |
| Ejlertsen, B; Evans, DB; Henriksen, KL; Lykkesfeldt, AE; Mouridsen, HT; Møller, S; Rasmussen, BB; Sasano, H | 1 |
| Oktay, K; Rodriguez-Wallberg, K; Schover, L | 1 |
| Ayata, A; Bilgi, O; Kandemir, EG; Karagöz, B; Ozgün, A; Türken, O; Unal, M; Uzun, G | 1 |
| Barisik, NO; Bilici, A; Gumus, M; Salepci, T; Salman, T; Seker, M; Ustaalioglu, BB; Yaylaci, M | 1 |
| Ang, BW; Cheng, CL; Chou, N; Lee, KM; Lee, SC; Wong, AL | 1 |
| Alberts, DS; Bartels, HG; Bartels, PH; Montironi, R; Scarpelli, M | 1 |
| Baxa, SE; Fabian, CJ; Khan, QJ; Kimler, BF; Klemp, JR; O'Dea, AP; Reddy, PS; Sharma, P | 1 |
| Keating, GM | 1 |
| Bachleitner-Hofmann, T; Blaha, P; Dubsky, P; Fitzal, F; Gnant, M; Jakesz, R; Steger, G | 1 |
| Anderson, J; Chen, YY; Chin, K; DeVries, S; Esserman, LJ; Hwang, ES; Lessing, J; Shim, V; Swain, R; Waldman, FM | 1 |
| Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B | 1 |
| Dewar, J; Ellis, MJ; Feltl, D; Lindemann, J; Llombart-Cussac, A; Macpherson, E; Robertson, JF; Rolski, J | 1 |
| Amakye, D; Bauerfeind, I; Buzdar, A; Chia, S; Chlebowski, R; Cutuli, B; Cuzick, J; Hadji, P; Linforth, R; Maass, N; Noguchi, S; Robidoux, A; Verma, S | 1 |
| Chen, L; Gao, Y; Gu, W; Li, Y; Zhang, Z | 1 |
| Kaide, A; Kodama, K; Matsuoka, J; Ootawa, Y; Ootsuka, N; Watanabe, N | 1 |
| Glück, S | 2 |
| Amir, E; Clemons, M; Cole, DE; Dowsett, M; Dranitsaris, G; Folkerd, E; Freedman, OC; Hanna, W; Kahn, H; O'Malley, F; Verma, S | 1 |
| Cuzick, J; Sapunar, F; Sestak, I | 1 |
| Noguchi, S; Taguchi, T | 1 |
| Baselga, J; Cortes, J | 1 |
| Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
| Bapsy, PP; Clemens, MR; Feyereislova, A; Jahn, M; Jones, A; Kaufman, B; Lehle, M; Mackey, JR; Révil, C; Tjulandin, S; Vaid, A; Wardley, A | 1 |
| Geisler, J; Lønning, PE | 3 |
| Lazarus, P; Sun, D | 1 |
| Caravelli, JF; Dang, C; Dickler, MN; Flombaum, CD; Fornier, M; Geneus, S; Grothusen, J; Hudis, CA; Lake, D; Melisko, ME; Norton, L; Park, JW; Patil, S; Paulson, M; Robson, M; Rugo, HS; Seidman, AD; Theodoulou, M; Traina, TA; Yeh, B | 1 |
| Kameda, N; Nihon-Yanagi, Y; Okazumi, S; Ueda, T | 1 |
| Bonanni, B; Cassano, E; Cazzaniga, M; Decensi, A; Gandini, S; Guerrieri-Gonzaga, A; Johansson, H; Lien, EA; Luini, A; Macis, D; Oldani, S; Pelosi, G; Serrano, D | 1 |
| Guarneri, V | 1 |
| Chen, S; Masri, S; Phung, S; Wang, X | 1 |
| Brites, MM; Figueiredo, A; Frutuoso, C; Saleiro, S; Santiago, F | 1 |
| Bremec, T; Demsar, J; Luzar, B; Pavlović, MD | 1 |
| Hirose, T; Honda, J; Kira, M; Nagao, T; Nakamura, Y; Sasa, M; Takahashi, M; Tangoku, A; Zembutsu, H | 1 |
| Joerger, M; Thürlimann, B | 1 |
| Dixon, JM; Hannon, R; Macaskill, EJ; McCaig, FM; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, O | 1 |
| Baumann, CK; Castiglione-Gertsch, M | 1 |
| Brodie, A; Chen, S; Fischgräbe, J; Götte, M; Kiesel, L; Macedo, LF; Radke, I; Smollich, M; Wülfing, P | 1 |
| Botteman, MF; Heeg, BMS; Kaura, S; Logman, JFS; van Hout, BA | 1 |
| Auboire, L; Landy, S; Le Hello, C; Maïza, D; Perrot, JY | 1 |
| Cigler, T; Findlay, B; Goss, PE; Hu, H; Johnston, D; Qi, S; Richardson, H; Tu, D; Verma, S; Yaffe, MJ | 1 |
| Babayev, SN; Barad, D; Kim, JY; Oktay, K | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Chetty, U; Wishart, GC | 1 |
| Smith, IE | 6 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nishiyama, K | 1 |
| Bastit, L; Briot, K; Kloos, I; Roux, C; Tubiana-Hulin, M | 1 |
| Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Suzuki, S | 1 |
| Enomoto, T; Hayashi, K; Kondou, Y; Kosaka, Y; Kuranami, M; Sengoku, N; Sugiyama, N; Watanabe, M | 1 |
| Chen, S; Liu, Z; Masri, S; Phung, S; Wang, E; Yuan, YC | 1 |
| Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG | 1 |
| Alonso, A; Laenen, A | 1 |
| Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C | 1 |
| Atherton, PJ; Dakhil, SR; Dalton, RJ; Hines, SL; Johnson, DB; Loprinzi, CL; Mattar, BI; Perez, EA; Reddy, PS; Sloan, JA | 1 |
| Colleoni, M; Dellapasqua, S | 1 |
| A'hern, R; Anderson, H; Crowder, RJ; Dowsett, M; Dunbier, AK; Ellis, MJ; Folkerd, EJ; Ghazoui, Z; Hoog, J; Nerurkar, A; Osin, P; Parker, JS; Perou, CM; Smith, IE | 1 |
| Brodie, A; Sabnis, G | 1 |
| Recht, A | 1 |
| Azria, D; Belkacemi, Y; Coelho, M; Crompton, NE; Fenoglietto, P; Gourgou, S; Gutowski, M; Lemanski, C; Moscardo, CL; Ozsahin, M; Romieu, G; Rosenstein, B; Zaman, K | 1 |
| Albaladejo, CV; Almenar, S; Calatrava, A; Campos, J; Cervera-Deval, J; Climent, MA; Fernandez-Serra, A; Garcia-Casado, Z; Gavila, J; Guerrero-Zotano, A; Guillem, V; Llombart-Bosch, A; Llombart-Cussac, A; Lopez-Guerrero, JA; Ruiz-Simon, A | 1 |
| Apatira, A; Brandt, R; Chang, B; Chua, J; Ding, P; Duan, M; Franci, C; Goff, D; Heckrodt, TJ; Hitoshi, Y; Holland, SJ; Hu, Y; Li, W; Pan, A; Payan, DG; Pine, P; Singh, R; Torneros, A; Yu, J; Zhang, J | 1 |
| Akli, S; Biernacka, A; Bui, T; Hunt, KK; Keyomarsi, K; Moulder, S; Tucker, SL; Wingate, H | 1 |
| Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS | 1 |
| Coleman, RE; Holen, I; Neville-Webbe, HL | 1 |
| Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
| Beriwal, S; Bhargava, R; Dabbs, DJ; O'Connor, SM | 1 |
| Baehner, FL; Baum, M; Bugarini, R; Buzdar, A; Cuzick, J; Dowsett, M; Dunbier, A; Forbes, J; Howell, A; Mallon, EA; Quinn, E; Salter, J; Shak, S; Wale, C | 1 |
| Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C | 1 |
| Adamietz, B; Beckmann, MW; Buchholz, S; Dall, P; Dilbat, G; Fasching, PA; Haeberle, L; Hein, A; Heinrich, S; Heusinger, K; Jud, SM; Lex, B; Loehberg, CR; Rauh, C; Reichler, B; Rix, N; Schulz-Wendtland, R | 1 |
| Morimoto, N; Shibaki, T | 1 |
| Crossley, M; Lejbak, L; Vrbancic, M | 1 |
| Batzler, A; Buzdar, AU; Desta, Z; Flockhart, DA; Goetz, MP; Ingle, JN; Northfelt, DW; Olson, JE; Perez, EA; Robson, ME; Schaid, DJ; Weinshilboum, RM; Weintraub, RA; Williard, CV | 1 |
| Cai, RG; Li, Q; Ma, F; Wang, JY; Xu, BH; Yao, SY; Yuan, P; Zhang, P | 1 |
| Oktay, K; Rodriguez-Wallberg, KA; Türkçüoğlu, I | 1 |
| Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Stephens, A; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Dowsett, M; Evans, AH; Evans, DB; Farmer, I; Johnston, SR; Martin, LA; Pancholi, S; Thornhill, A | 1 |
| Beckmann, MW; Benedict, A; Buchholz, S; Distler, W; Hadji, P; Harbeck, N; Jonat, W; Kaufmann, M; Kreienberg, R; Kreif, N; Lux, MP; Possinger, K; Raab, G; Schneeweiss, A; Tesch, H; Weyers, G; Wöckel, A | 1 |
| Abe, H; Aihara, T; Aogi, K; Hisamatsu, K; Hozumi, Y; Imoto, S; Ito, T; Iwata, H; Masuda, N; Mitsuyama, S; Mukai, H; Nakagami, K; Ogino, N; Ohashi, Y; Ohsumi, S; Shimizu, C; Takatsuka, Y; Tamura, M; Tanaka, S; Watanabe, T; Yamaguchi, T | 1 |
| Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Jung, SY; Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J | 1 |
| Fox, KR | 1 |
| Baiardi, P; Chiorino, G; Costa, A; Da Prada, GA; Fregoni, V; Ghimenti, C; Grosso, E; Marsoni, S; Mello-Grand, M; Miller, WR; Regolo, L; Scatolini, M; Singh, V; Villani, L; Zambelli, A | 1 |
| Bundred, N; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Llombart-Cussac, A; Miller, J; Neven, P; Schenk, N; von Minckwitz, G | 1 |
| Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Plísek, J; Solichová, D; Studentová, H | 1 |
| Devine, S; Sedjo, RL | 1 |
| Chen, S; Evans, D; Kijima, I; Ye, J | 1 |
| Amonkar, MM; Forbes, CA; Kessels, A; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Cuzick, J; Distler, W; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Goodwin, PJ; Pritchard, KI | 1 |
| Bouboukas, G; Kalofonos, H; Koutras, A; Makatsoris, T; Onyenadum, A; Peroukides, S; Starakis, I | 1 |
| Fang, L; He, Z; Li, L; Liu, Y; Sun, Y; Wang, M; Xu, X; Zhao, N | 1 |
| Curran, MP | 1 |
| Abe, Y; Ishida, J; Moriya, T; Omata, J; Osaki, A; Saeki, T; Shigekawa, T; Tamura, K; Tsuda, H; Ueda, S; Yamamoto, J | 1 |
| Bertolini, E; Letho-Gyselinck, H; Prati, C; Wendling, D | 1 |
| Kaminsky, A; Khalid, MK; Labban, G; Parda, D; Trombetta, MG; Valakh, V; Werts, ED | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Iorfida, M; Luini, A; Montagna, E; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Alexandrou, P; Dimitroulis, D; Kostakis, A; Kykalos, S; Mantas, D | 1 |
| Larionov, A; Miller, WR | 1 |
| Mouridsen, HT | 3 |
| Chen, LR | 1 |
| Bender, C; Blair-Belansky, H; Moore, PJ; Terhorst, L | 1 |
| Arun, B; Carlson, RW; Chiv, VY; Chung, CT; Dice, K; Green, M; Phan, SC; Rivera, E; Schurman, CM; Theriault, R; Valero, V | 1 |
| Agrawal, K; Mortimer, JE; Onami, S; Pal, SK | 1 |
| Anderson, TJ; Dixon, JM; Evans, DB; Larionov, A; Miller, WR | 1 |
| Balja, MP; Knezević, F; Sitić, S; Stanec, M; Supić, DK; Vrdoljak, DV | 1 |
| Bianco, AR; Clack, G; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Wells, M | 1 |
| Bernreuter, WK; Bland, KI; Carpenter, JT; Caterinicchia, V; De Los Santos, JF; Falkson, CI; Forero-Torres, A; Galleshaw, JA; Jones, CF; Krontiras, H; Li, Y; LoBuglio, AF; Meredith, RF; Nabell, LM; O'Malley, JP; Percent, IJ; Saleh, MN; Shah, JJ; Urist, MM | 1 |
| Karato, M; Matsui, K; Nagata, T; Shimada, Y; Tazawa, K; Tsukada, K | 1 |
| Markopoulos, C | 1 |
| Beer, B; Hubalek, M; Meraner, V; Oberacher, H; Oberguggenberger, A; Schubert, B | 1 |
| Delea, TE; Guo, A; Lipsitz, M | 1 |
| Jiao, J; Liao, Q; Xiang, H | 1 |
| Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B | 2 |
| Abe, M; Kiniwa, M; Matsuo, K; Nakagawa, F; Noguchi, S; Nukatsuka, M; Saito, H; Shibata, J; Uchida, J | 1 |
| Dixon, JM; Dixon, OM; Fallowfield, LJ; Langridge, C; Macaskill, EJ; McCaig, F; McHugh, M; Murray, J; Renshaw, L; Williams, L; Young, OE | 1 |
| Agrawal, A; Cheung, KL; Dowsett, M; Folkerd, E; Robertson, JF; Winterbottom, L | 1 |
| Bonetti, M; Cole, BF; Gelber, RD; Lazar, AA | 1 |
| Adachi, JD; Gordon, C; Papaioannou, A; Szabo, KA; Tozer, R; Webber, CE | 1 |
| Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM | 1 |
| Mylander, WC; Rosman, M; Tafra, L | 1 |
| Ewart, EK; Krell, J; Stebbing, J | 1 |
| Amant, F; Berteloot, P; Blomme, C; De Jonge, E; Depypere, H; Neven, P; Timmerman, D; Van Calster, B; Van de Putte, G; Van den Broecke, R; Van Ginderachter, J; Van Huffel, S; Vergote, I; Vlaemynck, G; Vlasselaer, J | 1 |
| Facina, G; Gebrim, LH; Logullo, AF; Mattar, A; Nonogaki, S; Soares, FA | 1 |
| Buzdar, AU; Kelly, CM | 2 |
| Adams, J; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Howell, A; Mackey, J | 1 |
| Chen, Z; Feng, J; Gu, K; Jiang, Z; Shao, Z; Song, S; Wang, C; Wang, J; Xu, B; Yang, J; Yu, S; Zhang, F; Zhang, Y | 1 |
| Chan, MS; Chanplakorn, N; Chow, LW; Loo, WT; Sasano, H; Toi, M; Yiu, CC | 1 |
| Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M | 1 |
| Chetver, L; Hussein, O; Zidan, J; Zucker, M | 1 |
| Belkacemi, Y; Bese, N; Boussen, H; Gligorov, J; Koukourakis, MI; Kuten, A; Tsoutsou, PG | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Sun, Z; Thompson, A; Thürlimann, B | 1 |
| Oktay, K; Rodriguez-Wallberg, KA | 1 |
| Tang, SC | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nagase, H; Noguchi, S | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Sestak, I | 1 |
| Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
| Gnant, M | 1 |
| Iwata, H | 1 |
| Fujimoto, A; Goto, K; Ichinose, Y; Kobayashi, T; Sasaoki, T; Uchida, S | 1 |
| Cochrane, RA; Davie, MW; Powell, DE | 1 |
| Desta, Z; Flockhart, DA; Jeter, S; Kadlubar, SA; Kamdem, LK; Liu, Y; Ogburn, E; Ramirez, J; Ratain, MJ; Shahverdi, K; Stearns, V; Ward, BA | 1 |
| Chakravarty, D; Challa, R; Cortez, V; Nair, BC; Tekmal, RR; Vadlamudi, RK; Vallabhaneni, S | 1 |
| Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Amano, S; Enomoto, K; Sakurai, K | 1 |
| Kawachi, H; Kubota, K; Kuwayama, T; Nakagawa, T; Oda, G; Sato, T; Sugihara, K; Yamamoto, K | 1 |
| Christiaens, MR; De Smet, L; Dieudonné, AS; Henry, NL; Leunen, K; Lintermans, A; Morales, L; Neven, P; Pans, S; Paridaens, R; Timmerman, D; Van Calster, B; Van Hoydonck, M; Vergote, I; Verhaeghe, J; Verschueren, K; Westhovens, R; Wildiers, H | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Koyama, H; Motomura, K; Nakahara, S | 1 |
| Komina, O; Maurer, M; Składanowski, A; Wesierska-Gadek, J | 1 |
| Aihara, T; Hozumi, Y; Masuda, N; Ohashi, Y; Ohsumi, S; Saito, T; Suemasu, K; Takehara, M; Takei, H | 2 |
| Järhult, J | 1 |
| Coşkun, U; Oktay, K; Sönmezer, M; Türkçüoğlu, I | 1 |
| Ahmad, I; Chhikara, BS; Kumar, A; Mandal, D; Parang, K; Tiwari, R | 1 |
| Crowe, S; Jost, L; Koeberle, D; Oehlschlegel, C; Pagani, O; Pilop, C; Ruhstaller, T; Thuerlimann, B; von Moos, R; Zaman, K | 1 |
| Chirgwin, J; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, R; Pienkowski, T; Price, KN; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Anderson, H; Buffa, FM; Detre, S; Dexter, T; Dowsett, M; Dunbier, AK; Ghazoui, Z; Harris, AL; Salter, J; Smith, IE | 1 |
| Coates, AS; Colleoni, M; Dell'Orto, P; Forbes, JF; Gelber, RD; Goldhirsch, A; Gusterson, BA; Láng, I; MacGrogan, G; Maiorano, E; Mastropasqua, MG; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Anderson, H; Arteaga, CL; Balko, JM; Dowsett, M; Dunbier, A; Ghazoui, Z; González-Angulo, AM; Miller, TW; Miller, WR; Mills, GB; Shyr, Y; Wu, H | 1 |
| Aihara, T; Hozumi, Y; Mukai, H; Ohashi, Y; Ohsumi, S; Shimozuma, K; Shinji, M; Takatsuka, Y | 1 |
| Chen, ZG; Cheng, ZY; Li, WJ; Liu, SF | 1 |
| Chen, K; Chen, X; Gao, H; Kiesewetter, D; Lang, L; Niu, G; Quan, Q; Sun, X; Yan, Y; Yang, M | 1 |
| Doughty, JC | 2 |
| Geisler, J | 2 |
| Tannock, IF | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| Maharramov, A; Ramazanov, MA; Saboktakin, MR; Tabatabaie, RM | 1 |
| Chen, S; Hong, Y; Rashid, R | 1 |
| Brodie, AM; Chumsri, S; Howes, T; Sabnis, GJ | 1 |
| Bu, H; Ni, YB; Yang, WJ; Zheng, H | 1 |
| Deshpande, PB; Karthik, A; Kumar, AR; Nayak, UY; Reddy, MS; Shavi, GV; Udupa, N | 1 |
| Arun, B; Brown, PH; Castiglione, M; Cuzick, J; DeCensi, A; Dunn, B; Forbes, JF; Glaus, A; Howell, A; Vogel, V; von Minckwitz, G; Zwierzina, H | 1 |
| Hong, SH; Jeong, J; Kim, SY; Lee, H; Lee, KS; Lee, YS; Nam, BH; Park, IH; Ro, J | 1 |
| Anderson, H; Dowsett, M; Dunbier, AK; Ghazoui, Z; Parker, JS; Perou, CM; Salter, J; Smith, IE | 1 |
| Bagalà, C; Barone, C; Basso, M; Cerchiaro, E; D'Argento, E; Inno, A; Marsico, VA; Vecchio, FM | 1 |
| Buzdar, AU; Cuzick, J; Dowsett, M; Forbes, J; Howell, A; Mallon, E; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Johnston, S; Martin, LA; Pancholi, S; Weigel, MT | 1 |
| Ganapathy, M; Kirma, NB; Nair, HB; Tekmal, RR; Vadlamudi, RK | 1 |
| Baigent, A; Lashen, H | 1 |
| Coombes, RC; Dowsett, M; Folkerd, EJ; Palmieri, C; Purohit, A; Reed, MJ; Stanczyk, FZ; Stanway, SJ; Ward, R | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, J; Xu, B; Yao, S; Yuan, P; Zhang, P | 1 |
| Bjelic-Radisic, V; Dubsky, P; Fesl, C; Gnant, M; Greil, R; Königsberg, R; Marth, C; Mlineritsch, B; Pfeiler, G; Pöstlberger, S; Samonigg, H; Seifert, M; Singer, CF; Steger, GG; Stoeger, H; Taucher, S | 1 |
| Allred, DC; Babiera, GV; DeSchryver, K; Ellis, MJ; Esserman, LJ; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Lin, L; Luo, J; Marcom, PK; Margenthaler, J; Olson, JA; Parker, JS; Prat, A; Snider, J; Suman, VJ; Unzeitig, GW; Watson, MA | 1 |
| Bighin, C; Del Mastro, L; Giraudi, S; Lambertini, M; Levaggi, A; Pronzato, P | 1 |
| Alappat, RM; Heytens, E; Lee, S; Moy, F; Oktay, K; Ozkavukcu, S | 1 |
| Landherr, L; Mészáros, E; Nagykálnai, T | 1 |
| Gelber, RD; Giobbie-Hurder, A; Price, KN; Regan, MM; Thürlimann, B | 1 |
| Anan, K; Doihara, H; Ikeda, T; Kimura, M; Komaki, K; Kusama, M; Mitsuyama, S; Yanagita, Y | 1 |
| Bauernhofer, T; Dubsky, P; Eidtmann, H; Eiermann, W; Fesl, C; Forsthuber, EP; Gnant, M; Greil, R; Heck, D; Hochreiner, G; Hubalek, M; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pristauz, G; Seifert, M; Steger, G; Stoeger, H | 1 |
| Gallicchio, L; Helzlsouer, KJ; Macdonald, R; Rushovich, E; Wood, B | 1 |
| Abrhale, T; Brodie, A; Macedo, L; Sabnis, G; Serrero, G; Tian, C; Yue, B | 1 |
| Arrowsmith, E; Barton, J; Burris, HA; Clark, BL; Hainsworth, JD; Rubin, M; Shipley, D; Yardley, DA | 1 |
| Armamento-Villareal, R; Ellis, MJ; Gao, F; Jamalabadi-Majidi, S; Napoli, N; Rastelli, AL; Taylor, ME | 1 |
| Alés-Martínez, JE; Alvarez, I; Andrés, R; Antolín, S; Antón, A; Barnadas, A; Cámara, C; Carrasco, E; Casas, I; García Saenz, JA; Lao, J; Llombart-Cussac, A; Martín, M; Ruiz, A | 1 |
| Bathini, V; Buttar, A; Khan, A; Mittal, K | 1 |
| Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC | 1 |
| Allawi, Z; Baum, M; Cuzick, J | 1 |
| Andrade, VP; Arroyo, CD; Brogi, E; King, TA; Mo, Q; Morrogh, M; Morrow, M; Patil, AJ; Qin, LX; Sakr, R | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Cushman, M; Flockhart, DA; Lu, WJ; Mayhoub, AS; Pei, Z; Xu, C | 1 |
| Jin, CH; Kim, DK; Nam, JS; Park, CY; Sheen, YY; Son, JY | 1 |
| Azim, HA; Barsoum, M; Baumgärtner, AK; Beckmann, MW; Fasching, PA; Harbeck, N; Huober, J; Kubista, E; May, C; Nimmrich, I; Paepke, S; Petruzelka, L; Ragosch, V; Reimer, T; Thomssen, C; Wallwiener, D | 1 |
| Dixon, J; Dixon, JM; Renshaw, L; Thomas, J | 1 |
| Acton, G; Alyasova, A; Bondarenko, I; Chau, A; Erlandsson, F; Ibrahim, NK; Jones, D; Komisarenko, V; Manikhas, A; Murray, JL; Pegram, M; Semiglazov, V; Senderovich, S; Shparyk, Y; Yariz, KO | 1 |
| Glück, S; Gorouhi, F | 1 |
| Armstrong, DK; Blackford, AL; Byrne, C; Davidson, NE; Donehower, MG; Dowsett, M; Emens, LA; Fetting, JH; Folkerd, E; Garrett-Mayer, E; Jeter, SC; Khouri, NF; Powers, PP; Prowell, TM; Skaar, TC; Stearns, V; Tarpinian, KS; Wolff, AC; Wright, LA | 1 |
| Bonnefoi, H; Chirgwin, J; Coates, AS; Ejlertsen, B; Goldhirsch, A; Price, KN; Regan, MM; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Li, AY; Sun, Y; Wang, G; Wang, S; Yang, D; Zhao, Y | 1 |
| Ciruelos Gil, EM; Fernández Martínez, R; Fernández Pérez, I; Garcerá Juan, S; Illarramendi Mañas, JJ; Iranzo González Cruz, V; Lao Romera, J; Peláez Fernández, I; Puertolas Hernández, TJ; Sampedro Gimeno, T | 1 |
| Cruz Jurado, J; Fernández Martínez, R; Galve Calvo, E; García Mata, J; García Palomo, A; Murillo Jaso, L; Peláez Fernández, I; Polo Marqués, E; Richart Aznar, P; Sampedro Gimeno, T | 1 |
| Alba Conejo, E; Bayo Calero, J; de la Cabeza Lomas Garrido, M; de la Haba Rodríguez, J; de Toro Salas, R; González Mancha, R; Martínez Guisado, A; Ruíz Borrego, M; Sánchez Muñoz, A | 1 |
| Champ, C; Gower-Thomas, K; Jones, M; Osborn, G; Vaughan-Williams, E | 1 |
| Bullen, C; Dalal, N; Ellenbogen, S; Tang, AC; Toumi, Z | 1 |
| Amador, DD; Font López, KC; Novoa Vargas, A | 1 |
| Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Hoffmann, E; Kamdem, LK; Kreutz, Y; Li, L; Nguyen, AT; Skaar, T; Stearns, V; Storniolo, AM; Tyndale, RF | 1 |
| Bedard, PL; Bradbury, I; Desmedt, C; Dixon, JM; Evans, DB; Haibe-Kains, B; Ignatiadis, M; Loi, S; Michiels, S; Miller, WR; Piccart, MJ; Singhal, SK; Sotiriou, C | 1 |
| Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G | 1 |
| Hurria, A | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Dowsett, M; Forbes, JF; Howell, A; Ring, A; Sestak, I | 1 |
| Bago-Horvath, Z; Böhm, G; Dubsky, P; Filipits, M; Gnant, M; Greil, R; Gruber, C; Haid, A; Jakesz, R; Jasarevic, Z; Jelen, A; Kemmerling, R; Pöstlberger, S; Rudas, M; Singer, CF | 1 |
| Amadloo, N; Ansari, M; Ashouri, Y; Hoseini, S; Mohammadianpanah, M; Mosalaei, A; Mosleh-Shirazi, MA; Nasrolahi, H; Omidvari, S; Tahmasebi, S; Talei, A | 1 |
| Aebi, S; Berthod, G; Brauchli, P; Genton, C; Giobbie-Hurder, A; Huober, J; Lüthi, J; Pagani, O; Schönenberger, A; Simcock, M; Thürlimann, B; Zaman, K | 1 |
| Iwaki, M; Mizumoto, K; Naito, E; Takeyama, M; Zako, M | 1 |
| Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP | 1 |
| Coates, AS; Ejlertsen, B; Forbes, JF; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Láng, I; Mauriac, L; Neven, P; Price, KN; Rabaglio, M; Regan, MM; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Schmidt, C | 1 |
| Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K | 1 |
| Brodie, A; Carboni, JM; Finckenstein, FG; Gottardis, MM; Greer, A; Haluska, P; Harrington, SC; Hou, X; Huang, F; Macedo, LF; Reeves, KA | 1 |
| Goss, PE; Jin, H; Shepherd, LE; Tu, D; Zhao, N | 1 |
| de Azambuja, E; Metzger-Filho, O | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Aydinli, K; Basgul, AY; Calay, Z; Dünder, I; Güdücü, N; Işçi, H | 1 |
| Barnadas, A; Estévez, LG; Lluch-Hernández, A; Rodriguez-Lescure, A; Rodriguez-Sanchez, C; Sanchez-Rovira, P | 1 |
| Balakrishnan, A; Ravichandran, D | 1 |
| Chino, A; Hirasaki, Y; Namiki, T; Ogawa, K; Okamoto, H; Ueda, K | 1 |
| Evans, DB; Hayashi, S; Kataoka, M; Kondoh, K; Mori, K; Moriya, Y; Sawada, N; Yamaguchi, Y; Yasuno, H | 1 |
| Baudry, K; Berthet, P; Bignon, YJ; Chabbert-Buffet, N; Chiesa, J; Clough, KB; Delaloge, S; Delnatte, C; Dreyfus, H; Dugast, C; Fricker, JP; Gesta, P; Gladieff, L; Lasset, C; Lemonnier, J; Lesur, A; Lortholary, A; Martin, AL; Mijonnet, S; Nogues, C; Prieur, F; Pujol, P; Roca, L; Tennevet, I; This, P; Vennin, P | 1 |
| Fritz, M; Kim, J; Mersereau, JE; Steiner, AZ | 1 |
| Bao, T; Blackford, AL; Stearns, V | 1 |
| Cohen, MH; Johnson, JR; Justice, R; Pazdur, R | 1 |
| Cai, RG; Li, Q; Lu, HH; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Akar, U; Arun, B; Brewster, A; Buzdar, AU; Esteva, FJ; Green, M; Gutierrez-Barrera, A; Hortobagyi, GN; Liu, D; Rivera, E; Sneige, N; Valero, V | 1 |
| Burkemper, NM; Crockett, JS | 1 |
| Akiyama, F; Fujiwara, Y; Ikeda, T; Imoto, S; Inaji, H; Iwata, H; Mitsuyama, S; Miyoshi, K; Noguchi, S; Takatsuka, Y; Tamura, M | 1 |
| Baniwal, SK; Berman, BP; Chimge, NO; Coetzee, S; Ellis, MJ; Frenkel, B; Khalid, O; Luo, J; Tripathy, D | 1 |
| Hawkins, N; Veenstra, D; Woods, B | 1 |
| Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
| Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I | 1 |
| Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N | 1 |
| Costantino, JP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; McDonnell, SK; Schaid, DJ; Sinnwell, JP; Weinshilboum, RM; Wickerham, DL | 1 |
| Fontein, DB; Liefers, GJ; Maartense, E; Meershoek-Klein Kranenbarg, E; Nortier, JW; Putter, H; Rutgers, EJ; van de Velde, CJ; van den Bosch, J | 1 |
| Bell, LN; Desta, Z; Flockhart, DA; Hayes, DF; Henry, NL; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Wolff, AC | 1 |
| Masmiquel Comas, L; Nicolau Ramis, J | 1 |
| Arai, T; Furukawa, H; Harada, H; Kamigaki, S; Miwa, H; Ooshiro, C; Yoneda, G | 1 |
| Cuzick, J; Howell, A; Mesher, D; Richmond, B; Singh, S | 1 |
| Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Ueda, Y | 1 |
| Ishiba, T; Kubota, K; Kuwayama, T; Nakagawa, T; Sato, T; Sugihara, K; Sugimoto, H | 1 |
| Bernardino, M; Coelho, AM; Diniz da Costa, AT; Jorge, CC; Lourenço, AV; Ribeirinho, AL | 1 |
| Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H | 1 |
| Bai, L; Lu, J; McEachern, D; Sun, H; Wang, S; Yang, CY | 1 |
| Aytemir, K; Canpolat, U; Kaya, EB; Oto, A; Sunman, H | 1 |
| Frederix, GW; Hövels, AM; Raaijmakers, JA; Schellens, JH; Severens, JL | 1 |
| Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Yanagita, Y | 1 |
| Burstein, HJ; Griggs, JJ | 1 |
| Bartsch, R; Dubsky, PC; Filipcic, L; Fitzal, F; Gnant, M; Greil, R; Haider, K; Jakesz, R; Kwasny, W; Luschin-Ebengreuth, G; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Sevelda, P; Singer, CF; Steger, GG; Stierer, M; Stöger, H; Taucher, S; Tausch, C | 1 |
| Carro, G; Harper, A; Hui, W; Lawton, J; Menas, P; Merkel, D | 1 |
| Buch, E; Carañana, V; Fuster Diana, C; Galán, A; Guerrero, Á; Guillem Porta, V; Llombart-Cussac, A; Rodríguez-Lescure, Á; Ruiz, A | 1 |
| Fukunaga, M; Horiguchi, J; Hozumi, Y; Ishikawa, T; Iwase, T; Kohno, N; Nakamura, S; Noguchi, S; Taguchi, T; Takahashi, M; Takahashi, S | 1 |
| Azzouz, F; Desta, Z; Flockhart, DA; Hayden, J; Hayes, DF; Henry, NL; Lemler, S; Li, L; Nguyen, AT; Stearns, V; Storniolo, AM; Tarpinian, K; Yakim, E | 1 |
| Ben-Aharon, I; Ben-Haroush, A; Farhi, J; Fisch, B; Pinkas, H; Sapir, O | 1 |
| Hata, K; Hirai, I; Tanaka, T; Tanino, H | 1 |
| Howell, A | 4 |
| Burkard, ME; Crone, E; Davis, LA; Gogineni, J; Hansen, KE; Shafer, MM; Tevaarwerk, A; Wisinski, KB | 1 |
| Fandzloch, M; Popławska, B; Sitkowski, J; Łakomska, I | 1 |
| Bergh, J; Brattström, D; Eiermann, W; Henriksson, R; Jönsson, PE; Lidbrink, EK; Lindemann, JP; Trudeau, M; Wiklund, F | 1 |
| Cuzick, J; Dowsett, M; Drury, S; Hayes, DF; Haynes, BP; Rae, JM; Salter, J; Sestak, I; Stearns, V; Thibert, JN | 1 |
| Kelly, CM; Pritchard, KI | 1 |
| Biasi, MO; Bouzyk, M; Coates, AS; Debled, M; Dell'orto, P; Ditzel, HJ; Gelber, RD; Goldhirsch, A; Kammler, R; Leyland-Jones, B; Lyng, MB; Maibach, R; Neven, P; Pagani, O; Price, KN; Rae, JM; Regan, MM; Tang, W; Thürlimann, B; Viale, G | 1 |
| Bartiromo, A; Botti, G; Buonfanti, G; Colantuoni, G; D'Aiuto, M; D'Aniello, R; Daniele, G; De Feo, G; De Laurentiis, M; De Maio, E; de Matteis, A; Di Bonito, M; Di Maio, M; Di Rella, F; Esposito, G; Gallo, C; Giordano, P; Gravina, A; Labonia, V; Landi, G; Lastoria, S; Maiolino, P; Morabito, A; Normanno, N; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rossi, E; Signoriello, S; Tinessa, V | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Hikino, H; Koike, M; Mukai, T; Murata, Y | 1 |
| Alkaied, H; Awasum, M; Brenner, A; Harris, K; Varma, S | 1 |
| Brown, M; Cuzick, J; Dowsett, M; Howell, A; Landberg, G; Lundgren, K; Pineda, S; Salter, J; Zabaglo, L | 1 |
| Airoud, K; Alfieri, RR; Andreis, D; Bertoni, R; Bonelli, MA; Bottini, A; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG; Tramonti, S | 1 |
| Andreopoulou, E; Axelrod, D; Carapetyan, K; Checka, C; Diflo, T; Dilawari, A; Guth, A; Muggia, F; Reich, E; Smith, J; Toth, H; Ursin, G; Utate, M | 1 |
| Cheng, FX; Fu, J; Li, WH; Liu, GX; Shen, ZH; Tang, Y | 1 |
| Brassesco, M; Carreras, R; Checa Vizcaíno, MA; Comadran, MG; Corchado, AR; Cuadri, ME | 1 |
| Cao, MZ; Gu, L; He, PQ; Jiang, ZF; Li, B; Li, HY; Liu, GY; Liu, JP; Liu, YH; Lou, LH; Ma, LW; Shao, ZM; Shen, ZZ; Su, FX; Sun, SR; Tang, JH; Tang, LL; Wang, S; Wang, SM; Wang, X; Wang, XJ; Yu, KD; Zhang, HW; Zhang, QY; Zheng, H; Zhou, Y | 1 |
| Aldridge, J; Bernhard, J; Cardoso, F; Coates, AS; Gelber, RD; Goldhirsch, A; Harvey, V; Pagani, O; Phillips, KA; Price, KN; Ribi, K; Thompson, A; Thürlimann, B | 1 |
| Di Leo, A; Malorni, L | 1 |
| Bane, F; Byrne, C; Conroy, RM; Gaora, PÓ; Hao, Y; Hill, AD; McBryan, J; McIlroy, M; O'Hara, J; Tibbitts, P; Vareslija, D; Young, LS | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Cuzick, J; Dowsett, M; Forbes, JF; Harvie, M; Howell, A; Sestak, I | 1 |
| Dowsett, M; Dunbier, A; Ghazoui, Z; Martin, LA; Pancholi, S; Weigel, MT | 1 |
| De La Fuente, M; Ertel, A; Jiao, X; Lisanti, MP; Pestell, RG; Pestell, TG; Velasco-Velázquez, M | 1 |
| Katano, M; Kubo, M; Kuroki, S; Ogawa, T; Okido, M; Onishi, H; Shimada, K; Tanaka, M; Umeda, S; Yokohata, K | 1 |
| Ito, Y | 1 |
| Haselden, J; Munot, K; Rajan, S | 1 |
| Hibino, M; Nakamura, M; Okuyama, M; Sasaki, Y; Tenma, K | 1 |
| Chen, S; Reddy, K; Smith, D; Wang, X; Wong, C | 1 |
| Kalyan, CS; Naresh, B; Pawar, SC; Priyamvada Devi, A; Setti, A; Venugopal Rao, V | 1 |
| Allred, DC; Babiera, GV; Ballman, K; Bose, R; Chang, LW; Chen, K; Crowder, R; Demeter, R; DeSchryver, K; Ding, L; Dooling, DJ; Du, F; Elhammali, A; Ellis, MJ; Esserman, L; Fulton, LL; Fulton, RS; Goiffon, RJ; Goldstein, TC; Guenther, JM; Harris, CC; Harrison, M; Hoog, J; Hunt, K; Kandoth, C; Koboldt, DC; Leitch, M; Ley, TJ; Lin, L; Lu, C; Luo, J; Maher, CA; Marcom, PK; Mardis, ER; Margenthaler, J; McDonald, S; McLellan, MD; McMichael, JF; Miller, CA; Ng, S; Oberkfell, B; Olson, J; Ota, D; Piwnica-Worms, D; Piwnica-Worms, H; Schierding, WS; Shen, D; Snider, J; Stuart, JM; Suman, VJ; Tao, Y; Unzeitig, G; Van Tine, BA; Vickery, TL; Wallis, JW; Watson, M; Weber, J; Wendl, MC; Wilson, RK | 1 |
| Bansal, VK; Singh, SK; Valyi-Nagy, T; Villano, JL; Wiley, EL | 1 |
| Bramati, A; Farina, G; Girelli, S; La Verde, N; Mihali, D; Moretti, A; Piva, S; Sburlati, P | 1 |
| Correa, PD; Han, S; Rizwanullah, M; Shrimali, RK | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C | 1 |
| Lee, S; Oktay, K | 1 |
| Brooks, JD; Dickler, MN; Goldfarb, SB; Jozefara, JE; King, V; Morris, EA; Nulsen, BF; Pike, MC; Sung, JS | 1 |
| Mewar, D; Michael, B; Tunn, E; Williams, S | 1 |
| A'Hern, RP; Dixon, JM; Dowsett, M; Folkerd, EJ; Renshaw, L | 1 |
| Ligibel, JA; Winer, EP | 1 |
| Riedmann, EM | 1 |
| Aogi, K; Fujisawa, T; Fukuda, H; Inoue, K; Iwata, H; Kinoshita, T; Masuda, N; Nakamura, K; Shibata, T; Shien, T | 1 |
| Stanton, V | 1 |
| Abraham, J; Caldas, C; Pharoah, PD | 1 |
| Cox, NJ; Flockhart, DA; Kroetz, DL; McLeod, HL; Nakamura, Y; Ratain, MJ | 1 |
| Albain, KS; Barlow, WE; Dakhil, SR; Gralow, JR; Hayes, DF; Hortobagyi, GN; Lew, DL; Livingston, RB; Mehta, RS; Tirumali, NR; Vandenberg, TA | 1 |
| Bjerre, K; Ejlertsen, B; Giobbie-Hurder, A; Henriksen, KL; Laenkholm, AV; Larsen, MS; Lykkesfeldt, AE; Rasmussen, BB | 1 |
| Brodie, AH; Chumsri, S; Gilani, RA; Jaiswal, AK; Kazi, AA; Sabnis, G; Schech, AJ; Shah, P | 1 |
| Arteaga, CL; Balko, JM; Garraway, LA; Kuba, MG; Mayer, IA; Meszoely, IM; Miller, TW; Sanders, ME; Wagle, N | 1 |
| Chatziralli, IP; Moschos, MM; Zagouri, F; Zografos, GC | 1 |
| Cai, RG; Fan, Y; Li, J; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
| Ferk, F; Komina, O; Maurer, M; Składanowski, A; Węsierska-Gądek, J; Zulehner, N | 1 |
| Alimirah, F; Gupta, A; Mehta, R; Mehta, RG; Murillo, G; Peng, X; Wiehle, R | 1 |
| Gelber, RD; Goldhirsch, A | 1 |
| Moore, KA; Potter, JE | 2 |
| Hammersmith, KM; Nagra, PK; Nottage, JM; Rapuano, CJ; Turaka, K | 1 |
| Hayashi, N; Iwase, H; Iwata, H; Kamigaki, S; Kinoshita, T; Masuda, N; Nakamura, S; Nishimura, R; Noguchi, S; Sagara, Y; Takei, H; Tsuda, H; Yanagita, Y | 1 |
| Castonguay, A; Doucet, C; Juhas, M; Maysinger, D | 1 |
| Cameron, DA; Chavarri-Guerra, Y; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Perez, EA; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, T | 1 |
| Bachner, M; Brase, JC; Dietze, O; Dubsky, P; Filipits, M; Gehrmann, MC; Gnant, M; Greil, R; Jakesz, R; Klug, E; Kronenwett, R; Luisser, I; Mayr, D; Petry, C; Rudas, M; Schmidt, M; Sedivy, R; Singer, CF; Weber, KE | 1 |
| Bonnefoi, H; Coates, AS; Colleoni, M; Ejlertsen, B; Ewertz, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Gray, KP; Láng, I; Mouridsen, HT; Paridaens, RJ; Price, KN; Rabaglio, M; Regan, MM; Smith, IE; Thürlimann, B | 1 |
| Barrios, C; Bundred, N; Campbell, I; Coleman, R; Davidson, N; de Boer, R; Eidtmann, H; Forbes, J; Frassoldati, A; Llombart, A; Martin, N; Modi, A; Neven, P; Paija, O; Sleeboom, HP; von Minckwitz, G | 1 |
| Dean, A; Dewar, J; Ellis, MJ; Emerson, L; Feltl, D; Lindemann, JP; Llombart-Cussac, A; Robertson, JF; Rolski, J | 1 |
| Beer, B; Gamper, E; Giesinger, J; Holzner, B; Hubalek, M; Kemmler, G; Marth, C; Meraner, V; Oberacher, H; Oberguggenberger, AS; Schubert, B; Sperner-Unterweger, B; Sztankay, M | 1 |
| A'Hern, R; Dowsett, M; Evans, DB; Farmer, I; Ghazoui, Z; Guest, S; Johnston, SR; Lane, HA; Martin, LA; Pancholi, S; Ribas, R; Thornhill, AM; Weigel, MT | 1 |
| Magee, PJ; Rowland, I | 1 |
| Goss, PE; Ingle, JN; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Lintermans, A; Neven, P; Vanderhaegen, J | 1 |
| Copur, MS; Jabbour, M; Ramaekers, R | 1 |
| Tempfer, C | 1 |
| Aksoy, S; Altundag, K; Sendur, MA; Zengin, N | 1 |
| Goss, PE; Higgins, MJ; Liedke, PE | 1 |
| Inaji, H; Ishitobi, M; Komoike, Y; Nakahara, S; Ohsumi, S; Suzuki, O; Tomita, Y; Yagi, T; Yoshinami, T | 1 |
| Bighin, C; Bisagni, G; Bruzzi, P; Cavazzini, G; Clavarezza, M; Del Mastro, L; Garrone, O; Lastraioli, S; Lunardi, G; Mansutti, M; Marroni, P; Notaro, R; Piccioli, P; Ponzone, R; Porpiglia, M; Puglisi, F; Serra, M | 1 |
| Bell, R; Bell, RJ; Chirgwin, J; Cicuttini, F; Davies-Tuck, M; Davis, SR; Hanna, F; Wang, Y | 1 |
| De, G; Diener, M; Namjoshi, M; Wu, EQ; Xie, J; Yang, H | 1 |
| Chen, S; Chu, P; Kanaya, N; Kubo, M; Liu, Z; Nishimura, R; Okido, M; Osako, T; Petrossian, K; Shimada, K; Takahashi, M; Warden, C; Ye, J; Yuan, YC | 1 |
| Gildea, JJ; Wang, J; Yue, W | 1 |
| Armstrong, AC; Lee, RJ; Wardley, AM | 1 |
| Berkenblit, A; Bondarenko, I; Brincat, S; Chan, A; Chow, L; Cincotta, M; Fumoleau, P; Garin, AM; Guimaraes, RC; Hachemi, S; Hayes, DF; Kang, LL; Krygowski, M; Lazar, AA; Moore, L; Neskovic-Konstantinovic, Z; Strahs, A; Sun, Y; Wolff, AC | 1 |
| Horváth, Z | 1 |
| Chan, FL; Chen, S; Cheung, WH; Chow, S; Leung, LK; Li, F | 1 |
| Furukawa, N; Kasai, T; Kobayashi, H; Komeda, S; Washida, A | 1 |
| Castañeda, G; Muñoz, L; Rodríguez, J | 1 |
| Aomatsu, N; Asano, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kawajiri, H; Morisaki, T; Nakamura, M; Onoda, N; Takashima, T | 1 |
| Billen, J; Jans, I; Lintermans, A; Neven, P; Pauwels, S; Vanderschueren, D; Verhaeghe, J; Vermeersch, P | 1 |
| Clarke Hillyer, G; Crew, KD; Danaceau, J; Hershman, DL; Kalinsky, K; Maurer, MA; Neugut, AI; Rotsides, DZ | 1 |
| Vieira-Baptista, P | 1 |
| Bartlett, JM; Baselga, J; Dixon, JM; Loi, S; Michiels, S; Piccart, MJ; Sabine, VS; Sahmoud, T; Sims, AH; Singhal, SK; Sotiriou, C | 1 |
| Futsuhara, K; Kai, T; Kojima, M; Tabei, T; Takei, H; Takeuchi, H; Yoshida, T | 1 |
| Glück, S; Untch, M; von Minckwitz, G | 1 |
| Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R | 1 |
| Tung, N | 1 |
| Dixon, JM; Majdak-Paredes, E; Raine, C; Schaverien, MV | 1 |
| Blettner, M; Hadji, P; Harbeck, N; Jackisch, C; Kreienberg, R; Lück, HJ; Windemuth-Kieselbach, C; Zaun, S | 1 |
| Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH | 1 |
| Cheng, J; Lei, L; Liu, G; Pan, L; Shao, Z; Sun, Y; Wang, X; Xu, J; Zhang, Y | 1 |
| Köberle, D; Thürlimann, B | 2 |
| Goss, PE; Smith, RE | 1 |
| Cummings, FJ | 1 |
| Assikis, VJ; Buzdar, A | 1 |
| Braun, S; Browman, GP; Burstein, HJ; Chlebowski, RT; Cobleigh, MA; Edge, SB; Goldstein, LJ; Gralow, J; Hudis, C; Ingle, JN; Langer, AS; Mamounas, EP; Perotti, J; Powles, TJ; Pritchard, KI; Whelan, TJ; Winer, EP | 1 |
| Bajetta, E; Bombardieri, E; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Pozzi, P; Salvucci, G; Seregni, E; Zilembo, N | 1 |
| Burton, G; Buzdar, A; Come, S; Dimery, I; Elledge, R; Ellis, M; Gertler, SZ; Jones, SE; May, JT; Morris, C; Osborne, CK; Parker, LM; Pippen, J; Webster, A | 1 |
| Aschermannova, A; Erikstein, B; Howell, A; Kleeberg, UR; Mauriac, L; Morris, C; Quaresma Albano, J; Robertson, JF; Vergote, I; Webster, A | 1 |
| Anderson, TJ; Dixon, JM; Miller, WR; Sahmoud, T; Stuart, M | 1 |
| Nabholtz, JM; Reese, D | 1 |
| Berruti, A; Dogliotti, L; Familiari, U; Gorzegno, G; Sperone, P | 1 |
| Bramwell, V; Vandenberg, T; Winquist, E | 1 |
| Enomoto, K; Kinoshita, T; Nishimura, M; Okamura, Y; Oura, S; Sakurai, T; Yokochi, H | 1 |
| Baum, M | 5 |
| Bruntsch, U | 1 |
| Mokbel, K | 3 |
| Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF | 1 |
| Beat, T | 1 |
| Atalay, G; Cardoso, F; Piccart, MJ | 1 |
| Vergote, I | 1 |
| McClellan, MB | 1 |
| Faulds, DM; Wellington, K | 1 |
| Basu, S; Last, A; Shinkfield, M | 1 |
| Dixon, JM; Miller, WR; Sahmoud, T; Stuart, M | 1 |
| Anderson, TJ; Dixon, JM; Miller, WR | 1 |
| Mokbel, K; Singh-Ranger, G | 2 |
| Robertson, JF | 1 |
| Jordan, VC | 2 |
| Stasi, R; Terzoli, E | 1 |
| Thornton, H | 3 |
| Adachi, I; Ikeda, T; Ohashi, Y; Sasaki, Y; Suwa, T; Tabei, T; Takatsuka, Y; Toi, M; Tominaga, T | 1 |
| Chiba, N; Mori, K; Yamamoto, Y; Yonekawa, H | 1 |
| Coleman, RE | 1 |
| Kalofonos, HP; Karamanos, NK; Kletsas, D; Mitropoulou, TN; Tzanakakis, GN | 1 |
| De Hoog, GS; Hatemi, G; Kantarcioğlu, AS; Mandel, NM; Yücel, A | 1 |
| Aumiller, J | 3 |
| Davidson, NE; Visvanathan, K | 1 |
| Martín de Vidales, C; Pérez-Torrubia, A; Zapatero, A | 1 |
| Jones, T; Karnon, J | 1 |
| Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y | 1 |
| Okamura, Y; Sakurai, T; Shimizu, Y; Suzuma, T; Umemura, T; Yang, QF; Yoshimura, G | 1 |
| Ali, SM; Brady, C; Carney, W; Chaudri-Ross, HA; Demers, L; Harvey, HA; Leitzel, K; Lipton, A; Wyld, P | 1 |
| Anderson, TJ; Cameron, D; Dixon, JM; Macfarlane, L; Miller, WR | 1 |
| Buzdar, A | 2 |
| Campos, SM; Winer, EP | 1 |
| Gertler, SZ; Mauriac, L; Osborne, CK; Pippen, JE; Quaresma Albano, J | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Bhatnagar, A; Boni, C; Chaudri-Ross, H; Dank, M; Gershanovich, M; Jaenicke, F; Lang, R; Monnier, A; Mouridsen, H; Perez-Carrion, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Sun, Y; Wyld, P | 1 |
| Brown, P; Wu, K | 1 |
| Berstein, LM; Harada, H; Lykkesfeldt, AE; Naftolin, F; Santen, RJ; Shanabrough, M; Wang, JP; Yue, W; Zheng, H | 1 |
| Dranitsaris, G; Trudeau, M; Verma, S | 1 |
| Casanovas, J; Milla, L; Milla-Santos, A; Pons, M; Portella, J; Puig-Gali, M; Rallo, L; Rodes, E | 1 |
| Dimmer, C; Goodare, H; Page, K | 1 |
| Burton, G; Kleeberg, U; Mauriac, L; Osborne, CK; Robertson, JF; Vergote, I | 1 |
| Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M | 1 |
| Höffken, K; Sayer, HG | 1 |
| Buzdar, A; Come, SE; Ellis, M; Gertler, S; Howell, A; Jones, SE; Kleeberg, UR; Mauriac, L; Morris, C; Osborne, CK; Robertson, JF; Vergote, I; Webster, A | 1 |
| Baum, M; Buzdar, A | 1 |
| Rocchi, A; Verma, S | 2 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Thürlimann, B | 2 |
| Bhatnager, A; Geisler, J; Lønning, PE | 1 |
| Brodie, AH; Mouridsen, HT | 1 |
| Rose, C | 2 |
| Dowsett, M; Ellis, MJ | 1 |
| Thomas, R | 1 |
| Dixon, JM; Jackson, J; Miller, WR | 1 |
| Carlini, P; Cognetti, F; Colella, E; Di Cosimo, S; Fabi, A; Ferretti, G; Frassoldati, A; Papaldo, P; Romiti, A; Ruggeri, EM; Tomao, S; Tonachella, R | 1 |
| Eckhardt, S | 1 |
| Cuzick, J; Forbes, J; Howell, T; O'Neill, C | 1 |
| Hazini, A; Pietropaolo, M; Repetto, L; Rosso, R; Sestini, A; Vannozzi, O | 1 |
| Gershanovich, M; Mouridsen, H | 1 |
| Lønning, P; Martoni, A; Pfister, C; Zamagni, C | 1 |
| Kmietowicz, Z | 1 |
| Carlson, RW; Henderson, IC | 1 |
| Aapro, MS; Forbes, JF | 1 |
| Hortobagyi, GN | 1 |
| Bryant, J; Wolmark, N | 1 |
| Burstein, HJ | 1 |
| Abrams, JS; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Therasse, P; Tu, D | 1 |
| Baird, A; Bross, PF; Chen, G; Jee, JM; Lostritto, RT; Morse, DE; Pazdur, R; Rahman, A; Rosario, LA; Williams, G; Williams, GM; Yang, P | 1 |
| Ben Ayed, F; Burdette-Radoux, S; Caicedo, JJ; Chaudri-Ross, HA; Davidson, N; Gershanovich, M; Gervasio, H; Johnson, S; Lang, R; Manikhas, G; Pluzanska, A; Rose, C; Thomas, R; Vtoraya, O | 1 |
| Chaudri-Ross, HA; Coop, A; Ellis, MJ; Evans, DB; Jänicke, F; Llombart-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B; Tao, Y | 1 |
| Gerber, B | 1 |
| Glendenning, A; Johnston, SR; Jones, T; Karnon, J | 1 |
| Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Milella, M; Papaldo, P; Ruggeri, EM | 1 |
| Fleming, GF | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, J; Houghton, J; Howell, A; Sahmoud, T | 1 |
| Hobson, K | 1 |
| Baum, M; Buzdar, A; Howell, A | 1 |
| Dixon, JM; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Dressman, H; Ellis, MJ; Marks, J; Rosen, E | 1 |
| Nabholtz, JM | 2 |
| Fallowfield, L; Howell, T; Jenkins, V; Shilling, V | 1 |
| Chow, LW; Toi, M; Wong, JL | 1 |
| Levenson, D | 1 |
| Bhatnagar, AS; Dixon, JM; Dowsett, M; Haynes, BP; Miller, WR | 1 |
| Twombly, R | 1 |
| Davidson, NE; Emens, L; Visvanathan, K | 1 |
| Pritchard, KI | 2 |
| Brodie, AH; Mouridsen, HT; Rose, C; Smith, IE | 1 |
| Bianco, AR; Clack, G; Coibion, M; Cuzick, J; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 1 |
| Altundag, K; Altundag, O | 1 |
| Runowicz, CD | 1 |
| Buzdar, A; Jones, D; Simons, WR | 1 |
| Howell, A; Robertson, JF; Vergote, I | 1 |
| DeGrendele, H | 1 |
| Howell, A; Mauriac, L; Osborne, CK | 1 |
| Goss, PE; Strasser-Weippl, K | 1 |
| Fallowfield, L; Howell, A; Hutton, S; Jenkins, V; Shilling, V | 1 |
| Aihara, T; Morino, H; Munakata, S; Takatsuka, Y | 1 |
| Cheung, KL; Forward, DP; Jackson, L; Robertson, JF | 1 |
| Kammerer, S | 1 |
| Eiermann, W | 1 |
| Hietanen, P; Mäkelä, M | 1 |
| Shahab, N | 1 |
| Harris, SR | 1 |
| Hellman, D; Hellman, S | 1 |
| Domont, J; Khayat, D; Namer, M; Spano, JP | 1 |
| Wilkinson, K | 1 |
| Kawakami, M; Saji, S; Toi, M | 1 |
| Ellis, MJ | 1 |
| Dixon, JM | 2 |
| Curran, MP; McKeage, K; Plosker, GL | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Long, BJ; MacPherson, N; Ragaz, J; Thiantanawat, A | 1 |
| Baron, M; d'Anjou, J; Dessogne, P | 1 |
| Campos, SM | 1 |
| Armeanu, S; Fersis, N; Friedrich, M; Gagulic, E; Pantic, L; Relakis, K; Smyczek-Gargya, B; Wallwiener, D | 1 |
| Altundag, K; Oyan, B; Ozisik, Y | 1 |
| Arora, A; Potter, JF | 1 |
| Baum, M; Bianco, R; Buzdar, A; Coleman, R; Constenla, M; Cuzick, J; Distler, W; Dowsett, M; Forbes, J; Guastalla, JP; Houghton, J; Howell, A; Locker, G; MacKey, J; Sainsbury, R; Tobias, J; Williams, N | 1 |
| Chaudri-Ross, HA; Mouridsen, HT | 1 |
| Aebi, S; Ballabeni, P; Goldhirsch, A; Hess, D; Köberle, D; Pagani, O; Perey, L; Rochlitz, C; Senn, I; Thürlimann, B | 1 |
| Clemons, M; Coleman, RE; Verma, S | 1 |
| Sainsbury, R | 1 |
| Curran, MP; Perry, CM; Simpson, D | 1 |
| Ellis, M | 1 |
| Aglietta, M; Cirillo, S; Gatti, M; Martincich, L; Montemurro, F; Regge, D; Russo, F | 1 |
| Gerken, P | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Chow, LW; Guan, XY; Loo, WT; Toi, M; Zhu, L | 1 |
| Howell, A; Tobias, JS | 1 |
| Cuzick, J; Locker, GY; Sainsbury, JR | 1 |
| Tobias, JS | 2 |
| Barrett, JC; Berrigan, D; Brodie, A; Hursting, SD; Jelovac, D; Macedo, L; Núñez, NP; Perkins, SN | 1 |
| Boccardo, F | 2 |
| Megahed, M; Reifenberger, J; Schulte, KW; Sonntag, M | 1 |
| Hillner, BE | 1 |
| Altundag, K; Buzdar, AU; Hortobagyi, G; Morandi, P; Rouzier, R; Theriault, RL | 1 |
| Abou-Jawde, RM; Alemany, CA; Budd, GT; Choueiri, TK | 1 |
| Becquart, D; Chaudri-Ross, HA; Gershanovich, M; Lang, R; Mouridsen, H; Perez-Carrion, R; Sun, Y | 1 |
| Chaudri-Ross, HA; Mouridsen, H | 1 |
| Bloomfield, D; Godward, S; Makris, A; Moody, AM; Thomas, R; Williams, M | 1 |
| Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I | 1 |
| Davis, GJ; Ravdin, PM | 1 |
| Hirono, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Okubo, S; Sonoo, H; Tanaka, K; Udagawa, K | 1 |
| Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M | 1 |
| Bianco, AR; Clack, G; Coibion, M; Duffy, S; Jackson, TL; Lansdown, M; Philips, K; Pollard, S; Wells, M | 2 |
| Cella, D; Cuzick, J; Fallowfield, L; Francis, S; Howell, A; Locker, G | 1 |
| Caruggi, M; Colombo, G; Marchetti, M | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Ingle, JN; Jelovac, D; Long, BJ; Macedo, L | 1 |
| Johnston, S; Stebbing, J | 1 |
| Bessho, T; Hirai, I; Kinoshita, T; Kokawa, Y; Nishida, M; Nishimura, O; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yokochi, H; Yoshimas, T | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Dowsett, M; Hills, M; Jackson, J; Miller, WR; Renshaw, L | 1 |
| Cheng, CW; Cheung, MN; Chow, LW; Loo, WT; Tse, EY | 1 |
| Casper, RF; Diamond, MP; Mitwally, MF | 1 |
| Duffy, SR; Taylor, L | 1 |
| Dowsett, M | 4 |
| Bajetta, E; Bombardieri, E; Del Vecchio, M; Ferrari, L; La Torre, I; Longarini, R; Martinetti, A; Paleari, D; Seregni, E; Toffolatti, L; Zilembo, N | 1 |
| Buzdar, A; Macahilig, C | 1 |
| de Cremoux, P; Diéras, V; Fourquet, A; Magdelénat, H; Pierga, JY; Poupon, MF; Sigal-Zafrani, B | 1 |
| Harwood, KV | 1 |
| Azria, D; Cunat, S; Evans, DB; Gourgou, S; Larbouret, C; Martineau, P; Ozsahin, M; Pèlegrin, A; Pujol, P; Romieu, G | 1 |
| Fentiman, IS | 1 |
| Travis, K | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 2 |
| Clemons, MJ; Freedman, OC; Verma, S | 2 |
| Michaud, LB | 2 |
| Henderson, IC | 1 |
| Harvey, HA | 2 |
| Bershtein, LM; Kovalevskii, AY; Poroshina, TE; Semiglazov, VF; Tsyrlina, EV; Zhil'tsova, EK; Zimarina, TS | 1 |
| Lykkesfeldt, AE; Sonne-Hansen, K | 1 |
| Ayaori, M; Hiraide, H; Kusuhara, M; Mochizuki, H; Ohsuzu, F; Sato, K; Sawada, S; Tamaki, K; Yonemura, A | 1 |
| Angeles Victoria, L; Basavilvazo Rodríguez, MA; Castelazo Rico, G; Hernández Valencia, M; Molotla Xolalpa, D; Zárate, A | 1 |
| Kondo, M; Miki, S; Ochiai, T; Okubo, I; Toi, M | 1 |
| Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R | 1 |
| Jakesz, R | 2 |
| Bundred, N | 1 |
| Deangelis, D; Goss, PE; Heath, M; Ingle, JN; Liu, S; Palmer, MJ; Perez, EA; Pritchard, PH; Shepherd, L; Tu, D; Wasan, KM | 1 |
| Akar, M; Buyuk, E; Libertella, N; Oktay, K; Rosenwaks, Z | 1 |
| Chen, S; Itoh, T; Karlsberg, K; Kijima, I; Smith, D; Ye, J; Yuan, YC | 1 |
| Baron, AT; Cora, EM; Hillman, DW; Ingle, JN; Lafky, JM; Maihle, NJ; Perez, EA; Suman, VJ | 1 |
| Baker, MA; Chettle, C | 1 |
| Ejlertsen, B; Joensuu, H; Lønning, PE; Rutqvist, LE | 1 |
| Katsumine, Y; Noda, N; Osawa, I; Uehara, S; Yuasa, H | 1 |
| Caraglia, M; Cigolari, S; Colucci, G; Del Prete, S; Fanelli, F; Febbraro, A; Ferrari, E; Formato, R; Gebbia, V; Giotta, G; Iaffaioli, RV; Ianniello, G; Incoronato, P; Manzione, L; Marano, O; Marzano, N; Nasti, G; Pappagallo, G; Pedicini, T; Pezzella, G; Pisano, A; Pisconti, S; Pizza, C; Quattrin, S; Tortoriello, A | 1 |
| Ansari, TN; Hussain, I; Mahmood, A; Samad, A | 1 |
| Gradishar, WJ; Sahmoud, T | 1 |
| Jones, SE; Pippen, J | 1 |
| Brown, P; Kalidas, M | 1 |
| Delozier, T; Khayat, D; Spano, JP | 1 |
| Dodwell, D; Vergote, I | 1 |
| Oktay, K | 1 |
| Carpi, A; Nicolini, A | 1 |
| Kaufmann, M; Rody, A | 2 |
| Karatza, EC; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D | 1 |
| Ariad, S; Baumgarten, A; Bobilev, D; Lavrenkov, K; Man, S; Shelef, I; Tokar, M | 1 |
| Come, SE; Elledge, RM; Howell, A; Jones, SE; Mauriac, L; Osborne, CK; Pippen, J; Robertson, JF; Vergote, I | 1 |
| Ingle, JN; Suman, VJ | 1 |
| Busbee, D; Chowdhary, R; Hokanson, R; Mankame, T | 1 |
| Cole, B; Gard, C; Glendenning, GA; Irish, W; Mouridsen, H; Sherrill, B | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, D; Hackl, W; Hamer, P; Harvey, HA; Lang, R; Leitzel, K; Lipton, A | 1 |
| Ponzone, R; Sismondi, P | 1 |
| Brodie, AM; Goloubeva, OG; Jelovac, D; Long, BJ; Macedo, L; Sabnis, G | 1 |
| Brodie, AM; Goloubeva, OG; Handratta, V; Jelovac, D; Macedo, L | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Long, B; Macedo, L; Sabnis, G | 1 |
| Senn, HJ; Thürlimann, B | 1 |
| Hamilton, AL; Nordman, IC; Spillane, AJ | 1 |
| Bae, K; Ellis, M; Klause, A; Tao, Y; Vickers, A | 1 |
| Ashley, SE; Blohmer, JU; Boeddinghaus, I; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Skene, A; Smith, IE; Walsh, G | 1 |
| Anderson, TJ; Dixon, JM; Evans, D; Krause, A; Larionov, A; Miller, WR; Murray, J; White, S | 1 |
| Amadori, D; Amoroso, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Puntoni, M; Restuccia, N; Rinaldini, M; Romeo, D; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Bhatnagar, AS; Mouridsen, HT | 1 |
| Bertelli, G; Bertolotti, L; Carlini, P; Conforti, S; Del Mastro, L; Febbraro, A; Garrone, O; Leonard, RC; Liossi, C; Marzano, N; Occelli, M | 1 |
| Børresen-Dale, AL; Frigessi, A; Geisler, J; Glad, I; Harada, N; Kristensen, VN; Linegjaerde, OC; Lønning, PE; Sørlie, T; Yoshimura, N | 1 |
| Banerjee, S; Barker, P; Dowsett, M; Folkerd, L; Iqbal, J; Smith, IE | 1 |
| Boulay, A; Chen, S; Evans, DB; Lane, HA; O'Reilly, T; Rudloff, J; Ye, J; Zumstein-Mecker, S | 1 |
| Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Milella, M; Mottolese, M; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E | 1 |
| Kopans, DB; Ryan, PD; Sgroi, DC | 1 |
| Johnson, JR; Kelly, R; Mann, BS; Pazdur, R; Sridhara, R; Williams, G | 1 |
| Noonan, D | 1 |
| Aghi, M; Brisman, JL; Kiehl, TR | 1 |
| Glassman, R; Stebbing, J | 1 |
| Abrams, JS; Cameron, DA; Castiglione, M; Davidson, NE; Goss, PE; Ingle, JN; Livingston, RB; Martino, S; Muss, HB; Norton, L; Palmer, MJ; Pater, JL; Perez, EA; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D | 5 |
| Chowdhury, S; Ellis, PA | 1 |
| Goss, PE; Ingle, JN; Liu, S; Martino, S; Muss, HB; Palmer, M; Pater, JL; Pritchard, K; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Chen, V | 1 |
| Bhatt, ML; Kirti, S; Kumar, S; Madhup, R; Srivastava, M; Srivastava, PK | 1 |
| Ando, M; Matsuyama, Y; Ooi, Y; Rai, Y; Sagara, Y; Takahama, T | 1 |
| Jiang, ZF; Song, ST | 1 |
| Oktay, KH | 1 |
| Doody, D; Dowsett, M; Folkerd, E; Haynes, B | 1 |
| Dickler, M | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Baum, M; Cuzick, J; Dowsett, M; Houghton, J; Howell, T; Wale, C | 1 |
| Dowsett, M; Johnston, SR; Martin, LA | 1 |
| Abram, P; Vergote, I | 1 |
| Chen, S; Itoh, T; Kijima, I | 1 |
| Howell, A; Locker, GY | 1 |
| Denes, AE | 1 |
| Bolat, F; Erkanli, S; Haberal, A; Kayaselcuk, F; Kuscu, E; Sakalli, H | 1 |
| Haberstich, R; Rodier, JF; Tuech, JJ; Wilt, M | 1 |
| Demonty, G | 1 |
| Mouridsen, HT; Robert, NJ | 1 |
| Koeberle, D; Thuerlimann, B | 2 |
| Castiglione-Gertsch, M; Coates, AS; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Wardley, A; Wardly, A | 1 |
| Swain, SM | 1 |
| Noguchi, S; Okishiro, M; Taguchi, T; Tamaki, Y; Tanji, Y; Yoneda, K | 1 |
| Curigliano, G; de Braud, F; De Pas, T; Fazio, N; Formica, V; Goldhirsch, A; Pietri, E; Spitaleri, G | 1 |
| Bertelli, G; Bertolotti, L; Castiglione, F; Del Mastro, L; Fusco, O; Garrone, O; Leonard, RC; Merlano, M; Occelli, M; Pepi, F | 1 |
| Sereda, D; Werth, VP | 1 |
| Tuma, RS | 1 |
| Ang, P; Chia, WK; Greaves, MW; Lim, YL | 1 |
| Rennie, I; Rundle, P | 1 |
| Arteaga, CL; Miller, T; Shin, I | 1 |
| A'Hern, R; Ashley, S; Boeddinghaus, I; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Francis, S; Griffith, C; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Buzdar, AU; Cuzick, J | 1 |
| Shan, ZZ; Shen, KW; Wang, LP | 1 |
| Gerber, B; Janni, W; Krause, A; Kundt, G; Makovitzky, J; Mylonas, I; Reimer, T | 1 |
| Monnier, A | 3 |
| Bhatnagar, AS | 3 |
| Goss, PE; Pritchard, KI; Shepherd, L | 1 |
| Aapro, M | 2 |
| Fodor, J | 1 |
| Brandman, J; Delea, T; Goss, PE; Johnston, SR; Karnon, J; Smith, R; Sung, J | 1 |
| Gltick, S | 1 |
| Keam, SJ; Scott, LJ | 1 |
| Higa, GM | 1 |
| Hargis, JB; Nakajima, ST | 1 |
| Anderson, TJ; Dixon, JM; Miller, WR; Murray, J; Renshaw, L; White, S | 1 |
| Abrial, C; Cabrespine, A; Chollet, P; Cure, H; Durando, X; Ferriere, JP; Kwiatkowski, F; Leheurteur, M; Mouret-Reynier, MA; Penault-Llorca, F | 1 |
| Baum, M; Buzdar, AU; Cuzick, J | 1 |
| Bines, J; Buzdar, AU; Cataliotti, L; de Oliveira, CT; Dube, P; Noguchi, S; Petrakova, K; Takatsuka, Y | 1 |
| Erban, JK | 1 |
| Alba, E; Barnadas, A; Carabante, F; Colomer, R; Fernández, R; Gil, M; González, J; Llombart, A; Mayordomo, JI; Palomero, I; Ramos, M; Ribelles, N; Ruiz, M; Soriano, V; Tusquets, I; Vera, R | 1 |
| Langenegger, T; Schiesser, D; Thürlimann, B; Wahl, P | 1 |
| Grana, G | 1 |
| Dunn, C; Keam, SJ | 1 |
| Geyer, H; Guddat, S; Haenelt, N; Koch, A; Kohler, M; Mareck, U; Opfermann, G; Schänzer, W; Thevis, M | 1 |
| Caporale, R; Cellai, C; Di Lollo, S; Laurenzana, A; Paglierani, M; Pancrazzi, A; Paoletti, F; Vannucchi, AM | 1 |
| Forbes, JF | 1 |
| Lane, HA; Lebwohl, D | 1 |
| Dowsett, M; Hayes, D; Lønning, PE; Santen, RJ; Smith, IE; Walsh, G; Yap, YS | 1 |
| Beer, TM; Deloughery, TG; Luoh, SW; Lycette, JL | 1 |
| Dixon, JM; Dowsett, M; Ellis, MJ; Evans, DB; Faratian, D; Krause, A; Miller, WR; Murray, J; Proia, AD; Renshaw, L; Tao, Y; Thomas, J; White, S; Young, O | 1 |
| Canorea, F; Del Castillo, A; Gil, JM; González, P; Rubio-Terrés, C | 1 |
| Ballester Navarro, I; Carrato Mena, A; Maciá Escalante, S; Pons Sanz, V; Rodríguez Lescure, A | 1 |
| Amadori, D; Benedetto, C; Boccardo, F; Buzzi, F; Distante, V; Fini, A; Franchi, R; Guglielmini, P; Massidda, B; Mesiti, M; Paladini, G; Porpiglia, M; Restuccia, N; Rinaldini, M; Rubagotti, A; Scali, S; Sismondi, P | 1 |
| Duffy, MJ | 1 |
| Tsukagoshi, S | 2 |
| Brown, MM; Manquez, ME; Shields, CL; Shields, JA | 1 |
| Buzdar, AU; Cuzick, J; Guastalla, JP; Nabholtz, JM | 1 |
| Brandman, J; Delea, T; El Ouagari, K; Karnon, J; Talbot, W | 1 |
| Findlay, BP; Goss, PE; Ingle, JN; Josse, RG; Liu, S; Martino, S; Palmer, MJ; Perez, EA; Pritchard, KI; Shenkier, TN; Shepherd, LE; Tozer, RG; Tu, D | 1 |
| Brandman, J; Delea, TE; Gross, PE; Johnston, SR; Karnon, J; Smith, RE; Sung, JC | 1 |
| Adams, JE; Clack, G; Cuzick, J; Dowsett, M; Eastell, R; Hannon, RA | 1 |
| Aguggini, S; Allevi, G; Bernardi, C; Berruti, A; Bersiga, A; Bodini, G; Bonardi, S; Bottini, A; Brizzi, MP; Bruzzi, P; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Harris, AL; Milani, M; Montruccoli, A | 1 |
| Bang, H; Cil, A; Hourvitz, A; Oktay, K; Oktem, O; Safro, B; Sahin, G | 1 |
| Brodie, A; Guo, Z; Macedo, LF; Qiu, Y; Sabnis, GJ; Tilghman, SL | 1 |
| Buzdar, A; Cuzick, J; Distler, W; Hoctin-Boes, G; Houghton, J; Howell, A; Locker, GY; Nabholtz, JM; Wale, C | 1 |
| Alran, S; Campana, F; de Cremoux, P; Languille, O; Malka, I; Rosty, C; Salmon, RJ; Sigal-Zafrani, B | 1 |
| Ellis, MJ; Harris, L; Isaacs, C; Kommarreddy, A; Mann, G; Marcom, PK; Novielli, N; Tao, Y; Wong, ZW | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 3 |
| Vakaet, L | 1 |
| Borstnar, S; Cufer, T; Mrhar, A; Piskur, P; Sonc, M | 1 |
| Asselain, B; Bredart, A; de la Rochefordière, A; Dolbeault, S; Poinsot, R; Sigal-Zafrani, B; This, P | 1 |
| Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yoshida, Y | 1 |
| Goss, PE; Ingle, JN; Moy, B; Pater, JL; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| El-Hajj, II; El-Saghir, NS; Makarem, JA; Otrock, ZK | 1 |
| Dodwell, D; Pippen, J | 1 |
| Del Mastro, L; Venturini, M | 1 |
| Barker, P; Cella, D; Cuzick, J; Fallowfield, L; Howell, A; Locker, G | 1 |
| Crane, J; Gaya, A; Stebbing, J | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP | 1 |
| Lønning, PE | 3 |
| Annemans, L; Moeremans, K | 1 |
| Brueggemeier, RW | 1 |
| Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C | 1 |
| Bujanda, L; Piérola, A; Zapata, E; Zubiaurre, L | 1 |
| Goodwin, GM | 1 |
| Ballerini, G; Cavalli, F; Conti-Beltraminelli, M; Forni, V; Goldhirsch, A; Graffeo, R; Mainetti, C; Pagani, O; Pianca, S; Richetti, A; Ruggeri, M; Schönholzer, C | 1 |
| Ali, SM; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Hackl, W; Hamer, P; Leitzel, K; Lipton, A; Souder, C | 1 |
| Amant, F; Berteloot, P; Christiaens, MR; De Smet, L; Leunen, K; Morales, L; Neven, P; Pans, S; Paridaens, R; Smeets, A; Timmerman, D; Van den Bogaert, W; Van Limbergen, E; Vergote, I; Verhaeghe, J; Weltens, C; Westhovens, R; Wildiers, H | 1 |
| Abrial, C; Chollet, P; Curé, H; Durando, X; Leheurteur, M; Mouret-Reynier, MA; Tacca, O | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
| Brodie, A; Jelovac, D; Sabnis, G | 1 |
| Chien, AJ; Goss, PE | 1 |
| Beresford, MJ; Makris, A; Ravichandran, D | 1 |
| Boccardo, F; Gnant, M; Greenwood, M; Jakesz, R; Jonat, W; Kaufmann, M; Rubagotti, A; Zuna, I | 1 |
| Goss, PE; Gottardt, H; Ingle, JN; Olson, JE; Scott, CG; Suman, VJ; Vachon, CM | 1 |
| Belosay, A; Brodie, AM; Njar, VC | 1 |
| Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM | 1 |
| Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Chu, QD; Li, BD; McDonald, JC | 1 |
| Cheng, ZY; He, F; Li, WJ; Zhou, JM; Zhu, XF | 1 |
| Barash, NIu; Bershteĭn, LM; Gamaiunova, VB; Ivanov, VG; Kovalenko, IG; Malysheva, SA; Poroshina, TE; Semiglazov, VF; Shcherbakova, EB; Tsyrlina, EV; Zhil'tsova, EK | 1 |
| Castiglione-Gertsch, M; Chirgwin, J; Coates, AS; Colleoni, M; Del Mastro, L; Forbes, JF; Gelber, RD; Goldhirsch, A; Jakobsen, EH; Keshaviah, A; Láng, I; Mauriac, L; Mouridsen, H; Nogaret, JM; Paridaens, R; Pienkowski, T; Price, KN; Smith, I; Thürlimann, B; Wardley, A | 1 |
| Endo, W; Fujie, Y; Fukunaga, H; Hojo, S; Maeura, Y; Okada, Y; Ota, H; Yoshioka, S | 1 |
| Inoue, K; Nagamoto, N; Ohsako, T; Tanaka, E; Yoshida, Y | 1 |
| Fabian, CJ; Khan, QJ; Kimler, BF; Mayo, MS; Metheny, T; Petroff, BK; Phillips, TA; Simonsen, M; Zalles, CM | 1 |
| Jänicke, F | 1 |
| A'Hern, R; Detre, S; Dixon, JM; Dowsett, M; Ebbs, SR; Hills, M; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Costantino, J; Cronin, W; Geyer, C; Harkins, B; Jeong, JH; Lembersky, B; Mamounas, EP; Paik, S; Wickerham, DL; Wolmark, N | 1 |
| Lewis, S | 1 |
| Imai, H; Kuroi, K; Ohsumi, S; Ono, M; Shimozuma, K | 1 |
| Cella, D; Dobrez, D; Gandhi, SK; Locker, GY; Mansel, R; Sorensen, S | 1 |
| Ellis, MJ; Rigden, CE | 1 |
| Eisner, A; Falardeau, J; Samples, JR; Toomey, MD; Vetto, JT | 1 |
| Castiglione-Gertsch, M; Coates, AS; Debled, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Láng, I; Mauriac, L; Monnier, A; Mouridsen, H; Nogaret, JM; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Thürlimann, B; Viale, G; Wardley, A; Zabaznyi, N | 1 |
| Cianfrocca, M; Wolff, AC | 1 |
| Nortier, JW; Seynaeve, C; van de Velde, CJ; van Nes, JG | 1 |
| Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z | 1 |
| Budd, GT; Margolis, R; Singh, AD | 1 |
| Chishima, T; Ichikawa, Y; Inui, K; Ishikawa, T; Matsumoto, C; Momiyama, N; Shimada, H; Togo, S | 1 |
| Azim, AA; Costantini-Ferrando, M; Lostritto, K; Oktay, K | 1 |
| Draxler, W; Gnant, M; Haider, K; Hammer, J; Handl-Zeller, L; Hofbauer, F; Jakesz, R; Kapp, K; Kwasny, W; Luschin-Ebengreuth, G; Pakisch, B; Pöstlberger, S; Pötter, R; Reiner, G; Rottenfusser, A; Schmid, M; Sedlmayer, F; Stierer, M; Taucher, S; Tausch, C | 1 |
| Marshall, E | 1 |
| Jonat, W; Mundhenke, C | 1 |
| Barnes, L; Crowley, V; Daly, P; Darby, C; Roche, M | 1 |
| Angeli, A; Ardine, M; Berruti, A; Bertoldo, F; Dogliotti, L; Mosca, A; Tucci, M; Vana, F | 1 |
| Akashi-Tanaka, S; Ando, M; Fujiwara, Y; Fukutomi, T; Hasegawa, T; Kinoshita, T; Omatsu, M; Seki, K; Shien, T; Shimizu, C; Terada, K | 1 |
| Lian, ZQ; Yang, MT | 1 |
| Hou, KY; Ji, JF; Jia, TZ; Li, HP; Wang, MP; Wang, YF; Xiao, Y; Zhao, HM | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Alimonti, A; Bria, E; Carlini, P; Cognetti, F; Cresti, N; Di Cosimo, S; Fabi, A; Ferretti, G; Giannarelli, D; Michelotti, A; Milella, M; Papaldo, P; Pellegrini, M; Ricci, S; Ruggeri, EM; Salesi, N | 1 |
| Baydal, R; Blanes, MD; Chirivella, I; Colio, JM; De-la-Morena, E; Laforga, J; Lluch, A; Perez-Fidalgo, JA; Roselló, S | 1 |
| Agrawal, A; Agrawal, DK; Murphy, RF | 1 |
| Brodie, A; Goloubeva, O; Jelovac, D; Sabnis, G; Schayowitz, A | 1 |
| Goss, PE; Ingle, JN; Pater, J; Shepherd, L; Tu, D | 1 |
| Monnier, AM | 1 |
| Chian, RC; Demirtas, E; Lostritto, K; Oktay, K; Son, WY; Tan, SL | 1 |
| Bell, R; Lewis, J | 1 |
| Berstein, LM; Bozhok, AA; Dashyan, GA; Ivanov, VG; Kletzel, A; Melnikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Ziltsova, EK | 1 |
| Gelmon, K | 1 |
| Ashworth, A; Dexter, T; Dixon, JM; Dowsett, M; Drury, S; Evans, DB; Fenwick, K; Larionov, A; Mackay, A; Miller, WR; Urruticoechea, A; White, S; Young, O | 1 |
| Lin, NU; Winer, EP | 1 |
| Eidtmann, H; Gademann, G; Hilfrich, J; Jonat, W; Kaufmann, M; von Minckwitz, G; Zuna, I | 1 |
| Gralow, JR | 1 |
| Blanchett, D; Demers, L; Goss, PE; Langecker, P; Ohorodnik, S; Santen, RJ; Settlage, J; Wang, S | 1 |
| Kaiser, J | 1 |
| Barghout, V; Delea, TE; Karnon, J; Papo, NL; Sofrygin, O; Thomas, SK | 1 |
| Barghout, V; Delea, T; Karnon, J | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F | 1 |
| Benedict, A; Fallowfield, L; Jones, D; Locker, G; Mansel, R | 1 |
| Gallagher, J; Habin, K; Winters, L | 1 |
| Cameron, DA; Langdon, SP; MacLeod, K; Smyth, JF; Walker, G; Williams, AR | 1 |
| Aguilar, H; Capellà, G; Dowsett, M; Germà-Lluch, JR; Martin, LA; Solé, X; Urruticoechea, A | 1 |
| Cameron, DA; Dixon, MJ; Green, RV; Julian, HS; Thomas, JS | 1 |
| Garg, S; Venkatesh, P | 1 |
| Delea, TE; El-Ouagari, K; Karnon, J; Sofrygin, O | 1 |
| Basso, AD; Black, S; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Robert Bishop, W; Taylor, SA | 1 |
| Braye, S; Castiglione-Gertsch, M; Coates, AS; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Maiorano, E; Mastropasqua, MG; Neven, P; Ohlschlegel, C; Orosz, Z; Price, KN; Raffoul, J; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Abreu, P; Banke-Bochita, J; Goss, PE; Hadji, P; Subar, M; Thomsen, T | 1 |
| Beeram, M; DeGraffenried, LA; Middleton, A; Russell, D; Tan, QT; Tekmal, RR | 1 |
| Amar, S; Perez, EA; Roy, V | 1 |
| Bagnardi, V; Bottiglieri, L; Colleoni, M; D'Alessandro, C; Dellapasqua, S; Ghisini, R; Goldhirsch, A; Luini, A; Magni, E; Pruneri, G; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Wadman, M | 1 |
| Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y | 1 |
| Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM | 1 |
| Kamby, C; Lindberg, H; Nielsen, DL; Tuxen, M | 1 |
| Anderson, TJ; Dixon, JM; Evans, DB; Hampton, G; Ho, S; Krause, A; Larionov, AA; Miller, WR; Murray, E; Murray, J; Renshaw, L; Walker, JR; White, S | 1 |
| Cufer, T | 1 |
| Fabian, CJ | 1 |
| Ellis, MJ; Ma, C | 1 |
| O'Shaughnessy, J | 1 |
| Perez, EA | 1 |
| Haidinger, R; Harbeck, N | 1 |
| Ellis, M; Ma, C | 1 |
| Altundag, K; Dede, D; Gullu, I; Harputluoglu, H | 1 |
| Barton, JC; Bertoli, LF | 1 |
| Jahanzeb, M | 1 |
| Schagen, SB; Schilder, CM | 1 |
| Atabekoglu, C; Sonmezer, M | 1 |
| Alba, E; Barnadas, A; Colomer, R; Constenla, M; Fernández, R; Gil, M; Gilabert, M; Llombart-Cussac, A; Lloveras, B; Mayordomo, JI; Ramos, M; Tusquets, I | 1 |
| Goss, PE; Wu, M | 1 |
| Graham, PH | 1 |
| Borg, S; De Lafontan, B; Laroche, M; Lassoued, S; Roché, H | 1 |
| Antoni, G; Bollet, MA; Campana, F; Cottu, P; Dendale, R; Fourquet, A; Kirova, YM; Laki, F; Pierga, JY; Salmon, R; Sigal-Zafrani, B | 1 |
| Bershteĭn, LM; Bozhok, AA; Damenia, AO; Dashian, GA; Donskikh, RV; Ivanov, VG; Klettsel', AA; Kochetova, IA; Krivorot'ko, PV; Mel'nikova, OA; Paltuev, RM; Semiglazov, VF; Semiglazov, VV; Tonuzov, EE; Voskresenskiĭ, DA; Zernov, KIu; Zhil'tsova, EK | 1 |
| Blanchett, D; Bondarenko, IN; Goss, P; Langecker, P; Manikhas, GN; Miller, WH; Pendergrass, KB | 1 |
| Dutta, U; Pant, K | 1 |
| Cooper, BC; Stilwill, SE | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Keshaviah, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B | 1 |
| Dodwell, D; Williamson, D | 1 |
| Altundag, K; Dizdar, O; Harputluoglu, H | 1 |
| Awada, A; Cardoso, F; De Grève, J; Dirix, L; Fontaine, C; Piccart, M; Sotiriou, C; Steinseifer, J; Tanaka, C; Tang, P; Wouters, C; Zoellner, U | 1 |
| Kotsis, L; Kovács, O; Krasznai, G | 1 |
| Anderson, TJ; Dixon, JM; Evans, DB; Krause, A; Larionov, A; Miller, WR; Walker, JR | 1 |
| Brodie, AM; Buzdar, AU; Come, SE; Coombes, RC; Goss, PE; Ingle, JN; Johnston, SRD; Miller, WR; Pritchard, KI; Winer, EP; Zujewski, JA | 1 |
| Prowell, TM; Stearns, V | 1 |
| Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C | 1 |
| Akiyama, F; Ikeda, T; Imoto, S; Inaji, H; Kurosumi, M; Noguchi, S; Sakamoto, G; Takatsuka, Y; Tsuda, H; Watanabe, T | 1 |
| Wengström, Y | 1 |
| Altermatt, HJ; Braye, S; Castiglione-Gertsch, M; Coates, AS; Del Curto, B; Dell'Orto, P; Gelber, RD; Goldhirsch, A; Gusterson, BA; Henriksen, KL; Lacroix-Triki, M; Lykkesfeldt, AE; Mastropasqua, MG; Méry, E; Price, KN; Rasmussen, BB; Regan, MM; Thürlimann, B; Viale, G | 1 |
| Baum, M; Buzdar, A; Cuzick, J; Forbes, JF; Howell, A; Tobias, JS | 1 |
| Botti, G; D'Aiuto, G; D'Aiuto, M; De Maio, E; de Matteis, A; Di Rella, F; Esposito, G; Gallo, C; Gravina, A; Labonia, V; Landi, G; Morabito, A; Nuzzo, F; Pacilio, C; Perrone, F; Piccirillo, MC; Rinaldo, M; Rossi, E | 1 |
| Russell, CA | 1 |
| Eisen, A; Messersmith, H; Pritchard, KI; Shelley, W; Trudeau, M | 1 |
| Miller, WR | 2 |
| Toi, M | 1 |
| Asnis-Alibozek, A; LaFountain, A; Mayer, E; Partridge, AH; Taylor, BS; Winer, E | 1 |
| Collingridge, D | 1 |
| Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G | 1 |
| Allred, C; Bishop, H; Buzdar, A; Carder, P; Cussac, AL; Cuzick, J; Dowsett, M; Ellis, I; Forbes, J; Houghton, J; Knox, F; Knox, J; Larsimont, D; Mallon, E; Quinn, E; Salter, J; Sasano, H; Speirs, V; Wale, C; Williams, N | 1 |
| Gao, YT; Gu, K; Lu, W; Matthews, CE; Shin, A; Shu, XO; Zheng, W | 1 |
| Alba, E; Artells, R; Baena, JM; Barnadas, A; Calvo, L; Carabantes, F; Colomer, R; Crespo, C; Gilabert, M; Llombart, A; Lloveras, B; Monzo, M; Muñoz, M; Plazaola, A; Rifa, J; Tusquets, I | 1 |
| Chow, LW; Loo, WT; Toi, M; Yip, AY | 1 |
| Cameron, D; Dixon, JM; Evans, DB; Kerr, GR; Macaskill, EJ; Miller, WR; Murray, J; Renshaw, L; Young, O | 1 |
| Giordano, SH; Hortobagyi, GN | 1 |
| Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C | 1 |
| Kodama, H; Matsumoto, M; Nakatani, K; Nishioka, A; Ogawa, Y; Sasaguri, S; Tanaka, Y; Ue, H | 1 |
| Blackwell, KL; Herold, CI | 2 |
| Ikeda, M; Kurebayashi, J; Miyake, A; Nakashima, K; Nomura, T; Shiiki, S; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Carpenter, R | 1 |
| Bastert, G; Jänicke, F; Kiesel, L; Krainick-Strobel, UE; Lichtenegger, W; Paepke, S; Tulusan, AH; Wackwitz, B; Wallwiener, D | 1 |
| Adams, JE; Beckmann, MW; Clack, G; Coleman, RE; Cuzick, J; Eastell, R; Hannon, RA; Howell, A; Mackey, JR | 1 |
| Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B | 1 |
| Goss, PE; He, Z; Ingle, JN; Martino, S; Muss, HB; Palmer, MJ; Pater, JL; Piccart, MJ; Pritchard, KI; Robert, NJ; Shepherd, LE; Tu, D; Whelan, TJ | 1 |
| Pennery, E | 1 |
| Ucci, G | 1 |
| Coates, A; Mouridsen, H; Thürlimann, B | 1 |
| A'Hern, RP; Cameron, DA; Dixon, JM; Dowsett, M; Folkerd, E; Macaskill, EJ; McHugh, M; Murray, J; Renshaw, L; Young, O | 1 |
| Marshall, C; Thomas, R; Walker, L; Williams, M | 1 |
| Anderson, H; Dexter, T; Dowsett, M; Dunbier, AK; Harper-Wynne, C; Kendall, A; Mackay, A; Urruticoechea, A | 1 |
| Antoniotti, S; Bussolati, B; Fiorio Pla, A; Grange, C; Merlino, A; Munaron, L; Tomatis, C | 1 |
| Kihara, M; Miyauchi, A | 1 |
| Dixon, JM; Dowsett, M; Evans, DB; Murray, J; Renshaw, L; Thomas, JS; White, S; Williams, L; Young, OE | 1 |
| Ali, SM; Brown-Shimer, S; Carney, W; Chaudri-Ross, HA; Demers, L; Evans, DB; Gaur, V; Hamer, P; Leitzel, K; Lipton, A; Pierce, K | 1 |
| Brodie, A; Goloubeva, OG; Macedo, LF; Sabnis, GJ | 1 |
| A'hern, R; Banerjee, S; Dowsett, M; Ghazoui, Z; Martin, LA; Pancholi, S; Smith, IE | 1 |
| Aguggini, S; Allevi, G; Berruti, A; Bersiga, A; Bonardi, S; Bottini, A; Brizzi, MP; Campo, L; Dionisio, R; Dogliotti, L; Fox, SB; Generali, D; Giardini, R; Harris, AL; Milani, M; Vergoni, F | 1 |
| Eisner, A; Falardeau, J; Toomey, MD; Vetto, JT | 1 |
| Adrover, E; Barnadas, A; Calvo, L; de la Haba, J; Estevez, LG; Gil, M; Llombart, A; Sánchez-Rovira, P | 1 |
| Bourgain, C; Collen, C; De Grève, J; De Mey, J; Fontaine, C; Huizing, M; Kaufman, L; Lamote, J; Meulemans, A; Neyns, B; Sacre, R; Schallier, D; Verfaillie, G; Vermorken, J | 1 |
| Fields, MM; Mellington, TE | 1 |
| Goyal, S; Julka, PK; Puri, T; Rath, GK | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
| Demers, L; Dowsett, M; Dyroff, M; Plourde, PV; Webster, A; Yates, R | 1 |
| Ashworth, A; Detre, S; Dowsett, M; Lee, K; Macaulay, VM; Nicholls, JE | 1 |
| Baron, J; Cutler, GB; Demers, LM; Klein, KO; Santen, RJ; Santner, SJ | 1 |
| Herenyiova, M; Weber, G; Yeh, YA | 1 |
| Adlercruetz, H; Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ; Trunet, PF | 1 |
| De Coster, R; Snoeck, E; Wouters, W | 1 |
| Dukes, M; Dyroff, M; Plourde, PV | 1 |
| Koymans, LM; Moereels, H; Vanden Bossche, HV | 1 |
| Demers, LM | 1 |
| Doody, D; Dowsett, M; Jacobs, S; Johnston, SR; Robertshaw, H; Smith, IE | 1 |
| Manni, A | 1 |
| Duval, M; Godbillon, J; Gosset, G; Gygax, D; Marfil, F; Pfister, CU; Sioufi, A; Winkler, B | 1 |
| Ahern, J; Dowsett, M; Iveson, TJ; Smith, IE; Smithers, DA; Trunet, PF | 1 |
| Brady, C; Demers, LM; Grossberg, H; Harvey, HA; Kambic, KB; Lipton, A; Santen, RJ | 1 |
| Detre, S; Dowsett, M; Grimshaw, R; Lee, K; Macaulay, VM; Rowlands, M | 1 |
| Azab, M; Blomqvist, C; Buzdar, A; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Plourde, PV; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Fujikura, T; Ideyama, Y; Kudoh, M; Mori, M; Nanya, T; Shikama, H; Susaki, Y | 1 |
| Castiglione-Gertsch, M | 1 |
| Azab, M; Blomqvist, C; Eiermann, W; Hellmund, R; Howell, A; Jonat, W; Lundgren, S; Mauriac, L; Roche, H; Tyrrell, C; Winblad, G | 1 |
| Buzdar, AU; Hortobagyi, GN; Plourde, PV | 1 |
| Dowsett, M; Geisler, J; King, N; Kormeset, PO; Lundgren, S; Lønning, PE; Ottestad, L; Walton, P | 1 |
| Detre, S; Dowsett, M; Grimshaw, R; Rowlands, M | 1 |
| Buzdar, AU; Jones, SE; Plourde, P; Vogel, CL; Webster, A; Wolter, J | 1 |
| Hannaford, M | 1 |
| Bisagni, G; Cocconi, G; Fraschini, F; Pfister, C; Scaglione, F; Trunet, PF | 1 |
| Bhatnagar, AS; Chaudri, HA; Hornberger, U; Trunet, PF | 1 |
| Blankenstein, RA; de Jong, PC; Donker, TH; Maitimu-Smeele, I; Nortier, HW; Slee, PH; Thijssen, JH; van de Ven, J | 1 |
| Camoriano, JK; Gerstner, JB; Gesme, DH; Hartmann, LC; Hatfield, AK; Ingle, JN; Johnson, PA; Loprinzi, CL; Mailliard, JA; Suman, VJ | 1 |
| Kohn, EC; Lambert, PA; Perry, RR; Somers, KD | 1 |
| Durgam, VR; Tekmal, RR | 1 |
| Amoroso, D; Boccardo, F; Brema, F; Cortesi, E; Farris, A; Guida, G; Iacobelli, S; Irtelli, L; Langenaeken, C; Mesiti, M; Mustacchi, G; Nardini, P; Pacini, P | 1 |
| Enomoto, K | 1 |
| Buzdar, AU; Howell, A; Jonat, W; Plourde, PV | 1 |
| Dixon, JM; Miller, WR; Mullen, P; Sourdaine, P; Telford, J; Watson, C | 1 |
| Buzdar, AU; Roseman, BJ; Singletary, SE | 1 |
| Blamey, RW; Cheung, KL; Ellis, IO; Elston, CW; Nicholson, RI; Pinder, SE; Robertson, JF; Willsher, PC | 1 |
| Goss, PE; Tye, LM | 1 |
| Dukes, M | 1 |
| Dowsett, M; Lønning, PE | 1 |
| Jonat, W | 1 |
| Aparicio, LA; Carrion, RP; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Robertson, JF; Vorobiof, DA | 1 |
| Bellmunt, J; Bezwoda, W; Chaudri, HA; Dombernowsky, P; Falkson, G; Fornasiero, A; Gardin, G; Gudgeon, A; Hatschek, T; Hoffmann, W; Hornberger, U; Leonard, R; Michel, J; Morgan, M; Panasci, L; Smith, I; Tjabbes, T; Trunet, PF | 1 |
| Beex, LV; Houston, SJ; Klijn, J; Langenaeken, C; Nooij, M; Paridaens, R; Piccart, MJ; Roy, JA; Tomiak, E; Van Glabbeke, M; Van Vreckem, A; Vinholes, J | 1 |
| alKhouri, N; Higa, GM | 1 |
| Dickson, RB; El-Ashry, D; Hannum, RS; Kern, FG; Kharbanda, S; Lopez, CA; Lorant, LA; McLeskey, SW; Tobias, CA; Trock, BJ; Zhang, L | 1 |
| Brodie, A; Liu, Y; Long, B; Lu, Q; Wang, JP; Yue, W | 1 |
| Beex, LV; Bonfrer, JM; Bruning, PF; Bruynseels, J; Klijn, JG; Nooij, M; Paridaens, R; Piccart, MJ | 1 |
| Buzdar, AU; Hortobagyi, GN | 1 |
| Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, HA; Friederich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, N; Reichardt, P; Romieu, G | 1 |
| Huang, ML; Langenaecken, C; Piotrovsky, VK; Van Peer, A | 1 |
| Hoctin-Boes, G; Steinberg, M; Yates, R | 1 |
| Blomqvist, CP; Buzdar, AU; Eiermann, W; Howell, A; Jonat, W; Jones, SE; Lee, D; Steinberg, M; Vogel, CL; Webster, A; Wolter, JM | 1 |
| Brodie, A; Liu, Y; Lu, Q; Wang, J; Yue, W | 1 |
| Dowsett, M; Geisler, J; Lønning, PE | 1 |
| Norton, A; Smith, IE | 1 |
| Adkins, JC; Wiseman, LR | 1 |
| Dowsett, M; Jacobs, S; Johnston, SR; Jones, A; Smith, IE; Trunet, P | 1 |
| Ambus, U; Bruynseels, J; Clark, RM; Crump, M; De Coster, R; Goss, PE; Tye, LM; Wadden, NA; Walde, D; Weizel, HA | 1 |
| Adkins, JC; Lamb, HM | 1 |
| Brodie, AM; Grigoryev, DN; Long, BJ; Thiantanawat, A; Tilghman, SL; Yue, W | 1 |
| Baum, M; Blackman, GM; Dowsett, M; Howell, A; King, N; Ponzone, R; Tobias, JS; von Euler, M; Welch, H | 1 |
| Bruynseels, J; De Coster, R; Goss, PE; Langenaeken, C; Walde, D | 1 |
| Berstein, LM; Diano, S; Eliza, M; Gutierrez, L; Harada, N; Lysiak, J; Mor, G; Naftolin, F; Santen, RJ; Wang, J; Yue, W | 1 |
| Hamilton, A; Piccart, M | 1 |
| Dowsett, M; Ingle, JN; Johnson, PA; Jordan, VC; Krook, JE; Loprinzi, CL; Mailliard, JA; Perez, EA; Suman, VJ; Wheeler, RH | 1 |
| Bajetta, E; Bichisao, E; Celio, L; Di Leo, A; Dowsett, M; Guillevin, L; Marchianò, A; Martinetti, A; Pozzi, P; Stani, S; Zilembo, N | 1 |
| Goss, PE; Schwartz, LH; Tannock, IF; Winer, EP | 1 |
| Blijham, GH; de Jong, PC | 1 |
| Benson, S; Cella, D; Fallowfield, LJ; Howell, A; Leaity, SK | 1 |
| Dowsett, M; Gundacker, H; Houston, SJ; Johnston, SR; Miles, DW; Pfister, C; Sioufi, A; Smith, IE; Verbeek, JA | 1 |
| Coombes, RC; Harper-Wynne, C | 1 |
| Coombes, RC; Doody, D; Dowsett, M; English, J; Howes, A; Miall, S | 1 |
| Bodrogi, I; Bonaventura, A; Buzzi, F; Campos, D; Chaudri, Kh; Friedrich, P; Gershanovich, M; Jeffrey, M; Lassus, M; Ludwig, H; Lurie, H; O'Higgins, NO; Reichard, P; Romieu, G | 1 |
| Bonneterre, J; Feutrie, ML | 1 |
| Chaudri, HA; Trunet, PF | 1 |
| Calvo, L; Clack, G; Dodwell, DJ; Dowsett, M; Kleeberg, UR; Perez-Carrion, R; Robertson, JF; Vorobiof, DA | 1 |
| Bland, KI; Buzdar, AU | 1 |
| Bland, KI | 1 |
| Meester, L; Nuijten, M; Waibel, F; Wait, S | 1 |
| Buzdar, A; Howell, A; Lee, D; Robertson, JF; von Euler, M | 1 |
| Brodie, AM; Njar, VC | 1 |
| Bellamy, C; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Renshaw, L | 1 |
| Coombes, RC; Dowsett, M; Harper-Wynne, C | 1 |
| Dowsett, M; Ingle, JN; Jordan, VC; Suman, VJ | 1 |
| Fowler, K; Gill, K; Kirma, N; Tekmal, RR | 1 |
| Harvey, HA; Santen, RJ | 1 |
| Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N | 1 |
| Buzdar, AU; Chaudri, HA; Trunet, PF | 1 |
| Huff, JL; Plopper, GE; Rust, WL | 1 |
| Berntsen, H; Geisler, J; Lonning, PE | 1 |
| Cappellini, GC; Casali, A; Casali, M; Giuntini, T; Sega, FM; Terzoli, E | 1 |
| Bellamy, C; Dixon, JM; Hoctin-Boes, G; Miller, WR; Renshaw, L; Stuart, M | 1 |
| Donaldson, K; Dowsett, M; Tsuboi, M; Wong, J; Yates, R | 1 |
| Fujiwara, K; Hohjoh, T; Ikeda, T; Kawaguchi, M; Kitajima, M; Masamura, S; Matsui, A; Mitsui, Y; Takayama, S; Tokura, H | 1 |
| Perey, L | 1 |
| Sonoo, H | 1 |
| Attolico, M; Crucitta, E; De Lena, M; Lorusso, V; Mazzei, A; Sambiasi, D | 1 |
| Dranitsaris, G; Leung, P; Mather, J; Oza, A | 1 |
| Bonneterre, J; Koralewski, L; Krzakowski, M; Mauriac, L; Robertson, J; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Biancone, L; Bussolati, B; Camussi, G; Cassoni, P; Montrucchio, G; Rola-Pleszczynski, M; Russo, S | 1 |
| Bonneterre, J; Koralewski, P; Krzakowski, M; Mauriac, L; Robertson, JF; Steinberg, M; Thürlimann, B; Vergote, I; von Euler, M; Webster, A | 1 |
| Burton, G; Buzdar, A; Harwin, W; Mangalik, A; Nabholtz, JM; Pollak, M; Steinberg, M; von Euler, M; Webster, A | 1 |
| Fujita, T; Kaiho, S; Kuwabara, K; Ogata, E; Oizumi, I; Okazaki, T; Tanaka, Y | 1 |
| Sonoo, H; Watanabe, T | 1 |
| Cattel, F; Messori, A; Trippoli, S; Vaiani, M | 1 |
| Baum, M; Thornton, H; Tobias, JS | 1 |
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Schwetz, BA | 1 |
| Kerbrat, P; Lefeuvre, C | 1 |
| Panasci, LC | 2 |
| Bagley, CM; Rowbotham, RK | 1 |
| Tonkin, K | 1 |
| Bolton, M; Copur, MS; Ledakis, P; Muhvic, J; Norvell, M | 1 |
| Costa, SD; Kaufmann, M | 1 |
| Berntsen, H; Detre, S; Dowsett, M; Einstein Lønning, P; Geisler, J; Lindtjørn, B; Ottestad, L | 1 |
| Apffelstaedt, J; Bapsy, PP; Becquart, D; Boni, C; Chaudri-Ross, HA; Dank, M; Dugan, M; Gershanovich, M; Jänicke, F; Lassus, M; Monnier, A; Mouridsen, H; Pérez-Carrión, R; Pluzanska, A; Salminen, E; Sleeboom, HP; Smith, R; Snyder, R; Staffler, B; Sun, Y; Verbeek, JA | 1 |
| Cameron, DA; Donnellan, PP; Douglas, SL; Leonard, RC | 1 |
| Purohit, A; Reed, MJ | 1 |
| Bergmann, L | 1 |
| Brady, C; Buzdar, A; Davidson, N; Douma, J; Elledge, R; Morgan, M; Nabholtz, J; Porter, L; Smith, R; Xiang, X | 1 |
| Tominaga, T | 1 |
| Cuzick, J; Dowsett, M; Howell, A; Jackson, I | 1 |
| Bairaktari, ET; Elisaf, MS; Kakaidi, B; Katsaraki, A; Nicolaides, C; Pavlidis, NA; Tzallas, CS | 1 |
| Bellamy, CO; Cameron, DA; Dixon, JM; Leonard, RC; Love, CD; Miller, WR; Smith, H | 1 |
| Hamilton, A; Volm, M | 1 |
| Buzdar, A; Howell, A | 1 |
| Borgs, M; Brady, C; Coop, A; Dugan, M; Ellis, MJ; Evans, DB; Jänicke, F; Llombert-Cussac, A; Mauriac, L; Miller, WR; Quebe-Fehling, E; Singh, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| Murray, R | 1 |
| Boeddinghaus, I; Dixon, M; Dowsett, M; Ebbs, S; Gui, G; Harper-Wynne, C; Hills, M; Sacks, N; Salter, J; Smith, I | 1 |
| Joy, AA; Mackey, JR | 1 |
| Cocconi, G | 1 |
| Bonneterre, J; Buzdar, A; Nabholtz, JM; Robertson, JF; Sahmoud, T; Steinberg, M; Thürlimann, B; von Euler, M; Webster, A | 1 |
| De Braud, F; Duval, M; Hornberger, U; Lelli, G; Martoni, A; Pfister, CU; Souppart, C; Zamagni, C | 1 |
| Feng, F; Jiang, Z; Xu, B | 1 |
| Nabholtz, JM; Reese, DM | 1 |
| Bando, H; Saji, S; Toi, M | 1 |
| Brink, S | 1 |
| Anker, G; Dowsett, M; Geisler, J; Haynes, B; Lønning, PE | 1 |
| Fenaroli, P; Labianca, R; Tondini, C | 1 |
| Carlini, P; Casali, A; Cognetti, F; De Marco, S; Fabi, A; Frassoldati, A; Nardi, M; Paoloni, F; Papaldo, P; Ruggeri, EM | 1 |
| Appfelstaedt, J; Borgs, M; Chaudri-Ross, HA; Dugan, M; Eiermann, W; Ellis, M; Eremin, J; Lassus, M; Llombart-Cussac, A; Mauriac, L; Paepke, S; Vinholes, J | 1 |
| A'Hern, R; Doody, D; Dowsett, M; Harper-Wynne, CL; Hills, MJ; Howes, A; Iqbal, J; Laidlaw, IJ; Lowe, FM; MacNeill, FA; Miall, S; Nasiri, N; Rayter, Z; Sacks, NP; Salter, J; Sauven, P; Shenton, K | 1 |
| Blankenstein, MA; Blijham, GH; Brodie, AM; Chen, T; DeJong, PC; Elbers, JR; Fulton, A; Long, BJ; Lu, Q; Macpherson, N; Nortier, JW; Schipper, ME; Slee, PH; Thijssen, JH; van de Ven, J; van Gorp, JM | 1 |
| Dixon, JM; Miller, WR | 1 |
| Anderson, TJ; Cameron, DA; Dixon, JM; Miller, WR | 1 |
| Junker, A; Possinger, K; Wiedemann, GJ | 1 |
| Chen, G; Cohen, MH; Johnson, JR; Li, N; Pazdur, R | 1 |
| Sledge, GW | 1 |
| Timms, B | 1 |
| Cohen, Y; Geffen, DB; Lavrenkov, K; Man, S | 1 |
| Buzdar, A; Johnson, PE | 1 |
| Nicholls, H | 1 |
| Bijnens, L; Michiels, B; Molenberghs, G; Thijs, H; Vangeneugden, T | 1 |
| Illiger, HJ | 1 |
| Soudon, J | 1 |
| Abe, R; Aoyama, H; Enomoto, K; Nakamura, Y; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T | 1 |
| Bajetta, E; Bombardieri, E; Buzzoni, R; Catena, L; Celio, L; Ferrari, L; Gattinoni, L; La Torre, I; Martinetti, A; Pozzi, P; Seregni, E; Vitali, M; Zilembo, N | 1 |
| Ellis, MJ; Shaw, HS | 1 |
| Jones, SE | 1 |
| Benedetto, C; De Nicola, B; Ferraris, F; Genta, F; Piccinno, R; Porpiglia, M; Vicelli, R | 1 |
| Abe, R; Ikeda, S; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H | 1 |
| Ikeda, S; Kimijima, I; Koyama, H; Nomizu, T; Nomura, Y; Ohashi, Y; Sano, M; Takashima, S; Tohge, T; Tominaga, T; Ueo, H | 1 |
| Alba, E; Colla, F; Farina, C; Mazzoleni, A; Ragonesi, G | 1 |
| Lynn, J | 1 |
| Bajetta, E; Bichisao, E; Zilembo, N | 1 |
| Ravdin, P | 1 |
| Baum, M; Budzar, AU; Cuzick, J; Forbes, J; Houghton, JH; Klijn, JG; Sahmoud, T | 1 |
| A'Hern, R; Dowsett, M; Harper-Wynne, C; Iqbal, J; Nasiri, N; Ross, G; Sacks, N; Salter, J | 1 |
| Borja, J; Pérez, N | 1 |
| Berdel, WE; Bremer, K; Peukert, M; Queisser, W; Wander, HE | 1 |
358 review(s) available for triazoles and Breast Cancer
| Article | Year |
|---|---|
Recent Trends in Drug Development for the Treatment of Adenocarcinoma Breast Cancer: Thiazole, Triazole, and Thiosemicarbazone Analogues as Efficient Scaffolds.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Drug Development; Female; Humans; Thiazoles; Thiosemicarbazones; Triazoles | 2022 |
1,2,3-Triazole Derivatives with Anti-breast Cancer Potential.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles | 2022 |
Influence of the anti-oestrogens tamoxifen and letrozole on thyroid function in women with early and advanced breast cancer: A systematic review.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Hypothyroidism; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2023 |
Letrozole: Pharmacology, toxicity and potential therapeutic effects.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Infertility, Female; Letrozole; Nitriles; Triazoles | 2022 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
CDK4/6 inhibitors in HER2-positive breast cancer.
Topics: Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Estradiol; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Receptor, ErbB-2; Triazoles | 2017 |
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Triazoles | 2017 |
HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Drug Substitution; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Network Meta-Analysis; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2017 |
Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinases; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Triazoles | 2017 |
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2- advanced breast cancer: a review.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
Personalized prevention in high risk individuals: Managing hormones and beyond.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Early Detection of Cancer; Female; Genes, BRCA1; Genes, BRCA2; Humans; Mammography; Middle Aged; Nitriles; Precision Medicine; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2018 |
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles | 2018 |
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
Pharmacogenomics of endocrine therapy in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genome-Wide Association Study; Humans; Japan; Letrozole; Musculoskeletal Physiological Phenomena; Nitriles; Pharmacogenetics; Phenotype; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Pharmacological; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Long-Term Care; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Female; Follow-Up Studies; Fractures, Bone; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Awards and Prizes; Breast Neoplasms; Chemotherapy, Adjuvant; Consensus Development Conferences as Topic; Disease-Free Survival; Female; Genes, erbB-2; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Precision Medicine; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Switzerland; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and endocrine therapy: host factors and breast cancer outcome.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Obesity; Postmenopause; Predictive Value of Tests; Premenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Nitriles; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction.
Topics: Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Humans; Letrozole; Nitriles; Oocytes; Pregnancy; Receptors, Estrogen; Reproductive Techniques, Assisted; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2013 |
Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Receptors, Estrogen; Review Literature as Topic; Triazoles | 2014 |
Cutaneous adverse effects of hormonal adjuvant therapy for breast cancer: a case of localised urticarial vasculitis following anastrozole therapy and a review of the literature.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Drug Eruptions; Female; Humans; Nitriles; Triazoles; Urticaria; Vasculitis | 2014 |
Current concepts in breast cancer chemoprevention.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Estrogen Antagonists; Estrogens; Female; Humans; Incidence; Nitriles; Postmenopause; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles; Women | 2014 |
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Topics: Adenocarcinoma; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Female; Humans; Mastectomy; Neoplasm Recurrence, Local; Nitriles; Time Factors; Triazoles | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Genetic Markers; Humans; Nitriles; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Reproducibility of Results; Tamoxifen; Treatment Outcome; Triazoles; Validation Studies as Topic | 2014 |
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Recurrence; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2014 |
Neoadjuvant chemotherapy in breast cancer: review of literature.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2013 |
Aromatase inhibitors in breast cancer prevention.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Invasiveness; Nitriles; Postmenopause; Risk; Triazoles | 2014 |
Is there a role for estrogen activity assays? Recombinant cell bioassay for estrogen: Development and applications.
Topics: Anastrozole; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Child; Estradiol; Female; Humans; Leuprolide; Male; Nitriles; Puberty, Precocious; Radioimmunoassay; Recombinant Proteins; Reference Values; Saccharomyces cerevisiae; Sensitivity and Specificity; Triazoles; Turner Syndrome | 2015 |
The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cytochrome P-450 CYP3A; Female; Glucuronosyltransferase; Humans; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Precision Medicine; Triazoles | 2014 |
Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Fertility Preservation; Humans; Letrozole; Lymphoma, Non-Hodgkin; Nitriles; Oocyte Retrieval; Ovarian Neoplasms; Ovulation Induction; Triazoles | 2014 |
Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2014 |
A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Nitriles; Patient Selection; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Failure; Treatment Outcome; Triazoles | 2015 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2015 |
Extended adjuvant endocrine therapy in hormone-receptor positive early breast cancer: current and future evidence.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2015 |
Palbociclib: first global approval.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclin-Dependent Kinases; Drug Approval; Drug Interactions; Drugs, Investigational; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Triazoles; United States; United States Food and Drug Administration | 2015 |
Testosterone and breast cancer prevention.
Topics: Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Drug Implants; Estrogens; Female; Humans; Nitriles; Testosterone; Triazoles | 2015 |
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles; United States | 2015 |
Ductal Carcinoma In Situ: Treatment Update and Current Trends.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Mammography; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Precision Medicine; Prognosis; Radiotherapy, Adjuvant; Tamoxifen; Triazoles | 2015 |
Development of cell-cycle checkpoint therapy for solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Proliferation; Clinical Trials as Topic; Cyclin-Dependent Kinases; Disease-Free Survival; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Staging; Nitriles; Nuclear Proteins; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Mastectomy; Mutation; Nitriles; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Tamoxifen; Triazoles | 2016 |
Network Meta-Analysis Comparing Overall Survival for Fulvestrant 500 mg Versus Alternative Therapies for Treatment of Postmenopausal, Estrogen Receptor-Positive Advanced Breast Cancer Following Failure on Prior Endocrine Therapy.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Network Meta-Analysis; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Unravelling exemestane: From biology to clinical prospects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Autophagy; Biotransformation; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2016 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Extended adjuvant endocrine therapy in hormone-receptor-positive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Fulvestrant for hormone-sensitive metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MicroRNAs; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2017 |
ADJUVANT (HORMONAL) THERAPY AS A CAUSE OF BONE LOSS IN PATIENTS WITH BREAST CANCER (REVIEW OF LITERATURE).
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Osteoporosis; Postmenopause; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2017 |
Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2008 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Never too late: reducing late breast cancer relapse risk.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Europe; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2008 |
Review of the ATAC study: tamoxifen versus anastrozole in early-stage breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Early Diagnosis; Humans; Nitriles; Tamoxifen; Triazoles | 2008 |
Overcoming recurrence risk: extended adjuvant endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Research Design; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2008 |
[Problems and future direction of preoperative systemic therapy for patients with operable breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Nitriles; Prednisone; Preoperative Care; Remission Induction; Survival Rate; Taxoids; Triazoles; Vincristine | 2008 |
Aromatase inhibitors and breast cancer.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Letrozole; Nitriles; Receptor Cross-Talk; Transplantation, Heterologous; Trastuzumab; Triazoles | 2009 |
[Adjuvant breast cancer treatment with hormono-radiotherapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2009 |
Comparative review of anastrozole, letrozole and exemestane in the management of early breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Breast Neoplasms; Disease Management; Early Detection of Cancer; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2009 |
Letrozole: a review of its use in the treatment of postmenopausal women with hormone-responsive early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2009 |
Breast cancer chemoprevention - a vision not yet realized.
Topics: Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality of Life; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Triazoles | 2009 |
Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Secondary Prevention; Survival Analysis; Tamoxifen; Triazoles; Women's Health | 2009 |
Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Estrogens; Female; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Pyrazoles; Randomized Controlled Trials as Topic; Recurrence; Salvage Therapy; Sulfonamides; Tamoxifen; Triazoles | 2010 |
A case of ectopic breast cancer with a literature review.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Choristoma; Female; Humans; Japan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Cytochrome P-450 CYP2D6; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Genotype; Humans; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
[A negative first-line work-up of Raynaud's phenomenon: And what if it were cancer?].
Topics: Adenocarcinoma, Mucinous; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogens; Female; Galantamine; Humans; Mammography; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Paraneoplastic Syndromes; Pravastatin; Progesterone; Radiotherapy, Adjuvant; Raynaud Disease; Seasons; Triazoles; Verapamil | 2010 |
Letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2010 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Adjuvant endocrine therapy for early breast cancer: the story so far.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Recent advancement in nonsteroidal aromatase inhibitors for treatment of estrogen-dependent breast cancer.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromones; Coumarins; Female; Flavonoids; Humans; Letrozole; Nitriles; Receptors, Estrogen; Sulfonamides; Triazoles | 2010 |
Anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2010 |
Fertility preservation in women with breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Counseling; Cryopreservation; Embryo, Mammalian; Female; Fertility; Gonadotropins; Heterozygote; Humans; Infertility, Female; Letrozole; Nitriles; Oocytes; Ovulation Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2011 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP2D6; Female; Letrozole; Mice; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Overview of adjuvant trials of aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2011 |
Preventive therapy for breast cancer: a consensus statement.
Topics: Anastrozole; Androstadienes; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Consensus Development Conferences as Topic; Diphosphonates; Estrogen Receptor Modulators; Expert Testimony; Female; Fenretinide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metformin; Nitriles; Norpregnenes; Piperidines; Premenopause; Pyrrolidines; Raloxifene Hydrochloride; Retinoids; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Triazoles | 2011 |
[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Triazoles | 2011 |
[Aromatase inhibitors and arthralgia].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Medication Adherence; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Risk Factors; Triazoles | 2011 |
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Postmenopause; Survival Analysis; Triazoles | 2011 |
Update on adjuvant hormonal treatment of early breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Management of patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease Management; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2011 |
Initialization of adjuvant hormonal treatment for breast cancer.
Topics: Adult; Age Factors; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Detection of Cancer; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Metaplastic breast carcinoma: a case report and systematic review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Letrozole; Metaplasia; Mixed Tumor, Malignant; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone and Bones; Breast Neoplasms; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2011 |
Approval summary: letrozole (Femara® tablets) for adjuvant and extended adjuvant postmenopausal breast cancer treatment: conversion of accelerated to full approval.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Approval; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United States; United States Food and Drug Administration | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles | 2012 |
Does hormonal therapy have a therapeutic role in metastatic primary small cell neuroendocrine breast carcinoma? Case report and literature review.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Triazoles | 2012 |
[Progress in study of the structure, catalytic mechanism and inhibitors of aromatase].
Topics: Androstenedione; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalysis; Coumarins; Estrogens; Flavonoids; Humans; Inhibitory Concentration 50; Letrozole; Nitriles; Sesquiterpenes; Structure-Activity Relationship; Triazoles; Xanthones | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Letrozole; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Transcriptional Activation; Triazoles | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Soy products in the management of breast cancer.
Topics: Anastrozole; Animals; Aryl Hydrocarbon Hydroxylases; Asian People; Breast Neoplasms; Cytochrome P-450 CYP1B1; Diet; Drug Interactions; Female; Humans; Incidence; Isoflavones; Meta-Analysis as Topic; Nitriles; Polymorphism, Genetic; Prognosis; Proto-Oncogene Proteins c-mdm2; Receptor, ErbB-2; Recurrence; Risk Factors; Soy Foods; Tamoxifen; Triazoles | 2012 |
Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2013 |
Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer.
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease Management; Disease Progression; Drug Therapy, Combination; Female; Geriatric Assessment; Health Status; Humans; Letrozole; Life Expectancy; Nitriles; Prognosis; Quality of Life; Treatment Outcome; Triazoles | 2013 |
Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Letrozole for the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Receptors, Estrogen; Treatment Outcome; Triazoles | 2002 |
Evolving uses of hormonal agents for breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Nitriles; Tamoxifen; Toremifene; Triazoles | 2002 |
Recent advances in aromatase inhibitor therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Premenopause; Triazoles | 2002 |
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Evidence-Based Medicine; Expert Testimony; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Anastrozole in the management of breast cancer.
Topics: Anastrozole; Animals; Breast Neoplasms; Disease Management; Drug Evaluation; Female; Humans; Nitriles; Survival Analysis; Triazoles | 2002 |
New generation aromatase inhibitors--from the advanced to the adjuvant setting.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
The evolving role of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Anastrozole: in early breast cancer.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Enzyme Inhibitors; Female; Half-Life; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Anti-tumor effects of letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Breast cancer chemoprevention--an update.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Forecasting; Genes, BRCA2; Humans; Incidence; Middle Aged; Nitriles; Odds Ratio; Receptors, Estrogen; Tamoxifen; Triazoles | 2002 |
Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Approval; Female; Humans; Nitriles; Tamoxifen; Triazoles; United States | 2002 |
Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Letrozole; Lipids; Nitriles; Postmenopause; Triazoles | 2003 |
Adjuvant endocrine therapy in postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Current and future status of adjuvant therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Female; Forecasting; Humans; Nitriles; Osteoporosis; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Is tamoxifen the Rosetta stone for breast cancer?
Topics: Acetyltransferases; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Metaphor; Nitriles; Nuclear Receptor Coactivator 1; Nuclear Receptor Coactivator 3; Oncogene Proteins; Phosphorylation; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Signal Transduction; Tamoxifen; Trans-Activators; Transcription Factors; Treatment Failure; Treatment Outcome; Triazoles | 2003 |
Aromatase inhibitors as adjuvant therapy in breast cancer.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Nitriles; Triazoles | 2003 |
[Present and future of adjuvant hormone therapy in breast cancer: clinical evidence and clinical trials].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2003 |
Current status of endocrine therapy for breast cancer.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Climacteric; Female; Goserelin; Humans; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Hormonal therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Progestins; Triazoles | 2003 |
Is low-dose tamoxifen useful for the treatment and prevention of breast cancer?
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Estrogens; Female; Humans; Ki-67 Antigen; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
The current status of aromatase inhibitors in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2003 |
Development of aromatase inhibitors and their pharmacologic profile.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2003 |
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2003 |
Emerging role of aromatase inhibitors in the adjuvant setting.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Aromatase inhibitors in prevention--data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2003 |
Safety issues surrounding the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Metabolism; Nitriles; Patient Satisfaction; Quality of Life; Safety; Tamoxifen; Triazoles | 2003 |
Should aromatase inhibitors replace tamoxifen?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
[Perspectives for the hormonal therapy of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles | 2003 |
The role of aromatase inhibitors in the treatment of metastatic breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2003 |
Pharmacokinetics of third-generation aromatase inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2003 |
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Endocrine System; Female; Humans; Menopause; Neoplasm Metastasis; Nitriles; Patient Selection; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evidence-Based Medicine; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Triazoles | 2003 |
Fulvestrant in postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Estradiol; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Rate; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2003 |
Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
[Adjuvant endocrine treatment of breast cancer beyond St. Gallen 2003].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2003 |
Role of anastrozole in adjuvant therapy for postmenopausal patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogens; Estrone; Humans; Nitriles; Postmenopause; Radioimmunoassay; Triazoles | 2003 |
Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2003 |
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
The pharmacology of letrozole.
Topics: Adrenocorticotropic Hormone; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrone; Humans; Letrozole; Nitriles; Triazoles | 2003 |
New findings about endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
The best use of adjuvant endocrine treatments.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Ovary; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Challenges in the endocrine management of breast cancer.
Topics: Adult; Aged; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Mastectomy, Segmental; Mice; Middle Aged; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
Focus on anastrozole and breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Enzyme Inhibitors; Estrogens; Female; Goserelin; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Triazoles | 2003 |
A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2003 |
The endocrine management of postmenopausal women with early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Neoplasm Staging; Postmenopause; Tamoxifen; Triazoles | 2004 |
[Neoadjuvant endocrine therapy for breast cancer: an overview].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2004 |
Anastrozole (Arimidex).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Half-Life; Humans; Metabolic Clearance Rate; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Triazoles | 2004 |
[Controversies in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Replacement Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2004 |
Importance of correlative science in advancing hormonal therapy and a new clinical paradigm for neoadjuvant therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Gene Expression Profiling; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors for breast cancer in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Drug Interactions; Economics, Pharmaceutical; Female; Forecasting; Geriatrics; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2004 |
Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Letrozole: a review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Cost-Benefit Analysis; Drug Tolerance; Economics, Pharmaceutical; Enzyme Inhibitors; Female; Half-Life; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Severity of Illness Index; Triazoles | 2004 |
Overcoming endocrine therapy resistance by signal transduction inhibition.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Tamoxifen; Triazoles | 2004 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
Current developments in hormonal therapy of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Middle Aged; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Role of aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Breast cancer (metastatic).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2004 |
Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Topics: Algorithms; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Trees; Drug Administration Schedule; Drug Monitoring; Estradiol; Female; Fulvestrant; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Safety; Selective Estrogen Receptor Modulators; Social Support; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Aromatase inhibitors and breast cancer: time for a change?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Evidence-Based Medicine; Female; Humans; Letrozole; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors in advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Aromatase inhibitors in early breast cancer therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Triazoles | 2004 |
Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Pamidronate; Postmenopause; Triazoles; Zoledronic Acid | 2004 |
Cost-effectiveness of letrozole versus tamoxifen as first-line hormonal therapy in treating postmenopausal women with advanced breast cancer in Japan.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Immunohistochemistry; Injections, Intramuscular; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2005 |
Aromatase inhibition: translation into a successful therapeutic approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Humans; Letrozole; Molecular Structure; Nitriles; Triazoles | 2005 |
Aromatase inhibitors in the treatment of early and advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Triazoles | 2005 |
Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Fulvestrant; Humans; Injections, Intramuscular; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors for the treatment and prevention of breast cancer.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Aromatase inhibitors in adjuvant setting in breast cancer].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Menopause; Nitriles; Triazoles | 2004 |
A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance; Estrogen Receptor Modulators; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Time Factors; Triazoles | 2005 |
Aromatase inhibitors for therapy of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Drug Evaluation; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Consensus Meeting of the 9th International Conference on Primary Therapy of Early Breast Cancer (St. Gall, January 26-29, 2005)].
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
The aromatase inhibitors in early breast cancer: who, when, and why?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Patient Selection; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Endpoint Determination; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Letrozole in the treatment of breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Female; Humans; Letrozole; Models, Molecular; Nitriles; Triazoles | 2005 |
Anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Recurrence; Survival Rate; Tamoxifen; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles | 2005 |
Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carrier Proteins; Cervical Vertebrae; Female; Fractures, Compression; Glycoproteins; Humans; Immunohistochemistry; Lumbar Vertebrae; Magnetic Resonance Imaging; Membrane Transport Proteins; Meningioma; Middle Aged; Nitriles; Radiography; Spinal Cord Neoplasms; Treatment Outcome; Triazoles | 2005 |
Breast cancer (metastatic).
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Nitriles; Progestins; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Recent advances in the use of aromatase inhibitors for women with postmenopausal breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Adjuvant endocrine therapy in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
The biology of steroid hormones and endocrine treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Goserelin; Humans; Nitriles; Postmenopause; Triazoles | 2005 |
New developments in the treatment of postmenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2005 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Life following aromatase inhibitors--where now for endocrine sequencing?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2005 |
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Defining the roles of aromatase inhibitors in the adjuvant treatment of early-stage breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Neoplasm Staging; Nitriles; Research Design; Tamoxifen; Triazoles | 2005 |
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2005 |
Letrozole as adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Neoadjuvant Therapy; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Adjuvant endocrine therapy for postmenopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Review of the development of letrozole and its use in advanced breast cancer and in the neoadjuvant setting.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Salvage Therapy; Triazoles | 2006 |
The extended adjuvant NCIC CTG MA.17 trials: initial and rerandomization studies.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Ontario; Randomized Controlled Trials as Topic; Research Design; Triazoles | 2006 |
The evolving role of letrozole in the adjuvant setting: first results from the large, phase III, randomized trial BIG 1-98.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles; Zoledronic Acid | 2006 |
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Models, Animal; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Letrozole : in postmenopausal hormone-responsive early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Triazoles; Venous Thrombosis | 2006 |
Emerging data on optimal adjuvant endocrine therapy: Breast International Group trial 1-98/MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2006 |
Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Topics: Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Everolimus; Female; Forecasting; Humans; Immunosuppressive Agents; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Sirolimus; Triazoles | 2006 |
Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole: Case report and review of the literature.
Topics: Acute Disease; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Incidence; Nitriles; Pulmonary Embolism; Triazoles; Venous Thrombosis | 2006 |
Pre-menopausal breast cancer and aromatase inhibitors: Treating a new generation of women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Therapy; Estrogens; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2006 |
Anastrozole for breast cancer: recent advances and ongoing challenges.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2006 |
Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2006 |
[Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Rate; Tamoxifen; Triazoles | 2006 |
The adjuvant endocrine treatment revolution: focus on anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Molecular Structure; Nitriles; Treatment Outcome; Triazoles | 2006 |
Time to response: comparison of fulvestrant and oral endocrine agents.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Breast cancer (metastatic).
Topics: Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Progestins; Tamoxifen; Taxoids; Triazoles | 2006 |
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Topics: Adult; Aged; Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2006 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Update on the use of aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
Neoadjuvant endocrine therapy in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Patient Selection; Tamoxifen; Triazoles | 2007 |
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Adjuvant therapy for patients who have node-positive breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Continuing with letrozole offers greater benefits.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Time Factors; Treatment Outcome; Triazoles | 2007 |
Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol; Estrogens; Female; Humans; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Thromboembolism; Triazoles; Triglycerides | 2007 |
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2006 |
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Ovariectomy; Ovary; Postmenopause; Premenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
[Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
[Advancement in endocrine therapy for breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
DNA methylation in breast and colorectal cancers.
Topics: Breast Neoplasms; Colorectal Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Indoles; Male; Phthalimides; Pyridines; Triazoles | 2007 |
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2007 |
Prescribing extended adjuvant letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Triazoles | 2007 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
Aromatase inhibitors and musculoskeletal pain in patients with breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Monitoring; Female; Humans; Musculoskeletal Diseases; Nitriles; Nurse's Role; Nursing Assessment; Nursing Research; Oncology Nursing; Pain; Pain Management; Pain Measurement; Patient Care Planning; Patient Education as Topic; Patient Selection; Postmenopause; Quality of Life; Receptors, Estrogen; Treatment Outcome; Triazoles | 2007 |
Letrozole: present and future role in the treatment of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Premenopause; Randomized Controlled Trials as Topic; Triazoles | 2007 |
[Antiestrogen treatment in postmenopausal patients with metastatic breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Nitriles; Postmenopause; Prognosis; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Reducing the risk of late recurrence in hormone-responsive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2007 |
The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Drug Resistance; Female; Humans; Letrozole; Musculoskeletal Diseases; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thromboembolism; Triazoles | 2007 |
The early days of letrozole.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Tolerance; Female; History, 20th Century; Humans; International Cooperation; Letrozole; Nitriles; Postmenopause; Triazoles | 2007 |
The discovery and mechanism of action of letrozole.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Middle Aged; Molecular Structure; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Structure-Activity Relationship; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Causality; Chemotherapy, Adjuvant; Comorbidity; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Incidence; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Osteoporosis; Rats; Survival Analysis; Tamoxifen; Triazoles | 2007 |
The patient experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Patient Education as Topic; Postmenopause; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Femara and the future: tailoring treatment and combination therapies with Femara.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2007 |
Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.
Topics: Adenocarcinoma; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Contraceptives, Oral; Female; Ferritins; Hemochromatosis Protein; Histocompatibility Antigens Class I; Humans; Membrane Proteins; Mutation; Nitriles; Phlebotomy; Porphyria Cutanea Tarda; Triazoles | 2007 |
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Postmenopause; Practice Guidelines as Topic; Quality of Life; Risk Assessment; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cognition; Female; Gonadotropin-Releasing Hormone; Humans; Neuropsychological Tests; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2007 |
Assisted reproduction and breast cancer.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cryopreservation; Embryo Transfer; Female; Fertility Agents, Female; Humans; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Pregnancy; Primary Ovarian Insufficiency; Quality of Life; Reproductive Techniques, Assisted; Tamoxifen; Triazoles | 2007 |
Update on the use of letrozole in breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2007 |
Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Triazoles | 2007 |
Aromatase inhibitors: past, present and future in breast cancer therapy.
Topics: Aminoglutethimide; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Fadrozole; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Arthralgia; Atrophy; Breast Neoplasms; Cardiovascular Diseases; Comorbidity; Female; Hot Flashes; Humans; Lubricants; Neoplasm Recurrence, Local; Nitriles; Patient Education as Topic; Quality of Life; Tamoxifen; Triazoles; Vagina; Weight Gain | 2008 |
Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Evidence-Based Medicine; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
A review of the BIG results: the Breast International Group 1-98 trial analyses.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles; United States | 2008 |
Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Aromatase inhibitors in early breast-cancer treatment: The story so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 2008 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Forecasting; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2008 |
Targeting breast cancer with hormonal treatment options.
Topics: Aftercare; Ambulatory Care; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor Modulators; Humans; Information Services; Internet; Letrozole; Nitriles; Nurse Practitioners; Patient Selection; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estradiol; Female; Humans; Hydrocortisone; Nitriles; Triazoles | 1995 |
Vorozole, a specific non-steroidal aromatase inhibitor.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estradiol; Female; Hormones; Humans; In Vitro Techniques; Male; Mammary Neoplasms, Experimental; Triazoles | 1994 |
Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Azoles; Breast Neoplasms; Female; Humans; Imidazoles; Male; Structure-Activity Relationship; Tetrazoles; Triazoles | 1994 |
Clinical use of aromatase inhibitors in the treatment of breast cancers.
Topics: Aminoglutethimide; Animals; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Letrozole; Nitriles; Rats; Triazoles | 1993 |
The control and biological importance of intratumoural aromatase in breast cancer.
Topics: Adenocarcinoma; Androgens; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Male; Mice; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Triazoles; Tumor Cells, Cultured | 1996 |
Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogens; Evaluation Studies as Topic; Female; Humans; Letrozole; Male; Nitriles; Postmenopause; Triazoles | 1996 |
New aromatase inhibitors for breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1997 |
[New drugs in metastatic breast cancer--1997].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Diphosphonates; Drug Resistance, Multiple; Female; Humans; Ibandronic Acid; Imidazoles; Letrozole; Nitriles; Tamoxifen; Taxoids; Triazoles; Zoledronic Acid | 1997 |
ARIMIDEX: a potent and selective aromatase inhibitor for the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Triazoles | 1997 |
Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Anastrozole: a new selective nonsteroidal aromatase inhibitor.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Nitriles; Postmenopause; Safety; Survival Rate; Treatment Outcome; Triazoles; United States | 1997 |
The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Anastrozole; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Models, Animal; Enzyme Inhibitors; Female; Humans; Mammary Neoplasms, Experimental; Nitriles; Postmenopause; Rats; Triazoles | 1997 |
Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Nitriles; Triazoles | 1997 |
Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Nitriles; Postmenopause; Prospective Studies; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 1997 |
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Nitriles; Triazoles | 1998 |
Anastrozole: a new addition to the armamentarium against advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 1998 |
Emerging role of aromatase inhibitors in the treatment of breast cancer.
Topics: Aged; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Pivotal trials of letrozole: a new aromatase inhibitor.
Topics: Aminoglutethimide; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Treatment Outcome; Triazoles | 1998 |
Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogens; Female; Humans; Nitriles; Triazoles | 1998 |
Theoretical considerations for the ideal aromatase inhibitor.
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1998 |
Pharmacological and clinical profile of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enzyme Inhibitors; Humans; Neoplasms, Hormone-Dependent; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Fadrozole; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 1998 |
Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 1998 |
Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Female; Humans; Intestinal Absorption; Letrozole; Nitriles; Postmenopause; Survival Rate; Triazoles | 1998 |
The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Belgium; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Severity of Illness Index; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Triazoles | 1999 |
[Aromatase inhibitors].
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Estrogen Antagonists; Estrone; Female; Humans; Letrozole; Nitriles; Triazoles | 1999 |
Aromatase inhibitors and their application in breast cancer treatment*.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mice; Nitriles; Tamoxifen; Triazoles | 2000 |
Drug and hormone interactions of aromatase inhibitors.
Topics: Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Enzyme Inhibitors; Estrogens; Fadrozole; Female; Humans; Letrozole; Male; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Sensitivity and Specificity; Tamoxifen; Triazoles | 1999 |
Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Topics: Aged; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 1999 |
Aromatase inhibitors: a dose-response effect?
Topics: Aminoglutethimide; Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrogens; Fadrozole; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1999 |
Aromatase inhibitors and their use in the sequential setting.
Topics: Androstenedione; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 1999 |
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 1999 |
Use of aromatase inhibitors in breast carcinoma.
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Design; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 1999 |
Steroidal aromatase inhibitors in elderly patients.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
[Chemo/endocrine therapy for breast cancer patients].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Gonadotropin-Releasing Hormone; Humans; Nitriles; Tamoxifen; Triazoles | 2000 |
[Aromatase inhibitors for treatment of advanced breast cancers].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Fadrozole; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2000 |
New aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Triazoles | 2000 |
Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2000 |
[Aromatase inhibitors: a review of clinical trials].
Topics: Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2000 |
[Development of a novel aromatase inhibitor, anastrozole (Arimidex)--its basic and clinical studies].
Topics: Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase I as Topic; Dogs; Enzyme Inhibitors; Female; Humans; Mice; Middle Aged; Nitriles; Postmenopause; Rats; Triazoles | 2001 |
Aromatase regulation and breast cancer.
Topics: 2-Methoxyestradiol; Adult; Animals; Aromatase; Aromatase Inhibitors; Aryl Hydrocarbon Hydroxylases; Breast; Breast Neoplasms; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Cytokines; Dietary Fats; Dinoprostone; Enzyme Activation; Enzyme Inhibitors; Estradiol; Estrogens; Female; Fibroblasts; Humans; Letrozole; Middle Aged; Nitriles; Obesity; Pesticides; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Triazoles | 2001 |
[Developments of hormonal agents for breast cancer].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2001 |
Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Topics: Anastrozole; Androstadienes; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Fadrozole; Female; Headache; Humans; Letrozole; Nausea; Nitriles; Treatment Outcome; Triazoles; Vomiting | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
Role of anti-aromatase agents in postmenopausal advanced breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Aromatase and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Survival Analysis; Treatment Outcome; Triazoles | 2001 |
A summary of second-line randomized studies of aromatase inhibitors.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Drug Tolerance; Enzyme Inhibitors; Estrogen Receptor Modulators; Fadrozole; Female; Humans; Letrozole; Megestrol Acetate; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
A vision for the future?
Topics: Anastrozole; Breast Neoplasms; Estradiol; Female; Fulvestrant; Goserelin; Humans; Menopause; Nitriles; Tamoxifen; Triazoles | 2001 |
Anastrozole (Arimidex)--an aromatase inhibitor for the adjuvant setting?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Triazoles | 2001 |
Are differences in the available aromatase inhibitors and inactivators significant?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
Preliminary data from ongoing adjuvant aromatase inhibitor trials.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors continue their ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Letrozole in the treatment of breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Costs and Cost Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Metabolic Clearance Rate; Nitriles; Postmenopause; Triazoles | 2002 |
Antiaromatase agents: evolving role in adjuvant therapy.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
[The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile].
Topics: Adult; Aminoglutethimide; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Forecasting; Humans; Letrozole; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triazoles | 2002 |
[Antiestrogen therapy in the treatment of breast neoplasms].
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Estrogen Antagonists; Female; Forecasting; Humans; Indoles; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2002 |
Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Topics: Aminoglutethimide; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles | 1992 |
464 trial(s) available for triazoles and Breast Cancer
| Article | Year |
|---|---|
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Topics: Adjuvants, Immunologic; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2023 |
Ten-year update: NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-42 randomized trial: extended letrozole therapy in early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2023 |
Topics: Acetaminophen; Administration, Oral; Adolescent; Adsorption; Adult; Allyl Compounds; Amylopectin; Amylose; Anaerobiosis; Animals; Anti-Bacterial Agents; Anura; Arginase; Arthritis, Rheumatoid; Asthma; Atmosphere; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; Bioelectric Energy Sources; Biofilms; Biofuels; Biomarkers; Biopolymers; Bioreactors; Brain; Brain Injuries, Traumatic; Breast Neoplasms; Calibration; Carbon Tetrachloride; Caspase 3; Catalysis; Catechin; Cations; Cattle; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Body; Cell Line, Tumor; Cell Plasticity; Chemical and Drug Induced Liver Injury; Chemistry Techniques, Synthetic; China; Chitosan; Chloride Channels; Chromatography, High Pressure Liquid; Chromosome Mapping; Cognition; Cognitive Dysfunction; Cohort Studies; Colitis, Ulcerative; Colloids; Coloring Agents; Congresses as Topic; Correlation of Data; Crystallization; Cyanoacrylates; Cyclohexane Monoterpenes; Cyprinidae; Cytochrome P-450 CYP1A1; Death, Sudden; Dent Disease; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Disease Progression; Disease Resistance; Disulfides; Drug Monitoring; Drug Stability; Ecotoxicology; Electricity; Electrodes; Endocytosis; Environmental Exposure; Environmental Monitoring; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; Esophageal and Gastric Varices; Esters; Fagopyrum; Female; Ferrosoferric Oxide; Flame Retardants; Flavobacteriaceae; Flow Cytometry; Follow-Up Studies; Formoterol Fumarate; Fusarium; Garlic; Gastrointestinal Hemorrhage; Gene Expression; Genes, Plant; Genetic Markers; Glial Fibrillary Acidic Protein; Gliosis; Global Health; Glutathione Transferase; Glycine max; Gum Arabic; Hemostasis, Endoscopic; Hepatocytes; Hippocampus; Humans; Hydrogen-Ion Concentration; Illinois; Immunoglobulin G; Indoleamine-Pyrrole 2,3,-Dioxygenase; Infant, Newborn; Infant, Small for Gestational Age; Injections, Intraperitoneal; Interleukin-4; Iowa; Iron; Ki-67 Antigen; Kidney; Kinetics; Kynurenine; Lakes; Levofloxacin; Lipid Peroxidation; Lipids; Liver; Liver Cirrhosis, Experimental; Magnetic Fields; Magnetic Iron Oxide Nanoparticles; Male; Manure; Maze Learning; Memory, Short-Term; Metal Nanoparticles; Metals, Heavy; Methane; Mice; Mice, Inbred C57BL; Mice, Knockout; Michigan; Microalgae; Microbial Consortia; Mitochondria; Models, Animal; Models, Chemical; Models, Neurological; Molecular Structure; Molecular Weight; Mutation; Myeloid-Derived Suppressor Cells; NADPH Oxidase 2; Neoplasm Recurrence, Local; Neurites; Neurons; Neuroprotective Agents; NF-kappa B; NIH 3T3 Cells; Nitric Oxide Synthase Type II; Nitrogen; Ohio; Ointments; Ontario; Organelle Biogenesis; Organophosphates; Organophosphorus Compounds; Oxidative Stress; Palladium; Particle Size; Pectins; Phenotype; Phytotherapy; Piperidines; Placenta; Plant Diseases; Plant Extracts; Polymers; Polymorphism, Genetic; Polyphenols; Powders; Pregnancy; Pregnancy Trimester, First; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Secondary; Proteins; Pyridines; Pyrimidines; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Aryl Hydrocarbon; Receptors, Chemokine; Receptors, Formyl Peptide; Receptors, Lipoxin; Recovery of Function; Recurrence; Reference Standards; Reference Values; Reproducibility of Results; Respiratory Function Tests; Retrospective Studies; Risk; Sensitivity and Specificity; Sewage; Signal Transduction; Sodium Glutamate; Soil; Solanum tuberosum; Solubility; Solutions; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spermatozoa; STAT3 Transcription Factor; Sulfamethoxazole; Tea; Temperature; Thermodynamics; Thrombin; Treatment Outcome; Triazoles; United States; Viscosity; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical; Water Purification; White Matter; Wisconsin; X-Ray Diffraction; Zea mays | 2013 |
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2021 |
ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoxazoles; Breast Neoplasms; Female; Hormones; Humans; Neoadjuvant Therapy; Nitriles; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2021 |
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2021 |
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study.
Topics: Aged; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2017 |
Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Reported Outcome Measures; Prospective Studies; Random Allocation; Treatment Outcome; Triazoles | 2017 |
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles | 2017 |
Stimulation of the ovaries in women with breast cancer undergoing fertility preservation: Alternative versus standard stimulation protocols; the study protocol of the STIM-trial.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Body Mass Index; Breast Neoplasms; Estrogens; Female; Fertility Preservation; Follicle Stimulating Hormone; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Research Design; Socioeconomic Factors; Tamoxifen; Triazoles; Young Adult | 2017 |
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Grading; Nitriles; Nuclear Receptor Coactivator 3; Postmenopause; Prognosis; Tamoxifen; Tissue Array Analysis; Treatment Outcome; Triazoles; Up-Regulation | 2017 |
Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Topics: Administration, Oral; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Dietary; Chemotherapy, Adjuvant; Cholecalciferol; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles | 2017 |
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2018 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Survival Rate; Treatment Outcome; Triazoles | 2017 |
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Mastectomy; Maximum Tolerated Dose; Middle Aged; Netherlands; Nitriles; Postmenopause; Prognosis; Prospective Studies; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Topics: Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2018 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden | 2017 |
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2018 |
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Denmark; Female; Humans; Letrozole; Lymph Node Excision; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2018 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Denmark; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2018 |
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2018 |
Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Intraepithelial Lymphocytes; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid | 2018 |
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Piperazines; Postmenopause; Pyridines; Survival Analysis; Treatment Outcome; Triazoles | 2018 |
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Electrocardiography; Female; Heart Rate; Humans; Letrozole; Middle Aged; Nitriles; Piperazines; Pyridines; Triazoles | 2018 |
Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; China; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Response Evaluation Criteria in Solid Tumors; Taiwan; Triazoles | 2018 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen Anastrozole trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Endometrial Neoplasms; Female; Follow-Up Studies; Fractures, Bone; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Receptors, Steroid; Time Factors; Treatment Outcome; Triazoles | 2013 |
Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Goserelin; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2013 |
A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Preoperative Care; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2013 |
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Female; Humans; Introns; Letrozole; Middle Aged; Models, Genetic; Multivariate Analysis; Nitriles; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Failure; Triazoles | 2013 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Administration Schedule; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Topics: Adult; Amenorrhea; Anastrozole; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Estradiol; Female; Humans; Middle Aged; Nitriles; Ovary; Primary Ovarian Insufficiency; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles; Uterine Hemorrhage | 2013 |
Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Topics: Adolescent; Adult; Age of Onset; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Goserelin; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Pregnancy; Survival Analysis; Treatment Outcome; Triazoles; Young Adult | 2013 |
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone and Bones; Breast Neoplasms; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Grading; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2013 |
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Hot Flashes; Humans; Letrozole; Medication Adherence; Middle Aged; Musculoskeletal Pain; Nitriles; Sleep Wake Disorders; Time Factors; Triazoles; Urinary Bladder Diseases; Vaginal Diseases | 2014 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Obesity; Overweight; Postmenopause; Retrospective Studies; Triazoles; Young Adult | 2013 |
Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Prospective Studies; Receptors, Estrogen; Tamoxifen; Triazoles | 2013 |
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Letrozole; Mammography; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Prospective Studies; Triazoles | 2013 |
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Double-Blind Method; Female; Humans; Longitudinal Studies; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Risk Factors; Treatment Outcome; Triazoles | 2014 |
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Female; Humans; Incidence; Medication Adherence; Middle Aged; Nitriles; Prospective Studies; Treatment Outcome; Triazoles | 2014 |
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2014 |
FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Triazoles; Zoledronic Acid | 2014 |
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Female; HSP90 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Triazoles | 2014 |
Optimum duration of neoadjuvant letrozole to permit breast conserving surgery.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2014 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Female; Humans; Letrozole; Metformin; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Research Design; Triazoles | 2014 |
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bones of Lower Extremity; Breast Neoplasms; Calcium; Canada; Chemotherapy, Adjuvant; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Time Factors; Treatment Outcome; Triazoles; United States; Vitamin D | 2014 |
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Letrozole; Middle Aged; Morpholines; Multimodal Imaging; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Tomography, X-Ray Computed; Triazoles | 2014 |
A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Estrogen Receptor beta; Female; Flax; Gonadal Steroid Hormones; Humans; Lignans; Linear Models; Middle Aged; Nitriles; Pilot Projects; Treatment Outcome; Triazoles; Young Adult | 2014 |
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Lymph Node Excision; Mastectomy; Medication Adherence; Middle Aged; Nitriles; Patient Education as Topic; Postmenopause; Triazoles | 2014 |
Health-related quality of life and psychological distress during neoadjuvant endocrine therapy with letrozole to determine endocrine responsiveness in postmenopausal breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Triazoles | 2014 |
Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Prospective Studies; Surveys and Questionnaires; Survival Analysis; Treatment Outcome; Triazoles | 2014 |
Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
Topics: Adult; Anti-Mullerian Hormone; Breast Neoplasms; Chorionic Gonadotropin; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; In Vitro Oocyte Maturation Techniques; Letrozole; Nitriles; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Triazoles | 2014 |
Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Early Detection of Cancer; Female; Follow-Up Studies; Goserelin; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mucin-1; Nitriles; Pilot Projects; Single-Blind Method; Tamoxifen; Treatment Outcome; Triazoles | 2014 |
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Genital Neoplasms, Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles; Young Adult | 2014 |
Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Exercise; Female; Follow-Up Studies; Humans; Letrozole; Life Style; Middle Aged; Neoplasm Staging; Nitriles; Obesity; Postmenopause; Prognosis; Quality of Life; Surveys and Questionnaires; Telephone; Triazoles; Weight Loss | 2014 |
Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Feasibility Studies; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Staging; Nitriles; Ovariectomy; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2014 |
A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Liver; Middle Aged; Nitriles; Prospective Studies; Tamoxifen; Treatment Failure; Triazoles | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases; Triazoles | 2014 |
Electroacupuncture for fatigue, sleep, and psychological distress in breast cancer patients with aromatase inhibitor-related arthralgia: a randomized trial.
Topics: Aged; Anastrozole; Androstadienes; Anxiety; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Depression; Electroacupuncture; Fatigue; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Sleep Wake Disorders; Stress, Psychological; Treatment Outcome; Triazoles | 2014 |
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcitonin; Calcium; Female; Femur; Humans; Middle Aged; Nitriles; Osteocalcin; Osteoporosis; Pain; Phosphorus; Spine; Triazoles | 2014 |
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; Nitriles; Postmenopause; Testosterone; Triazoles | 2015 |
Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Triazoles | 2014 |
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Breast Neoplasms; Data Interpretation, Statistical; Female; Follow-Up Studies; Hormones; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Regression Analysis; Risk; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2015 |
NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Triazoles | 2014 |
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Protocols; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Postmenopause; Preoperative Care; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Triazoles; Zoledronic Acid | 2014 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hot Flashes; Humans; Kaplan-Meier Estimate; Middle Aged; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; North America; Piperazines; Postmenopause; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Republic of Korea; South Africa; Time Factors; Treatment Outcome; Triazoles | 2015 |
Does patient education work in breast cancer? Final results from the global CARIATIDE study.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Patient Education as Topic; Tamoxifen; Triazoles | 2015 |
Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Electroretinography; Evoked Potentials, Visual; Female; Humans; Letrozole; Middle Aged; Nerve Fibers; Nitriles; Optic Nerve; Retina; Tomography, Optical Coherence; Triazoles; Visual Acuity | 2016 |
Evaluating the feasibility of performing window of opportunity trials in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Administration Schedule; Feasibility Studies; Female; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Prospective Studies; Triazoles | 2015 |
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Germany; Hormones; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Spain; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor A | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Letrozole; Middle Aged; Nitriles; Phosphorylation; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Joint Diseases; Middle Aged; Nitriles; Postmenopause; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2016 |
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition Disorders; Female; Humans; Letrozole; Memory; Middle Aged; Nitriles; Postmenopause; Psychomotor Performance; Quality of Life; Tamoxifen; Triazoles | 2015 |
Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2015 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Doxorubicin; Everolimus; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Triazoles | 2015 |
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Treatment Outcome; Triazoles | 2015 |
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPP.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Outcome Assessment, Health Care; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinoxalines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Sulfonamides; Treatment Outcome; Triazoles | 2015 |
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Early Detection of Cancer; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Double-Blind Method; Female; Humans; Incidence; International Cooperation; Middle Aged; Nitriles; Odds Ratio; Risk Factors; Severity of Illness Index; Triazoles | 2016 |
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Triazoles | 2016 |
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Combined Modality Therapy; Female; Fibrosis; Genome-Wide Association Study; Humans; Letrozole; Middle Aged; Nitriles; Nuclear Proteins; Polymorphism, Single Nucleotide; Radiotherapy, Adjuvant; Triazoles | 2016 |
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2016 |
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Administration, Oral; Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Embolism; Female; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Thrombosis; Triazoles | 2016 |
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Double-Blind Method; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2016 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Early Termination of Clinical Trials; Female; Gefitinib; Humans; Middle Aged; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2016 |
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Indoles; Letrozole; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Panobinostat; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triazoles | 2016 |
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Estradiol; Female; Fulvestrant; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Hypoglycemic Agents; Maximum Tolerated Dose; Middle Aged; Nitriles; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Treatment Outcome; Triazoles | 2016 |
Fulvestrant decreases anastrozole drug concentrations when taken concurrently by patients with metastatic breast cancer treated on SWOG study S0226.
Topics: Anastrozole; Breast Neoplasms; Drug Interactions; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2016 |
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2016 |
Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Bone Density; Breast Neoplasms; Cholecalciferol; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Nitriles; Triazoles; Vitamin D | 2016 |
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Follicle Stimulating Hormone; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Receptors, Estrogen; Triazoles | 2016 |
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cancer Pain; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Nitriles; Pain Measurement; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; Preoperative Care; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Sulfonamides; Triazoles | 2016 |
Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Comorbidity; Female; Humans; Middle Aged; Nitriles; Postmenopause; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents; Autonomic Nervous System Diseases; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Multivariate Analysis; Musculoskeletal Diseases; Nitriles; Proportional Hazards Models; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Vasomotor System | 2016 |
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2016 |
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence.
Topics: Aged; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole.
Topics: Arthralgia; Breast Neoplasms; Calcium; Cholecalciferol; Dietary Supplements; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles; Vitamin D | 2016 |
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Postmenopause; Quality of Life; Recurrence; Secondary Prevention; Triazoles | 2016 |
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Estradiol; Female; Follow-Up Studies; France; Fulvestrant; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Survival Rate; Triazoles | 2016 |
Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D2; Cyclin D3; Cyclin E; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; DNA, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oncogene Proteins; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retinoblastoma Protein; Signal Transduction; Triazoles | 2016 |
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neutropenia; Nitriles; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Survival Analysis; Treatment Outcome; Triazoles | 2016 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Retreatment; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2016 |
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Clinical Decision-Making; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Gene Expression Profiling; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy, Segmental; Middle Aged; Molecular Typing; Neoadjuvant Therapy; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Registries; Tamoxifen; Taxoids; Treatment Outcome; Triazoles; Young Adult | 2017 |
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2016 |
Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2017 |
Palbociclib and Letrozole in Advanced Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinases; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neutropenia; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Triazoles | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Depression; Disease-Free Survival; Dyspnea; Female; Hot Flashes; Humans; Hypertension; Letrozole; Lymphatic Metastasis; Mastectomy; Middle Aged; Myalgia; Neoplasm Staging; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triazoles | 2017 |
Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Counseling; Cryopreservation; Disease-Free Survival; Female; Fertility; Fertilization in Vitro; Gonadotropins; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Ovulation Induction; Prospective Studies; Triazoles | 2008 |
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
Evaluation of endometrial thickness in hormone receptor positive early stage breast cancer postmenopausal women switching from adjuvant tamoxifen treatment to anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Linear Models; Nitriles; Osteoporosis; Premenopause; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2008 |
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Double-Blind Method; Female; Humans; Memory; Middle Aged; Neuropsychological Tests; Nitriles; Postmenopause; Triazoles | 2008 |
Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Decision Support Techniques; Feedback; Female; Health Knowledge, Attitudes, Practice; Humans; Informed Consent; Middle Aged; Nitriles; Patient Education as Topic; Patient Selection; Pilot Projects; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Teaching Materials; Triazoles | 2008 |
Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Triazoles | 2008 |
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases; Breast Neoplasms; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Nitriles; Placebos; Triazoles | 2008 |
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Endocrine System; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Tamoxifen; Triazoles | 2008 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Incidence; Japan; Joint Diseases; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles; White People | 2009 |
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Administration Schedule; Estrogen Receptor alpha; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Ki-67 Antigen; Letrozole; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neoadjuvant Therapy; Nitriles; Phosphorylation; Triazoles | 2009 |
Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; United Kingdom | 2009 |
Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Topics: Aromatase Inhibitors; Biopsy, Fine-Needle; Breast Neoplasms; Cell Nucleus; Clinical Trials, Phase II as Topic; Epithelial Cells; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Letrozole; Mammography; Menopause; Nitriles; Pilot Projects; Predictive Value of Tests; Risk Factors; Treatment Outcome; Triazoles | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Estrogen Antagonists; Female; Follow-Up Studies; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Premenopause; Receptors, Estrogen; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Bone Quality Test (BQT) scores of fingernails in postmenopausal patients treated with adjuvant letrozole or tamoxifen for early breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nails; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nitriles; Pilot Projects; Postmenopause; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2009 |
[Lipid metabolism disorders at the breast cancer patients receiving hormonotherapy].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cholesterol, LDL; Dyslipidemias; Estrogen Antagonists; Female; Humans; Letrozole; Lipid Metabolism Disorders; Nitriles; Tamoxifen; Time Factors; Toremifene; Triazoles; Triglycerides | 2009 |
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Cyclin D1; Double-Blind Method; Europe; Everolimus; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Palpation; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Ribosomal Protein S6 Kinases; Sirolimus; Time Factors; Treatment Outcome; Triazoles; United States | 2009 |
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Dehydroepiandrosterone Sulfate; Diphosphonates; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Imidazoles; Letrozole; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Progesterone; Receptors, Estrogen; Tamoxifen; Testosterone; Triazoles; Zoledronic Acid | 2009 |
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prognosis; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Fractures, Bone; Humans; Incidence; Letrozole; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles | 2009 |
Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Therapy, Combination; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Cyclooxygenase 2; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Tissue Array Analysis; Triazoles | 2009 |
Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal; Cohort Studies; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Hormone Replacement Therapy; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Tamoxifen; Triazoles | 2009 |
Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2009 |
A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Drug Administration Schedule; Estradiol; Female; Humans; Ki-67 Antigen; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2010 |
Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Risk Factors; Tamoxifen; Triazoles | 2009 |
[Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Tegafur; Triazoles; Uracil | 2009 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Statistics, Nonparametric; Survival Analysis; Trastuzumab; Treatment Outcome; Triazoles | 2009 |
Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Female; Genotype; Humans; Nitriles; Pharmacogenetics; Precancerous Conditions; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Update of the BIG 1-98 Trial: where do we stand?
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2009 |
A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone and Bones; Bone Resorption; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
A randomized, placebo-controlled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women.
Topics: Antineoplastic Agents; Bone Density; Breast; Breast Neoplasms; Double-Blind Method; Female; Humans; Insulin-Like Growth Factor I; Letrozole; Lipids; Mammography; Middle Aged; Nitriles; Postmenopause; Triazoles | 2010 |
Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Risedronic Acid; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Risk Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Dermatitis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radiation-Sensitizing Agents; Survival Analysis; Triazoles | 2010 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2010 |
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Genetic Testing; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2010 |
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Statistics, Nonparametric; Tamoxifen; Triazoles | 2010 |
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Humans; Incidence; Middle Aged; Models, Economic; Nitriles; Tamoxifen; Triazoles | 2010 |
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2010 |
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Density; Breast Neoplasms; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Goserelin; Humans; Immunohistochemistry; Injections, Subcutaneous; Kaplan-Meier Estimate; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Postmenopause; Premenopause; Probability; Prognosis; Proportional Hazards Models; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triazoles | 2010 |
Adding zoledronic acid to endocrine therapy in the adjuvant treatment of hormone-sensitive breast cancer in premenopausal women: a new care standard or a provocative idea?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Survival Rate; Time Factors; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2010 |
Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Nitriles; Pilot Projects; Positron-Emission Tomography; Postmenopause; Prospective Studies; Radiopharmaceuticals; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tomography, X-Ray Computed; Treatment Outcome; Triazoles | 2011 |
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogens; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Triazoles | 2010 |
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Goserelin; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Triazoles | 2010 |
The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrium; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Pilot Projects; Positron-Emission Tomography; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Endocrine System; Humans; Letrozole; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Quality of Life; Sexual Dysfunction, Physiological; Tamoxifen; Treatment Outcome; Triazoles; Uterus | 2011 |
Short-term anastrozole therapy reduces Ki-67 and progesterone receptor expression in invasive breast cancer: a prospective, placebo-controlled, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Middle Aged; Nitriles; Prospective Studies; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Female; Hip; Humans; Lumbar Vertebrae; Nitriles; Tamoxifen; Time; Triazoles | 2011 |
Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Disease Progression; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2011 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States | 2011 |
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cognition; Cross-Sectional Studies; Female; Humans; International Agencies; Letrozole; Longitudinal Studies; Menopause; Nitriles; Prognosis; Survival Rate; Tamoxifen; Triazoles | 2011 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Topics: Administration, Oral; Anastrozole; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Gene Expression; Genome-Wide Association Study; Humans; Interleukin-17; Linkage Disequilibrium; Musculoskeletal Diseases; Nitriles; Pharmacogenetics; Polymorphism, Single Nucleotide; Triazoles | 2010 |
The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Japan; Lipids; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles; Triglycerides | 2011 |
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2011 |
Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Resorption; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2010 |
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Nitriles; Premenopause; Prospective Studies; Recurrence; Retrospective Studies; Risk; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Triazoles | 2011 |
Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone and Bones; Breast Neoplasms; Female; Humans; Lipid Metabolism; Lipids; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Toremifene; Triazoles | 2011 |
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Topics: Adult; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Neoplasm Staging; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2011 |
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.
Topics: Aged; Anastrozole; Androstadienes; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Female; Humans; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Testosterone; Triazoles | 2011 |
Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease-Free Survival; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2011 |
Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Ergocalciferols; Female; Humans; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Parathyroid Hormone; Triazoles; Vitamin D | 2011 |
Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2012 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecoxib; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Neoadjuvant Therapy; Nitriles; Pyrazoles; Receptors, Androgen; Sulfonamides; Treatment Outcome; Triazoles | 2011 |
Differentially expressed genes in window trials are influenced by the wound-healing process: lessons learned from a pilot study with anastrozole.
Topics: Aged; Aged, 80 and over; Anastrozole; Antigens, CD34; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Paraffin Embedding; Pilot Projects; Preoperative Period; Triazoles; Wound Healing | 2012 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Treatment Outcome; Triazoles | 2012 |
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2011 |
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Immunoglobulin Allotypes; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Receptors, Estrogen; Receptors, IgG; Receptors, Progesterone; Triazoles | 2011 |
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Menopause; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
[Letrozole vs. tamoxifen as neoadjuvant therapy for postmenopausal patients with hormone-dependent locally-advanced breast cancer].
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Double-Blind Method; Estrogens; Female; Humans; Letrozole; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Progesterone; Prospective Studies; Remission Induction; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles; Ultrasonography | 2011 |
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Body Mass Index; Breast Neoplasms; Cross-Over Studies; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Humans; Letrozole; Middle Aged; Nitriles; Pharmacogenetics; Postmenopause; Prospective Studies; Triazoles | 2011 |
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Organ Size; Osteoporosis, Postmenopausal; Postmenopause; Triazoles; Zoledronic Acid | 2012 |
Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the Arimidex, Tamoxifen Alone or in Combination trial.
Topics: Adult; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk; Tamoxifen; Triazoles | 2011 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles | 2011 |
The efficacy and safety of neoadjuvant chemotherapy +/- letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial.
Topics: Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Nitriles; Postmenopause; Statistics, Nonparametric; Treatment Outcome; Triazoles; Tumor Burden | 2012 |
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid | 2012 |
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Australia; Biomarkers, Tumor; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Europe; Female; Humans; Kaplan-Meier Estimate; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Second Primary; New Zealand; Nitriles; North America; Postmenopause; Proportional Hazards Models; Receptors, Steroid; Risk Factors; Selective Estrogen Receptor Modulators; South Africa; South America; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2011 |
Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover.
Topics: Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Double-Blind Method; Feasibility Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heterozygote; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Ovariectomy; Postmenopause; Prognosis; Prospective Studies; Retrospective Studies; Triazoles | 2012 |
Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Nitriles; Postoperative Period; Tamoxifen; Triazoles | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2011 |
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Data Mining; Female; Genome-Wide Association Study; Genome, Human; Humans; Linkage Disequilibrium; Models, Genetic; Nitriles; Polymorphism, Single Nucleotide; Raloxifene Hydrochloride; Software; Tamoxifen; Triazoles | 2012 |
High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Long-Term Care; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nitriles; Patient Compliance; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Time Factors; Treatment Outcome; Triazoles | 2012 |
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Lipids; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2012 |
Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Topics: Adult; Aged; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Arthralgia; Biomarkers; Breast Neoplasms; Double-Blind Method; Female; Humans; Logistic Models; Middle Aged; Nitriles; Odds Ratio; Placebos; Postmenopause; Risk Assessment; Risk Factors; Treatment Outcome; Triazoles; United Kingdom; Vitamin D; Vitamin D Deficiency | 2012 |
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Depression; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Stress, Psychological; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles | 2012 |
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Austria; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2012 |
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Time Factors; Treatment Outcome; Triazoles | 2012 |
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Humans; Imidazoles; Japan; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles; Zoledronic Acid | 2012 |
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Female; Follow-Up Studies; Humans; Letrozole; Medication Adherence; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Prospective Studies; Triazoles; Withholding Treatment | 2012 |
Aromatase inhibitors and calcium absorption in early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Calcium; Diet; Female; Humans; Intestinal Absorption; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles; Vitamin D | 2012 |
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Recurrence; Triazoles | 2012 |
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 CYP2D6; Disease-Free Survival; Drug Administration Schedule; Female; Genotype; Humans; International Cooperation; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Estradiol; Female; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tamoxifen; Triazoles; Zoledronic Acid | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin D1; Female; Follow-Up Studies; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Patient Compliance; Physician-Patient Relations; Postmenopause; Practice Patterns, Physicians'; Prospective Studies; Surveys and Questionnaires; Triazoles | 2012 |
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cognition; Estrogen Antagonists; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2012 |
Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Anti-Inflammatory Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Prednisolone; Triazoles | 2012 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Etidronic Acid; Female; Humans; Lipids; Middle Aged; Nitriles; Risedronic Acid; Treatment Outcome; Triazoles; Triglycerides | 2012 |
A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Letrozole; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Tamoxifen; Trastuzumab; Triazoles; Young Adult | 2012 |
Combination anastrozole and fulvestrant in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2012 |
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Mastectomy; Middle Aged; Nitriles; Phosphorylation; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Female; Goserelin; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Premenopause; Quality of Life; Survival; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Estrogen Receptor Modulators; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Obesity; Odds Ratio; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Triazoles; Zoledronic Acid | 2013 |
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles | 2012 |
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Lipids; Lipoprotein(a); Middle Aged; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2012 |
Phase II study of neoadjuvant anastrozole and concurrent radiotherapy for postmenopausal breast cancer patients.
Topics: Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Prospective Studies; Receptors, Estrogen; Treatment Outcome; Triazoles | 2014 |
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Placebos; Postmenopause; Sirolimus; Treatment Outcome; Triazoles | 2013 |
Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Medication Adherence; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Pilot Projects; Postmenopause; Surveys and Questionnaires; Treatment Outcome; Triazoles | 2012 |
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Letrozole; Middle Aged; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; History, 18th Century; Hot Flashes; Humans; Hypercholesterolemia; Kaplan-Meier Estimate; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Time Factors; Treatment Outcome; Triazoles | 2013 |
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cance
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Early Detection of Cancer; Female; Follow-Up Studies; Humans; Medication Adherence; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Prospective Studies; Triazoles | 2013 |
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; North America; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Logistic Models; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quality of Life; Survival Rate; Triazoles | 2002 |
Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Antigens, Nuclear; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Middle Aged; Neoadjuvant Therapy; Nitriles; Nuclear Proteins; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2002 |
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Nitriles; Patient Selection; Postmenopause; Surveys and Questionnaires; Tamoxifen; Triazoles | 2002 |
Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2002 |
Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Topics: Aged; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogens; Estrone; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radioimmunoassay; Receptors, Estrogen; Triazoles | 2002 |
Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Safety; Survival Rate; Triazoles | 2003 |
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Switzerland; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
Topics: Age Factors; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Liver Neoplasms; Lung Neoplasms; Nitriles; Postmenopause; Retrospective Studies; Treatment Outcome; Triazoles | 2003 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
Topics: Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen; Triazoles | 2003 |
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Remission Induction; Survival Analysis; Tamoxifen; Triazoles | 2003 |
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Salvage Therapy; Treatment Outcome; Triazoles | 2003 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Treatment Outcome; Triazoles | 2003 |
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Anastrozole and quinapril can be safely coadministered to elderly women with breast cancer and hypertension: a pharmacokinetic study.
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antihypertensive Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Interactions; Female; Humans; Hypertension; Nitriles; Quinapril; Tetrahydroisoquinolines; Triazoles | 2003 |
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2003 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2003 |
Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Double-Blind Method; ErbB Receptors; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Protein Biosynthesis; Proteins; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins | 2003 |
A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Drug Costs; Female; Humans; Letrozole; Life Tables; Nitriles; Postmenopause; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; United States | 2003 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update ana
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Advanced breast cancer updates on anastrozole versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report.
Topics: Androstadienes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Celecoxib; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Pyrazoles; Sulfonamides; Treatment Outcome; Triazoles | 2003 |
The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Cognition Disorders; Depression; England; Estrogens; Female; Humans; Memory Disorders; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Nitriles; Personality Inventory; Pilot Projects; Reaction Time; Self-Assessment; Tamoxifen; Triazoles; Verbal Learning | 2004 |
Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Disease-Free Survival; Estradiol; Female; Goserelin; Humans; Injections, Subcutaneous; Middle Aged; Nitriles; Premenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Switzerland; Tamoxifen; Triazoles | 2004 |
Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Celecoxib; Cyclooxygenase Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Prognosis; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Treatment Outcome; Triazoles | 2004 |
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Female; Humans; Mastectomy; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Risk Factors; Tamoxifen; Triazoles; United Kingdom; United States | 2004 |
The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Enzyme Inhibitors; Evidence-Based Medicine; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2004 |
Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Karnofsky Performance Status; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Decision Making; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Postmenopause; Quality of Life; Single-Blind Method; Treatment Outcome; Triazoles | 2004 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, Statistical; Demography; Dyspareunia; Female; Hot Flashes; Humans; Letrozole; Logistic Models; Memory Disorders; Menopause; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Patient Selection; Prospective Studies; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles; Urination Disorders; Vaginal Diseases; Withholding Treatment | 2004 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Protocols; Double-Blind Method; Endometrium; Female; Humans; Hysteroscopy; Nitriles; Sensitivity and Specificity; Tamoxifen; Triazoles; Ultrasonography | 2005 |
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Genes, erbB-2; Humans; Lymphatic Metastasis; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Progesterone; Triazoles | 2004 |
Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Endometrium; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Nitriles; Postmenopause; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Biomarker investigations from the ATAC trial: the role of TA01.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Oligonucleotide Array Sequence Analysis; Patient Care Planning; Prognosis; Tamoxifen; Triazoles | 2004 |
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Double-Blind Method; Female; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Japan; Lipids; Lipoprotein Lipase; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
[Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Prospective Studies; Survival Rate; Tamoxifen; Triazoles | 2004 |
The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
Topics: Aged; Aromatase Inhibitors; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Probability; Reference Values; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
Topics: Adult; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility; Humans; Letrozole; Nitriles; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Letrozole improves disease-free survival vs tamoxifen in adjuvant treatment of early breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Zoledronic acid prevents cancer treatment-induced bone loss.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2005 |
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2005 |
Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Topics: Administration, Oral; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Triazoles | 2005 |
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
Topics: Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Triazoles | 2005 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography | 2005 |
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Postmenopause; Survival Analysis; Survival Rate; Triazoles | 2005 |
Quality-adjusted survival in a crossover trial of letrozole versus tamoxifen in postmenopausal women with advanced breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Odds Ratio; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers; Bone Resorption; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Humans; Lipids; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Incidence; Letrozole; Lymphatic Metastasis; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Health Status; Humans; Letrozole; Middle Aged; Nitriles; Pain; Placebos; Postmenopause; Quality of Life; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Do biomarker changes during neoadjuvant endocrine therapy reflect breast tumor receptor status?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Receptor, ErbB-2; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Female; Humans; Middle Aged; Nitriles; Polyps; Risk Factors; Tamoxifen; Triazoles | 2006 |
Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2005 |
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Secondary Prevention; Survival Rate; Tamoxifen; Triazoles | 2005 |
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Tamoxifen; Triazoles | 2006 |
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2006 |
Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dilatation and Curettage; Endometrium; Female; Humans; Hysteroscopy; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles; Ultrasonography; Uterine Hemorrhage | 2006 |
Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
Topics: Aged; Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2006 |
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.
Topics: Aged; Anastrozole; Breast Neoplasms; Confidence Intervals; Cross-Sectional Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Logistic Models; Mastectomy; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Preoperative Care; Receptors, Estrogen; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Fractures, Bone; Hip; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Postmenopause; Radiography; Risk; Tamoxifen; Triazoles | 2006 |
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor A | 2006 |
Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles | 2006 |
Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Triazoles | 2006 |
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2007 |
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Comorbidity; Disease-Free Survival; Ethnicity; Female; Humans; Letrozole; Mental Health; Middle Aged; Minority Groups; Nitriles; Pain; Patient Compliance; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; White People | 2006 |
Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Follow-Up Studies; Health Status; Humans; Nitriles; Odds Ratio; Patient Dropouts; Postmenopause; Quality of Life; Risk Assessment; Surveys and Questionnaires; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Double-Blind Method; ErbB Receptors; Female; Humans; Letrozole; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Mammography; Middle Aged; Nitriles; Pilot Projects; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Triazoles; Zoledronic Acid | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogen Antagonists; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.
Topics: Adult; Aged; Anticarcinogenic Agents; Aromatase Inhibitors; Biomarkers; Biopsy, Fine-Needle; Breast Neoplasms; Cell Nucleus; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Replacement Therapy; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Ki-67 Antigen; Letrozole; Mammography; Middle Aged; Nitriles; Pilot Projects; Postmenopause; Receptors, Estrogen; Risk Assessment; Risk Factors; Testosterone; Time Factors; Treatment Outcome; Triazoles | 2007 |
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-fr
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Patient Selection; Postmenopause; Tamoxifen; Triazoles | 2006 |
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Letrozole in advanced breast cancer: the PO25 trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Cross-Over Studies; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Nitriles; Oocytes; Ovulation Induction; Prospective Studies; Triazoles | 2007 |
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Radiotherapy Dosage; Survival Rate; Tamoxifen; Triazoles | 2007 |
The FACE trial: letrozole or anastrozole as initial adjuvant therapy?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Research Design; Triazoles | 2007 |
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Japan; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Prospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Triazoles | 2007 |
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Polymerase Chain Reaction; Postmenopause; Receptors, Estrogen; Triazoles; Up-Regulation | 2007 |
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Secondary Prevention; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Topics: Androstenedione; Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Estradiol; Female; Gas Chromatography-Mass Spectrometry; Humans; Letrozole; Nitriles; Placebos; Postmenopause; Radioimmunoassay; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Estradiol; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2007 |
Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Letrozole; Nitriles; Ovarian Neoplasms; Predictive Value of Tests; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2007 |
Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cicatrix; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Triazoles | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2008 |
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Topics: Adult; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2007 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Gefitinib; Humans; Ki-67 Antigen; Mastectomy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Triazoles | 2007 |
Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Lipids; Menopause; Middle Aged; Nitriles; Peptide Fragments; Placebos; Procollagen; Single-Blind Method; Tamoxifen; Triazoles | 2007 |
Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasm Staging; Nitriles; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2007 |
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Farnesyltranstransferase; Female; Humans; Letrozole; Middle Aged; Nitriles; Quinolones; Time Factors; Treatment Outcome; Triazoles | 2008 |
Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cluster Analysis; Databases, Nucleic Acid; Female; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Transcription, Genetic; Triazoles | 2007 |
Letrozole in the neoadjuvant setting: the P024 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Female; Humans; Immunohistochemistry; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles | 2007 |
Letrozole in the extended adjuvant setting: MA.17.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Quality of Life; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
A decade of letrozole: FACE.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2007 |
[Phase II clinical trial of neoadjuvant hormone therapy in comparison with chemotherapy of patients with breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Doxorubicin; Female; Humans; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Paclitaxel; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Topics: Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Steroid; Toremifene; Triazoles | 2007 |
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2007 |
Switching to anastrozole after tamoxifen improves survival in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Survivors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
The ATAC trial: the vanguard trial for use of aromatase inhibitors in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Drug Interactions; Everolimus; Feasibility Studies; Female; Humans; Immunosuppressive Agents; Letrozole; Male; Middle Aged; Nitriles; Sirolimus; Treatment Outcome; Triazoles | 2008 |
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2008 |
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Triazoles | 2008 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Alkylating; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2008 |
Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gonadal Hormones; Humans; Letrozole; Middle Aged; Nitriles; Premenopause; Prospective Studies; Statistics, Nonparametric; Tamoxifen; Treatment Outcome; Triazoles; Triptorelin Pamoate | 2008 |
ERBB2 status and outcome of endocrine treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; ErbB Receptors; Female; Humans; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2008 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Tissue Array Analysis; Treatment Outcome; Triazoles | 2008 |
Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Drug Evaluation; Female; Humans; Imatinib Mesylate; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Pilot Projects; Piperazines; Postmenopause; Pyrimidines; Signal Transduction; Triazoles | 2008 |
Increase in response rate by prolonged treatment with neoadjuvant letrozole.
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Life Expectancy; Mastectomy; Mastectomy, Segmental; Neoadjuvant Therapy; Nitriles; Time Factors; Treatment Outcome; Triazoles | 2009 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Risk Factors; Triazoles | 2008 |
Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Mammography; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2008 |
Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Invasiveness; Nitriles; Postmenopause; Prospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Estrogens; Humans; Kaplan-Meier Estimate; Letrozole; Lymphatic Metastasis; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Nitriles; Patient Acceptance of Health Care; Placebos; Postmenopause; Progesterone; Proportional Hazards Models; Recurrence; Tamoxifen; Triazoles | 2008 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2008 |
Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Quality of Life; Tamoxifen; Triazoles | 2008 |
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women.
Topics: Affect; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cross-Over Studies; Estrogen Receptor Modulators; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nitriles; Patient Participation; Patient Selection; Postmenopause; Prospective Studies; Quality of Life; Research Design; Sample Size; Surveys and Questionnaires; Tamoxifen; Triazoles | 2008 |
A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Progesterone; Treatment Outcome; Triazoles | 2009 |
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Tissue Inhibitor of Metalloproteinase-1; Triazoles | 2008 |
The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogen Antagonists; Female; Humans; Middle Aged; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Down-Regulation; Female; Humans; Letrozole; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinases; Proto-Oncogene Proteins c-akt; Tissue Array Analysis; TOR Serine-Threonine Kinases; Triazoles | 2008 |
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles | 2008 |
ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Topics: Administration, Oral; Aldosterone; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estradiol; Female; Humans; Hydrocortisone; Nitriles; Triazoles | 1995 |
Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Biological Assay; Breast Neoplasms; Estradiol; Female; Humans; Letrozole; Nitriles; Radioimmunoassay; Recombination, Genetic; Sensitivity and Specificity; Triazoles | 1995 |
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Remission Induction; Triazoles | 1995 |
Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogens; Estrone; Fadrozole; Female; Humans; Letrozole; Middle Aged; Nitriles; Radioimmunoassay; Triazoles | 1994 |
Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Drug Administration Schedule; Estradiol; Female; Humans; Middle Aged; Postmenopause; Sex Hormone-Binding Globulin; Treatment Outcome; Triazoles | 1994 |
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrone; Humans; Letrozole; Microsomes; Middle Aged; Nitriles; Triazoles | 1993 |
The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Topics: Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Aromatase Inhibitors; Breast Neoplasms; Cosyntropin; Estradiol; Estrogens; Estrone; Female; Humans; Hydrocortisone; Letrozole; Neoplasm Staging; Nitriles; Potassium; Sodium; Time Factors; Triazoles | 1993 |
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Prognosis; Survival Rate; Tamoxifen; Triazoles | 1996 |
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Quality of Life; Remission Induction; Survival Rate; Triazoles | 1996 |
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 1996 |
A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Pregnanes; Triazoles | 1997 |
Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study.
Topics: Adult; Aged; Aldosterone; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Hydrocortisone; Letrozole; Middle Aged; Nitriles; Pilot Projects; Triazoles | 1996 |
Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
Topics: Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Middle Aged; Triazoles | 1997 |
A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Survival Rate; Triazoles | 1997 |
Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Middle Aged; Postmenopause; Triazoles | 1997 |
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Female; Humans; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 1997 |
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Survival Rate; Triazoles | 1998 |
Vorozole (Rivizor): an active and well tolerated new aromatase inhibitor for the treatment of advanced breast cancer patients with prior tamoxifen exposure. Investigational Drug Branch of the European Organization for Research and Treatment of Cancer (EOR
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nausea; Tamoxifen; Triazoles | 1998 |
Vorozole (R83842) in the treatment of postmenopausal advanced breast cancer: relationship of serum levels of vorozole and clinical results (a study of the EORTC Breast Cancer Cooperative Group).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Hormones; Humans; Middle Aged; Postmenopause; Statistics as Topic; Treatment Outcome; Triazoles | 1998 |
Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Topics: Administration, Oral; Aged; Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Prognosis; Survival Rate; Treatment Failure; Triazoles | 1998 |
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Megestrol; Nitriles; Postmenopause; Proportional Hazards Models; Survival Rate; Triazoles | 1998 |
In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Topics: Adult; Aged; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrone; Female; Humans; Letrozole; Middle Aged; Neoplasm Proteins; Nitriles; Postmenopause; Triazoles | 1995 |
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Topics: Aged; Aged, 80 and over; Aldosterone; Androgens; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 1995 |
The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Interactions; Endocrinology; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 1999 |
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Triazoles | 1999 |
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Middle Aged; Postmenopause; Triazoles | 1999 |
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1999 |
Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Topics: Anastrozole; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Female; Humans; Nitriles; Postmenopause; Prospective Studies; Receptors, Estrogen; Treatment Outcome; Triazoles | 1999 |
Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Topics: Adult; Androstenedione; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Goserelin; Humans; Middle Aged; Ovary; Postmenopause; Premenopause; Triazoles | 1999 |
[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
Topics: Aged; Aminoglutethimide; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Survival Analysis; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex) with intramuscular formestane in postmenopausal women with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anastrozole; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Estrogens; Female; Humans; Injections, Intramuscular; Middle Aged; Nitriles; Triazoles | 1999 |
Critique of survival update analysis from two phase III anastrozole clinical trials.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Survival Rate; Triazoles | 1999 |
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Europe; Female; Humans; Megestrol Acetate; Nitriles; Postmenopause; Prospective Studies; Survival Analysis; Triazoles; United States | 1999 |
The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography | 2000 |
Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2000 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2000 |
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Estrogens; Female; Hormones; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Proteins; Receptors, Growth Factor; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Logistic Models; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2001 |
Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Safety; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Letrozole as primary medical therapy for locally advanced and large operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Treatment Outcome; Triazoles | 2001 |
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Disease Progression; Double-Blind Method; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Logistic Models; Neoadjuvant Therapy; Nitriles; Odds Ratio; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Prostaglandin; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Double-Blind Method; Female; Hemorrhage; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Tamoxifen; Thromboembolism; Treatment Outcome; Triazoles | 2001 |
Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Area Under Curve; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2001 |
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Cross-Over Studies; Enzyme Inhibitors; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radioimmunoassay; Triazoles | 2002 |
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Humans; Ki-67 Antigen; Luteinizing Hormone; Middle Aged; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2002 |
[Superiority of letrozole compared with tamoxifen as first line therapy of postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group].
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Palliative Care; Postmenopause; Survival Rate; Tamoxifen; Triazoles | 2002 |
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Triazoles | 2002 |
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Survival Rate; Triazoles | 2002 |
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Survival Rate; Triazoles | 2002 |
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
Topics: Aged; Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Endpoint Determination; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Prognosis; Tamoxifen; Triazoles | 2002 |
Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Topics: Administration, Oral; Aged; Biomarkers; Biopsy, Needle; Breast Diseases; Breast Neoplasms; Cell Division; Confidence Intervals; Drug Administration Schedule; Enzyme Inhibitors; Epithelial Cells; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Primary Prevention; Probability; Receptors, Estrogen; Reference Values; Sensitivity and Specificity; Statistics, Nonparametric; Triazoles | 2002 |
971 other study(ies) available for triazoles and Breast Cancer
| Article | Year |
|---|---|
Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Female; Humans; Models, Molecular; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma; Structure-Activity Relationship; Triazoles | 2021 |
A One-Pot Six-Component Reaction for the Synthesis of 1,5-Disubstituted Tetrazol-1,2,3-Triazole Hybrids and Their Cytotoxic Activity against the MCF-7 Cell Line.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Female; Humans; MCF-7 Cells; Tetrazoles; Triazoles | 2021 |
The dicyano compound induces autophagic or apoptotic cell death via Twist/c-Myc axis depending on metastatic characteristics of breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Signal Transduction; Triazoles; Twist-Related Protein 1 | 2022 |
Co-targeting BET bromodomain BRD4 and RAC1 suppresses growth, stemness and tumorigenesis by disrupting the c-MYC-G9a-FTH1axis and downregulating HDAC1 in molecular subtypes of breast cancer.
Topics: Aminoquinolines; Animals; Azepines; Breast Neoplasms; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Female; Ferritins; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone Deacetylase 1; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Oxidoreductases; Proto-Oncogene Proteins c-myc; Pyrimidines; rac1 GTP-Binding Protein; Transcription Factors; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Hydrazines; Mice; Mice, Nude; Triazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2022 |
Benzotriazole Ultraviolet Stabilizers Promote Breast Cancer Cell Proliferation via Activating Estrogen-Related Receptors α and γ at Human-Relevant Levels.
Topics: Breast Neoplasms; Cell Proliferation; ERRalpha Estrogen-Related Receptor; Estrogens; Female; Humans; Receptors, Estrogen; Triazoles | 2022 |
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pterocarpans; Triazoles | 2022 |
Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Schiff Bases; Structure-Activity Relationship; Triazoles; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
Topics: Aniline Compounds; Animals; Breast Neoplasms; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Receptor, Transforming Growth Factor-beta Type I; Transforming Growth Factor beta; Triazoles | 2022 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; Nitriles; Pyrimidines; Triazoles | 2022 |
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer.
Topics: Androgen Receptor Antagonists; Androgens; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Naphthalenes; Piperidines; Pyrrolidines; Radiation Tolerance; Receptors, Androgen; Receptors, Estrogen; Tamoxifen; Thiazoles; Triazoles | 2022 |
Anastrozole and related glucuronic acid conjugate are electrophilic species.
Topics: Anastrozole; Animals; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Female; Glucuronic Acid; Humans; Nitriles; Rats; Triazoles | 2022 |
4th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Receptors, Estrogen; Triazoles | 2022 |
Topics: Breast Neoplasms; Female; Fullerenes; Humans; MCF-7 Cells; Nanostructures; Triazoles | 2022 |
Synthesis and anticancer activity of novel Eugenol derivatives against breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Eugenol; Female; Humans; MCF-7 Cells; Structure-Activity Relationship; Triazoles | 2023 |
Synthesis of ribavirin 1,2,3- and 1,2,4-triazolyl analogs with changes at the amide and cytotoxicity in breast cancer cell lines.
Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Female; Humans; MCF-7 Cells; Ribavirin; Structure-Activity Relationship; Triazoles | 2023 |
Synthesis, biological evaluation, and molecular modeling studies of new benzoxazole derivatives as PARP-2 inhibitors targeting breast cancer.
Topics: Amides; Amines; Antineoplastic Agents; Benzoxazoles; Breast Neoplasms; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Female; Humans; Molecular Docking Simulation; Molecular Structure; Poly(ADP-ribose) Polymerase Inhibitors; Structure-Activity Relationship; Triazoles | 2022 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Nitriles; Ribosomes; TOR Serine-Threonine Kinases; Triazoles | 2023 |
Dual aromatase-steroid sulfatase inhibitors (DASI's) for the treatment of breast cancer: a structure guided ligand based designing approach.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Quantitative Structure-Activity Relationship; Steryl-Sulfatase; Triazoles | 2023 |
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Mitogen-Activated Protein Kinases; Nitriles; Triazoles | 2023 |
Electrochemical Synthesis of New Isoxazoles and Triazoles Tethered with Thiouracil Base as Inhibitors of Histone Deacetylases in Human Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Isoxazoles; Structure-Activity Relationship; Triazoles | 2023 |
Ferrozoles: Ferrocenyl derivatives of letrozole with dual effects as potent aromatase inhibitors and cytostatic agents.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cytostatic Agents; Female; Humans; Letrozole; MCF-7 Cells; Metallocenes; Molecular Docking Simulation; Nitriles; Triazoles | 2023 |
Effects of
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Estradiol; Female; Fulvestrant; Genotype; Humans; Nitriles; Triazoles | 2023 |
Secosteroid thiosemicarbazides and secosteroid-1,2,4-triazoles as antiproliferative agents targeting breast cancer cells: Synthesis and biological evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Structure; Structure-Activity Relationship; Triazoles | 2023 |
Breast Tumor Cells Evade the Cytotoxic Action of Anastrozole, Aspirin, and Clopidogrel Cocktail.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aspirin; Breast Neoplasms; Clopidogrel; Female; Humans; Mammary Neoplasms, Animal; Nitriles; Tamoxifen; Triazoles | 2023 |
Proliferation, Migration and Invasion of Breast Cancer Cell Lines Are Inhibited by 1,5-Disubstituted Tetrazol-1,2,3-triazole Hybrids through Interaction with p53.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Triazoles; Tumor Suppressor Protein p53 | 2023 |
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Azepines; Breast Neoplasms; Carcinoma, Lobular; Cell Cycle; Cell Proliferation; Cohort Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Transcription Factors; Triazoles; Tumor Cells, Cultured | 2019 |
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Poly (ADP-Ribose) Polymerase-1; Structure-Activity Relationship; Triazoles; Wound Healing | 2019 |
Anti-cancer potential of novel glycosylated 1,4-substituted triazolylchalcone derivatives.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Chalcone; Click Chemistry; Cycloaddition Reaction; Drug Screening Assays, Antitumor; Female; Glycosylation; Humans; Molecular Structure; Structure-Activity Relationship; Triazoles | 2019 |
In Vitro Biological Estimation of 1,2,3-Triazolo[4,5-d]pyrimidine Derivatives as Anti-breast Cancer Agent: DFT, QSAR and Docking Studies.
Topics: Antineoplastic Agents; Breast Neoplasms; Humans; Linear Models; MCF-7 Cells; Molecular Docking Simulation; Neural Networks, Computer; Pyrimidines; Quantitative Structure-Activity Relationship; Triazoles | 2020 |
Topics: Animals; Apoptosis; Arginine; Breast Neoplasms; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Neuropeptide Y; Tissue Distribution; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.
Topics: Azepines; Binding Sites; Breast Neoplasms; Cell Proliferation; Enhancer Elements, Genetic; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Protein Binding; Proteins; Transcription Factors; Transcription, Genetic; Triazoles | 2019 |
Using time series analysis to forecast the health-related quality of life of post-menopausal women with non-metastatic ER+ breast cancer: A tutorial and case study.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Postmenopause; Quality of Life; Triazoles | 2020 |
Initial Studies with
Topics: Aged; Aromatase; Breast Neoplasms; Carbon Radioisotopes; Female; Humans; Immunohistochemistry; Middle Aged; Positron-Emission Tomography; Triazoles | 2020 |
1,2,3-Triazole tethered 1,2,4-trioxanes: Studies on their synthesis and effect on osteopontin expression in MDA-MB-435 breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds; Humans; Molecular Structure; Osteopontin; Structure-Activity Relationship; Triazoles | 2020 |
4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Topics: Animals; Antineoplastic Agents, Immunological; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Assays; Female; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inhibitory Concentration 50; Kynurenine; Metabolic Networks and Pathways; Mice; Molecular Docking Simulation; Primary Cell Culture; Recombinant Proteins; T-Lymphocytes, Cytotoxic; Triazoles; Tryptophan; Tryptophan Oxygenase; Tumor Escape | 2019 |
A Combination of an Antimitotic and a Bromodomain 4 Inhibitor Synergistically Inhibits the Metastatic MDA-MB-231 Breast Cancer Cell Line.
Topics: Antimitotic Agents; Antineoplastic Agents; Apoptosis; Azepines; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mitosis; Neoplasm Metastasis; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Sulfonamides; Transcription Factors; Triazoles | 2019 |
HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred NOD; Mice, SCID; Protein Stability; Pyrazoles; Random Allocation; Triazoles; Xenograft Model Antitumor Assays | 2020 |
Novel 1,2,4-triazole derivatives: Design, synthesis, anticancer evaluation, molecular docking, and pharmacokinetic profiling studies.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Biotransformation; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Molecular Structure; Protein Binding; Receptor, Adenosine A2B; Structure-Activity Relationship; Triazoles | 2020 |
Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Isatin; MCF-7 Cells; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Structure-Activity Relationship; Triazoles | 2021 |
ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
Topics: A549 Cells; Activating Transcription Factor 2; Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Feedback, Physiological; Female; Ferroptosis; HeLa Cells; Heterocyclic Compounds, 4 or More Rings; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms; NF-E2-Related Factor 2; Proteins; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2021 |
Synthesis and anticancer activity evaluation of naphthalene-substituted triazole spirodienones.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Naphthalenes; Structure-Activity Relationship; Triazoles | 2021 |
The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer.
Topics: Animals; Breast Neoplasms; Female; HSP90 Heat-Shock Proteins; Humans; Mice; Triazoles | 2021 |
Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship; Thymidylate Synthase; Thymol; Triazoles | 2021 |
New 3-(1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one-based triazole derivatives: Design, synthesis, and biological evaluation as antiproliferative and apoptosis-inducing agents.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Design; Female; Humans; Inhibitory Concentration 50; Neoplasms; Quinolines; Reactive Oxygen Species; Structure-Activity Relationship; Triazoles | 2021 |
The Cost-Effectiveness of Adjuvant Tamoxifen Treatment of Hormone Receptor-Positive Early Breast Cancer Among Premenopausal and Perimenopausal Ghanaian Women.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Ghana; Hormones; Humans; Nitriles; Perimenopause; Tamoxifen; Triazoles | 2021 |
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Topics: Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Receptors, Estrogen; Triazoles | 2017 |
Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Estrogens; Female; Gonadotropins; Humans; Middle Aged; Neoplasm Staging; Nitriles; Obesity; Postmenopause; Prognosis; Triazoles | 2017 |
A novel long-acting biodegradable depot formulation of anastrozole for breast cancer therapy.
Topics: Absorbable Implants; Anastrozole; Animals; Breast Neoplasms; Drug Implants; Female; Humans; Lactic Acid; Nitriles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Triazoles | 2017 |
The prognostic significance of Cdc6 and Cdt1 in breast cancer.
Topics: Animals; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; DNA Replication; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Nuclear Proteins; Prognosis; RAW 264.7 Cells; Receptors, Estrogen; Survival Analysis; Tamoxifen; Triazoles; Up-Regulation | 2017 |
Evaluation of Active Hexose Correlated Compound (AHCC) in Combination With Anticancer Hormones in Orthotopic Breast Cancer Models.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Female; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Polysaccharides; Tamoxifen; Triazoles | 2017 |
Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.
Topics: Animals; Breast Neoplasms; Cancer Pain; Cell Line, Tumor; Disease Models, Animal; Female; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Interleukin-10; Mice; Mice, Inbred C57BL; Neurogenic Inflammation; Proprotein Convertases; Receptors, Lysosphingolipid; Serine Endopeptidases; Signal Transduction; Sphingosine-1-Phosphate Receptors; Spinal Cord; Sulfones; Triazoles | 2017 |
Study of the Cytotoxic and Bactericidal Effects of Sila-substituted Thioalkyne and Mercapto-thione Compounds based on 1,2,3-Triazole Scaffold.
Topics: Alkynes; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Female; Gram-Positive Bacteria; Humans; Inhibitory Concentration 50; MCF-7 Cells; Microbial Sensitivity Tests; Reverse Transcriptase Polymerase Chain Reaction; Thiones; Triazoles | 2017 |
Multi-Reservoir Phospholipid Shell Encapsulating Protamine Nanocapsules for Co-Delivery of Letrozole and Celecoxib in Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Celecoxib; Drug Carriers; Drug Combinations; Female; Humans; Letrozole; MCF-7 Cells; Mice, Inbred BALB C; Nanocapsules; Nitriles; Phospholipids; Protamines; Rats, Sprague-Dawley; Triazoles | 2017 |
Inhibition of 17beta-hydroxysteroid dehydrogenase type 7 modulates breast cancer protein profile and enhances apoptosis by down-regulating GRP78.
Topics: 17-Hydroxysteroid Dehydrogenases; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Enzyme Inhibitors; Epithelial Cells; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Letrozole; Molecular Sequence Annotation; Nitriles; Organ Specificity; Postmenopause; Protein Interaction Mapping; Proto-Oncogene Proteins c-bcl-2; Receptors, G-Protein-Coupled; RNA, Small Interfering; Signal Transduction; Triazoles | 2017 |
Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Chemotherapy, Adjuvant; Fatty Liver; Female; Humans; Incidence; Letrozole; Lipids; Middle Aged; Nitriles; Propensity Score; Retrospective Studies; Tamoxifen; Triazoles | 2017 |
Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; China; Cost-Benefit Analysis; Drug Costs; Estradiol; Female; Fulvestrant; Humans; Markov Chains; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2017 |
Anastrozole-induced Autoimmune Hepatitis: A Rare Complication of Breast Cancer Therapy.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Female; Hepatitis, Autoimmune; Humans; Liver; Neoplasm Staging; Nitriles; Triazoles | 2017 |
High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Letrozole; Luteal Phase; Nitriles; Ovulation Induction; Progesterone; Recombinant Proteins; Triazoles | 2017 |
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Topics: Acetanilides; Animals; Antineoplastic Agents; Azepines; Benzodiazepines; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Homologous Recombination; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Triazoles | 2017 |
Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells.
Topics: Breast Neoplasms; Cells, Cultured; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MyoD Protein; Nitriles; Transcription, Genetic; Triazoles | 2017 |
Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Risk Factors; Tamoxifen; Triazoles | 2018 |
Appendix 2: Advanced breast cancer: MCBS eUpdate published online 25 April 2017 (www.esmo.org/Guidelines/Breast-Cancer).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Medical Oncology; Nitriles; Piperazines; Pyridines; Triazoles | 2017 |
Surgery versus monitoring and endocrine therapy for low-risk DCIS: The COMET Trial.
Topics: Adult; Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Guideline Adherence; Humans; Letrozole; Middle Aged; Nitriles; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Triazoles | 2017 |
Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Female; Humans; Letrozole; Models, Economic; Nitriles; Ontario; Piperazines; Protein Kinase Inhibitors; Pyridines; Quality of Life; Stochastic Processes; Time Factors; Treatment Outcome; Triazoles | 2017 |
Isolated Retinal Metastasis From Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Middle Aged; Nitriles; Radiosurgery; Receptors, Estrogen; Receptors, Progesterone; Retinal Neoplasms; Triazoles | 2017 |
[Indoleamine 2,3-Dioxygenase Activity during Letrozol Therapy for an Elderly Breast Cancer Patient].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Mammography; Nitriles; Tomography, X-Ray Computed; Triazoles | 2017 |
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Topics: Adipose Tissue; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Enophthalmos; Female; Humans; Letrozole; Nitriles; Orbit; Orbital Neoplasms; Regeneration; Tomography, X-Ray Computed; Triazoles | 2018 |
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study.
Topics: Adult; Breast Neoplasms; Cohort Studies; Female; Fertility Preservation; Humans; Infertility, Female; Neoplasm Recurrence, Local; Ovulation Induction; Proportional Hazards Models; Risk Factors; Sweden; Triazoles | 2018 |
Folate Conjugated Hybrid Nanocarrier for Targeted Letrozole Delivery in Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Folic Acid; Humans; Letrozole; Male; MCF-7 Cells; Nanoparticles; Nitriles; Rats, Wistar; Triazoles | 2017 |
Complexity of intermittent letrozole adjuvant therapy.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Letrozole; Nitriles; Triazoles | 2018 |
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.
Topics: Anastrozole; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Survival; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Half-Life; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 3; Myeloid Cell Leukemia Sequence 1 Protein; Nanoparticles; Nitriles; Particle Size; Polyesters; Polyethylene Glycols; Proto-Oncogene Proteins c-myc; Solubility; Triazoles | 2018 |
[A Case of Breast Cancer with Local Recurrence in the Reconstructed Breast Tissue].
Topics: Adult; Anastrozole; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Mammaplasty; Mastectomy; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nitriles; Treatment Outcome; Triazoles | 2017 |
[A Case of Stage IV Breast Cancer with Extensive Metastasis Successfully Treated with S-1 plus Anastrozole Therapy].
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; Humans; Lymphatic Metastasis; Nitriles; Oxonic Acid; Tegafur; Triazoles | 2017 |
The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Benzoquinones; Biological Products; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; MAP Kinase Signaling System; MCF-7 Cells; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase C; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2018 |
[A Case of Advanced Breast Cancer Effectively Treated with Bevacizumab and Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2018 |
Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study.
Topics: Aged; Anastrozole; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Female; Hot Flashes; Humans; Middle Aged; Nitriles; Postmenopause; Quality of Life; Triazoles | 2017 |
RE: "Cost-effectiveness analysis of fulvestrant versus anastrozole as first-line treatment for hormone receptor-positive advanced breast cancer," by Ding H., et al.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Estradiol; Fulvestrant; Humans; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2018 |
A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy.
Topics: Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Indoles; Isoindoles; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Triazoles; Zinc Compounds | 2018 |
A Case of Psoriasis Complicated by Breast Cancer after Systemic Treatments Including Biologics.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biological Products; Breast Neoplasms; Female; Humans; Immunosuppressive Agents; Nitriles; Psoriasis; Triazoles | 2018 |
Late distant recurrence of breast carcinoma and metastasis to the main bronchus and choroid: A case report.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Bronchi; Bronchial Neoplasms; Bronchoscopy; Choroid; Choroid Neoplasms; Female; Fluorescein Angiography; Humans; Letrozole; Long Term Adverse Effects; Lymphatic Metastasis; Mastectomy; Middle Aged; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2018 |
Design, Synthesis and Biological Evaluation of 1H-1,2,3-Triazole-Linked-1H-Dibenzo[b,h]xanthenes as Inductors of ROS-Mediated Apoptosis in the Breast Cancer Cell Line MCF-7.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Chemistry Techniques, Synthetic; Drug Design; Humans; Intracellular Space; MCF-7 Cells; Reactive Oxygen Species; Triazoles; Xanthenes | 2019 |
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Models, Biological; Models, Economic; Nitriles; Piperazines; Postmenopause; Protein Kinase Inhibitors; Purines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles; United States | 2018 |
[Evaluation of Patient Adherence to Anastrozole Therapy for Breast Cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Humans; Middle Aged; Nitriles; Patient Compliance; Retrospective Studies; Triazoles | 2018 |
Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
Topics: Azepines; Breast Neoplasms; Cell Line, Tumor; Computational Biology; Epigenesis, Genetic; Female; Forkhead Box Protein M1; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Protein Kinase Inhibitors; Transcriptome; Triazoles | 2018 |
Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.
Topics: Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Plasticity; Chromatin; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Triazoles; Triple Negative Breast Neoplasms | 2018 |
CREBBP/EP300 Bromodomain Inhibition Affects the Proliferation of AR-Positive Breast Cancer Cell Lines.
Topics: Androgens; Azepines; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; CREB-Binding Protein; Down-Regulation; E1A-Associated p300 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Isoxazoles; Protein Domains; Receptors, Androgen; Triazoles | 2019 |
Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail.
Topics: Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Nude; Mice, SCID; Middle Aged; Protein Kinase C; Protein Stability; Snail Family Transcription Factors; Transcription Factors; Transcription, Genetic; Triazoles; Zinc Finger Protein GLI1 | 2020 |
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Clinical Trials, Phase II as Topic; Dexamethasone; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Male; Naphthalenes; Neoplasm Staging; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Triazoles | 2019 |
[A case of crescentic glomerulonephritis developed under oral anastrozole treatment].
Topics: Administration, Oral; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Female; Glomerulonephritis; Humans; Nitriles; Triazoles | 2013 |
Anastrozole-associated joint pain and other symptoms in patients with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Cohort Studies; Female; Humans; Incidence; Middle Aged; Models, Statistical; Nitriles; Pain Measurement; Triazoles | 2013 |
Should all postmenopausal patients with hormone receptor-positive breast cancer receive initial therapy with aromatase inhibitors?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Receptors, Estrogen; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Reply to S. Pauwels et al.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2013 |
Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Biopsy; Breast; Breast Neoplasms; Cluster Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunity; Ki-67 Antigen; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
[Three patients with local recurrence of ER-positive breast cancer for whom anastrozole was clinically effective].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2013 |
Effect of selumetinib on the growth of anastrozole-resistant tumors.
Topics: Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; MAP Kinase Kinase 1; Mice; Mice, Nude; Nitriles; Ovariectomy; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Does zoledronic acid have additive effect on suppression of plasma estrogen levels?
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Synergism; Estrogens; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid | 2013 |
Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Neoplasm Recurrence, Local; Nitriles; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2013 |
Hypofractionated stereotactic radiotherapy with the hypoxic sensitizer AK-2123 (sanazole) for reirradiation of brain metastases: a preliminary feasibility report.
Topics: Administration, Oral; Adult; Aged; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiosurgery; Triazoles | 2013 |
[Therapy concept: herceptin in combination with arimidex].
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Germany; Humans; Neoplasm Staging; Nitriles; Prognosis; Receptor, ErbB-2; Trastuzumab; Triazoles | 2002 |
Effect of aromatase inhibitors on bone mineral density in a Japanese breast cancer population.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Diphosphonates; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Triazoles | 2013 |
GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
Topics: Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor; Humans; Kaplan-Meier Estimate; Letrozole; MCF-7 Cells; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Triazoles | 2013 |
1-Phenyl-4-benzoyl-1H-1,2,3-triazoles as orally bioavailable transcriptional function suppressors of estrogen-related receptor α.
Topics: Administration, Oral; Aniline Compounds; Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line; Cell Line, Tumor; Drug Screening Assays, Antitumor; ERRalpha Estrogen-Related Receptor; Female; Genes, Reporter; Humans; Luciferases; Male; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; RNA, Messenger; Structure-Activity Relationship; Transcription, Genetic; Triazoles | 2013 |
Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; bcl-2-Associated X Protein; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Humans; Letrozole; Nitriles; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Tamoxifen; Triazoles; Up-Regulation | 2013 |
Anti-Ri antibody-associated paraneoplastic brainstem encephalitis successfully treated after treating the underlying malignancy with letrozole.
Topics: Aged, 80 and over; Antibodies, Anti-Idiotypic; Antineoplastic Agents; Brain Stem Neoplasms; Breast Neoplasms; Encephalitis; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2013 |
Cutaneous leukocytoclastic vasculitis associated with letrozole.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles; Vasculitis, Leukocytoclastic, Cutaneous | 2014 |
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; HSP90 Heat-Shock Proteins; Humans; Inflammation; Mice, SCID; Molecular Targeted Therapy; Protein Stability; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Treatment Outcome; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Topics: Actin Cytoskeleton; Amides; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Shape; Drug Resistance, Neoplasm; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Letrozole; Mesoderm; Neoplasm Invasiveness; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Proteomics; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Triazoles; Vimentin | 2013 |
Posterior reversible encephalopathy syndrome: more than meets the eye.
Topics: Anastrozole; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Electroencephalography; Fatal Outcome; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Multiple Primary; Nitriles; Posterior Leukoencephalopathy Syndrome; Risk Assessment; Triazoles | 2013 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Topics: Aged; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Estrogens; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2013 |
Tamoxifen therapy for patients with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Premenopause; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2013 |
Tamoxifen therapy for patients with breast cancer - Authors' reply.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2013 |
Androgen metabolite-dependent growth of hormone receptor-positive breast cancer as a possible aromatase inhibitor-resistance mechanism.
Topics: Androgens; Androstane-3,17-diol; Aromatase Inhibitors; Breast Neoplasms; Dihydrotestosterone; Drug Resistance, Neoplasm; Female; Green Fluorescent Proteins; Humans; Letrozole; MCF-7 Cells; Multienzyme Complexes; Nitriles; Progesterone Reductase; Receptors, Androgen; Receptors, Estrogen; Response Elements; Signal Transduction; Steroid Isomerases; Testosterone; Triazoles | 2013 |
Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Topics: Aniline Compounds; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Gene Expression Regulation, Neoplastic; Humans; Inositol 1,4,5-Trisphosphate; Mammary Glands, Human; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurokinin-1 Receptor Antagonists; Phosphorylation; Receptors, Neurokinin-1; Reference Values; Substance P; Triazoles | 2013 |
Cancer-related genes transcriptionally induced by the fungicide penconazole.
Topics: Breast Neoplasms; Cell Line, Tumor; Endocrine Disruptors; Female; Fungicides, Industrial; Gene Expression Profiling; Gene Expression Regulation; Humans; Oligonucleotide Array Sequence Analysis; Pesticide Residues; Thyroid Neoplasms; Triazoles; Vitis; Wine | 2014 |
Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Incidence; Letrozole; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin; Receptors, Interleukin-17; Receptors, Progesterone; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Triazoles | 2013 |
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Topics: Anastrozole; Breast Neoplasms; Female; Gene Expression Profiling; Humans; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk; Tamoxifen; Triazoles | 2013 |
Key genes for modulating information flow play a temporal role as breast tumor coexpression networks are dynamically rewired by letrozole.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Computational Biology; Female; Gene Expression Profiling; Gene Regulatory Networks; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Time Factors; Triazoles | 2013 |
A UK national survey of breast surgeons on primary endocrine therapy of early operable breast cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; General Surgery; Health Surveys; Humans; Letrozole; Nitriles; Practice Patterns, Physicians'; Tamoxifen; Triazoles | 2013 |
Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Transcription Factors; Treatment Outcome; Triazoles | 2013 |
The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Topics: Animals; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertility Preservation; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Letrozole; Mice; Nitriles; Oocytes; Ovulation Induction; Tissue and Organ Harvesting; Triazoles | 2013 |
Combination endocrine treatments unproven in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2013 |
Aromatase inhibitors and safety: clinical or statistical significance?
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2013 |
Reply to e. Esin et al.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2013 |
Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer?
Topics: Adult; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Cryopreservation; Estradiol; Female; Fertility Preservation; Gonadotropins; Humans; Italy; Letrozole; Neoplasm Proteins; Nitriles; Oocyte Retrieval; Oocytes; Oogenesis; Ovulation Induction; Receptors, Estrogen; Retrospective Studies; Triazoles; Up-Regulation | 2013 |
Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Female; Humans; Letrozole; Middle Aged; Nitriles; Obesity; Postmenopause; Prospective Studies; Receptors, Estrogen; Survival Analysis; Triazoles | 2013 |
Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
Topics: Animals; Apoptosis; Aromatase; Breast Neoplasms; Cell Proliferation; Drug Synergism; Elafin; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Mice; Nitriles; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Tardive dyskinesia associated with anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Female; Humans; Middle Aged; Movement Disorders; Nitriles; Triazoles | 2013 |
Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Incidence; Menopause; Middle Aged; Nitriles; Patient Compliance; Prospective Studies; Qualitative Research; Testosterone; Triazoles | 2013 |
[Effectiveness of the correction of hepatotoxicity during combined chemoradiotherapy for cancer patients].
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Chemoradiotherapy; Drug Administration Schedule; Female; Glioma; Humans; Infusions, Intravenous; Liver; Male; Middle Aged; Neoplasms; Protective Agents; Severity of Illness Index; Treatment Outcome; Triazoles | 2013 |
Psychometric analysis of the Patient Assessment of Own Functioning Inventory in women with breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chi-Square Distribution; Factor Analysis, Statistical; Female; Humans; Middle Aged; Neuropsychological Tests; Nitriles; Postmenopause; Prospective Studies; Psychometrics; Quality of Life; Reproducibility of Results; Triazoles | 2013 |
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
Topics: Adult; Breast Neoplasms; Cohort Studies; Comorbidity; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Fertility Agents; Fertility Preservation; Gonadotropins; Humans; Infertility, Female; Letrozole; New York; Nitriles; Ovulation Induction; Prevalence; Retrospective Studies; Risk Factors; Treatment Outcome; Triazoles | 2013 |
A polymorphism at the 3'-UTR region of the aromatase gene is associated with the efficacy of the aromatase inhibitor, anastrozole, in metastatic breast carcinoma.
Topics: 17-Hydroxysteroid Dehydrogenases; 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Frequency; Genotype; Humans; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Proteins; Retrospective Studies; Survival Analysis; Triazoles | 2013 |
Concordant effects of aromatase inhibitors on gene expression in ER+ Rat and human mammary cancers and modulation of the proteins coded by these genes.
Topics: Anastrozole; Animals; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Nitriles; Oligonucleotide Array Sequence Analysis; Rats; Real-Time Polymerase Chain Reaction; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles | 2013 |
Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Letrozole; MCF-7 Cells; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles; Ubiquitin-Conjugating Enzymes | 2013 |
Investigation of aryl halides as ketone bioisosteres: refinement of potent and selective inhibitors of human cytochrome P450 19A1 (aromatase).
Topics: Aromatase; Aromatase Inhibitors; Benzene Derivatives; Breast Neoplasms; Female; Humans; Hydrocarbons, Halogenated; Isomerism; Ketones; Models, Molecular; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2013 |
[Establishment of an aromatase inhibitor letrozole-resistant breast cancer cell model].
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Triazoles | 2013 |
Rapid response of breast cancer to neoadjuvant intramammary testosterone-anastrozole therapy: neoadjuvant hormone therapy in breast cancer.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Implants; Female; Humans; Mammary Glands, Human; Neoadjuvant Therapy; Nitriles; Testosterone; Triazoles; Ultrasonography | 2014 |
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Differentiation; Cell Growth Processes; Clinical Trials, Phase III as Topic; Female; Gene Expression Profiling; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Signal Transduction; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Hydroxyprostaglandin Dehydrogenases; Letrozole; Middle Aged; Nitriles; Receptors, Progesterone; ROC Curve; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Models, Economic; Models, Structural; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Triazoles; Uncertainty | 2014 |
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type I; Estradiol; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Obesity; Overweight; Peptide Fragments; Peptides; Postmenopause; Procollagen; Receptors, Estrogen; Triazoles | 2014 |
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Incidence; Letrozole; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Nitriles; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; Tumor Burden | 2014 |
Computational studies on the anastrozole and letrozole, effective chemotherapy drugs against breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carbon-13 Magnetic Resonance Spectroscopy; Computer Simulation; Female; Humans; Letrozole; Models, Molecular; Molecular Conformation; Nitriles; Proton Magnetic Resonance Spectroscopy; Static Electricity; Triazoles; Vibration | 2014 |
Breast cancer chemoprevention: little progress in practice?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Female; Humans; Nitriles; Triazoles | 2014 |
[An elderly patient with advanced breast cancer who responded to treatment with letrozole-a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Neoplasm Invasiveness; Neoplasm Metastasis; Nitriles; Triazoles | 2013 |
NICE urged to recommend anastrozole for breast cancer prevention.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Female; Humans; Nitriles; Triazoles | 2013 |
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Risk; Risk Assessment; Tamoxifen; Transcriptome; Treatment Outcome; Triazoles | 2014 |
Women commencing anastrozole, letrozole or tamoxifen for early breast cancer: the impact of comorbidity and demographics on initial choice.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Australia; Breast Neoplasms; Cohort Studies; Comorbidity; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Practice Guidelines as Topic; Premenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Tumor Burden | 2014 |
[A case of advanced breast carcinoma effectively treated postoperatively with tegafur-uracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Tegafur; Triazoles | 2013 |
Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Axilla; Biopsy, Large-Core Needle; Breast Neoplasms; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Tamoxifen; Triazoles | 2015 |
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Triazoles | 2014 |
Efficacy and safety of Trastuzumab added to standard treatments for HER2-positive metastatic breast cancer patients.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2013 |
Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer.
Topics: Animals; Breast Neoplasms; Cell Adhesion; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Letrozole; Maleic Anhydrides; Mice; Molecular Structure; NIH 3T3 Cells; Nitriles; Polyethylene; Polyvinyl Alcohol; Structure-Activity Relationship; Triazoles | 2014 |
Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Topics: Aged; Aged, 80 and over; Anastrozole; Androgens; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Chromatography, Liquid; Cross-Sectional Studies; Estradiol; Estrogens; Female; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Middle Aged; Nitriles; Obesity; Postmenopause; Prognosis; Tandem Mass Spectrometry; Tissue Distribution; Triazoles | 2014 |
Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Hypoxia; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Letrozole; MCF-7 Cells; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Spheroids, Cellular; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2014 |
Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoembryonic Antigen; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Immunity, Cellular; Immunotherapy; Interferon-beta; Interleukin-2; Letrozole; Middle Aged; Mucin-1; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Proportional Hazards Models; Selective Estrogen Receptor Modulators; T-Lymphocytes; Tamoxifen; Tissue Polypeptide Antigen; Toremifene; Triazoles | 2014 |
Influence networks based on coexpression improve drug target discovery for the development of novel cancer therapeutics.
Topics: Antineoplastic Agents; Breast Neoplasms; Computational Biology; Drug Discovery; Gene Expression Profiling; Humans; Letrozole; Molecular Targeted Therapy; Nitriles; Receptors, Estrogen; RNA, Messenger; Triazoles | 2014 |
New trials highlight breast cancer therapy and prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Triazoles | 2014 |
A joint test for progression and survival with interval-censored data from a cancer clinical trial.
Topics: Antineoplastic Agents; Bias; Breast Neoplasms; Clinical Trials as Topic; Data Interpretation, Statistical; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Models, Statistical; Nitriles; Triazoles | 2014 |
Dasatinib-letrozole gets split verdict.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Dasatinib; Female; Humans; Letrozole; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Receptor, ErbB-2; Receptors, Estrogen; Thiazoles; Treatment Outcome; Triazoles | 2014 |
Anastrozole may aid breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2014 |
[Long-term results of personalized treatment in 72 breast cancer patients who failed chemotherapy].
Topics: Adult; Aged; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diphosphonates; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lung Neoplasms; Medicine, Chinese Traditional; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Treatment Failure; Triazoles; Zoledronic Acid | 2013 |
Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Topics: Aged; Anastrozole; Androgens; Aromatase; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Triazoles | 2014 |
Radiation recall reaction with letrozole therapy in breast cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Nitriles; Radiodermatitis; Radiotherapy; Triazoles | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Retrospective Studies; Survival Rate; Tamoxifen; Time Factors; Triazoles | 2014 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
Prevention: targeted therapy-anastrozole prevents breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Molecular Targeted Therapy; Nitriles; Postmenopause; Triazoles | 2014 |
Graphene oxide based magnetic nanocomposites for efficient treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Survival; Drug Carriers; Female; Graphite; Humans; Magnetite Nanoparticles; MCF-7 Cells; Nitriles; Oxides; Particle Size; Triazoles | 2014 |
The bone substudy of MA.27: does bone make a difference?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2014 |
[A case of postmenopausal breast cancer becoming HER2 positive after neoadjuvant hormone therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Mammography; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles | 2014 |
EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis.
Topics: Aniline Compounds; Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Random Allocation; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2014 |
An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Topics: Animals; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenomics; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Nuclear Proteins; Repressor Proteins; RNA-Binding Proteins; Signal Transduction; Tamoxifen; Transcription Factors; Triazoles | 2014 |
Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Remodeling; Breast Neoplasms; Dehydroepiandrosterone Sulfate; Estradiol; Female; Follicle Stimulating Hormone; Gonadal Steroid Hormones; Humans; Longitudinal Studies; Luteinizing Hormone; Middle Aged; Nitriles; Postmenopause; Sex Hormone-Binding Globulin; Single-Blind Method; Testosterone; Triazoles | 2015 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Palbociclib ups PFS in HER2-/ER+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2014 |
Is there any cumulative dose for trastuzumab?
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Echocardiography; Female; Heart Diseases; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Taxoids; Trastuzumab; Triazoles | 2015 |
Luminescence modulations of rhenium tricarbonyl complexes induced by structural variations.
Topics: Alkylation; Breast Neoplasms; Cell Line, Tumor; Coordination Complexes; Female; Humans; Luminescence; Luminescent Agents; Luminescent Measurements; Optical Imaging; Rhenium; Triazoles | 2014 |
Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Patient Compliance; Proportional Hazards Models; Treatment Refusal; Triazoles | 2014 |
A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Attitude to Health; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Medication Adherence; Middle Aged; Nitriles; Qualitative Research; Quality of Life; Tamoxifen; Triazoles | 2014 |
Anti-aromatase effect of resveratrol and melatonin on hormonal positive breast cancer cells co-cultured with breast adipose fibroblasts.
Topics: Adipose Tissue; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Estradiol; Female; Fibroblasts; Gene Expression Regulation; Humans; Ki-67 Antigen; Letrozole; Melatonin; Nitriles; Resveratrol; Stilbenes; Testosterone; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins | 2014 |
Weight loss interventions and breast cancer survival: the time is now.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Telephone; Triazoles; Weight Loss | 2014 |
Another pill for breast cancer prevention.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2014 |
Drug cuts breast cancer risk by more than half.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Health Promotion; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles; Women's Health | 2014 |
Is there a role for hormonal therapy in neuroendocrine carcinoma of the breast? A Paradigmatic case report.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Neuroendocrine; Cytodiagnosis; Diagnostic Errors; Female; Humans; Letrozole; Lymphatic Metastasis; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2014 |
BETs abet Tam-R in ER-positive breast cancer.
Topics: Acetylation; Azepines; Benzodiazepines; Breast Neoplasms; Cell Cycle Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Histone-Lysine N-Methyltransferase; Histones; Humans; Nuclear Proteins; Protein Serine-Threonine Kinases; Receptors, Estrogen; Repressor Proteins; RNA-Binding Proteins; Tamoxifen; Transcription Factors; Triazoles | 2014 |
Silk fibroin rods for sustained delivery of breast cancer therapeutics.
Topics: Anastrozole; Animals; Antineoplastic Agents; Biodegradation, Environmental; Breast Neoplasms; Drug Delivery Systems; Female; Fibroins; Kinetics; Microscopy, Electron, Scanning; Nitriles; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Time Factors; Triazoles | 2014 |
Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Letrozole; Nitriles; Pilot Projects; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Triazoles; Tumor Suppressor Protein p53 | 2014 |
Molecular changes in lobular breast cancers in response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Cohort Studies; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2014 |
Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2.
Topics: Apoptosis; Breast Neoplasms; Casein Kinase II; Cell Cycle; Cell Proliferation; Cell Survival; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; MicroRNAs; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Triazoles | 2014 |
[Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mastectomy; Nitriles; Time Factors; Tomography, X-Ray Computed; Triazoles | 2014 |
AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Topics: Anastrozole; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; MCF-7 Cells; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Receptors, Androgen; Tamoxifen; Triazoles | 2014 |
Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Letrozole; Middle Aged; Musculoskeletal Pain; Nitriles; Prospective Studies; Tamoxifen; Triazoles | 2014 |
A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Topics: Apoptosis; Aurora Kinase A; Biomarkers, Tumor; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Cyanoacrylates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estradiol; Estrogen Antagonists; Fulvestrant; G2 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; RNA Interference; Survival Analysis; Tamoxifen; Triazoles | 2015 |
Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Australia; Breast Neoplasms; Developed Countries; Drug Utilization Review; England; Female; France; Humans; Internationality; Letrozole; Longitudinal Studies; Netherlands; Nitriles; Scandinavian and Nordic Countries; Tamoxifen; Triazoles | 2015 |
In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Topics: Angiogenesis Inhibitors; Aniline Compounds; Animals; Breast Neoplasms; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Endothelial Cells; Female; Humans; Male; MCF-7 Cells; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Neovascularization, Physiologic; Protein Kinase Inhibitors; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor Receptor-2; Wound Healing | 2014 |
Primary Hormonal Therapy for Elderly Breast Cancer Patients: Single Institution Experience.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Receptors, Estrogen; Retrospective Studies; Spain; Tamoxifen; Treatment Outcome; Triazoles | 2015 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in Kazakhstan.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Disease Progression; Everolimus; Female; Humans; Kazakhstan; Letrozole; Nitriles; Postmenopause; Receptor, ErbB-2; Triazoles | 2015 |
Morphea following radiation therapy in a patient with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Nitriles; Radiation Injuries; Radiotherapy, High-Energy; Scleroderma, Localized; Triazoles | 2015 |
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles | 2015 |
No pain, no gain: a fallacy so far.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Musculoskeletal System; Nitriles; Triazoles; Vasomotor System | 2015 |
Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Topics: Animals; Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; MCF-7 Cells; Mice, Nude; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Inhibitory Concentration 50; Letrozole; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Nitriles; Structure-Activity Relationship; Triazoles | 2014 |
An unusual cause of jaundice in a patient with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Fatty Liver; Female; Humans; Jaundice; Liver; Liver Function Tests; Middle Aged; Nitriles; Triazoles | 2014 |
Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Class I Phosphatidylinositol 3-Kinases; Diagnosis, Differential; Female; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Mastectomy, Segmental; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Triazoles | 2015 |
Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Culture Techniques; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Models, Biological; Nitriles; Tamoxifen; Triazoles | 2015 |
MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cluster Analysis; Cohort Studies; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; MicroRNAs; Neoplasm Recurrence, Local; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured; Up-Regulation | 2015 |
Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells.
Topics: Aromatase Inhibitors; Aurora Kinase A; Aurora Kinase B; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MCF-7 Cells; Organophosphates; Quinazolines; Small Molecule Libraries; Triazoles | 2015 |
Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
Topics: Antineoplastic Agents; Azepines; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Estradiol; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Receptors, Estrogen; RNA Polymerase II; Transcription, Genetic; Triazoles | 2015 |
Surgical resection of a liver metastasis from breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Liver Neoplasms; Lymph Node Excision; Mastectomy; Nitriles; Triazoles | 2015 |
[A case of hyoid bone metastasis from breast cancer].
Topics: Aged; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Lymphatic Metastasis; Nitriles; Triazoles | 2014 |
Antiproliferative effects of anastrozole on MCF-7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Nitriles; Receptors, Androgen; Signal Transduction; Testosterone; Triazoles | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Gonadotropin-Releasing Hormone; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptors, Estrogen; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Triazoles | 2015 |
Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells.
Topics: Animals; Anoikis; Aromatase; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal; Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Signal Transduction; Testosterone; Triazoles; Tumor Cells, Cultured | 2015 |
PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Topics: Anastrozole; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Liposomes; MCF-7 Cells; Nitriles; Particle Size; Polyethylene Glycols; Rats; Rats, Wistar; Structure-Activity Relationship; Surface Properties; Triazoles | 2016 |
Breast cancer risk reduction therapy: the low-hanging fruit.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma in Situ; Female; Humans; Hyperplasia; Nitriles; Practice Patterns, Physicians'; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2015 |
Solitary uterine metastasis of invasive lobular carcinoma after adjuvant endocrine therapy: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Carrier Proteins; Combined Modality Therapy; Female; Glycoproteins; Humans; Leiomyoma; Membrane Transport Proteins; Middle Aged; Nitriles; Triazoles; Uterine Neoplasms | 2015 |
Patterns of change in cognitive function with anastrozole therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Educational Status; Female; Humans; Longitudinal Studies; Memory; Middle Aged; Nitriles; Postmenopause; Triazoles | 2015 |
Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Letrozole; MAP Kinase Signaling System; Mice; Mice, Nude; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Nitriles; Postmenopause; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Transcription, Genetic; Treatment Outcome; Triazoles; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Tamoxifen; Triazoles | 2015 |
[Long-term survival of a breast cancer patient with carcinomatous pleuritis and carcinomatous cardiac tamponade successfully treated by multimodality therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Cardiac Tamponade; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Paclitaxel; Pleurisy; Triazoles | 2015 |
The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Costs; Drugs, Generic; Evaluation Studies as Topic; Female; Humans; Letrozole; Medicare; Medication Adherence; Nitriles; Non-Randomized Controlled Trials as Topic; Poverty; Triazoles; United States | 2015 |
Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Depressive Disorder; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Nitriles; Population Surveillance; Proportional Hazards Models; Retrospective Studies; Risk; Taiwan; Tamoxifen; Trastuzumab; Triazoles | 2015 |
Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Letrozole; MCF-7 Cells; Molecular Structure; NF-E2-Related Factor 2; Nitriles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Triazoles; Ubiquitination | 2015 |
Multiple gene aberrations and breast cancer: lessons from super-responders.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Everolimus; Female; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Neoplasm Proteins; Nitriles; Phosphatidylinositol 3-Kinases; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2015 |
Has the time come for genomic tests to guide the use of adjuvant chemotherapy in node-positive breast cancer?
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2015 |
Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cytokine Receptor gp130; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Letrozole; Minichromosome Maintenance Complex Component 4; Neoadjuvant Therapy; Nerve Tissue Proteins; Nitriles; Oligonucleotide Array Sequence Analysis; Precision Medicine; Predictive Value of Tests; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome; Triazoles; Ultrasonography | 2015 |
Synthesis, molecular docking and anticancer studies of peptides and iso-peptides.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; NF-kappa B; Peptides; Triazoles | 2015 |
Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.
Topics: Adjuvants, Pharmaceutic; Anastrozole; Anilides; Animals; Antifungal Agents; Antineoplastic Agents; Breast Neoplasms; Cholestanetriol 26-Monooxygenase; Dexmedetomidine; Enzyme Inhibitors; Fadrozole; Female; Hypnotics and Sedatives; Mice; Mice, Inbred C57BL; Nitriles; Protein Binding; Thiazoles; Tosyl Compounds; Triazoles | 2015 |
Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cyclin-Dependent Kinase 4; Disease-Free Survival; Drug Approval; Estrogen Receptor alpha; Female; Humans; Letrozole; Molecular Targeted Therapy; Neoplasm Metastasis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Triazoles | 2015 |
More Options for Fertility Preservation for Patients With Cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility Preservation; Follicle Stimulating Hormone; Humans; Infertility, Female; Nitriles; Ovulation Induction; Pregnancy; Triazoles | 2015 |
Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility Preservation; Follicle Stimulating Hormone; Follow-Up Studies; Humans; Infertility, Female; Letrozole; Neoplasm Staging; Nitriles; Ovulation Induction; Pregnancy; Pregnancy Outcome; Treatment Outcome; Triazoles; United States | 2015 |
Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cross-Sectional Studies; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Humans; Letrozole; Middle Aged; Nitriles; Paclitaxel; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2015 |
Healthcare professionals' preferences for surgery or primary endocrine therapy to treat older women with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Attitude of Health Personnel; Breast Neoplasms; Female; Geriatrics; Humans; Letrozole; Mastectomy; Nitriles; Oncology Nursing; Patient Preference; Receptors, Estrogen; Surgeons; Surveys and Questionnaires; Tamoxifen; Triazoles; United Kingdom | 2015 |
Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Female; Fertility Preservation; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Infertility, Female; Letrozole; Luteal Phase; Nitriles; Ovulation Induction; Progesterone; Sperm Injections, Intracytoplasmic; Triazoles | 2015 |
Triazole analog 1-(1-benzyl-5-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)-2-(4-bromophenylamino)-1-(4-chlorophenyl)ethanol induces reactive oxygen species and autophagy-dependent apoptosis in both in vitro and in vivo breast cancer models.
Topics: Animals; Apoptosis; Autophagy; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Ethanol; Female; HEK293 Cells; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Triazoles | 2015 |
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Letrozole; Mice, Nude; Nitriles; Pyridines; Receptor, ErbB-2; Tretinoin; Triazoles; Xenograft Model Antitumor Assays | 2015 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinations; Female; Humans; Letrozole; Middle Aged; Nitriles; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Triazoles | 2015 |
Picking the optimal endocrine adjuvant treatment for pre-menopausal women.
Topics: Age Factors; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Letrozole; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2015 |
Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Patient Selection; Prognosis; Tamoxifen; Time Factors; Triazoles | 2015 |
Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Topics: Adjuvants, Pharmaceutic; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis; Triazoles; Zoledronic Acid | 2016 |
Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Letrozole; Mice, Inbred BALB C; Mice, Nude; Neuregulin-1; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Phosphorylation; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2015 |
Evaluation of the Effect of 1,3-Bis(4-Phenyl)-1H-1,2,3-Triazolyl-2-Propanolol on Gene Expression Levels of JAK2-STAT3, NF-κB, and SOCS3 in Cells Cultured from Biopsies of Mammary Lesions.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cells, Cultured; Female; Gene Expression; Humans; Inflammation; Inhibitory Concentration 50; Janus Kinase 2; Middle Aged; NF-kappa B; Propranolol; Prospective Studies; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Triazoles | 2015 |
Drug Use Evaluation of Letrozole in Breast Cancer Patients at Regional Cancer Hospitals in Thailand.
Topics: Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Drug Utilization; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Prognosis; Receptors, Estrogen; Retrospective Studies; Thailand; Triazoles | 2015 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
[Multiple smooth colon stenosis in 76-year-old female patient].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diagnosis, Differential; Female; Humans; Intestinal Obstruction; Letrozole; Neoplasm Invasiveness; Nitriles; Treatment Outcome; Triazoles | 2015 |
Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2015 |
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
Topics: Azepines; Benzamides; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endopeptidases; Enzyme Induction; Female; Histone Deacetylase Inhibitors; Humans; MAP Kinase Signaling System; MCF-7 Cells; Nuclear Proteins; Protein Serine-Threonine Kinases; Pyrimidines; RNA-Binding Proteins; RNA, Small Interfering; Transcription Factors; Triazoles; Up-Regulation | 2015 |
[Fertility preservation in breast cancer patients by embryo cryopreservation after ovarian stimulation with letrozole and FSH].
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Female; Fertility Preservation; Follicle Stimulating Hormone; Humans; Infertility, Female; Nitriles; Ovulation Induction; Pregnancy; Triazoles | 2015 |
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Joint Diseases; Middle Aged; Neoplasm Staging; Nitriles; Patient Outcome Assessment; Postmenopause; Prognosis; Prospective Studies; Quality of Life; Risk Factors; Surveys and Questionnaires; Triazoles | 2016 |
Nanomedicine of anastrozole for breast cancer: Physicochemical evaluation, in vitro cytotoxicity on BT-549 and MCF-7 cell lines and preclinical study on rat model.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Humans; MCF-7 Cells; Nanomedicine; Nanoparticles; Nitriles; Particle Size; Rats; Triazoles | 2015 |
Aromatase Inhibition and Capecitabine Combination as 1st or 2nd Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Diarrhea; Disease Progression; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Retreatment; Retrospective Studies; Survival Rate; Triazoles | 2015 |
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Estradiol; Everolimus; Female; Follow-Up Studies; Fulvestrant; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Prognosis; Retrospective Studies; Survival Rate; Tamoxifen; Triazoles | 2015 |
Hypervitaminosis B12 As an Additional Prognostic Indicator in Elderly Adults with a Neoplastic Disease: Report of a Case and Review of the Literature.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Geriatric Assessment; Humans; Life Expectancy; Mammography; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Triazoles; Vitamin B 12 | 2015 |
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Breast Neoplasms; Female; Genetic Association Studies; Genetic Variation; Genotype; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Triazoles | 2015 |
The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study.
Topics: Adiponectin; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Composition; Body Mass Index; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Leptin; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2016 |
JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Azepines; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Epigenesis, Genetic; Female; Genes, myc; Humans; Molecular Targeted Therapy; Neoplasm Proteins; Nuclear Proteins; Promoter Regions, Genetic; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Transcription Factors; Triazoles; Tumor Stem Cell Assay | 2016 |
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Eye Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Peptides; Receptors, Estrogen; Retrospective Studies; RGS Proteins; Transcription Factors; Treatment Outcome; Trefoil Factor-3; Triazoles | 2015 |
Adjuvant Ovarian Suppression, High-dose Chemotherapy and Immunotherapy for Premenopausal Patients with High-risk Breast Cancer.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Endpoint Determination; Etoposide; Female; Humans; Ifosfamide; Immunotherapy; Interleukin-2; Isotretinoin; Leuprolide; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Triazoles; Triple Negative Breast Neoplasms | 2015 |
Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization.
Topics: Animals; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Epithelial-Mesenchymal Transition; Female; Homeodomain Proteins; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Metastasis; Neoplastic Stem Cells; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Smad Proteins; Thrombospondins; Transforming Growth Factor beta; Transplantation, Heterologous; Triazoles | 2015 |
A computational method for drug repositioning using publicly available gene expression data.
Topics: Antineoplastic Agents; Breast Neoplasms; Computational Biology; Databases, Genetic; Drug Repositioning; Female; Gene Expression Regulation, Neoplastic; Hepatitis C; Humans; Letrozole; Lung Neoplasms; Nitriles; Triazoles | 2015 |
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2016 |
Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Pterocarpans; Transcription Factors; Triazoles | 2015 |
[Efficacies of aromatase inhibitors in the treatment of hormone dependent metastatic breast cancer in postmenopausal women: a report of 148 cases].
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Hormones; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Postmenopause; Triazoles | 2015 |
Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase; Breast Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Ginkgo biloba; Humans; Mammary Neoplasms, Animal; MCF-7 Cells; Mice; Neoplasms, Experimental; Nitriles; Plant Extracts; RNA, Messenger; Triazoles | 2016 |
Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Drug Therapy, Combination; Female; Fertility; Fertility Preservation; Gonadotropins; Humans; Letrozole; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nitriles; Ovulation Induction; Prospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2016 |
Endothelial Robo4 suppresses breast cancer growth and metastasis through regulation of tumor angiogenesis.
Topics: ADP-Ribosylation Factor 6; ADP-Ribosylation Factors; Animals; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Endothelial Cells; Female; Gene Knockout Techniques; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neovascularization, Pathologic; Nerve Tissue Proteins; Receptors, Cell Surface; Receptors, Immunologic; Signal Transduction; Triazoles; Vascular Endothelial Growth Factor A; Zonula Occludens-1 Protein | 2016 |
miR-155 Drives Metabolic Reprogramming of ER+ Breast Cancer Cells Following Long-Term Estrogen Deprivation and Predicts Clinical Response to Aromatase Inhibitors.
Topics: Anastrozole; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Estrogens; Female; Glycolysis; Hexokinase; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Nude; MicroRNAs; Neoadjuvant Therapy; Nitriles; Phosphorylation; Receptors, Estrogen; Triazoles | 2016 |
[A Case of Locally Advanced Breast Cancer Treated with Modified Radical Mastectomy with Immediate Reconstruction Using a Tissue Expander after Endocrine Therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Implants; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Mastectomy, Modified Radical; Middle Aged; Nitriles; Tissue Expansion Devices; Triazoles | 2015 |
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved.
Topics: Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Papillary; Female; Gene Expression; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2016 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Line, Tumor; Cell Self Renewal; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Fulvestrant; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Vitro Techniques; Interleukin-6; Letrozole; Leuprolide; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Nitriles; Oxidative Phosphorylation; Peptides; Real-Time Polymerase Chain Reaction; Receptor, Notch3; Receptors, Estrogen; Receptors, Notch; Signal Transduction; Tamoxifen; Triazoles | 2016 |
Unilateral Internal Carotid Artery Occlusion After Letrozole Treatment in a Postmenopausal Woman with Breast Cancer.
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Breast Neoplasms; Carotid Artery Diseases; Carotid Artery, Internal; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Triazoles | 2016 |
Assessing survival benefit when treatment delays disease progression.
Topics: Aromatase Inhibitors; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Mastectomy; Neoplasm Staging; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Rate; Triazoles | 2016 |
Long-Term Disease-Free Survival in a Young Patient With Hormone Receptor-Positive Breast Cancer and Oligometastatic Disease in the Brain.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carmustine; Chemoradiotherapy; Craniotomy; Cyclophosphamide; Decanoic Acids; Disease-Free Survival; Doxorubicin; Female; Humans; Leuprolide; Nitriles; Paclitaxel; Polyesters; Radiosurgery; Receptors, Estrogen; Triazoles; Young Adult | 2016 |
The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy.
Topics: Affect; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cognition; Employment; Female; Humans; Middle Aged; Nitriles; Postmenopause; Self Report; Surveys and Questionnaires; Survivors; Triazoles | 2016 |
Prognostic and predictive effects of diabetes, hypertension, and coronary artery disease among women on extended adjuvant letrozole: NCIC CTG MA.17.
Topics: Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Disease-Free Survival; Female; Humans; Hypertension; Letrozole; Lymphatic Metastasis; Middle Aged; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2016 |
Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Humans; Hyperuricemia; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Triazoles | 2016 |
Pictilisib Plus Anastrozole Reduces Proliferation in ER+ Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Humans; Nitriles; Phosphatidylinositol 3-Kinases; Postmenopause; Triazoles | 2016 |
CYR61 Confers the Sensitivity to Aromatase Inhibitor Letrozole in ER Positive Breast Carcinoma.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cysteine-Rich Protein 61; Drug Resistance, Neoplasm; Female; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2017 |
Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Female; Fertility Preservation; Gonadotropins; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Treatment Outcome; Triazoles | 2016 |
Twin delivery after IVF-ET with variable dose letrozole-FSH protocol of lower estradiol in a patient previously treated for breast cancer: a case report.
Topics: Adenocarcinoma, Mucinous; Adult; Aromatase Inhibitors; Breast Neoplasms; Embryo Transfer; Estradiol; Female; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Infertility, Female; Letrozole; Menotropins; Nitriles; Ovulation Induction; Pregnancy; Pregnancy, Twin; Triazoles | 2016 |
Evaluating Markers for Guiding Treatment.
Topics: Age Factors; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Body Mass Index; Breast Neoplasms; Clinical Decision-Making; Decision Support Techniques; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Letrozole; Logistic Models; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Effects of letrozole on breast cancer micro-metastatic tumor growth in bone and lung in mice inoculated with murine 4T1 cells.
Topics: Animals; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Letrozole; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Micrometastasis; Nitriles; Triazoles | 2016 |
Letrozole-induced functional changes in carcinoma-associated fibroblasts and their influence on breast cancer cell biology.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Coculture Techniques; Female; Fibroblasts; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Letrozole; MCF-7 Cells; Nitriles; Real-Time Polymerase Chain Reaction; Transcriptome; Triazoles | 2016 |
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gene Expression Profiling; Health Status Indicators; Humans; Lymph Nodes; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2016 |
Complete response and long-term survival of leptomeningeal carcinomatosis from breast cancer with maintenance endocrine therapy.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Letrozole; Meningeal Carcinomatosis; Methotrexate; Nitriles; Spinal Neoplasms; Triazoles | 2016 |
Changing Adjuvant Breast-Cancer Therapy with a Signal for Prevention.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2016 |
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Letrozole; Markov Chains; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Switzerland; Treatment Outcome; Triazoles | 2016 |
Synthesis and biological evaluation of novel tamoxifen-1,2,4-triazole conjugates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Female; Humans; Microbial Sensitivity Tests; Molecular Structure; Stereoisomerism; Tamoxifen; Triazoles | 2016 |
Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance; Gene Expression Profiling; Gene Silencing; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; Intercellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome; Triazoles | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; DNA Mutational Analysis; Drug Administration Schedule; ErbB Receptors; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Letrozole; Mutation; Neuregulin-1; Nitriles; Receptor, ErbB-2; RNA, Messenger; Treatment Outcome; Triazoles | 2017 |
Circulating oxysterol metabolites as potential new surrogate markers in patients with hormone receptor-positive breast cancer: Results of the OXYTAM study.
Topics: Adult; Aged; Androstadienes; Aromatase; Aromatase Inhibitors; Biomarkers; Body Mass Index; Breast Neoplasms; Cholestanes; Cholesterol; Feasibility Studies; Female; Gas Chromatography-Mass Spectrometry; Hormones; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Oxidative Stress; Oxysterols; Pilot Projects; Prognosis; Prospective Studies; Reproducibility of Results; Signal Transduction; Tamoxifen; Triazoles | 2017 |
Hypercalcemic crisis associated with anastrozole use in a patient with breast cancer and primary hyperparathyroidism.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Carcinoma In Situ; Breast Neoplasms; Calcium; Female; Humans; Hypercalcemia; Hyperparathyroidism; Middle Aged; Nitriles; Parathyroid Hormone; Parathyroidectomy; Treatment Outcome; Triazoles | 2016 |
Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Likelihood Functions; Lymph Nodes; Lymphatic Metastasis; Nitriles; Predictive Value of Tests; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Tamoxifen; Triazoles; Tumor Burden | 2016 |
Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Curcumin; Down-Regulation; Drug Screening Assays, Antitumor; Female; Half-Life; HEK293 Cells; Humans; Male; Membrane Potential, Mitochondrial; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Triazoles | 2016 |
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Breast Neoplasms; Disease-Free Survival; Female; Homeodomain Proteins; Humans; Nitriles; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Interleukin-17; Receptors, Progesterone; Tamoxifen; Triazoles | 2016 |
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Republic of Korea; Survival Analysis; Treatment Outcome; Triazoles | 2017 |
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Carbanilides; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Letrozole; MCF-7 Cells; Mice, Nude; Molecular Targeted Therapy; Neoplasm Invasiveness; Nitriles; Ovariectomy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Receptors, Estrogen; Signal Transduction; Spheroids, Cellular; Time Factors; Transfection; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Arm; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Lupus Erythematosus, Cutaneous; Nitriles; Thorax; Triazoles | 2016 |
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Germany; Humans; Integrative Medicine; Letrozole; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Triazoles | 2017 |
Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Breast Neoplasms; Female; Humans; Lasers, Gas; Middle Aged; Nitriles; Retrospective Studies; Surveys and Questionnaires; Tamoxifen; Treatment Outcome; Triazoles; Vagina; Vaginal Diseases; Vulva | 2016 |
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinolines; Receptor, ErbB-2; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles | 2017 |
Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Arthralgia; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Protective Factors; Proto-Oncogene Proteins; Risk Factors; Treatment Outcome; Triazoles | 2017 |
Synthesis and cytotoxicity study of novel 3-(triazolyl)coumarins based fluorescent scaffolds.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Coumarins; Cycloaddition Reaction; Female; Fluorescent Dyes; HeLa Cells; Humans; MCF-7 Cells; Optical Imaging; Theranostic Nanomedicine; Triazoles; Uterine Cervical Neoplasms | 2016 |
Ribociclib Lengthens Breast Cancer Survival.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Purines; Treatment Outcome; Triazoles | 2016 |
New orally active DNA minor groove binding small molecule CT-1 acts against breast cancer by targeting tumor DNA damage leading to p53-dependent apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Curcumin; DNA; DNA Damage; Female; Humans; Molecular Docking Simulation; Rats; Triazoles; Tumor Suppressor Protein p53 | 2017 |
Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; CCR5 Receptor Antagonists; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL5; Culture Media, Conditioned; Cyclohexanes; Endothelial Cells; Female; Humans; Maraviroc; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Proto-Oncogene Proteins c-akt; Receptors, CCR5; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Triazoles; Tumor Burden; Tumor Microenvironment | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Palbociclib improves survival in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2017 |
Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment.
Topics: Alendronate; Alkaline Phosphatase; Anastrozole; Animals; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Disease Models, Animal; Drugs, Chinese Herbal; Female; Mice, Inbred BALB C; Nitriles; Osteoporosis; Ovariectomy; Triazoles | 2017 |
Abemaciclib Shows Promise for Early Breast Cancer.
Topics: Aminopyridines; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Humans; Ki-67 Antigen; Nitriles; Receptor, ErbB-2; Survival Analysis; Treatment Outcome; Triazoles | 2017 |
Design, Synthesis, in vitro Antiproliferative Activity, Binding Modeling of 1,2,4,-Triazoles as New Anti-Breast Cancer Agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Design; Female; Humans; In Vitro Techniques; MCF-7 Cells; Models, Molecular; Triazoles | 2016 |
The Effect of Undaria pinnatifida Fucoidan on the Pharmacokinetics of Letrozole and Tamoxifen in Patients With Breast Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Herb-Drug Interactions; Humans; Letrozole; Middle Aged; Nitriles; Phytotherapy; Polysaccharides; Tamoxifen; Triazoles; Undaria | 2018 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid | 2017 |
Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cognitive Dysfunction; Female; Humans; Middle Aged; Neuropsychological Tests; Nitriles; Prognosis; Receptor, ErbB-2; Triazoles | 2017 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles | 2016 |
[Two Cases of Lung Metastasis from Breast Cancer Successfully Treated with Endocrine Therapy].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Letrozole; Lung Neoplasms; Nitriles; Treatment Outcome; Triazoles | 2016 |
In vitro evaluation of Selective Inhibitors of Nuclear Export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells.
Topics: Acrylamides; Acrylates; Active Transport, Cell Nucleus; Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Nucleus; Dog Diseases; Dogs; Female; Hydrazines; Reverse Transcriptase Polymerase Chain Reaction; Triazoles | 2017 |
Letrozole not superior to anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Prognosis; Triazoles | 2017 |
Comparison of the effects of nobiletin and letrozole on the activity and expression of aromatase in the MCF-7 breast cancer cell line.
Topics: Aromatase; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Flavones; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Letrozole; MCF-7 Cells; Nitriles; Structure-Activity Relationship; Triazoles | 2017 |
Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Cohort Studies; Estradiol; Estrone; Female; Humans; Middle Aged; Nitriles; Triazoles | 2017 |
Subcutaneous testosterone-letrozole therapy before and concurrent with neoadjuvant breast chemotherapy: clinical response and therapeutic implications.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Breast Implants; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Testosterone; Treatment Outcome; Triazoles; Tumor Burden | 2017 |
Efficient T3P
Topics: Adenocarcinoma; Anhydrides; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; DNA Fragmentation; Female; G1 Phase Cell Cycle Checkpoints; Green Chemistry Technology; Humans; Indoles; Ligands; MCF-7 Cells; Molecular Docking Simulation; Organophosphonates; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Thiadiazoles; Triazoles | 2017 |
Higher Pretreatment and Aromatase Inhibitor Treatment-Related Cardiovascular Disease Risks in Postmenopausal Hormone Receptor-Positive Patients with Early Stage Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2017 |
Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Hepatectomy; Humans; Letrozole; Liver Neoplasms; Male; Markov Chains; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Piperazines; Pyridines; Quality-Adjusted Life Years; Survival Rate; Taxoids; Triazoles | 2017 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles | 2017 |
Estimating efficacy in trials with selective crossover.
Topics: Antineoplastic Agents; Binomial Distribution; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Cross-Over Studies; Disease-Free Survival; Female; Humans; Letrozole; Likelihood Functions; Models, Statistical; Nitriles; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2017 |
High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Ethnicity; Female; Humans; Insurance, Health; Medicaid; Medically Uninsured; Neoplasm Staging; Nitriles; Safety-net Providers; Tamoxifen; Treatment Outcome; Triazoles; United States | 2017 |
Fertility preservation: a vital survivorship issue for young women with breast cancer.
Topics: Adult; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Follicle Stimulating Hormone; Hormones; Humans; Infertility, Female; Letrozole; Nitriles; Ovulation Induction; Triazoles | 2008 |
Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Atrophy; Breast Neoplasms; Fatal Outcome; Female; Glomerulosclerosis, Focal Segmental; Humans; Inflammation; Nitriles; Triazoles | 2007 |
Is long-term adjuvant treatment of breast cancer with anastrozole indicated?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Nitriles; Time Factors; Triazoles | 2008 |
[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Female; Fibromyalgia; Humans; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2008 |
Stopping treatment can reverse acquired resistance to letrozole.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Phosphorylation; Receptor, ErbB-2; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Regression of chronic lymphocytic leukemia with aromatase inhibitor-letrozole?
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Leukemia, Lymphocytic, Chronic, B-Cell; Mastectomy, Segmental; Neoplasms, Multiple Primary; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2009 |
Method to test whether late extended letrozole, rather than self- selection, improves the outcome in patients with breast cancer who have completed 5 years of tamoxifen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Placebos; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Humans; Letrozole; Mastectomy; Middle Aged; Nitriles; Treatment Outcome; Triazoles; Young Adult | 2008 |
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Topics: Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens; Flow Cytometry; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2008 |
Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo.
Topics: Animals; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Proliferation; Dietary Supplements; DNA Primers; Estradiol; Female; Genistein; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2008 |
Cutaneous vasculitis in breast cancer treated with chemotherapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Nitriles; Paraneoplastic Syndromes; Skin Diseases, Vascular; Tamoxifen; Triazoles; Vasculitis | 2008 |
[Extended adjuvant hormone therapy (in breast cancer): Why? To whom? What? How long?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Estrogen Receptor Modulators; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Time Factors; Triazoles | 2008 |
Characterization of the weak estrogen receptor alpha agonistic activity of exemestane.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Microarray Analysis; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 2009 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthritis; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Drug Interactions; Female; Humans; Joint Diseases; Likelihood Functions; Logistic Models; Middle Aged; Multivariate Analysis; Nitriles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles | 2008 |
Vitreo-retinal traction and anastrozole use.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fovea Centralis; Humans; Middle Aged; Nitriles; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2009 |
Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis; Retrospective Studies; Triazoles | 2008 |
Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Triazoles | 2008 |
Abnormal cervical smear: a sign of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles; Uterine Cervical Neoplasms; Vaginal Smears | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Estrogen Receptor Modulators; Female; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Decision Making; Disease-Free Survival; Estrogen Receptor Modulators; Female; Genotype; Humans; Markov Chains; Middle Aged; Nitriles; Patient Participation; Postmenopause; Tamoxifen; Triazoles | 2008 |
Extending the benefits of adjuvant therapy in early HR+ breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Triazoles | 2008 |
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Topics: Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Postmenopause; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Risk Factors; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Primary uterine rhabdomyosarcoma in a patient with a history of breast cancer and gastrointestinal stromal tumor.
Topics: Aged; Anastrozole; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Gastrointestinal Stromal Tumors; Humans; Neoplasms, Second Primary; Nitriles; Rhabdomyosarcoma, Embryonal; Stomach; Triazoles; Uterine Neoplasms; Uterus | 2008 |
A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor.
Topics: Administration, Oral; Animals; Aromatase Inhibitors; Azasteroids; Breast Neoplasms; Cell Proliferation; Estrogens; Female; Humans; Letrozole; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Rats; Rats, Wistar; Steryl-Sulfatase; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
Topics: Anastrozole; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Radiography; Triazoles | 2008 |
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2008 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neoplasms; Female; Hot Flashes; Humans; Joints; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Odds Ratio; Postmenopause; Predictive Value of Tests; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles; Vasomotor System | 2008 |
Sonographic evaluation of endothelial function in letrozole and tamoxifen users.
Topics: Aged; Aromatase Inhibitors; Brachial Artery; Breast Neoplasms; Carotid Artery, External; Case-Control Studies; Endothelium, Vascular; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
Breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk; Time Factors; Triazoles | 2008 |
A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Genital Diseases, Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Retrospective Studies; Tamoxifen; Triazoles | 2009 |
A case of prolonged disease-free survival in a patient with choroidal metastasis from breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Choroid Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Triazoles | 2009 |
Anastrozole: brain draining or sparing?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attention; Breast Neoplasms; Cognition; Humans; Memory; Nitriles; Postmenopause; Triazoles | 2008 |
Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Female; Follow-Up Studies; Humans; Mental Recall; Middle Aged; Neoplasms, Hormone-Dependent; Neuropsychological Tests; Nitriles; Prospective Studies; Psychometrics; Reaction Time; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Creatine Kinase; Female; Humans; Immunoglobulin G; Middle Aged; Neoplasm Metastasis; Nitriles; Paraneoplastic Syndromes; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Patient Compliance; Postmenopause; Tamoxifen; Triazoles | 2009 |
A case of Meigs syndrome mimicking metastatic breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; CA-125 Antigen; Carcinoma, Ductal, Breast; Diagnosis, Differential; Female; Fibroma; Gynecologic Surgical Procedures; Humans; Letrozole; Mastectomy; Meigs Syndrome; Middle Aged; Nitriles; Ovarian Neoplasms; Pleural Effusion; Triazoles | 2009 |
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Immunohistochemistry; Letrozole; Microarray Analysis; Middle Aged; Nitriles; Patient Selection; Pilot Projects; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cell Count; Forkhead Transcription Factors; Humans; Letrozole; Middle Aged; Nitriles; Predictive Value of Tests; Prognosis; T-Lymphocytes, Regulatory; Treatment Outcome; Triazoles | 2009 |
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Estrogens; Female; Genes, erbB-2; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Ovariectomy; Transfection; Trastuzumab; Triazoles; Tumor Cells, Cultured | 2009 |
Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biopsy; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Letrozole; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Postmenopause; Prospective Studies; Receptors, Estrogen; RNA, Neoplasm; Triazoles | 2009 |
Effectiveness of a letter notification program for women with early-stage breast cancer eligible for extended adjuvant letrozole.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Correspondence as Topic; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Patient Acceptance of Health Care; Triazoles | 2009 |
Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer.
Topics: Adult; Aged; Anastrozole; Blood Platelets; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Platelet Count; Retrospective Studies; Tamoxifen; Triazoles | 2010 |
Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Nitriles; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2009 |
[A case of metastatic breast cancer resistant to anastrozole treatment responding to high-dose toremifene].
Topics: Anastrozole; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Middle Aged; Nitriles; Tomography, X-Ray Computed; Toremifene; Triazoles | 2009 |
Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo[3,2-c]quinoline and quinolinoquinoline derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type I; Female; Humans; Indoles; Leukemia; Quinolines; Thiazoles; Topoisomerase I Inhibitors; Triazoles | 2009 |
Accelerated cutaneous nodulosis associated with aromatase inhibitor therapy in a patient with rheumatoid arthritis.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Female; Hand; Humans; Letrozole; Nitriles; Rheumatoid Nodule; Triazoles | 2009 |
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzodioxoles; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
[Nineteen years postoperatively, anastrozole, UFT and cyclophosphamide combination therapy remained effective against recurrent hormone responsive breast cancer with intraabdominal lymphnode, pleural, skin and bone metastases in old age following sixteen-
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Female; Hormone Replacement Therapy; Humans; Lymphatic Metastasis; Nitriles; Pleural Neoplasms; Radiography; Recurrence; Skin Neoplasms; Tamoxifen; Tegafur; Time Factors; Triazoles; Uracil | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Data Interpretation, Statistical; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Synthesis, structure elucidation and antitumour activity of N-substituted amides of 3-(3-ethylthio-1,2,4-triazol-5-yl)propenoic acid.
Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Female; Fibroblasts; Humans; Lung Neoplasms; Skin; Triazoles | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Therapy, Combination; Female; Goserelin; Humans; Nitriles; Premenopause; Tamoxifen; Triazoles | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Confidence Intervals; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Imidazoles; Nitriles; Premenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Nitriles; Premenopause; Triazoles; Vitamin D; Vitamins; Zoledronic Acid | 2009 |
Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Drug Therapy, Combination; Female; Goserelin; Humans; Imidazoles; Nitriles; Premenopause; Receptor, ErbB-2; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2009 |
Adverse events and bone health during anastrozole therapy in postmenopausal Japanese breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Breast Neoplasms; Cerebral Infarction; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Japan; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Topics: Anastrozole; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Fulvestrant; Humans; Letrozole; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2009 |
Preservation of fertility in patients with cancer.
Topics: Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fertility; Humans; Letrozole; Neoplasms; Nitriles; Ovary; Ovulation Induction; Recurrence; Time Factors; Triazoles | 2009 |
Hemicentral retinal artery occlusion in a breast cancer patient using anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Retinal Artery Occlusion; Triazoles | 2009 |
Metastasis of lobular breast carcinoma to the uterus in a patient under anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Diagnosis, Differential; Female; Humans; Middle Aged; Nitriles; Triazoles; Uterine Neoplasms | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Goserelin; Hematoma, Subdural, Intracranial; Humans; Indoles; Letrozole; Leukopenia; Nitriles; Pyrroles; Skull; Sunitinib; Triazoles | 2009 |
Knowledge discovery processing and data mining in karyometry.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Papillary; Cell Nucleus; Colonic Neoplasms; Computational Biology; Female; Humans; Karyometry; Letrozole; Neoplasm Recurrence, Local; Nitriles; Precancerous Conditions; Triazoles; Urinary Bladder Neoplasms | 2009 |
Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dietary Supplements; Fatigue; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles; Vitamin D; Vitamin D Deficiency | 2010 |
Synthesis of 6-N,N,N-trimethyltriazole chitosan via "click chemistry" and evaluation for gene delivery.
Topics: Breast Neoplasms; Cell Proliferation; Cells, Cultured; Chitosan; DNA; Drug Delivery Systems; Female; Gene Transfer Techniques; Green Fluorescent Proteins; Humans; Kidney; Nanoparticles; Plasmids; Transfection; Triazoles | 2009 |
Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nitriles; Paclitaxel; Postmenopause; Treatment Outcome; Triazoles; Tumor Burden | 2010 |
How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lapatinib; Nitriles; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Risk Assessment; Survival Analysis; Time Factors; Trastuzumab; Triazoles | 2009 |
NCCN Guideline update: Breast Cancer Version 1.2004.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Combined Modality Therapy; Female; Humans; Letrozole; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2004 |
Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2010 |
Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Letrozole; Nitriles; Pharmacogenetics; Receptors, Estrogen; Tamoxifen; Triazoles | 2010 |
Impact of aromatase inhibitors on bone health in breast cancer patients.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Letrozole; Nitriles; Triazoles; Vitamin D | 2010 |
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Letrozole; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Prognosis; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2010 |
A remarkable case of cutaneous metastatic breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Epirubicin; Female; Humans; Mammaplasty; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Nitriles; Radiography; Skin Neoplasms; Taxoids; Triazoles | 2009 |
Drug-induced pruritic micropapular eruption: anastrozole, a commonly used aromatase inhibitor.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Diagnostic Errors; Drug Eruptions; Female; Humans; Mastectomy, Segmental; Nitriles; Postoperative Complications; Pruritus; Radiotherapy, Adjuvant; Scabies; Triazoles | 2009 |
Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estradiol; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Nitriles; Perimenopause; Postmenopause; Triazoles | 2009 |
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Endothelin A Receptor Antagonists; Endothelin-1; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Nitriles; Pyrrolidines; Receptor, Endothelin A; Tamoxifen; Time Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Markov Chains; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.
Topics: Adult; Breast Neoplasms; Female; Genes, BRCA1; Humans; Infertility; Letrozole; Mutation; Nitriles; Ovarian Neoplasms; Ovary; Ovulation Induction; Risk; Triazoles | 2010 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Introduction to sessions on guidelines and endocrine therapy, the influence of breast screening on number of mastectomies and the challenge between molecular science and traditional dogma in the treatment of breast cancer. Introduction to Session 6.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Mass Screening; Mastectomy; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Radiotherapy, Adjuvant; Retrospective Studies; Triazoles | 2009 |
[A case of inflammatory breast cancer responding to anastrozole].
Topics: Adenocarcinoma, Scirrhous; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Inflammation; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2009 |
[A successful case of advanced breast cancer of the elderly treated with the only breast-hormone therapy as PST].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aortic Aneurysm, Thoracic; Aortic Dissection; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Hypertension; Nitriles; Receptors, Estrogen; Triazoles | 2009 |
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Female; Gene Expression Profiling; Humans; Letrozole; MicroRNAs; Molecular Sequence Data; Nitriles; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Testosterone; Transfection; Transforming Growth Factor beta1; Triazoles | 2010 |
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles | 2010 |
The Functional Living Index-Cancer: estimating its reliability based on clinical trial data.
Topics: Aged; Antineoplastic Agents; Belgium; Breast Neoplasms; Discriminant Analysis; Female; Humans; Longitudinal Studies; Megestrol Acetate; Middle Aged; Patient Participation; Psychometrics; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Triazoles | 2010 |
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.
Topics: Aged; Anastrozole; Breast Neoplasms; Estradiol; Estrogens; Female; Gene Expression Profiling; Humans; Ki-67 Antigen; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles | 2010 |
Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Letrozole; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Receptor, ErbB-2; Signal Transduction; Transfection; Trastuzumab; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Radiotherapy, antihormonal therapy, and personalised medicine.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Precision Medicine; Radiation Injuries; Tamoxifen; Triazoles | 2010 |
A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.
Topics: 3' Untranslated Regions; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans; Immunohistochemistry; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Polymorphism, Genetic; Postmenopause; Treatment Outcome; Triazoles | 2010 |
R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Breast Neoplasms; Carcinoma; Female; HeLa Cells; Humans; K562 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oncogene Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Survival Analysis; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cyclin E; Drug Resistance, Neoplasm; Female; G1 Phase; Humans; Letrozole; Molecular Weight; Nitriles; Postmenopause; Prognosis; Purines; Roscovitine; Triazoles | 2010 |
Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Imidazoles; Letrozole; Nitriles; Triazoles; Zoledronic Acid | 2010 |
Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
Topics: Anastrozole; Anesthetics, Combined; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Early Detection of Cancer; Female; Gonadal Steroid Hormones; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Nitriles; Practice Guidelines as Topic; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Tamoxifen; Triazoles | 2010 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemoprevention; Double-Blind Method; Female; Health Knowledge, Attitudes, Practice; Humans; Mammography; Mass Screening; Middle Aged; Nitriles; Patient Selection; Randomized Controlled Trials as Topic; Risk Factors; Socioeconomic Factors; Surveys and Questionnaires; Triazoles | 2010 |
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Letrozole; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
Endocrine therapy is associated with low performance on some estrogen-sensitive cognitive tasks in postmenopausal women with breast cancer.
Topics: Aged; Anastrozole; Breast Neoplasms; Case-Control Studies; Cognition Disorders; Estrogen Antagonists; Fatigue; Female; Humans; Memory Disorders; Middle Aged; Mood Disorders; Neuropsychological Tests; Nitriles; Postmenopause; Statistics, Nonparametric; Surveys and Questionnaires; Tamoxifen; Triazoles | 2010 |
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Estrogens; Estrone; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Testosterone; Triazoles | 2010 |
[Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Goserelin; Humans; Middle Aged; Nitriles; Premenopause; Prognosis; Survival Rate; Treatment Outcome; Triazoles | 2010 |
GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Female; Fertility; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Letrozole; Nitriles; Recombinant Proteins; Triazoles | 2010 |
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Cell Line, Tumor; Cytoprotection; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Humans; Letrozole; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Purines; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Profiling; Humans; Neoadjuvant Therapy; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Triazoles | 2010 |
Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
Topics: Adult; Aged; Aged, 80 and over; alpha-Tocopherol; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Chromatography, High Pressure Liquid; Cohort Studies; Erythrocytes; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Nitriles; Tamoxifen; Triazoles | 2010 |
Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Databases as Topic; Delivery of Health Care; Drug Costs; Female; Health Knowledge, Attitudes, Practice; Humans; Insurance, Health; Letrozole; Logistic Models; Medication Adherence; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Retrospective Studies; Risk Assessment; Risk Factors; Treatment Outcome; Triazoles; United States | 2011 |
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression.
Topics: Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; DNA Primers; Down-Regulation; Drug Synergism; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Panobinostat; Promoter Regions, Genetic; Triazoles | 2010 |
Obesity and hormone therapy in breast cancer: an unfinished puzzle.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Estrogen Antagonists; Female; Humans; Menopause; Nitriles; Obesity; Tamoxifen; Triazoles | 2010 |
Prolonged survival of neoplastic meningitis from breast cancer with letrozole and intrathecal methotrexate: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Injections, Spinal; Letrozole; Meningitis; Methotrexate; Middle Aged; Nitriles; Prognosis; Survival Rate; Triazoles | 2011 |
The transdermal patches for site-specific delivery of letrozole: a new option for breast cancer therapy.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Breast Neoplasms; Female; Letrozole; Mice; Nitriles; Tissue Distribution; Transdermal Patch; Triazoles | 2010 |
Rheumatoid arthritis and aromatase inhibitors.
Topics: Adenocarcinoma; Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthritis, Rheumatoid; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2011 |
Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pennsylvania; Radiation Injuries; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors; Triazoles | 2011 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubicin; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Polyethylene Glycols; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles; Tumor Burden | 2011 |
A rare case of breast cancer metastasis.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Kidney Neoplasms; Mastectomy, Modified Radical; Middle Aged; Nephrectomy; Nitriles; Triazoles | 2010 |
The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; Nitriles; Research Design; Tamoxifen; Treatment Outcome; Triazoles | 2010 |
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Nitriles; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2010 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuvant; Cognition; Dyspareunia; Female; Hot Flashes; Humans; Middle Aged; Nausea; Nitriles; Pain; Psychometrics; Reproducibility of Results; Self Report; Triazoles; Urinary Incontinence; Weight Loss | 2011 |
Cognitive changes associated with endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Cognition; Cognition Disorders; Female; Humans; Letrozole; Memory; Neoplasms, Hormone-Dependent; Nitriles; Prospective Studies; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; United States; Women's Health | 2010 |
Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cluster Analysis; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Prospective Studies; Time Factors; Transcriptome; Treatment Outcome; Triazoles | 2012 |
Rectal metastasis from lobular carcinoma of the breast: a case report.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Nitriles; Rectal Neoplasms; Treatment Outcome; Triazoles | 2010 |
[An elderly advanced breast cancer with a good response to anastrozole].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Staging; Nitriles; Tomography, X-Ray Computed; Triazoles; Ultrasonography | 2010 |
Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important.
Topics: Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Therapy, Combination; Female; Humans; Nitriles; Osteoporosis; Triazoles | 2010 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of tamoxifen, anastrozole, and letrozole in human plasma and its application to a clinical study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Letrozole; Middle Aged; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Tandem Mass Spectrometry; Triazoles | 2010 |
Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cost-Benefit Analysis; Drug Substitution; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Receptors, Estrogen; Triazoles; United Kingdom; United States | 2010 |
Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Proliferation; Doxorubicin; Drug Combinations; Estrogen Receptor alpha; Estrogens; Female; Fluorouracil; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oxonic Acid; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tegafur; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured; Uracil | 2011 |
Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Topics: Adult; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Middle Aged; Nitriles; Ovary; Premenopause; Tamoxifen; Triazoles | 2010 |
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Ki-67 Antigen; Letrozole; Models, Statistical; Neoplasms; Nitriles; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Reproducibility of Results; Tamoxifen; Triazoles | 2010 |
Cortical and trabecular bone at the radius and tibia in postmenopausal breast cancer patients: a Peripheral Quantitative Computed Tomography (pQCT) study.
Topics: Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Radiography; Radius; Tibia; Triazoles | 2011 |
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chromosome Mapping; Chromosomes, Human, Pair 14; Clinical Trials, Phase III as Topic; Estrogens; Female; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Logistic Models; Middle Aged; Musculoskeletal System; Neoplasm Staging; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Proto-Oncogene Proteins; Randomized Controlled Trials as Topic; Receptors, Interleukin-17; Retrospective Studies; Severity of Illness Index; Triazoles | 2010 |
What is the value of the 21 gene recurrence score in HER2-negative patients?
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Kaplan-Meier Estimate; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Neoplasm; Tamoxifen; Triazoles | 2010 |
Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Luteinizing Hormone; Nitriles; Triazoles | 2010 |
Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Female; HSP70 Heat-Shock Proteins; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2010 |
Effect of letrozole on plasma lipids, triglycerides, and estradiol in postmenopausal women with metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Estradiol; Estrogens; Female; Humans; Letrozole; Lipids; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Prospective Studies; Triazoles; Triglycerides | 2010 |
Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Nitriles; Quality of Life; Radiotherapy; Trastuzumab; Triazoles | 2010 |
Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Receptor alpha; Estrogen Receptor beta; Fadrozole; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Nitriles; Phosphorylation; Predictive Value of Tests; Prognosis; Retrospective Studies; Serine; Tamoxifen; Triazoles | 2010 |
10 years of ATAC: one question answered, many others unresolved.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Nitriles; Tamoxifen; Triazoles | 2010 |
[Advanced breast cancer in a patient achieving long-term SD after letrozole administration for liver metastasis developing during anastrozole therapy].
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Liver Neoplasms; Nitriles; Triazoles | 2010 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Carcinoma; Case-Control Studies; Collagen Type I; Cross-Sectional Studies; Female; Humans; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Risk Factors; Triazoles | 2011 |
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, Liquid; Cytochrome P-450 CYP3A; Female; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Metabolic Networks and Pathways; Microsomes, Liver; Nitriles; Oxidation-Reduction; Tandem Mass Spectrometry; Triazoles | 2010 |
Significance of ER-Src axis in hormonal therapy resistance.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Co-Repressor Proteins; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Female; Gene Knockdown Techniques; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Pyrimidines; Receptor, ErbB-2; RNA Interference; src-Family Kinases; Tamoxifen; Thiazoles; Transcription Factors; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Disease-Free Survival; Estradiol; Female; Gonadotropin-Releasing Hormone; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Triazoles | 2011 |
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan | 2010 |
[A case of stage IV breast cancer with bone metastases that responded well for long-term to hormonal therapy].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2010 |
Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Body Mass Index; Breast Neoplasms; Cohort Studies; Female; Hand Strength; Humans; Letrozole; Middle Aged; Musculoskeletal Diseases; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Syndrome; Tamoxifen; Triazoles | 2011 |
Risk of Ipsilateral breast tumor recurrence in patients treated with Tamoxifen or Anastrozole following breast-conserving surgery with or without radiotherapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Triazoloacridone C-1305 abrogates the restriction checkpoint in cells lacking functional p53 and promotes their accumulation in the G2/M phase of the cell cycle.
Topics: Acridines; Breast Neoplasms; Cyclin-Dependent Kinase 2; Female; G2 Phase; HL-60 Cells; Humans; Immunoblotting; Phosphorylation; Topoisomerase II Inhibitors; Triazoles; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Anastrozole can cause severe hypercalcaemia mimicking primary hyperparathyroidism.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Calcium; Female; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Nitriles; Parathyroid Hormone; Triazoles | 2014 |
Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cryopreservation; Drug Administration Schedule; Emergency Medical Services; Female; Fertility; Humans; Infertility, Female; Letrozole; Menstrual Cycle; Nitriles; Oocyte Retrieval; Oocytes; Ovulation Induction; Preservation, Biological; Time Factors; Triazoles | 2011 |
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Ovarian Neoplasms; Pyrans; Pyrimidines; src-Family Kinases; Triazoles | 2011 |
Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Proliferation; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Nitriles; Predictive Value of Tests; Receptors, Estrogen; Sensitivity and Specificity; Triazoles | 2011 |
A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Proportional Hazards Models; Proto-Oncogene Proteins c-myc; RNA Interference; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
[Synthesis of 5-aryl-4-cyano-1H-1, 2, 3-triazoles and biological evaluation of their inhibitory action on tyrosine kinase].
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crystallization; Crystallography, X-Ray; Female; Humans; Phosphorylation; Protein-Tyrosine Kinases; Receptor, ErbB-2; Triazoles | 2009 |
PET imaging of early response to the tyrosine kinase inhibitor ZD4190.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Glucose; Humans; Integrin alphaVbeta3; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radioactive Tracers; Time Factors; Treatment Outcome; Triazoles; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |
10-year analysis of the ATAC trial: wrong conclusion?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Synthesis and in vitro studies of biodegradable thiolated chitosan hydrogels for breast cancer therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Stability; Hydrogels; Letrozole; Nanoparticles; Nitriles; Sulfhydryl Compounds; Tensile Strength; Triazoles | 2011 |
Binding features of steroidal and nonsteroidal inhibitors.
Topics: Amino Acids; Androgens; Androstadienes; Androstenedione; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Estrogens; Estrone; Female; Humans; Letrozole; Mutagenesis, Site-Directed; NADPH-Ferrihemoprotein Reductase; Neoplasms, Hormone-Dependent; Nitriles; Protein Conformation; Structure-Activity Relationship; Triazoles | 2011 |
Aromatase inhibitors and xenograft studies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Benzamides; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Nitriles; Phosphorylation; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles; Xenograft Model Antitumor Assays | 2011 |
[Significance of HER2 testing in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Delivery Systems; Female; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Trastuzumab; Triazoles | 2011 |
Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Area Under Curve; Breast Neoplasms; Chitosan; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Diffusion; Glutaral; Humans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Microspheres; Nitriles; Particle Size; Polymers; Spectroscopy, Fourier Transform Infrared; Triazoles | 2011 |
Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aromatase; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Polymorphism, Single Nucleotide; Triazoles | 2011 |
Association between breast cancer subtypes and response to neoadjuvant anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Recurrence; Treatment Outcome; Triazoles | 2011 |
Anastrozole-related acute hepatitis with autoimmune features: a case report.
Topics: Acute Disease; Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Hepatitis, Autoimmune; Humans; Nitriles; Treatment Outcome; Triazoles | 2011 |
Predictive algorithms for adjuvant therapy: TransATAC.
Topics: Algorithms; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Neoplasm Recurrence, Local; Nitriles; Prognosis; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Insulin-Like Growth Factor I; Models, Biological; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Triazoles | 2011 |
Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Cycle Proteins; Drug Resistance, Neoplasm; Estrogen Receptor beta; Female; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Ovarian hyperstimulation syndrome in a patient treated with tamoxifen for breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Substitution; Female; Humans; Middle Aged; Nitriles; Ovarian Hyperstimulation Syndrome; Ovariectomy; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Steryl-Sulfatase; Tamoxifen; Triazoles | 2011 |
Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Goserelin; Humans; Letrozole; Middle Aged; Nitriles; Premenopause; Treatment Outcome; Triazoles | 2011 |
Letrozole withdrawal response in locally advanced breast cancer.
Topics: Aged; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hepacivirus; Humans; Letrozole; Liver; Liver Cirrhosis; Nitriles; Triazoles; Withholding Treatment | 2011 |
Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.
Topics: Adult; Age Factors; Anti-Mullerian Hormone; Breast Neoplasms; Cryopreservation; Embryonic Development; Female; Fertility Preservation; Follicle Stimulating Hormone; Follicular Fluid; Follow-Up Studies; Humans; Inhibins; Letrozole; Nitriles; Oocytes; Treatment Outcome; Triazoles | 2011 |
GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.
Topics: Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Intercellular Signaling Peptides and Proteins; Letrozole; Nitriles; Progranulins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Triazoles | 2011 |
Effective role of hormonal therapy in metastatic primary neuroendocrine breast carcinoma.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Neuroendocrine; Diagnosis, Differential; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Does trauma or an intercurrent surgical intervention lead to a short-term increase in breast cancer recurrence rates?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Factors; Surgical Procedures, Operative; Tamoxifen; Triazoles; Wounds and Injuries | 2012 |
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Catalytic Domain; Computer Simulation; Drug Discovery; Female; Humans; Isoenzymes; Kinetics; Letrozole; Microsomes; Models, Molecular; Nitriles; Tamoxifen; Testosterone; Thermodynamics; Triazoles | 2012 |
EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Female; Hep G2 Cells; Humans; Luciferases; Lung Neoplasms; Mice; Mice, Transgenic; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Smad2 Protein; Triazoles | 2011 |
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Breast; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Mammography; Middle Aged; Nitriles; Postmenopause; Prognosis; Prospective Studies; Triazoles | 2011 |
Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.
Topics: Apoptosis; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Enzyme Activators; Female; Gene Knockdown Techniques; Humans; Inhibitor of Apoptosis Proteins; Oligopeptides; Protein Binding; Radiation-Sensitizing Agents; RNA Interference; Triazoles | 2012 |
Is primary endocrine therapy effective in treating the elderly, unfit patient with breast cancer?
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Retrospective Studies; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Early Detection of Cancer; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Microarray Analysis; Middle Aged; Neoplasm, Residual; Nitriles; Prognosis; Receptors, Estrogen; Time Factors; Triazoles | 2011 |
Embracing the complexity of comorbidity.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2011 |
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Nitriles; Outcome Assessment, Health Care; Postmenopause; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2011 |
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Breast Neoplasms; Female; Hip; Humans; Letrozole; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis; Postmenopause; Radiography; Randomized Controlled Trials as Topic; Retrospective Studies; Tamoxifen; Triazoles | 2012 |
Choroidal and optic disc metastases from breast cancer and their response to combination pharmacotherapy with tamoxifen, cyclophosphamide hydrate, letrozole, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Choroid Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Nitriles; Optic Disk; Optic Nerve Neoplasms; Retinal Detachment; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
The breast cancer chemoprevention debate.
Topics: Anastrozole; Androstadienes; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Clinical Trials as Topic; Female; Humans; Models, Statistical; Nitriles; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Disease Progression; Female; Follow-Up Studies; Humans; Letrozole; Nitriles; Receptor, ErbB-2; Survival Rate; Tamoxifen; Treatment Outcome; Triazoles | 2012 |
Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Oligonucleotide Array Sequence Analysis; Pyrazoles; Receptor, IGF Type 1; Receptor, Insulin; Tamoxifen; Triazines; Triazoles; Xenograft Model Antitumor Assays | 2011 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Leiomyoma; Letrozole; Middle Aged; Neoplasms, Multiple Primary; Nitriles; Triazoles; Uterine Neoplasms | 2011 |
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Survival Analysis; Triazoles | 2011 |
A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines.
Topics: Aconitine; Aconitum; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Drugs, Chinese Herbal; Female; Hemorrhage; Humans; Medicine, Kampo; Middle Aged; Mucous Membrane; Nitriles; Phytotherapy; Qi; Triazoles; Vagina | 2011 |
Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Genes, Reporter; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Premenopause; Tamoxifen; Thymidine Phosphorylase; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report.
Topics: Adult; Breast Neoplasms; Female; Fertilization in Vitro; Gonadotropins; Humans; Letrozole; Male; Nitriles; Oocytes; Ovarian Hyperstimulation Syndrome; Ovulation Induction; Sperm Injections, Intracytoplasmic; Triazoles | 2012 |
Effect of simvastatin on the pharmacokinetics of anastrozole.
Topics: Aged; Anastrozole; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Interactions; Estradiol; Estrone; Female; Humans; Middle Aged; Nitriles; Pilot Projects; Simvastatin; Triazoles | 2012 |
[Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Lipid Metabolism; Lipids; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Triazoles; Triglycerides | 2011 |
Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.
Topics: Aged; Anastrozole; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Fine-Needle; Breast Neoplasms; DNA; Female; Genotype; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Middle Aged; Neoplasms, Second Primary; Nitriles; Polymerase Chain Reaction; Prognosis; Triazoles | 2012 |
Grover disease (transient acantholytic dermatosis) induced by anastrozole.
Topics: Acantholysis; Aged; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Ichthyosis; Nitriles; Triazoles | 2011 |
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Core Binding Factor Alpha 1 Subunit; Drug Resistance, Neoplasm; Estradiol; Female; Fluorescent Antibody Technique; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Letrozole; Nitriles; Real-Time Polymerase Chain Reaction; Signal Transduction; Triazoles | 2012 |
Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2D6; Decision Support Techniques; Economics, Pharmaceutical; Female; Genotype; Humans; Markov Chains; Nitriles; Pharmacogenetics; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles; United Kingdom | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcium Carbonate; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Etidronic Acid; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Severity of Illness Index; Triazoles; Vitamin D | 2012 |
[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
Topics: Animals; Breast Neoplasms; Calcitonin; Carcinoma, Medullary; Clinical Trials as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Disease Susceptibility; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Infections; Liraglutide; Pancreatitis; Pharmacovigilance; Pioglitazone; Pyrazines; Risk Assessment; Safety-Based Drug Withdrawals; Sitagliptin Phosphate; Species Specificity; Thiazolidinediones; Thyroid Neoplasms; Triazoles; Urinary Bladder Neoplasms | 2012 |
[A case of an elderly breast cancer patient achieving partial response with toremifene without efficacy of letrozole as a preoperative primary endocrine therapy].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Salvage Therapy; Toremifene; Triazoles | 2011 |
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hormone Replacement Therapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Middle Aged; Nitriles; Paclitaxel; Time Factors; Triazoles | 2011 |
[A case of scalp metastases from breast cancer successfully treated with letrozole].
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Letrozole; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Nitriles; Scalp; Skin Neoplasms; Triazoles | 2011 |
Primary breast cancer of the vulva: a case report.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Female; Histocytochemistry; Humans; Immunohistochemistry; Letrozole; Nitriles; Radiotherapy; Triazoles; Vulva; Vulvar Neoplasms | 2012 |
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
Topics: Animals; Apoptosis Regulatory Proteins; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, SCID; Mitochondrial Proteins; Ovarian Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction; Triazoles; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2012 |
Myocardial infarction due to coronary thrombus formation in a postmenopausal woman with breast cancer after initiation of letrozol therapy.
Topics: Aromatase Inhibitors; Breast Neoplasms; Coronary Thrombosis; Electrocardiography; Female; Humans; Letrozole; Middle Aged; Myocardial Infarction; Nitriles; Postmenopause; Radiography; Triazoles | 2012 |
Aromatase inhibitors in premenopausal breast cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Goserelin; Humans; Neoadjuvant Therapy; Nitriles; Tamoxifen; Triazoles | 2012 |
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2012 |
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic.
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Female; Humans; Incidence; Neoplasms, Hormone-Dependent; Nitriles; Outpatients; Retrospective Studies; Triazoles | 2012 |
High yield of oocytes without an increase in circulating estradiol levels in breast cancer patients treated with follicle-stimulating hormone and aromatase inhibitor in standard gonadotropin-releasing hormone analogue protocols.
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Clinical Protocols; Embryo Implantation, Delayed; Estradiol; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Oocytes; Ovary; Reproductive Techniques, Assisted; Retrospective Studies; Treatment Outcome; Triazoles | 2011 |
[A case of liver metastasis of breast cancer responding to letrozole].
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Liver Neoplasms; Nitriles; Tomography, X-Ray Computed; Triazoles | 2012 |
Genesis and outcome of a breast cancer trial to develop the aromatase inhibitor anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2012 |
Platinum(II) complexes with 5,7-disubstituted-1,2,4-triazolo [1,5-a]pyrimidines: spectroscopical characterization and cytotoxic activity in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Magnetic Resonance Spectroscopy; Organoplatinum Compounds; Pyrimidines; Triazoles | 2012 |
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cytochrome P-450 CYP2D6; Female; Genotype; Germ-Line Mutation; Glucuronosyltransferase; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Odds Ratio; Postmenopause; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Risk Factors; Tamoxifen; Triazoles; United Kingdom | 2012 |
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
[A case of recurrent breast cancer with brain metastases successfully treated with vinorelbine and anastrozole after multiple chemo-endocrine therapies].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Receptors, Estrogen; Recurrence; Triazoles; Vinblastine; Vinorelbine | 2012 |
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Immunosuppressive Agents; Letrozole; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2012 |
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Mammography; Nitriles; Pilot Projects; Risk Factors; Triazoles | 2012 |
The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Estradiol; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Letrozole; Menstrual Cycle; Nitriles; Oocyte Retrieval; Ovary; Ovulation Induction; Prospective Studies; Retrospective Studies; Triazoles | 2012 |
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2012 |
AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
Topics: Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Letrozole; MAP Kinase Signaling System; Neoplasm Recurrence, Local; Nitriles; Nuclear Receptor Coactivator 3; Promoter Regions, Genetic; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Proto-Oncogene Proteins c-myc; Transcription, Genetic; Trefoil Factor-1; Triazoles; Tumor Suppressor Proteins; Up-Regulation | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |
Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tamoxifen; Triazoles; Weight Gain | 2012 |
Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoadjuvant Therapy; Neoplasm Proteins; Nitriles; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Estrogen; RNA Interference; RNA, Small Interfering; Signal Transduction; Triazoles | 2012 |
CCR5 antagonist blocks metastasis of basal breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CCR5 Receptor Antagonists; Chemokine CCL5; Cyclohexanes; Female; Gene Expression Regulation, Neoplastic; Humans; Maraviroc; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplasms, Basal Cell; Piperazines; Pyrimidines; Receptors, CCR5; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Breast cancer associated with an accessory nipple.
Topics: Aged, 80 and over; Aromatase Inhibitors; Biopsy, Large-Core Needle; Breast Neoplasms; Choristoma; Female; Humans; Letrozole; Nipples; Nitriles; Triazoles; Ultrasonography, Interventional; Ultrasonography, Mammary | 2011 |
[A case of elderly locally-advanced breast cancer with skin ulcer responding to letrozole].
Topics: Aged, 80 and over; Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Letrozole; Neoplasm Grading; Neoplasm Staging; Nitriles; Skin Ulcer; Triazoles | 2012 |
Impact of Aromatase protein variants and drug interactions in breast cancer: a molecular docking approach.
Topics: Anastrozole; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Catalytic Domain; Drug Interactions; Female; Humans; Ligands; Models, Molecular; Mutant Proteins; Nitriles; Triazoles | 2012 |
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA Repair; Exome; Exons; Female; Genetic Variation; Genome, Human; Humans; Letrozole; MAP Kinase Kinase 4; MAP Kinase Kinase Kinase 1; Mutation; Nitriles; Receptors, Estrogen; Treatment Outcome; Triazoles | 2012 |
Long-term survival in an untreated patient with leptomeningeal carcinomatosis from breast primary.
Topics: Antineoplastic Agents; Breast Neoplasms; Chronic Disease; Female; Humans; Hypesthesia; Immunohistochemistry; Letrozole; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Neural Conduction; Nitriles; Spinal Neoplasms; Survival; Triazoles | 2013 |
Safe chemotherapy and hormone therapy for treating early breast cancer in a glucose 6-phosphate dehydrogenase-deficient patient: case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Letrozole; Middle Aged; Nitriles; Taxoids; Triazoles | 2012 |
Positron emission tomography with computed tomography (PET-CT) to evaluate the response of bone metastases to non-surgical treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Ibandronic Acid; Letrozole; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Spinal Neoplasms; Tomography, X-Ray Computed; Triazoles | 2010 |
Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer?
Topics: Adult; Aromatase Inhibitors; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Embryo Transfer; Female; Fertility Preservation; Follicle Stimulating Hormone, Human; Humans; Letrozole; Nitriles; Oocyte Retrieval; Pregnancy; Pregnancy Rate; Retrospective Studies; Triazoles | 2012 |
Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Letrozole; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Retrospective Studies; Subtraction Technique; Triazoles | 2012 |
Inflammatory osteoarthritis which was precipitated by Arimidex and resolved with tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Female; Humans; Middle Aged; Nitriles; Osteoarthritis; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2010 |
Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Estrone; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles | 2012 |
Aromatase inhibition in obese women: how much is enough?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2012 |
Successful combination: existing drugs boost cancer vaccine responses.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cancer Vaccines; Daclizumab; Disease Models, Animal; Female; Humans; Immunoglobulin G; Letrozole; Lung Neoplasms; Membrane Glycoproteins; Mice; Nitriles; Treatment Outcome; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cytochrome P-450 CYP2D6; Female; Glucuronosyltransferase; Humans; Neoplasm Recurrence, Local; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Tamoxifen; Triazoles | 2012 |
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.
Topics: Animals; Aromatase Inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Nitriles; Receptor, ErbB-2; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
Topics: Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Letrozole; Middle Aged; Molecular Sequence Data; Mutation; Nitriles; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Estrogen; Triazoles | 2012 |
Macular oedema due to letrozole: a first case report.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Diagnosis, Differential; Female; Fluorescein Angiography; Fundus Oculi; Humans; Letrozole; Macular Edema; Nitriles; Tomography, Optical Coherence; Triazoles | 2012 |
[Endobronchial metastases from breast cancer: a clinicopathological and survival analysis].
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Letrozole; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Nitriles; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Triazoles | 2012 |
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Topics: Acridines; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Breast Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Breaks; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Topoisomerase II Inhibitors; Triazoles; Tumor Suppressor Protein p53 | 2012 |
Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Genes, erbB-1; Humans; Letrozole; Nitriles; Norpregnadienes; Progestins; Promegestone; Receptors, Progesterone; RNA, Messenger; RNA, Neoplasm; Tamoxifen; Testosterone; Triazoles; Tumor Stem Cell Assay | 2013 |
Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Prognosis; Triazoles | 2012 |
Lichen sclerosus in a breast cancer survivor on an aromatase inhibitor: a case report.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clobetasol; Drug Eruptions; Female; Glucocorticoids; Humans; Middle Aged; Nitriles; Triazoles; Vulvar Lichen Sclerosus | 2013 |
Dry eye syndrome in aromatase inhibitor users.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Blepharitis; Breast Neoplasms; Conjunctival Diseases; Dry Eye Syndromes; Female; Humans; Keratitis; Letrozole; Middle Aged; Nitriles; Ovarian Neoplasms; Retrospective Studies; Triazoles; Vision Disorders | 2013 |
New ruthenium(II)-letrozole complexes as anticancer therapeutics.
Topics: Adenine; Adenocarcinoma; Antineoplastic Agents; Aromatase Inhibitors; Autophagy; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coordination Complexes; Crystallography, X-Ray; Curcumin; Drug Interactions; Drug Screening Assays, Antitumor; Female; Glioblastoma; Humans; Letrozole; Nitriles; Ruthenium; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2012 |
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Nitriles; Practice Guidelines as Topic; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Risk Assessment; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
Adherence evaluation of endocrine treatment in breast cancer: methodological aspects.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Data Collection; Female; Humans; Medication Adherence; Middle Aged; Nitriles; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Triazoles | 2012 |
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Nucleolus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Anastrozole and fulvestrant in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Humans; Nitriles; Triazoles | 2012 |
Anastrozole and fulvestrant in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Humans; Nitriles; Triazoles | 2012 |
Anastrozole and fulvestrant in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Humans; Nitriles; Triazoles | 2012 |
Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2012 |
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrone; Female; Genetic Association Studies; Genotype; Humans; Letrozole; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Postmenopause; Prospective Studies; Triazoles | 2013 |
Aromatase inhibitors associated with knee subchondral bone expansion without cartilage loss.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Female; Humans; Letrozole; Magnetic Resonance Imaging; Menisci, Tibial; Middle Aged; Nitriles; Postmenopause; Prospective Studies; Tibia; Triazoles | 2013 |
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Everolimus; Female; Health Care Costs; Humans; Letrozole; Middle Aged; Nitriles; Receptor, ErbB-2; Severity of Illness Index; Sirolimus; Treatment Failure; Triazoles; United States | 2013 |
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Topics: Aged; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Letrozole; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; NF-kappa B p50 Subunit; Nitriles; Panobinostat; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Topics: Androstenedione; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; CD24 Antigen; Cell Line; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Estradiol; Estrogen Receptor alpha; Female; Gene Expression; Humans; Hyaluronan Receptors; Letrozole; Neoplastic Stem Cells; Nitriles; RNA, Messenger; Spheroids, Cellular; Triazoles | 2013 |
Letrozole: advancing hormone therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Neoplasm Staging; Nitriles; Postmenopause; Quality of Life; Tamoxifen; Triazoles | 2012 |
[Quality of life analysis of postmenopausal, early breast cancer patients treated with anastrozole (RADAR-II)].
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Health Status; Humans; Hungary; Middle Aged; Neoplasm Staging; Nitriles; Patient Satisfaction; Postmenopause; Prospective Studies; Quality of Life; Surveys and Questionnaires; Triazoles | 2012 |
The citrus flavonone hesperetin prevents letrozole-induced bone loss in a mouse model of breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Citrus; Estradiol; Female; Hesperidin; Humans; Letrozole; MCF-7 Cells; Mice; Mice, Nude; Nitriles; Osteoporosis; Selective Estrogen Receptor Modulators; Triazoles; Xenograft Model Antitumor Assays | 2013 |
Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Carrier Proteins; Chemotherapy, Adjuvant; Fatal Outcome; Female; Glycoproteins; Humans; Letrozole; Membrane Transport Proteins; Middle Aged; Nitriles; Triazoles; Uterine Neoplasms | 2013 |
Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples.
Topics: Antidepressive Agents, Second-Generation; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Citalopram; Depression; Drug Monitoring; Female; Humans; Letrozole; Limit of Detection; Middle Aged; Nitriles; Reproducibility of Results; Spectrometry, Fluorescence; Triazoles | 2013 |
[A case of advanced breast carcinoma treated with topical S-1 plus letrozole].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Drug Combinations; Female; Humans; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Oxonic Acid; Tegafur; Treatment Outcome; Triazoles | 2012 |
[A successful case of a super-elderly breast cancer patient treated with hormone therapy].
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy, Large-Core Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Neoplasm Staging; Nitriles; Quality of Life; Triazoles; Ultrasonography | 2012 |
Need for estradiol assays with a lower functional sensitivity in clinical studies examining postmenopausal women treated with aromatase inhibitors.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Index; Breast Neoplasms; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2013 |
Lichen sclerosus in a breast cancer survivor.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles; Vulvar Lichen Sclerosus | 2013 |
Lichen sclerosus in breast cancer survivor.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles; Vulvar Lichen Sclerosus | 2013 |
A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06).
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2014 |
What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Practice Guidelines as Topic; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2013 |
Therapeutic mammaplasty--extending indications and achieving low incomplete excision rates.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Mammaplasty; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Nitriles; Patient Satisfaction; Retrospective Studies; Treatment Outcome; Triazoles | 2013 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Female; Hot Flashes; Humans; Middle Aged; Nitriles; Prospective Studies; Republic of Korea; Severity of Illness Index; Tamoxifen; Treatment Outcome; Triazoles | 2013 |
18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Ki-67 Antigen; Letrozole; Middle Aged; Misonidazole; Multimodal Imaging; Neoplasms, Hormone-Dependent; Nitriles; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Triazoles | 2013 |
Promising results for Arimidex and Femara.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2001 |
Stick with tried-and-true breast cancer treatment.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
New alternative to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estradiol; Female; Fulvestrant; Humans; Nitriles; Triazoles | 2002 |
Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androgens; Biological Availability; Biomarkers; Biopsy, Needle; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogens; Female; Humans; Middle Aged; Neoplasm Staging; Nitriles; Osteocalcin; Postmenopause; Prognosis; Prospective Studies; Sensitivity and Specificity; Sex Hormone-Binding Globulin; Treatment Outcome; Triazoles | 2002 |
Reversible pancytopenia caused by oral letrozole assumption in a patient with recurrent breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pancytopenia; Triazoles | 2002 |
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Nitriles; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2002 |
[Advanced breast cancer with lung and pleural metastases responsive to anastrozole--a case report].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Lung Neoplasms; Middle Aged; Nitriles; Pleural Effusion, Malignant; Pleural Neoplasms; Postmenopause; Receptors, Estrogen; Triazoles | 2002 |
[Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Anastrozole versus progestins/tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Forecasting; Humans; Multicenter Studies as Topic; Nitriles; Progestins; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2002 |
Letrozole's superiority over progestins and tamoxifen challenges standards of care in endocrine therapy for metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Progestins; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Selective oestrogen receptor downregulator.
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Down-Regulation; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2002 |
From the Food and Drug Administration.
Topics: Adenine; Anastrozole; Antineoplastic Agents, Hormonal; Antiviral Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Hepatitis B, Chronic; Humans; Nitriles; Organophosphonates; Triazoles; United States; United States Food and Drug Administration | 2002 |
Invasive lobular carcinoma of the breast presenting successively with colonic and gastric metastases.
Topics: Aged; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Endoscopy; Female; Humans; Nitriles; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Triazoles | 2002 |
Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor-positive advanced breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Multicenter Studies as Topic; Nitriles; Reproducibility of Results; Research Design; Retrospective Studies; Survival; Tamoxifen; Triazoles | 2002 |
Current role of endocrine therapy in the management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Has tamoxifen had its day?
Topics: Anastrozole; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
A new day dawns: women without oestrogen or is a balance best?
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Estrogen Antagonists; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Nitriles; Triazoles | 2002 |
Questions about anastrozole for early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Female; Humans; Nitriles; Triazoles | 2002 |
Advances in breast oncology: the 2002 ASCO meeting.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Docetaxel; Evidence-Based Medicine; Female; Humans; Nitriles; Paclitaxel; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Technology Assessment, Biomedical; Triazoles | 2002 |
New treatment option for postmenopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Cyclophosphamide; Doxorubicin; Drainage; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy, Radical; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Pleural Effusion, Malignant; Pleurisy; Triazoles | 2002 |
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.
Topics: Breast Neoplasms; Cell Division; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Hormones; Humans; Letrozole; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Nitriles; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 2003 |
Paecilomyces variotii central nervous system infection in a patient with cancer.
Topics: Antifungal Agents; Breast Neoplasms; Central Nervous System Infections; Cerebrospinal Fluid; Female; Humans; Microbial Sensitivity Tests; Middle Aged; Mycoses; Opportunistic Infections; Paecilomyces; Triazoles | 2003 |
[Summit meeting of breast cancer experts--many new ideas and practical progress. When the breast becomes malignant].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Mammography; Mass Screening; Nitriles; Quality Assurance, Health Care; Tamoxifen; Triazoles | 2003 |
Update on ATAC.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Anastrozole (Arimidex) vs. tamoxifen for treatment of early breast cancer.
Topics: Anastrozole; Asthenia; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Estrogen Antagonists; Fees, Pharmaceutical; Female; Headache; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Biological; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Stochastic Processes; Tamoxifen; Triazoles | 2003 |
Anastrozole-induced remission of diaphragmatic paralysis from metastatic breast cancer treated with multiple prior therapies.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Mediastinal Neoplasms; Middle Aged; Nitriles; Remission Induction; Respiratory Paralysis; Triazoles | 2003 |
Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Chemotherapy, Adjuvant; Female; Humans; Ki-67 Antigen; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
Anastrozole as a preventive agent in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Humans; Informed Consent; Nitriles; Postmenopause; Triazoles | 2003 |
New approaches to the understanding of tamoxifen action and resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Farnesol; Female; Humans; Immunoenzyme Techniques; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nitriles; Receptors, Estrogen; Salicylates; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2003 |
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Canada; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Humans; Letrozole; Meta-Analysis as Topic; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
ATAC trial: reporting interim results is not helpful.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Breast cancer prevention.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Utilization; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2003 |
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cranial Irradiation; Female; Humans; Letrozole; Lymphatic Metastasis; Meningeal Neoplasms; Middle Aged; Nitriles; Remission Induction; Survivors; Treatment Outcome; Triazoles | 2003 |
[Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].
Topics: Adult; Age Factors; Aged; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Immunotherapy; Letrozole; Meta-Analysis as Topic; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Premenopause; Prognosis; Quality of Health Care; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Toremifene; Trastuzumab; Triazoles | 2003 |
Economic evaluation of antiaromatase agents in the second-line treatment of metastatic breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Female; Humans; Letrozole; Megestrol; Middle Aged; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Survival Analysis; Triazoles | 2003 |
Role of biologic markers in patient selection and application to disease prevention.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Enzyme Inhibitors; ErbB Receptors; Estradiol; Female; Humans; Letrozole; Nitriles; Patient Selection; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Factors; Tamoxifen; Triazoles | 2003 |
Examining quality of life issues in relation to endocrine therapy for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Decision Making; Enzyme Inhibitors; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Quality of Life; Tamoxifen; Triazoles | 2003 |
Anastrozole for ductal carcinoma in situ.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Attitude to Health; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Female; Humans; Mass Screening; Nitriles; Triazoles | 2003 |
Doctors test drug to prevent cancer in high risk women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Risk Factors; Triazoles | 2003 |
Future directions in the endocrine therapy of breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Endocrine System; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2003 |
Letrozole after tamoxifen for breast cancer--what is the price of success?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Alopecia in a premenopausal breast cancer woman treated with letrozole and triptorelin.
Topics: Adult; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Hormones; Humans; Letrozole; Nitriles; Premenopause; Triazoles; Triptorelin Pamoate | 2003 |
Adjuvant aromatase inhibitors: are we there yet?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2003 |
Searching for the next tamoxifen.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Research; Tamoxifen; Triazoles; United States | 2003 |
ATAC trial did not report interim results.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2003 |
The effects of hormone therapy on cognition in breast cancer.
Topics: Affect; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition; Cognition Disorders; Enzyme Inhibitors; Female; Humans; Memory; Middle Aged; Nitriles; Pilot Projects; Psychometrics; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2003 |
Breast cancer drug shows promise for some survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Nitriles; Secondary Prevention; Tamoxifen; Treatment Outcome; Triazoles; United States | 2003 |
Critics question price of success in halted clinical trial of aromatase inhibitor letrozole.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Controlled Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Estrogen Receptor Modulators; Ethics, Research; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Single-Blind Method; Survival Analysis; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States | 2003 |
Hormonal therapy: introduction.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Nitriles; Prognosis; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2003 |
Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Receptor, ErbB-2; Tamoxifen; Triazoles | 2003 |
Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
Top 10 health stories of 2003.
Topics: Aging; Angioplasty, Balloon, Coronary; Antineoplastic Agents; Breast Neoplasms; Dietary Carbohydrates; Disease Outbreaks; Genome, Human; Guideline Adherence; Hormone Replacement Therapy; Humans; Hypertension; Letrozole; Myocardial Infarction; Nitriles; Obesity; Public Health; Severe Acute Respiratory Syndrome; Triazoles | 2003 |
Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Health Care Costs; Health Services; Humans; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2003 |
Benefit of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2003 |
Spreading the word, but not too thinly.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Editorial Policies; Estradiol; Female; Fulvestrant; Humans; Nitriles; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Treatment Outcome; Triazoles | 2004 |
Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Time Factors; Triazoles | 2004 |
Prevention strategies with aromatase inhibitors.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Enzyme Inhibitors; Female; Humans; Isoenzymes; Membrane Proteins; Models, Biological; Neoplasms; Nitriles; Placebos; Postmenopause; Prostaglandin-Endoperoxide Synthases; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Anthracyclines; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Bridged-Ring Compounds; Feasibility Studies; Female; Goserelin; Humans; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Nitriles; Pilot Projects; Sentinel Lymph Node Biopsy; Tamoxifen; Taxoids; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2004 |
[New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].
Topics: Adolescent; Adult; Age Factors; Anastrozole; Anticarcinogenic Agents; Breast Neoplasms; Celecoxib; Child; Double-Blind Method; Estrogen Antagonists; Female; Germany; Hormone Replacement Therapy; Humans; Hysterectomy; Life Style; Mammography; Menarche; Menopause; Middle Aged; Nitriles; Ovariectomy; Pregnancy; Pyrazoles; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Sulfonamides; Tamoxifen; Triazoles; Uterine Cervical Neoplasms | 2003 |
[Interview with Prof. Dr. Wolfgang Eiermann. Which women need a medicamentous breast cancer prophylaxis?].
Topics: Age Factors; Anastrozole; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Life Style; Mammography; Middle Aged; Nitriles; Quality of Life; Risk Assessment; Risk Factors; Tamoxifen; Triazoles | 2003 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Research Design; Tamoxifen; Time Factors; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Letrozole in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Drugs may improve long-term outcomes after breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
New treatment boosts outlook for breast cancer survivors.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2004 |
Role of endocrine therapy in the neoadjuvant surgical setting.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Patient Selection; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Letrozole; Linear Models; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles; Uterus | 2004 |
[The uterine sarcoma, a new risk identified for tamoxifen].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinosarcoma; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Metrorrhagia; Middle Aged; Neoplasms, Second Primary; Nitriles; Risk; Tamoxifen; Triazoles; Uterine Neoplasms | 2004 |
Changes in vascular endothelial growth factor (VEGF) after chemoendocrine therapy in breast cancer.
Topics: Androstadienes; Angiopoietin-1; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; DNA Primers; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neovascularization, Pathologic; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tamoxifen; Taxoids; Triazoles; Vascular Endothelial Growth Factor A | 2004 |
Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?
Topics: Aged; Anticoagulants; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Contraindications; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Pulmonary Embolism; Risk; Tamoxifen; Triazoles; Venous Thrombosis; Warfarin | 2004 |
Adjuvant use of anastrozole in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Nitriles; Triazoles | 2004 |
Long-term insurance for breast cancer survivors.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Insurance, Long-Term Care; Letrozole; Nitriles; Tamoxifen; Triazoles | 2004 |
Comment on "Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results" by J.-M. Nabholtz et al.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Letrozole; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Triazoles | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Letrozole; Magnetic Resonance Imaging; Middle Aged; Nitriles; Pamidronate; Pilot Projects; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2004 |
Letrozole (Femara).
Topics: Administration, Oral; Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Oncology Nursing; Randomized Controlled Trials as Topic; Risk Assessment; Triazoles | 2004 |
An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Randomized Controlled Trials as Topic; Triazoles | 2004 |
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Topics: Animals; Antineoplastic Agents; Aromatase; Body Composition; Breast Neoplasms; Cell Division; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Letrozole; Mice; Mice, Nude; Mice, Transgenic; Nitriles; Ovariectomy; Tamoxifen; Transplantation, Heterologous; Triazoles | 2004 |
[Ulcus terebrans. Therapy options and their limits].
Topics: Aged; Anastrozole; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Ductal, Breast; Combined Modality Therapy; Debridement; Female; Humans; Incidental Findings; Neoplasm Staging; Neoplasms, Multiple Primary; Nitriles; Palliative Care; Radioisotope Teletherapy; Scalp; Skin Neoplasms; Skin Ulcer; Triazoles | 2004 |
Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Middle Aged; Models, Theoretical; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2004 |
[Therapeutic effects of Anastrozole in patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cholesterol; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Triazoles | 2004 |
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Receptors, Estrogen; Survival Rate; Triazoles | 2004 |
Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Odds Ratio; Postmenopause; Quality of Life; Surveys and Questionnaires; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Budgets; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Female; Humans; Italy; Letrozole; Markov Chains; Megestrol; Models, Economic; National Health Programs; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2004 |
Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Topics: Androstadienes; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Random Allocation; Tamoxifen; Time Factors; Triazoles | 2004 |
[Anastrozole-resistant breast cancer responsive to exemestane--a case report].
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Resistance, Neoplasm; Female; Humans; Nitriles; Postmenopause; Triazoles | 2004 |
The responsiveness of a tumour to any kind of therapy is reflected by the objective response rate.
Topics: Anastrozole; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Arimidex inhibition on proliferation of human breast solid tumors measured by ATP bioluminescence.
Topics: Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Proliferation; Female; Humans; Luminescent Measurements; Luminescent Proteins; Middle Aged; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles; Tumor Cells, Cultured | 2004 |
Oestrogen-selective modulation of FSH and LH secretion by pituitary gland.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogens; Female; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Nitriles; Pituitary Gland; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2005 |
New drugs reduce risk of death from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 2004 |
Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Female; Glycoproteins; Humans; Middle Aged; Nitriles; Osteopontin; Osteoprotegerin; Postmenopause; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Sialoglycoproteins; Survival Analysis; Triazoles | 2004 |
How rapidly do oncologists respond to clinical trial data?
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Evidence-Based Medicine; Female; Health Care Surveys; Humans; Medical Oncology; Middle Aged; Nitriles; Postmenopause; Practice Patterns, Physicians'; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Letrozole sensitizes breast cancer cells to ionizing radiation.
Topics: Antineoplastic Agents; Aromatase; Breast Neoplasms; Cell Cycle; Cell Survival; Female; Flow Cytometry; Humans; Letrozole; Nitriles; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Transfection; Triazoles | 2005 |
Anastrozole data show continued delay in relapse, but no clear survival advantage.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles; United Kingdom | 2005 |
Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Receptors, Progesterone; RNA, Messenger; Tamoxifen; Triazoles | 2004 |
Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Topics: Androgens; Androstenedione; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Culture Media; Dose-Response Relationship, Drug; Estrogen Antagonists; Estrogens; Estrone; Female; Humans; Letrozole; Nitriles; Receptors, Estrogen; Testosterone; Triazoles; Tumor Cells, Cultured | 2005 |
Letrozole better than tamoxifen in postmenopausal women.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles | 2005 |
[Breast carcinoma: new, much promising trends. The cancer anxiety of women -- will be taken better care soon?].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Clinical Trials as Topic; Female; Fractures, Bone; Germany; Humans; Mammography; Middle Aged; Multicenter Studies as Topic; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Risk Factors; Tamoxifen; Time Factors; Triazoles | 2005 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
[Efforts in the individualization of the adjuvant systemic therapy in breast cancer--ASCO, 2004].
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Planning; Patient Satisfaction; Patient Selection; Predictive Value of Tests; Quality of Life; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Tamoxifen; Triazoles | 2004 |
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Tamoxifen; Triazoles; Up-Regulation | 2005 |
Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Case-Control Studies; ErbB Receptors; Female; Humans; Letrozole; Nitriles; Postmenopause; Solubility; Triazoles | 2005 |
Remission of macroglobulinemia during anastrozole treatment for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Nitriles; Remission Induction; Triazoles; Waldenstrom Macroglobulinemia | 2005 |
[Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Neoplasm Invasiveness; Nitriles; Paclitaxel; Skin Neoplasms; Sternum; Triazoles | 2005 |
Current and future perspectives on fulvestrant.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estradiol; Female; Fulvestrant; Humans; Nitriles; Receptors, Estrogen; Triazoles | 2005 |
Anastrozole: new indication. Adjuvant treatment of non metastatic breast cancer: useful for some patients.
Topics: Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Nitriles; Survival Rate; Tamoxifen; Triazoles | 2005 |
Alternative to tamoxifen effective for preventing breast cancer recurrence.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2005 |
Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cryopreservation; Embryo, Mammalian; Estrogen Antagonists; Female; Fertility; Fertilization in Vitro; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Tamoxifen; Triazoles | 2005 |
Regression of choroidal metastases from breast carcinoma using aromatase inhibitors.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Choroid Neoplasms; Female; Humans; Nitriles; Triazoles | 2005 |
Diabetes insipidus caused by isolated intracranial metatstases in patient with breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Deamino Arginine Vasopressin; Diabetes Insipidus; Fatal Outcome; Female; Humans; Letrozole; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Nitriles; Pituitary Neoplasms; Renal Agents; Triazoles | 2005 |
Altered gene expression in human cells induced by the agricultural chemical Enable.
Topics: Agriculture; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Fungicides, Industrial; Gene Expression; Gene Expression Profiling; Humans; Neoplasms, Hormone-Dependent; Nitriles; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Triazoles | 2004 |
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Disease Progression; Estrogen Antagonists; Female; Humans; Letrozole; Nitriles; Prognosis; Receptor, ErbB-2; Survival Analysis; Tamoxifen; Triazoles | 2005 |
Selected highlights from the 27th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2004.
Topics: Anastrozole; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Estradiol; Female; Fulvestrant; Gonadal Steroid Hormones; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2005 |
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Administration Schedule; Enzyme Activation; Estrogen Receptor alpha; Female; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nitriles; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Postmenopause; Tamoxifen; Triazoles; Xenograft Model Antitumor Assays | 2005 |
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; GRB2 Adaptor Protein; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Models, Biological; Nitriles; Receptors, Estrogen; Shc Signaling Adaptor Proteins; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Adjuvant hormone therapy for breast cancer: alternatives to tamoxifen.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Aromatase inhibitors: cellular and molecular effects.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Ki-67 Antigen; Letrozole; Neoadjuvant Therapy; Nitriles; Oligonucleotide Array Sequence Analysis; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Female; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Triazoles | 2005 |
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Gene Expression; Humans; Nitriles; Oligonucleotide Array Sequence Analysis; Triazoles | 2005 |
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma; Cell Proliferation; Cell Survival; Drug Interactions; Estrogens; Everolimus; Female; Humans; Immunosuppressive Agents; Letrozole; Nitriles; Protein Kinases; Receptors, Estrogen; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazoles; Tumor Cells, Cultured | 2005 |
Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Diagnosis, Differential; Female; Humans; Mammography; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Radiotherapy, Adjuvant; Receptors, Estrogen; Sentinel Lymph Node Biopsy; Tamoxifen; Triazoles | 2005 |
Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dizziness; Double-Blind Method; Drug Approval; Female; Follow-Up Studies; Headache; Humans; Letrozole; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Skin Diseases; Tamoxifen; Time Factors; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2005 |
Breast cancer's 'new era'.
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Humans; Letrozole; Nitriles; Secondary Prevention; Treatment Outcome; Triazoles; United States | 2003 |
Promising switch to anastrozole for breast-cancer treatment.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 2005 |
Letrozole for brain and scalp metastases from breast cancer--a case report.
Topics: Aromatase Inhibitors; Brain Neoplasms; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Letrozole; Middle Aged; Nitriles; Scalp; Skin Neoplasms; Tomography, X-Ray Computed; Triazoles | 2006 |
[Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy; Neoadjuvant Therapy; Nitriles; Postmenopause; Preoperative Care; Sternum; Triazoles | 2005 |
[Aromatase inhibitors in the treatment of breast cancer: current status and some problems].
Topics: Adult; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Triazoles | 2005 |
Options for preservation of fertility in women.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cryopreservation; Drug Therapy, Combination; Embryo, Mammalian; Female; Fertility; Gonadotropins; Humans; Letrozole; Neoplasms; Nitriles; Ovary; Tamoxifen; Transplantation, Heterotopic; Triazoles | 2005 |
A step too far?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Female; Humans; Nitriles; Scotland; Triazoles; United Kingdom | 2005 |
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Estrogen Antagonists; Humans; Inhibitory Concentration 50; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Tamoxifen; Time Factors; Triazoles | 2005 |
Case 24-2005: a woman with estrogen-receptor-positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Diseases, Metabolic; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Nitriles; Receptors, Estrogen; Tamoxifen; Triazoles | 2005 |
Lobular carcinoma of the breast metastatic to the uterus in a patient under adjuvant anastrozole therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Keratins; Mastectomy, Modified Radical; Middle Aged; Mucin-1; Nitriles; Ovariectomy; Triazoles; Ultrasonography; Vagina | 2006 |
Anal localization as first manifestation of metastatic ductal breast carcinoma.
Topics: Aged; Anastrozole; Anus Neoplasms; Biopsy, Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Colectomy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Neoplasm Staging; Nitriles; Rare Diseases; Risk Assessment; Treatment Outcome; Triazoles | 2005 |
Treatment guidelines for adjuvant breast cancer are moving toward double standards: one for the rich and one for the poor.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Decision Making; Developing Countries; Disease-Free Survival; Drug Costs; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2005 |
Aromatase inhibitors--a triumph of translational oncology.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Models, Animal; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2005 |
Influence of adjuvant anastrozole on bone mineral density in Japanese postmenopausal breast cancer patients: is there a racial difference?
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Asian People; Biomarkers; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogens; Female; Humans; Japan; Middle Aged; Nitriles; Postmenopause; Triazoles; White People | 2006 |
Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy.
Topics: Adult; Anticonvulsants; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Breast Neoplasms; Drug Interactions; Humans; Lung Diseases, Fungal; Male; Phenytoin; Pyrimidines; Stevens-Johnson Syndrome; Triazoles; Voriconazole | 2006 |
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Confidence Intervals; Disease Progression; Drug Administration Schedule; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2005 |
Improvement in dermatomyositis rash associated with the use of antiestrogen medication.
Topics: Adult; Anastrozole; Biopsy; Breast Neoplasms; Dermatomyositis; Diagnosis, Differential; Estrogen Antagonists; Exanthema; Female; Follow-Up Studies; Glucocorticoids; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Skin; Tamoxifen; Triazoles | 2006 |
Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2005 |
Latest studies hint at survival advantage with aromatase inhibitors in early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Europe; Female; Humans; Letrozole; Meta-Analysis as Topic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome; Triazoles | 2006 |
Toxic epidermal necrolysis in patient with breast cancer receiving letrozole.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Fatal Outcome; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Stevens-Johnson Syndrome; Triazoles | 2006 |
Photodynamic therapy for solitary retinal metastasis from breast carcinoma.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Middle Aged; Nitriles; Photochemotherapy; Retinal Neoplasms; Triazoles | 2006 |
ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Topics: Acetyltransferases; Androstenedione; Aromatase Inhibitors; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Corticosterone; Drug Resistance, Neoplasm; Female; Histone Acetyltransferases; Humans; Letrozole; Nitriles; Nuclear Receptor Coactivator 3; Oncogene Proteins; Promoter Regions, Genetic; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Trans-Activators; Transcriptional Activation; Triazoles | 2006 |
[Advance and current status of exemestane and androstadienes in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Nitriles; Postmenopause; Triazoles | 2005 |
Effectiveness of letrozole in the breast cancer treatment continuum.
Topics: Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Treatment Outcome; Triazoles | 2006 |
Changing the gold standard in adjuvant therapy for breast cancer:from tamoxifen to aromatase inhibition.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2005 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Triazoles | 2006 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Topics: Adult; Amenorrhea; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Menstruation; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Premenopause; Tamoxifen; Triazoles | 2006 |
Does survival increase in metastatic breast cancer with recently available anticancer drugs?
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Analysis; Tamoxifen; Triazoles | 2006 |
Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis.
Topics: Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Data Interpretation, Statistical; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Humans; Letrozole; Lymphatic Metastasis; Nitriles; Secondary Prevention; Tamoxifen; Triazoles | 2006 |
Letrozole or tamoxifen in early breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2006 |
[Advances in the treatment of breast carcinoma. New therapy schedules with astonishing success quotas].
Topics: Age Factors; Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Female; Humans; Mammography; Meta-Analysis as Topic; Middle Aged; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Risk; Tamoxifen; Taxoids; Time Factors; Trastuzumab; Triazoles | 2006 |
Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Endostatins; Female; Fibroblast Growth Factor 2; Humans; Letrozole; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prospective Studies; Triazoles | 2006 |
Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Renal Dialysis; Tamoxifen; Triazoles | 2006 |
Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Humans; Male; Nitriles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Substance Abuse Detection; Tandem Mass Spectrometry; Triazoles | 2006 |
Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086.
Topics: Azepines; Breast Neoplasms; Cathepsin D; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Movement; Humans; Platelet Activating Factor; Triazoles | 2006 |
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Follicle Stimulating Hormone; Humans; Letrozole; Luteinizing Hormone; Middle Aged; Neoplasm Staging; Nitriles; Ovariectomy; Practice Guidelines as Topic; Tamoxifen; Triazoles | 2006 |
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Female; Gene Amplification; Genes, erbB-1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Letrozole; Middle Aged; Neoadjuvant Therapy; Nitriles; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome; Triazoles | 2006 |
Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Estrogen Antagonists; Estrogens; Fees, Pharmaceutical; Female; Follow-Up Studies; Humans; Letrozole; Markov Chains; Middle Aged; Models, Theoretical; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Triazoles | 2006 |
Primary hormone treatment in postmenopausal women with breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Contraindications; Estrogens; Female; Humans; Letrozole; Mastectomy; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Radiography; Receptors, Estrogen; Triazoles | 2006 |
Estrogen receptors: role in breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Hormone Replacement Therapy; Humans; Letrozole; Models, Biological; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Management of choroidal metastases from breast carcinomas using aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Choroid Neoplasms; Combined Modality Therapy; Female; Humans; Letrozole; Mastectomy, Radical; Mastectomy, Segmental; Mastectomy, Simple; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Female; Humans; Letrozole; Middle Aged; Nitriles; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Cost-Benefit Analysis; Decision Support Techniques; Disease Progression; Female; Humans; Letrozole; Markov Chains; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Time Factors; Triazoles; United States | 2006 |
Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
Topics: Adult; Breast Neoplasms; Chorionic Gonadotropin; Cost-Benefit Analysis; Cryopreservation; Embryo Transfer; Estradiol; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Letrozole; Nitriles; Oocytes; Ovulation Induction; Retrospective Studies; Triazoles | 2006 |
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Topics: Androgen Receptor Antagonists; Androgens; Androstenedione; Aromatase; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dihydrotestosterone; Estradiol; Estrogen Receptor alpha; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; RNA, Small Interfering; Transfection; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Letrozole; Nitriles; Patient Selection; Progesterone; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Economics, Pharmaceutical; Humans; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Slovenia; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
Quality of life in a randomized control trial? Comments concerning MA 17.
Topics: Antineoplastic Agents, Hormonal; Bias; Breast Neoplasms; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Patient Compliance; Patient Dropouts; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Surveys and Questionnaires; Survival Analysis; Triazoles | 2006 |
Joint symptoms: a practical problem of anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Interviews as Topic; Joint Diseases; Middle Aged; Nitriles; Postmenopause; Triazoles | 2006 |
Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Ovary; Premenopause; Receptors, Steroid; Triazoles | 2006 |
Fertility preservation strategies for breast cancer patients.
Topics: Antineoplastic Agents; Breast Neoplasms; Evidence-Based Medicine; Female; Fertility; Humans; Letrozole; Nitriles; Triazoles | 2006 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Receptors, Estrogen; Receptors, Progesterone; Sensitivity and Specificity; Survival Rate; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2006 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; British Columbia; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prognosis; Risk Factors; Survival Rate; Tamoxifen; Triazoles | 2007 |
Anastrozole-induced hepatotoxicity.
Topics: Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Chemical and Drug Induced Liver Injury; Female; Humans; Liver Diseases; Liver Function Tests; Nausea; Nitriles; Triazoles | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuvant; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Irritable Mood; Letrozole; Middle Aged; Nitriles; Substance Withdrawal Syndrome; Triazoles | 2006 |
Henoch-Schönlein purpura (HSP) during treatment with anastrozole.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; IgA Vasculitis; Nitriles; Triazoles | 2007 |
Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Carpal Tunnel Syndrome; Female; Humans; Letrozole; Magnetic Resonance Imaging; Middle Aged; Musculoskeletal Diseases; Nitriles; Pain; Severity of Illness Index; Triazoles; Ultrasonography; Wrist Joint | 2007 |
Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Nitriles; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Triazoles | 2006 |
Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Nitriles; Postmenopause; Quality of Life; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |
Aromatase and breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Letrozole; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Topics: Animals; Apoptosis Regulatory Proteins; Aromatase; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Histone Acetyltransferases; Hormones; Humans; Imidazoles; Letrozole; Mice; Mice, Nude; Microsomes; Mitogen-Activated Protein Kinases; Nitriles; Nuclear Receptor Coactivator 3; Ovariectomy; Placenta; Pregnancy; Trans-Activators; Tretinoin; Triazoles; Xenograft Model Antitumor Assays | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles | 2006 |
Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase.
Topics: Breast Neoplasms; Cell Proliferation; Enzyme Inhibitors; Humans; Phosphorylation; Receptor, ErbB-2; Triazoles; Tumor Cells, Cultured | 2007 |
[Correlation of hormone-metabolic status in breast cancer and effectiveness of adjuvant hormone therapy].
Topics: Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; C-Peptide; Chemotherapy, Adjuvant; Estradiol; Female; Humans; Insulin; Insulin Resistance; Letrozole; Middle Aged; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors; Triazoles | 2006 |
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Belgium; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Nitriles; Postmenopause; Proportional Hazards Models; Quality-Adjusted Life Years; Tamoxifen; Triazoles | 2007 |
[Two patients having recurrent breast cancer with brain metastases well controlled with a gamma knife radio-surgery].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Female; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Pleurisy; Pleurodesis; Radiosurgery; Triazoles | 2006 |
[Locally advanced breast cancer with a good response to sequential endocrine monotherapy--a case report].
Topics: Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Drug Administration Schedule; Female; Humans; Nitriles; Remission Induction; Tamoxifen; Triazoles | 2007 |
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Sample Size; Tamoxifen; Triazoles | 2007 |
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Health Services Research; Humans; Markov Chains; Middle Aged; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Triazoles; United Kingdom; United States | 2007 |
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.
Topics: Adult; Aged; Amenorrhea; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Case-Control Studies; Chemotherapy, Adjuvant; Female; Humans; Lasers; Middle Aged; Nitriles; Ophthalmoscopy; Optic Disk; Selective Estrogen Receptor Modulators; Survival Rate; Survivors; Tamoxifen; Triazoles; Visual Acuity | 2007 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Estrogens; Fatal Outcome; Female; Fluorouracil; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Mastectomy, Modified Radical; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Nitriles; Radiotherapy, Adjuvant; Translocation, Genetic; Triazoles | 2006 |
Unusual macular degeneration following breast cancer.
Topics: Adenocarcinoma; Anastrozole; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Choroid Neoplasms; Female; Humans; Lymphatic Metastasis; Macular Degeneration; Mastectomy, Radical; Middle Aged; Nitriles; Technetium; Tomography, X-Ray Computed; Triazoles | 2007 |
[A case of advanced breast cancer with multiple liver metastases resistant to chemotherapy responding to high-dose toremifene].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Middle Aged; Nitriles; Quality of Life; Remission Induction; Toremifene; Triazoles | 2007 |
Cancer research. Budget pressure puts high-profile study in doubt.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Budgets; Controlled Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Postmenopause; Triazoles; United States | 2007 |
A case of porphyria cutanea tarda resulting in digital amputation and improved by anastrazole.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Fingers; Hand Dermatoses; Humans; Lymphoma, B-Cell; Middle Aged; Nitriles; Porphyria Cutanea Tarda; Treatment Outcome; Triazoles | 2007 |
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Bone Density; Breast Neoplasms; Canada; Chemotherapy, Adjuvant; Collagen Type I; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Letrozole; Middle Aged; Nitriles; Peptides; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
[Clinical study of aromatase inhibitors in advanced breast cancer].
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles | 2007 |
Parotid gland metastasis of a breast cancer.
Topics: Anastrozole; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Mastectomy, Radical; Middle Aged; Nitriles; Parotid Gland; Parotid Neoplasms; Receptors, Estrogen; Time Factors; Treatment Outcome; Triazoles | 2007 |
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Topics: Androstadienes; Androstenedione; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor Modulators; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Tamoxifen; Triazoles; Wortmannin | 2007 |
Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Data Interpretation, Statistical; Disease-Free Survival; Female; Humans; Letrozole; Nitriles; Patient Selection; Research Design; Sample Size; Treatment Outcome; Triazoles | 2008 |
Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
In vitro maturation of germinal vesicle oocytes recovered after premature luteinizing hormone surge: description of a novel approach to fertility preservation.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Cell Culture Techniques; Cryopreservation; Drug Administration Schedule; Embryo Culture Techniques; Female; Fertility; Fertility Agents, Female; Fertilization in Vitro; Follicle Stimulating Hormone; Humans; Infertility, Female; Letrozole; Luteinizing Hormone; Nitriles; Oocyte Retrieval; Ovulation; Ovulation Induction; Sperm Injections, Intracytoplasmic; Time Factors; Treatment Outcome; Triazoles | 2008 |
Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colles' Fracture; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Postmenopause; Risk Assessment; Tamoxifen; Triazoles; Wrist Injuries | 2007 |
Optimal use of aromatase inhibitors: to lead or to follow?
Topics: Aged; Alleles; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Recurrence; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Clinical research. No lifeline for proposed breast cancer prevention trial.
Topics: Antineoplastic Agents; Biomedical Research; Breast Neoplasms; Budgets; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Triazoles; United States | 2007 |
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Costs; Female; Humans; Letrozole; Markov Chains; Middle Aged; Models, Econometric; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2007 |
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; United Kingdom | 2008 |
NCI and the STELLAR trial.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; United States | 2007 |
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Topics: Animals; Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Breast Neoplasms; Cyclin D; Cyclins; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Ki-67 Antigen; Letrozole; Mice; Nitriles; Peptides; Postmenopause; Receptors, Estrogen; Trefoil Factor-1; Triazoles | 2008 |
Regression of choroidal metastasis from breast carcinoma following Letrozole therapy.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Choroid Neoplasms; Estrogen Receptor Modulators; Female; Fluorescein Angiography; Humans; Letrozole; Nitriles; Remission Induction; Tomography, Optical Coherence; Triazoles | 2007 |
Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Ovariectomy; Piperidines; Pyridines; S Phase; Tamoxifen; Triazoles | 2007 |
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Flow Cytometry; Fulvestrant; Humans; Letrozole; Nitriles; Protein Kinases; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Triazoles | 2007 |
Hope for axed cancer-prevention trial.
Topics: Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Letrozole; National Institutes of Health (U.S.); Nitriles; Preventive Medicine; Raloxifene Hydrochloride; Triazoles; United States | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Interactions; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Risedronic Acid; Triazoles | 2007 |
Aromatase inhibitor-associated arthralgias: Pathogenesis, frequency and management.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2007 |
High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: a confirmatory prospective study.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Female; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2007 |
Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Receptor Modulators; Female; Humans; Middle Aged; Nitriles; Sjogren's Syndrome; Tamoxifen; Triazoles | 2007 |
Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Estrogen Antagonists; Female; Humans; Middle Aged; Nitriles; Postmenopause; Radiotherapy Dosage; Retrospective Studies; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Resolution of endometrial hyperplasia with adjuvant anastrozole treatment in postmenopausal breast cancer: a case report.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Endometrial Hyperplasia; Female; Humans; Middle Aged; Nitriles; Postmenopause; Treatment Outcome; Triazoles; Uterine Hemorrhage | 2007 |
Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Mastectomy, Segmental; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Triazoles | 2007 |
[Solitary oesophageal metastasis of breast cancer after 17 years latency].
Topics: Adenocarcinoma; Anastrozole; Antineoplastic Agents, Hormonal; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Deglutition; Esophageal Neoplasms; Esophagus; Fatal Outcome; Female; Humans; Intubation; Middle Aged; Minimally Invasive Surgical Procedures; Nitriles; Palliative Care; Radiotherapy, Adjuvant; Thoracotomy; Tomography, X-Ray Computed; Treatment Outcome; Triazoles | 2007 |
Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Letrozole; Nitriles; Oligonucleotide Array Sequence Analysis; Postmenopause; Receptors, Estrogen; Triazoles | 2008 |
Endocrine and targeted manipulation of breast cancer: summary statement for the Sixth Cambridge Conference.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 2008 |
Extended adjuvant therapy for breast cancer--how much is enough?
Topics: Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Austria; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2007 |
Letrozole as adjuvant therapy for postmenopausal women with early breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles; United States | 2007 |
Long-term outcomes of aromatase inhibition for breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; Fractures, Bone; Humans; Nitriles; Postmenopause; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Prescriptions; Female; Humans; Longitudinal Studies; Middle Aged; Neoplasm Staging; Nitriles; Patient Compliance; Triazoles | 2008 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Epothilones; Everolimus; Female; Fluorouracil; Humans; Letrozole; Nitriles; Sirolimus; Tamoxifen; Taxoids; Trastuzumab; Triazoles | 2008 |
Joint effects of body size, energy intake, and physical activity on breast cancer risk.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Body Size; Breast Neoplasms; Energy Intake; Energy Metabolism; Female; Humans; Letrozole; Mastectomy, Segmental; Middle Aged; Motor Activity; Neoadjuvant Therapy; Nitriles; Postmenopause; Receptors, Estrogen; Time Factors; Treatment Outcome; Triazoles | 2009 |
A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.
Topics: 3' Untranslated Regions; Aromatase; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Female; Humans; Letrozole; Nitriles; Patient Selection; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Postmenopause; Prospective Studies; Triazoles | 2008 |
Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Female; Humans; Letrozole; Life Expectancy; Middle Aged; Nitriles; Randomized Controlled Trials as Topic; Risk Factors; Triazoles | 2008 |
Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer.
Topics: Administration, Oral; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Combined Modality Therapy; Erythema Multiforme; Female; Humans; Middle Aged; Nitriles; Radiotherapy; Triazoles | 2008 |
[Efficacy of sequential treatment with anastrozole following exemestane compared with exemestane following anastrozole in patients with metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Retrospective Studies; Survival Rate; Triazoles | 2008 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms | 2008 |
Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Risk Assessment; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2008 |
Inappropriate ATAC on tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Biopsy, Needle; Breast; Breast Neoplasms; Estrogens; Female; Gene Expression Profiling; Genetic Markers; Humans; Letrozole; Middle Aged; Nitriles; Oligonucleotide Array Sequence Analysis; Postmenopause; Triazoles | 2008 |
Arachidonic acid-induced Ca2+ entry is involved in early steps of tumor angiogenesis.
Topics: Arachidonic Acid; Breast Neoplasms; Calcium; Calcium Signaling; Cell Proliferation; Cell Separation; Humans; Neovascularization, Pathologic; Triazoles; Tumor Cells, Cultured | 2008 |
[A case of elderly breast cancer achieving partial response by letrozole with stable disease to anastrozole as neoadjuvant endocrine therapy].
Topics: Aged, 80 and over; Anastrozole; Breast Neoplasms; Endocrine System; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Postmenopause; Tomography, X-Ray Computed; Triazoles; Ultrasonography | 2008 |
Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model.
Topics: Anastrozole; Animals; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Estradiol; Female; Fulvestrant; Humans; Mice; Mice, Nude; Nitriles; Organ Size; Ovariectomy; Receptors, Growth Factor; Signal Transduction; Triazoles; Tumor Burden; Tumor Cells, Cultured; Uterus; Xenograft Model Antitumor Assays | 2008 |
Retinal hemorrhages in anastrozole users.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Female; Fluorescein Angiography; Humans; Middle Aged; Nitriles; Patient Selection; Retinal Hemorrhage; Retrospective Studies; Tamoxifen; Tomography, Optical Coherence; Triazoles | 2008 |
Tolerance of adjuvant letrozole outside of clinical trials.
Topics: Aged; Antineoplastic Agents; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Drug Therapy, Combination; Female; Humans; Letrozole; Mastectomy; Middle Aged; Nitriles; Postmenopause; Retrospective Studies; Triazoles | 2008 |
Excellent response to letrozole in brain metastases from breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Cranial Irradiation; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Neurologic Examination; Nitriles; Palliative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Triazoles | 2008 |
An in vivo model of intratumoural aromatase using aromatase-transfected MCF7 human breast cancer cells.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Estradiol; Female; Humans; Letrozole; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nitriles; Transfection; Transplantation, Heterologous; Triazoles | 1995 |
Quercetin: synergistic action with carboxyamidotriazole in human breast carcinoma cells.
Topics: Aminoimidazole Carboxamide; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Drug Synergism; Female; Humans; Quercetin; Signal Transduction; Triazoles; Tumor Cells, Cultured | 1995 |
Arimidex: a potent and selective fourth-generation aromatase inhibitor.
Topics: Administration, Oral; Anastrozole; Animals; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Dogs; Estrogens; Female; Hormones; In Vitro Techniques; Macaca nemestrina; Male; Nitriles; Postmenopause; Rats; Triazoles | 1994 |
Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20,267 in biological fluids.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibody Specificity; Aromatase Inhibitors; Breast Neoplasms; Chromatography, High Pressure Liquid; Female; Guinea Pigs; Humans; Immunoenzyme Techniques; Letrozole; Male; Nitriles; Triazoles | 1994 |
Anastrozole for metastatic breast cancer.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Neoplasm Metastasis; Nitriles; Triazoles | 1996 |
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell.
Topics: Adenocarcinoma; Aromatase Inhibitors; Breast Neoplasms; Cell Division; DNA; Enzyme Inhibitors; Estradiol; Fadrozole; Fluorouracil; Humans; Luciferases; Plasmids; Receptors, Estrogen; Testosterone; Transcription, Genetic; Transfection; Triazoles; Tumor Cells, Cultured | 1996 |
New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Nitriles; Triazoles | 1996 |
Aromatase inhibitors in metastatic breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Female; Humans; Megestrol Acetate; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles | 1996 |
Oestrogen formation in breast: clinical and biological importance.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Estrogens; Female; Humans; Letrozole; Mice; Mice, Nude; Nitriles; Signal Transduction; Transfection; Triazoles; Tumor Cells, Cultured | 1996 |
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Postmenopause; Tamoxifen; Triazoles | 1997 |
Clinical development plan: (+)-vorozole.
Topics: Animals; Anticarcinogenic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Approval; Enzyme Inhibitors; Estradiol; Female; Humans; Male; Neoplasms, Experimental; Rats; Research Design; Triazoles | 1996 |
Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Calcium Channel Blockers; Cell Survival; Collagenases; Drug Screening Assays, Antitumor; Female; Gelatinases; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Neoplasm Invasiveness; Receptors, Estrogen; Triazoles; Tumor Cells, Cultured | 1997 |
Aromatase inhibitors come of age.
Topics: Aminoglutethimide; Anastrozole; Androstenedione; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Humans; Letrozole; Nitriles; Triazoles | 1997 |
A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoglutethimide; Analysis of Variance; Anastrozole; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Enzyme Inhibitors; Fadrozole; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Nitriles; Ovariectomy; Postmenopause; Triazoles; Tumor Cells, Cultured | 1997 |
Regulation of aromatase activity within the breast.
Topics: Adipose Tissue; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Enzyme Inhibitors; Female; Fibroblasts; Humans; Letrozole; Nitriles; Triazoles | 1997 |
Predictors of response to second-line endocrine therapy for breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Gonanes; Goserelin; Humans; Megestrol Acetate; Middle Aged; Nitriles; Ovariectomy; Predictive Value of Tests; Remission Induction; Tamoxifen; Triazoles | 1997 |
Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
Topics: Androstenedione; Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Division; Cell Line; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblast Growth Factors; Fulvestrant; Humans; Letrozole; Luciferases; Mice; Mice, Nude; Nitriles; Ovariectomy; Polymerase Chain Reaction; Receptors, Progesterone; Recombinant Fusion Proteins; RNA, Messenger; Tamoxifen; Transcription, Genetic; Transfection; Transplantation, Heterologous; Triazoles; Tumor Cells, Cultured | 1998 |
[Two new therapeutic principles in the management of breast cancer and colorectal cancer: selective oral aromatase inhibition and thymidilate synthase inhibition].
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Nitriles; Palliative Care; Triazoles | 1997 |
Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer.
Topics: Anastrozole; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Organ Size; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles; Tumor Cells, Cultured; Uterus | 1998 |
Toremifene and letrozole for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Estrogen Antagonists; Female; Hot Flashes; Humans; Letrozole; Middle Aged; Nausea; Nitriles; Postmenopause; Toremifene; Triazoles | 1998 |
Effects of demographic variables on vorozole pharmacokinetics in healthy volunteers and in breast cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Body Height; Body Weight; Breast Neoplasms; Female; Humans; Male; Middle Aged; Population; Regression Analysis; Sex Factors; Triazoles | 1998 |
Letrozole for advanced breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Triazoles | 1998 |
Aromatase inhibitors and their future role in post-menopausal women with early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 1998 |
Intratumoral aromatase model: the effects of letrozole (CGS 20267).
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Mice; Mice, Inbred BALB C; Neoplasms, Hormone-Dependent; Nitriles; Tamoxifen; Triazoles; Tumor Cells, Cultured | 1998 |
The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity.
Topics: Anastrozole; Androstenedione; Aromatase; Aromatase Inhibitors; Base Sequence; Breast Neoplasms; Cell Division; Cells, Cultured; Choriocarcinoma; DNA Primers; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Female; Fibroblasts; Fulvestrant; Humans; Letrozole; Microsomes; Nitriles; Placenta; RNA, Messenger; Triazoles; Tumor Cells, Cultured | 1998 |
Rivizor--a new third-generation aromatase inhibitor for the treatment of advanced breast cancer after tamoxifen failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoembryonic Antigen; Disease Progression; Enzyme Inhibitors; Estrogen Antagonists; Female; Gonadal Steroid Hormones; Humans; Middle Aged; Tamoxifen; Time Factors; Treatment Failure; Treatment Outcome; Triazoles | 1999 |
Macrophages, estrogen and the microenvironment of breast cancer.
Topics: Antineoplastic Agents; Aromatase; Breast; Breast Neoplasms; Carcinoma in Situ; Cell Division; Cell Line; Enzyme Inhibitors; Estradiol; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hyperplasia; Immunohistochemistry; Letrozole; Macrophages; Monocytes; Nitriles; Placenta; Pregnancy; Testosterone; Tetradecanoylphorbol Acetate; Transcription, Genetic; Triazoles | 1998 |
Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Evaluation Studies as Topic; Female; Hormone Replacement Therapy; Humans; Megestrol Acetate; Menopause; Middle Aged; Nitriles; Pilot Projects; Quality of Life; Surveys and Questionnaires; Tamoxifen; Time Factors; Triazoles | 1999 |
Letrozole: updated duration of response.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Postmenopause; Survival Analysis; Triazoles | 1999 |
Safety and tolerability of endocrine therapies used in the treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Tolerance; Female; Humans; Megestrol Acetate; Nitriles; Safety; Tamoxifen; Triazoles | 1999 |
Future directions in endocrine treatment of advanced breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Megestrol Acetate; Nitriles; Tamoxifen; Triazoles | 1999 |
Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
Topics: Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Cost-Benefit Analysis; Female; Humans; Letrozole; Markov Chains; Models, Biological; Models, Economic; Nitriles; Postmenopause; Triazoles; United Kingdom | 1999 |
Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Enzyme Inhibitors; Estrogens; Female; Fibroblasts; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Triazoles; Tumor Cells, Cultured | 1999 |
Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands.
Topics: Animals; Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Hyperplasia; Letrozole; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasms, Hormone-Dependent; Nitriles; Ovariectomy; Precancerous Conditions; Receptors, Estrogen; Triazoles | 1999 |
Letrozole: which dose to be used?
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Postmenopause; Triazoles | 2000 |
Screening assay for promigratory/antimigratory compounds.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Fluoresceins; Fluorescent Dyes; Humans; Neoplasm Metastasis; Propidium; Spectrometry, Fluorescence; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2000 |
A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chromatography, High Pressure Liquid; Estradiol; Estrone; Female; Humans; Nitriles; Postmenopause; Radioimmunoassay; Reproducibility of Results; Sensitivity and Specificity; Triazoles | 2000 |
Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Premenopause; Salvage Therapy; Treatment Outcome; Triazoles | 2000 |
Effects of the aromatase inhibitor anastrozole on serum oestrogens in Japanese and Caucasian women.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Asian People; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogens; Estrone; Female; Humans; Japan; Middle Aged; Nitriles; Triazoles; White People | 2000 |
[Aromatase inhibitors in the treatment of breast cancer].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Costs and Cost Analysis; Decision Support Techniques; Female; Humans; Letrozole; Megestrol Acetate; Nitriles; Quality of Life; Randomized Controlled Trials as Topic; Triazoles | 2000 |
An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Triazoles | 2000 |
PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis.
Topics: Animals; Azepines; Breast Neoplasms; Cell Division; Cell Movement; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Phospholipid Ethers; Platelet Activating Factor; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Triazoles; Tumor Cells, Cultured | 2000 |
Gonadotropins stimulate growth of MCF-7 human breast cancer cells by promoting intracellular conversion of adrenal androgens to estrogens.
Topics: Anastrozole; Androgens; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Chorionic Gonadotropin, beta Subunit, Human; Dehydroepiandrosterone; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Fulvestrant; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
Endocrine options for breast cancer treatment: looking beyond tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Goserelin; Humans; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2000 |
Clarification of anastrozole/megestrol acetate trial program design.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Female; Humans; Megestrol Acetate; Nitriles; Prospective Studies; Research Design; Triazoles | 2000 |
Clinical trials in cancer: what makes for a successful study?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Double-Blind Method; Drug Industry; Female; Humans; Interinstitutional Relations; Mastectomy; Medical Audit; Motivation; Multicenter Studies as Topic; Nitriles; Patient Selection; Patients; Physician-Patient Relations; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Tamoxifen; Triazoles | 2000 |
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |
From the Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colitis, Ulcerative; Dermatologic Agents; Humans; Information Services; Isotretinoin; Letrozole; Mesalamine; Nitriles; Risk; Suppositories; Triazoles; United States; United States Food and Drug Administration | 2001 |
The Twenty-third Annual San Antonio Breast Cancer Symposium.
Topics: Anastrozole; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Estradiol; Estrogen Antagonists; Female; Fluorouracil; Fulvestrant; Humans; Letrozole; Male; Mastectomy; Nitriles; Prognosis; Survival Analysis; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors and arthralgia.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 2001 |
Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
Topics: Aged; Antineoplastic Agents; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Humans; Letrozole; Lipids; Lipoprotein(a); Middle Aged; Nitriles; Postmenopause; Risk Factors; Triazoles; Triglycerides | 2001 |
Use of ErbB-1 and ErbB-2 to select endocrine therapy for breast cancer: will it play in Peoria?
Topics: Antineoplastic Agents; Breast Neoplasms; ErbB Receptors; Estrogen Antagonists; Female; Humans; Letrozole; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Receptor, ErbB-2; Tamoxifen; Triazoles | 2001 |
Aromatase inhibitors: treatment of advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles | 2001 |
Aromatase inhibitors and inactivators in breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2001 |
Anastrozole: licence extension. No advantage over tamoxifen in advanced-stage breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Female; France; Humans; Neoplasm Staging; Nitriles; Postmenopause; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Division; Female; Gene Amplification; Humans; Immunohistochemistry; Ki-67 Antigen; Multicenter Studies as Topic; Nitriles; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Triazoles | 2001 |
Letrozole in second-line therapy of advanced breast cancer: more questions than answers.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Canada; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Female; Humans; Letrozole; Megestrol Acetate; Neoplasm Metastasis; Nitriles; Palliative Care; Postmenopause; Treatment Outcome; Triazoles | 2001 |
False shortening of time to progression in letrozole 2.5-mg dose?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Letrozole; Nitriles; Triazoles | 2001 |
[Clinical study of anastrozole in the treatment of postmenopausal women with advanced breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Humans; Middle Aged; Nitriles; Postmenopause; Triazoles | 1999 |
New breast cancer drug.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Recurrence; Triazoles; United States | 2001 |
Superior efficacy of letrozole versus tamoxifen as first-line therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Pre-operative endocrine therapy for postmenopausal women: when and why?
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Postmenopause; Preoperative Care; Randomized Controlled Trials as Topic; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2001 |
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Topics: Adult; Aged; Anastrozole; Androstenedione; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Letrozole; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles | 2001 |
World's largest breast cancer treatment trial supports anastrozole use.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2002 |
Aromatase and COX-2 expression in human breast cancers.
Topics: Adipocytes; Adult; Aged; Aged, 80 and over; Animals; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cyclooxygenase 2; Dinoprostone; Endothelium; Enzyme Inhibitors; Epithelial Cells; Estrogen Receptor Modulators; Estrogens; Female; Humans; Immunohistochemistry; Isoenzymes; Letrozole; Mammary Neoplasms, Experimental; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Prostaglandin-Endoperoxide Synthases; Stromal Cells; Tamoxifen; Triazoles | 2001 |
Local endocrine effects of aromatase inhibitors within the breast.
Topics: Anastrozole; Androstadienes; Aromatase; Aromatase Inhibitors; Breast; Breast Neoplasms; Cells, Cultured; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogens; Estrone; Female; Fibroblasts; Humans; In Vitro Techniques; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Triazoles | 2001 |
Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.
Topics: Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Immunohistochemistry; Ki-67 Antigen; Letrozole; Menopause; Neoplasms, Hormone-Dependent; Nitriles; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triazoles | 2001 |
[Aromatase inhibitors of the 3rd generation. What can the "pill against breast cancer" really do?].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Humans; Letrozole; Nitriles; Triazoles | 2002 |
Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Approval; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles; United States; United States Food and Drug Administration | 2002 |
Hormones 'R' us.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Humans; Nitriles; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
Breast cancer studies challenge tamoxifen therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2000 |
Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Retrospective Studies; Survival Analysis; Triazoles | 2002 |
Selection models and pattern-mixture models to analyse longitudinal quality of life data subject to drop-out.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Female; Humans; Longitudinal Studies; Models, Statistical; Neoplasms, Hormone-Dependent; Patient Dropouts; Quality of Life; Triazoles | 2002 |
New breast cancer drugs expand treatment options.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Letrozole; Nitriles; Tamoxifen; Triazoles | 2002 |
Comparison of in vitro exemestane activity versus other antiaromatase agents.
Topics: Aminoglutethimide; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Choriocarcinoma; Female; Humans; Nitriles; Triazoles; Tumor Cells, Cultured | 2000 |
Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Letrozole; Middle Aged; Nitriles; Postmenopause; Time Factors; Triazoles | 2002 |
A better medication for treating breast cancer?
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Nitriles; Tamoxifen; Triazoles | 2002 |
The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant.
Topics: Administration, Oral; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Estrogen Receptor Modulators; Female; Humans; Injections, Intramuscular; Nitriles; Nurse's Role; Oncology Nursing; Patient Education as Topic; Triazoles | 2002 |
Endocrine effects of nonsteroidal aromatase inhibitors and their clinical impact.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cross-Over Studies; Enzyme Inhibitors; Estrogens; Female; Humans; Letrozole; Nitriles; Postmenopause; Research Design; Triazoles | 2002 |
Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Enzyme Inhibitors; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Tamoxifen; Triazoles | 2002 |
Estrogen as therapy for breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials, Phase II as Topic; Diethylstilbestrol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Letrozole; Megestrol Acetate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Salvage Therapy; Tamoxifen; Treatment Outcome; Triazoles | 2002 |
1,2,4-Triglycidylurazol in advanced breast cancer: a trial of the phase II study group of the Association of Medical Oncology, German Cancer Society.
Topics: Adult; Aged; Breast Neoplasms; Drug Evaluation; Female; Hematologic Diseases; Humans; Middle Aged; Triazoles | 1987 |